Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein‐coupled receptors

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein‐coupled receptors Conflict of interestThe authors state that there are no conflicts of interest to declare.OverviewG protein‐coupled receptors (GPCRs) are the largest class of membrane proteins in the human genome. The term "7TM receptor" is commonly used interchangeably with "GPCR", although there are some receptors with seven transmembrane domains that do not signal through G proteins. GPCRs share a common architecture, each consisting of a single polypeptide with an extracellular N‐terminus, an intracellular C‐terminus and seven hydrophobic transmembrane domains (TM1‐TM7) linked by three extracellular loops (ECL1‐ECL3) and three intracellular loops (ICL1‐ICL3). About 800 GPCRs have been identified in man, of which about half have sensory functions, mediating olfaction (∼400), taste (33), light perception (10) and pheromone signalling (5) [1362]. The remaining ∼350 non‐sensory GPCRs mediate signalling by ligands that range in size from small molecules to peptides to large proteins; they are the targets for the majority of drugs in clinical usage [1519, 1631], although only a minority of these receptors are exploited therapeutically. The first classification scheme to be proposed for GPCRs [1030] divided them, on the basic of sequence homology, into six classes. These classes and their prototype members were as follows: Class A (rhodopsin‐like), Class B (secretin receptor family), Class C (metabotropic glutamate), Class D (fungal mating pheromone receptors), Class E (cyclic AMP receptors) and Class F (frizzled/smoothened). Of these, classes D and E are not found in vertebrates. An alternative classification scheme "GRAFS" [1737] divides vertebrate GPCRs into five classes, overlapping with the A‐F nomenclature, viz:Glutamate family (class C), which includes metabotropic glutamate receptors, a calcium‐sensing receptor and GABAB receptors, as well as three taste type 1 receptors and a family of pheromone receptors (V2 receptors) that are abundant in rodents but absent in man [1362].Rhodopsin family (class A), which includes receptors for a wide variety of small molecules, neurotransmitters, peptides and hormones, together with olfactory receptors, visual pigments, taste type 2 receptors and five pheromone receptors (V1 receptors).Adhesion family GPCRs are phylogenetically related to class B receptors, from which they differ by possessing large extracellular N‐termini that are autoproteolytically cleaved from their 7TM domains at a conserved "GPCR proteolysis site" (GPS) which lies within a much larger (˜ 320 residue) "GPCR autoproteolysis‐inducing" (GAIN) domain, an evolutionary ancient mofif also found in polycystic kidney disease 1 (PKD1)‐like proteins, which has been suggested to be both required and sufficient for autoproteolysis [1609].Frizzled family consists of 10 Frizzled proteins (FZD(1‐10)) and Smoothened (SMO). The FZDs are activated by secreted lipoglycoproteins of the WNT family, whereas SMO is indirectly activated by the Hedgehog (HH) family of proteins acting on the transmembrane protein Patched (PTCH).Secretin family (class B), encoded by 15 genes in humans. The ligands for receptors in this family are polypeptide hormones of 27‐141 amino acid residues; nine of the mammalian receptors respond to ligands that are structurally related to one another (glucagon, glucagon‐like peptides (GLP‐1, GLP‐2), glucose‐dependent insulinotropic polypeptide (GIP), secretin, vasoactive intestinal peptide (VIP), pituitary adenylate cyclase‐activating polypeptide (PACAP) and growth‐hormone‐releasing hormone (GHRH)) [738].GPCR familiesFamilyClass AClass B (Secretin)Class C (Glutamate)AdhesionFrizzledReceptors with known ligands1971512011Orphans87 (54)a‐8 (1)a26 (6)a0Sensory (olfaction)390b,c‐‐‐‐Sensory (vision)10d opsins‐‐‐‐Sensory (taste)30c taste 2‐3c taste 1‐‐Sensory (pheromone)5c vomeronasal 1‐‐‐‐Total71915223311aNumbers in brackets refer to orphan receptors for which an endogenous ligand has been proposed in at least one publication, see [414]; b[1511]; c[1362]; d[1941].Much of our current understanding of the structure and function of GPCRs is the result of pioneering work on the visual pigment rhodopsin and on the β2 adrenoceptor, the latter culminating in the award of the 2012 Nobel Prize in chemistry to Robert Lefkowitz and Brian Kobilka [1021, 1137].Family structureS19 Orphan and other 7TM receptorsS19 Class A OrphansŰ Class B OrphansS28 Class C OrphansS28 Taste 1 receptorsS29 Taste 2 receptorsS30 Other 7TM proteinsS30 5‐Hydroxytryptamine receptorsS34 Acetylcholine receptors (muscarinic)S36 Adenosine receptorsS37 Adhesion Class GPCRsS39 AdrenoceptorsS43 Angiotensin receptorsS44 Apelin receptorS45 Bile acid receptorS45 Bombesin receptorsS47 Bradykinin receptorsS48 Calcitonin receptorsS50 Calcium‐sensing receptorS51 Cannabinoid receptorsS52 Chemerin receptorS52 Chemokine receptorsS57 Cholecystokinin receptorsS58 Class Frizzled GPCRsS59 Complement peptide receptorsS60 Corticotropin‐releasing factor receptorsS61 Dopamine receptorsS63 Endothelin receptorsS64 G protein‐coupled estrogen receptorS65 Formylpeptide receptorsS66 Free fatty acid receptorsS67 GABAB receptorsS69 Galanin receptorsS70 Ghrelin receptorS71 Glucagon receptor familyS72 Glycoprotein hormone receptorsS73 Gonadotrophin‐releasing hormone receptorsS74 GPR18, GPR55 and GPR119S76 Histamine receptorsS77 Hydroxycarboxylic acid receptorsS78 Kisspeptin receptorS79 Leukotriene receptorsS80 Lysophospholipid (LPA) receptorsS82 Lysophospholipid (S1P) receptorsS83 Melanin‐concentrating hormone receptorsS84 Melanocortin receptorsS85 Melatonin receptorsS86 Metabotropic glutamate receptorsS88 Motilin receptorS89 Neuromedin U receptorsS90 Neuropeptide FF/neuropeptide AF receptorsS91 Neuropeptide S receptorS91 Neuropeptide W/neuropeptide B receptorsS92 Neuropeptide Y receptorsS94 Neurotensin receptorsS95 Opioid receptorsS97 Orexin receptorsS98 Oxoglutarate receptorS98 P2Y receptorsS100 Parathyroid hormone receptorsS101 Platelet‐activating factor receptorS102 Prokineticin receptorsS103 Prolactin‐releasing peptide receptorS104 Prostanoid receptorsS106 Proteinase‐activated receptorsS107 QRFP receptorS108 Relaxin family peptide receptorsS110 Somatostatin receptorsS110 Succinate receptorS111 Tachykinin receptorsS112 Thyrotropin‐releasing hormone receptorsS113 Trace amine receptorS114 Urotensin receptorS115 Vasopressin and oxytocin receptorsS116 VIP and PACAP receptorsOrphan and other 7TM receptorsClass A OrphansOverviewTable 1 lists a number of putative GPCRs identified by NC‐IUPHAR[557], for which preliminary evidence for an endogenous ligand has been published, or for which there exists a potential link to a disease, or disorder. These GPCRs have recently been reviewed in detail [414]. The GPCRs in Table 1 are all Class A, rhodopsin‐like GPCRs. Class A orphan GPCRs not listed in Table 1 are putative GPCRs with as‐yet unidentified endogenous ligands.Table 1Class A orphan GPCRs with putative endogenous ligandsGPR1GPR3GPR4GPR6GPR12GPR15GPR17GPR20GPR22GPR26GPR31GPR34GPR35GPR37GPR39GPR50GPR63GRP65GPR68GPR75GPR84GPR87GPR88GPR132GPR149GPR161GPR183LGR4LGR5LGR6MAS1MRGPRDMRGPRX1MRGPRX2P2RY10TAAR2In addition the orphan receptors GPR18, GPR55 and GPR119 which are reported to respond to endogenous agents analogous to the endogenous cannabinoid ligands have been grouped together (GPR18, GPR55 and GPR119).NomenclatureGPR1GPR3HGNC, UniProtGPR1, P46091GPR3, P46089Endogenous agonistschemerin (RARRES2, Q99969) [101]–Agonists–diphenyleneiodonium chloride [2179]CommentsReported to act as a co‐receptor for HIV [1791]. See review [414] for discussion of pairing with chemerin.sphingosine 1‐phosphate was reported to be an endogenous agonist [1997], but this finding was not replicated in subsequent studies [2182]. Reported to activate adenylyl cyclase constitutively through Gs [494]. Gene disruption results in premature ovarian ageing [1128], reduced β‐amyloid deposition [1943] and hypersensitivity to thermal pain [1689] in mice. First small molecule inverse agonist [903] and agonists identified [2179].NomenclatureGPR4GPR6GPR42HGNC, UniProtGPR4, P46093GPR6, P46095GPR42, O15529Endogenous ligandsProtons––CommentsAn initial report suggesting activation by lysophosphatidylcholine and sphingosylphosphorylcholine [2225] has been retracted [1470]. GPR4, GPR65, GPR68 and GPR132 are now thought to function as proton‐sensing receptors detecting acidic pH [414, 1775]. Gene disruption is associated with increased perinatal mortality and impaired vascular proliferation [2173]. Negative allosteric modulators of GPR4 have been reported [1967].An initial report that sphingosine 1‐phosphate (S1P) was a high‐affinity ligand (EC50 value of 39nM) [855, 1997] was not repeated in arrestin‐based assays [1854, 2182]. Reported to activate adenylyl cyclase constitutively through Gs and to be located intracellularly [1521]. GPR6‐deficient mice showed reduced striatal cyclic AMP production in vitro and selected alterations in instrumental conditioning in vivo. [1200].–NomenclatureGPR12GPR15GPR17HGNC, UniProtGPR12, P47775GPR15, P49685GPR17, Q13304Endogenous agonists––UDP‐glucose [134, 359], LTC4 [359], UDP‐galactose [134, 359], uridine diphosphate [134, 359], LTD4 [359]CommentsReports that sphingosine 1‐phosphate is a ligand of GPR12 [854, 1997] have not been replicated in arrestin‐based assays [1854, 2182]. Gene disruption results in dyslipidemia and obesity [158].Reported to act as a co‐receptor for HIV [490]. In an infection‐induced colitis model, Gpr15 knockout mice were more prone to tissue damage and inflammatory cytokine expression [991].Reported to be a dual leukotriene and uridine diphosphate receptor [359]. Another group instead proposed that GPR17 functions as a negative regulator of the CysLT1 receptor response to leukotriene D4 (LTD4). For further discussion, see [414]. Reported to antagonize CysLT1 receptor signalling in vivo and in vitro [1239]. See reviews [258] and [414].NomenclatureGPR19GPR20GPR21GPR22GPR25GPR26GPR27HGNC, UniProtGPR19, Q15760GPR20, Q99678GPR21, Q99679GPR22, Q99680GPR25, O00155GPR26, Q8NDV2GPR27, Q9NS67Comments–Reported to inhibit adenylyl cyclase constitutively through Gi/o [743]. GPR20 deficient mice exhibit hyperactivity characterised by increased total distance travelled in an open field test [213].Gpr21 knockout mice were resistant to diet‐induced obesity, exhibiting an increase in glucose tolerance and insulin sensitivity, as well as a modest lean phenotype [1516].Gene disruption results in increased severity of functional decompensation following aortic banding [10]. Identified as a susceptibility locus for osteoarthritis [520, 975, 2011].–Has been reported to activate adenylyl cyclase constitutively through Gs [923]. Gpr26 knockout mice show increased levels of anxiety and depression‐like behaviours [2209].Knockdown of Gpr27 reduces endogenous mouse insulin promotor activity and glucose‐stimulated insulin secretion [1059].NomenclatureGPR31GPR32GPR33GPR34HGNC, UniProtGPR31, O00270GPR32, O75388GPR33, Q49SQ1GPR34, Q9UPC5Potency order of endogenous ligands–resolvin D1>LXA4––Endogenous agonists12S‐HETE [700] – Mouseresolvin D1 [1052], LXA4 [1052]–lysophosphatidylserine [1008, 1891]Labelled ligands–[3H]resolvin D1 (Agonist) [1052]––CommentsSee [414] for discussion of pairing.resolvin D1 has been demonstrated to activate GPR32 in two publications [331, 1052]. The pairing was not replicated in a recent study based on arrestin recruitment [1854]. GPR32 is a pseudogene in mice and rats. See reviews [258] and [414].GPR33 is a pseudogene in most individuals, containing a premature stop codon within the coding sequence of the second intracellular loop [1696].Lysophosphatidylserine has been reported to be a ligand of GPR34 in several publications, but the pairing was not replicated in a recent study based on arrestin recruitment [1854]. Fails to respond to a variety of lipid‐derived agents [2182]. Gene disruption results in an enhanced immune response [1168]. Characterization of agonists at this receptor is discussed in [859] and [414].NomenclatureGPR35GPR37HGNC, UniProtGPR35, Q9HC97GPR37, O15354Endogenous agonists2‐oleoyl‐LPA [1503], kynurenic acid [1854, 2066]–Agonists–neuropeptide head activator [1652]CommentsSeveral studies have shown that kynurenic acid is an agonist of GPR35 but it remains controversial whether the proposed endogenous ligand reaches sufficient tissue concentrations to activate the receptor [1061]. 2‐oleoyl‐LPA has also been proposed as an endogenous ligand [1503] but these results were not replicated in an arrestin assay [1854]. The phosphodiesterase inhibitor zaprinast [1937] has become widely used as a surrogate agonist to investigate GPR35 pharmacology and signalling [1937]. GPR35 is also activated by the pharmaceutical adjunct pamoic acid [2218]. See reviews [414] and [453].Reported to associate and regulate the dopamine transporter [1269] and to be a substrate for parkin [1267]. Gene disruption results in altered striatal signalling [1268]. The peptides prosaptide and prosaposin are proposed as endogenous ligands for GPR37 and GPR37L1 [1324].NomenclatureGPR37L1GPR39GPR45GPR50HGNC, UniProtGPR37L1, O60883GPR39, O43194GPR45, Q9Y5Y3GPR50, Q13585Endogenous agonists–Zn2+ [813]––CommentsThe peptides prosaptide and prosaposin are proposed as endogenous ligands for GPR37 and GPR37L1 [1324].Zn2+ has been reported to be a potent and efficacious agonist of human, mouse and rat GPR39 [2176]. obestatin (GHRL, Q9UBU3), a fragment from the ghrelin precursor, was reported initially as an endogenous ligand, but subsequent studies failed to reproduce these findings. GPR39 has been reported to be down‐regulated in adipose tissue in obesity‐related diabetes [285]. Gene disruption results in obesity and altered adipocyte metabolism [1567]. Reviewed in [414].–GPR50 is structurally related to MT1 and MT2 melatonin receptors, with which it heterodimerises constitutively and specifically [1155]. Gpr50 knockout mice display abnormal thermoregulation and are much more likely than wild‐type mice to enter fasting‐induced torpor [117].NomenclatureGPR52GPR61GPR62GPR63GPR65HGNC, UniProtGPR52, Q9Y2T5GPR61, Q9BZJ8GPR62, Q9BZJ7GPR63, Q9BZJ6GPR65, Q8IYL9Endogenous ligands––––ProtonsCommentsFirst small molecule agonist reported [1774].GPR61 deficient mice exhibit obesity associated with hyperphagia [1422]. Although no endogenous ligands have been identified, 5‐(nonyloxy)tryptamine has been reported to be a low affinity inverse agonist [1925].–sphingosine 1‐phosphate and dioleoylphosphatidic acid have been reported to be low affinity agonists for GPR63 [1459] but this finding was not replicated in an arrestin‐based assay [2182].GPR4, GPR65, GPR68 and GPR132 are now thought to function as proton‐sensing receptors detecting acidic pH [414, 1775]. Reported to activate adenylyl cyclase; gene disruption leads to reduced eosinophilia in models of allergic airway disease [1044].NomenclatureGPR68GPR75GPR78GPR79GPR82HGNC, UniProtGPR68, Q15743GPR75, O95800GPR78, Q96P69GPR79, –GPR82, Q96P67Endogenous ligandsProtons––––Allosteric modulatorslorazepam (Positive) [838]––––CommentsGPR68 was previously identified as a receptor for sphingosylphosphorylcholine (SPC) [2157], but the original publication has been retracted [2156]. GPR4, GPR65, GPR68 and GPR132 are now thought to function as proton‐sensing receptors detecting acidic pH [414, 1775]. A family of 3,5‐disubstituted isoxazoles were identified as agonists of GPR68 [1691].CCL5 (CCL5, P13501) was reported to be an agonist of GPR75 [856], but the pairing could not be repeated in an arrestin assay [1854].GPR78 has been reported to be constitutively active, coupled to elevated cAMP production [923].–Mice with Gpr82 knockout have a lower body weight and body fat content associated with reduced food intake, decreased serum triglyceride levels, as well as higher insulin sensitivity and glucose tolerance [507].NomenclatureGPR83GPR84GPR85GPR87GPR88GPR101HGNC, UniProtGPR83, Q9NYM4GPR84, Q9NQS5GPR85, P60893GPR87, Q9BY21GPR88, Q9GZN0GPR101, Q96P66Endogenous agonists–––LPA [1401, 1911]––AgonistsPEN {Mouse} [655] – Mouse, Zn2+ [1409] – Mousedecanoic acid [1854, 2067], undecanoic acid [2067], lauric acid [2067]–––CommentsOne isoform has been implicated in the induction of CD4(+) CD25(+) regulatory T cells (Tregs) during inflammatory immune responses [731]. The extracellular N‐terminal domain is reported as an intramolecular inverse agonist [1410].Medium chain free fatty acids with carbon chain lengths of 9‐14 activate GPR84 [1901, 2067]. A surrogate ligand for GPR84, 6‐n‐octylaminouracil has also been proposed [1901]. See review [414] for discussion of classification. Mutational analysis and molecular modelling of GPR84 has been reported [1463].Proposed to regulate hippocampal neurogenesis in the adult, as well as neurogenesis‐dependent learning and memory [319].–Gene disruption results in altered striatal signalling [1203]. Small molecule agonists have been reported [151].Mutations in GPR101 have been linked to gigantism and acromegaly [1982].NomenclatureGPR132GPR135GPR139GPR141GPR142GPR146HGNC, UniProtGPR132, Q9UNW8GPR135, Q8IZ08GPR139, Q6DWJ6GPR141, Q7Z602GPR142, Q7Z601GPR146, Q96CH1Endogenous ligandsProtons–––––CommentsGPR4, GPR65, GPR68 and GPR132 are now thought to function as proton‐sensing receptors detecting acidic pH [414, 1775]. Reported to respond to lysophosphatidylcholine [934], but later retracted [2126].–Peptide agonists have been reported [867].–Small molecule agonists have been reported [1968, 2196].Yosten et al. demonstrated inhibition of proinsulin C‐peptide (INS, P01308)‐induced stimulation of cFos expression folllowing knockdown of GPR146 in KATO III cells, suggesting proinsulin C‐peptide as an endogenous ligand of the receptor [2193].NomenclatureGPR148GPR149GPR150GPR151GPR152GPR153GPR160HGNC, UniProtGPR148, Q8TDV2GPR149, Q86SP6GPR150, Q8NGU9GPR151, Q8TDV0GPR152, Q8TDT2GPR153, Q6NV75GPR160, Q9UJ42Comments–Gpr149 knockout mice displayed increased fertility and enhanced ovulation, with increased levels of FSH receptor and cyclin D2 mRNA levels [491].–GPR151 responded to galanin with an EC50 value of 2 μM, suggesting that the endogenous ligand shares structural features with galanin (GAL, P22466) [853].–––NomenclatureGPR161GPR162GPR171GPR173GPR174GPR176GPR182HGNC, UniProtGPR161, Q8N6U8GPR162, Q16538GPR171, O14626GPR173, Q9NS66GPR174, Q9BXC1GPR176, Q14439GPR182, O15218Endogenous agonists––––lysophosphatidylserine [864]––CommentsA C‐terminal truncation (deletion) mutation in Gpr161 causes congenital cataracts and neural tube defects in the vacuolated lens (vl) mouse mutant [1289]. The mutated receptor is associated with cataract, spina bifida and white belly spot phenotypes in mice [1039]. Gene disruption is associated with a failure of asymmetric embryonic development in zebrafish [1151].–GPR171 has been shown to be activated by the endogenous peptide BigLEN {Mouse}. This receptor‐peptide interaction is believed to be involved in regulating feeding and metabolism responses [654].–See [859] which discusses characterization of agonists at this receptor.–Rat GPR182 was first proposed as the adrenomedullin receptor [947]. However, it was later reported that rat and human GPR182 did not respond to adrenomedullin [973] and GPR182 is not currently considered to be a genuine adrenomedullin receptor [756].NomenclatureGPR183LGR4HGNC, UniProtGPR183, P32249LGR4, Q9BXB1Endogenous agonists7α,25‐dihydroxycholesterol [729, 1191], 7α,27‐dihydroxycholesterol [1191], 7β, 25‐dihydroxycholesterol [1191], 7β, 27‐dihydroxycholesterol [1191]R‐spondin‐2 (RSPO2, Q6UXX9) [277], R‐spondin‐1 (RSPO1, Q2MKA7) [277], R‐spondin‐3 (RSPO3, Q9BXY4) [277], R‐spondin‐4 (RSPO4, Q2I0M5) [277]CommentsTwo independent publications have shown that 7α,25‐dihydroxycholesterol is an agonist of GPR183 and have demonstrated by mass spectrometry that this oxysterol is present endogenously in tissues [729, 1191]. Gpr183‐deficient mice show a reduction in the early antibody response to a T‐dependent antigen. GPR183‐deficient B cells fail to migrate to the outer follicle and instead stay in the follicle centre [966, 1557].LGR4 does not couple to heterotrimeric G proteins or recruit arrestins when stimulated by the R‐spondins, indicating a unique mechanism of action. R‐spondins bind to LGR4, which specifically associates with Frizzled and LDL receptor‐related proteins (LRPs) that are activated by the extracellular Wnt molecules and then trigger canonical Wnt signalling to increase gene expression [277, 426, 1686]. Gene disruption leads to multiple developmental disorders [911, 1219, 1849, 2092].NomenclatureLGR5LGR6MAS1MAS1LHGNC, UniProtLGR5, O75473LGR6, Q9HBX8MAS1, P04201MAS1L, P35410Endogenous agonistsR‐spondin‐2 (RSPO2, Q6UXX9) [277], R‐spondin‐1 (RSPO1, Q2MKA7) [277], R‐spondin‐3 (RSPO3, Q9BXY4) [277], R‐spondin‐4 (RSPO4, Q2I0M5) [277]R‐spondin‐1 (RSPO1, Q2MKA7) [277, 426], R‐spondin‐2 (RSPO2, Q6UXX9) [277, 426], R‐spondin‐3 (RSPO3, Q9BXY4) [277, 426], R‐spondin‐4 (RSPO4, Q2I0M5) [277, 426]––Agonists––angiotensin‐(1‐7) (AGT, P01019) [645] – Mouse–CommentsThe four R‐spondins can bind to LGR4, LGR5, and LGR6, which specifically associate with Frizzled and LDL receptor‐related proteins (LRPs), proteins that are activated by extracellular Wnt molecules and which then trigger canonical Wnt signalling to increase gene expression [277, 426].–––NomenclatureMRGPRDMRGPREMRGPRFMRGPRGHGNC, UniProtMRGPRD, Q8TDS7MRGPRE, Q86SM8MRGPRF, Q96AM1MRGPRG, Q86SM5Endogenous agonistsβ‐alanine [1797, 1854]–––CommentsAn endogenous peptide with a high degree of sequence similarity to angiotensin‐(1‐7) (AGT, P01019), alamandine (AGT), was shown to promote NO release in MRGPRD‐transfected cells. The binding of alamandine to MRGPRD to was shown to be blocked by D‐Pro7‐angiotensin‐(1‐7), β‐alanine and PD123319 [1102]. Genetic ablation of MRGPRD+ neurons of adult mice decreased behavioural sensitivity to mechanical stimuli but not to thermal stimuli [292]. See reviews [414] and [1847].See reviews [414] and [1847].MRGPRF has been reported to respond to stimulation by angiotensin metabolites [620]. See reviews [414] and [1847].See reviews [414] and [1847].NomenclatureMRGPRX1MRGPRX2MRGPRX3MRGPRX4OPN3OPN4OPN5HGNC, UniProtMRGPRX1, Q96LB2MRGPRX2, Q96LB1MRGPRX3, Q96LB0MRGPRX4, Q96LA9OPN3, Q9H1Y3OPN4, Q9UHM6OPN5, Q6U736Endogenous agonistsbovine adrenal medulla peptide 8‐22 (PENK, P01210) [315, 1144, 1854]PAMP‐20 (ADM, P35318) [942]–––––Agonists–cortistatin‐14 {Mouse, Rat} [942, 1667, 1854]–––––Selective agonists–PAMP‐12 (human) [942]–––––CommentsReported to mediate the sensation of itch [1196, 1808]. Reports that bovine adrenal medulla peptide 8‐22 (PENK, P01210) was the most potent of a series of proenkephalin A‐derived peptides as an agonist of MRGPRX1 in assays of calcium mobilisation and radioligand binding [1144] were replicated in an independent study using an arrestin recruitment assay [1854]. See reviews [414] and [1847].A diverse range of substances has been reported to be agonists of MRGPRX2, with cortistatin 14 the highest potency agonist in assays of calcium mobilisation [1667], also confirmed in an independent study using an arrestin recruitment assay [1854]. See reviews [414] and [1847].–See reviews [414] and [1847].––Evidence indicates OPN5 triggers a UV‐sensitive Gi‐mediated signalling pathway in mammalian tissues [1028].NomenclatureP2RY8P2RY10TAAR2TAAR3TAAR4PHGNC, UniProtP2RY8, Q86VZ1P2RY10, O00398TAAR2, Q9P1P5TAAR3P, Q9P1P4TAAR4P, –Potency order of endogenous ligands––β‐phenylethylamine>tryptamine [189]––Endogenous agonists–sphingosine 1‐phosphate [1401], LPA [1401]–––Comments––Probable pseudogene in 10–15% of Asians due to a polymorphism (rs8192646) producing a premature stop codon at amino acid 168 [414].TAAR3 is thought to be a pseudogene in man though functional in rodents [414].Pseudogene in man but functional in rodents [414].NomenclatureTAAR5TAAR6TAAR8TAAR9HGNC, UniProtTAAR5, O14804TAAR6, Q96RI8TAAR8, Q969N4TAAR9, Q96RI9CommentsTrimethylamine is reported as an agonist [2058] and 3‐iodothyronamine an inverse agonist [450].––TAAR9 appears to be functional in most individuals but has a polymorphic premature stop codon at amino acid 61 (rs2842899) with an allele frequency of 10–30% in different populations [2023].Class C OrphansNomenclatureGPR156GPR158GPR179GPRC5AGPRC5BGPRC5CGPRC5DGPRC6 receptorHGNC, UniProtGPR156, Q8NFN8GPR158, Q5T848GPR179, Q6PRD1GPRC5A, Q8NFJ5GPRC5B, Q9NZH0GPRC5C, Q9NQ84GPRC5D, Q9NZD1GPRC6A, Q5T6X5Comments–––––––GPRC6 is a related Gq‐coupled receptor which responds to basic amino acids [2090].Taste 1 receptorsOverviewWhilst the taste of acid and salty foods appear to be sensed by regulation of ion channel activity, bitter, sweet and umami tastes are sensed by specialised GPCR. Two classes of taste GPCR have been identified, T1R and T2R, which are similar in sequence and structure to Class C and Class A GPCR, respectively. Activation of taste receptors appears to involve gustducin‐ (Gαt3) and Gα14‐mediated signalling, although the precise mechanisms remain obscure. Gene disruption studies suggest the involvement of PLCβ2 [2215], TRPM5 [2215] and IP3 [802] receptors in post‐receptor signalling of taste receptors. Although predominantly associated with the oral cavity, taste receptors are also located elsewhere, including further down the gastrointestinal system, in the lungs and in the brain.Sweet/UmamiT1R3 acts as an obligate partner in T1R1/T1R3 and T1R2/T1R3 heterodimers, which sense umami or sweet, respectively. T1R1/T1R3 heterodimers respond to L‐glutamic acid and may be positively allosterically modulated by 5'‐nucleoside monophosphates, such as 5'‐GMP[1162]. T1R2/T1R3 heterodimers respond to sugars, such as sucrose, and artificial sweeteners, such as saccharin[1440].NomenclatureTAS1R1TAS1R2TAS1R3HGNC, UniProtTAS1R1, Q7RTX1TAS1R2, Q8TE23TAS1R3, Q7RTX0Taste 2 receptorsOverviewThe composition and stoichiometry of bitter taste receptors is not yet established. Bitter receptors appear to separate into two groups, with very restricted ligand specificity or much broader responsiveness. For example, T2R5 responded to cycloheximide, but not 10 other bitter compounds [302], while T2R14 responded to at least eight different bitter tastants, including (‐)‐α‐thujone and picrotoxinin[124].Specialist database BitterDB contains additional information on bitter compounds and receptors [2113].NomenclatureTAS2R1TAS2R3TAS2R4TAS2R5TAS2R7TAS2R8TAS2R9HGNC, UniProtTAS2R1, Q9NYW7TAS2R3, Q9NYW6TAS2R4, Q9NYW5TAS2R5, Q9NYW4TAS2R7, Q9NYW3TAS2R8, Q9NYW2TAS2R9, Q9NYW1NomenclatureTAS2R10TAS2R13TAS2R14TAS2R16TAS2R19TAS2R20TAS2R30HGNC, UniProtTAS2R10, Q9NYW0TAS2R13, Q9NYV9TAS2R14, Q9NYV8TAS2R16, Q9NYV7TAS2R19, P59542TAS2R20, P59543TAS2R30, P59541NomenclatureTAS2R31TAS2R38TAS2R39TAS2R40HGNC, UniProtTAS2R31, P59538TAS2R38, P59533TAS2R39, P59534TAS2R40, P59535Antagonists6‐methoxysakuranetin (pIC50 5.6) [1000], GIV3727 (pIC50 5.1–5.2) [1823]–––NomenclatureTAS2R41TAS2R42TAS2R43TAS2R45TAS2R46TAS2R50TAS2R60HGNC, UniProtTAS2R41, P59536TAS2R42, Q7RTR8TAS2R43, P59537TAS2R45, P59539TAS2R46, P59540TAS2R50, P59544TAS2R60, P59551Other 7TM proteinsNomenclatureGPR107GPR137OR51E1TPRA1GPR143GPR157HGNC, UniProtGPR107, Q5VW38GPR137, Q96N19OR51E1, Q8TCB6TPRA1, Q86W33GPR143, P51810GPR157, Q5UAW9Endogenous agonists––––levodopa [1207]–CommentsGPR107 is a member of the LUSTR family of proteins found in both plants and animals, having similar topology to G protein‐coupled receptors [489]–OR51E1 is a putative olfactory receptor.TPRA1 shows no homology to known G protein‐coupled receptors.Loss‐of‐function mutations underlie ocular albinism type 1 [109].GPR157 has ambiguous sequence similarities to several different GPCR families (class A, class B and the slime mould cyclic AMP receptor). Because of its distant relationship to other GPCRs, it cannot be readily classified.Further reading on Orphan and other 7TM receptorsDavenport AP et al. (2013) International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein‐coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev 65: 967‐86 [PMID:23686350]Gilissen J et al. (2016) Insight into SUCNR1 (GPR91) structure and function. Pharmacology & Therapeutics 159: 56‐65 [PMID:25118328]Insel PA et al. (2015) G Protein‐Coupled Receptor (GPCR) Expression in Native Cells: "Novel" endoGPCRs as Physiologic Regulators and Therapeutic Targets. Molecular Pharmacology 88: 181‐187 [PM:25737495]Khan MZ et al. (2017) Neuro‐psychopharmacological perspective of Orphan receptors of Rhodopsin (class A) family of G protein‐coupled receptors. Psychopharmacology (Berl) 234: 1181‐1207 [PMID:28289782]Mackenzie AE et al. (2017) The emerging pharmacology and function of GPR35 in the nervous system. Neuropharmacology 113: 661‐671 [PMID:26232640]Ngo T et al. (2016) Identifying ligands at orphan GPCRs: current status using structure‐based approaches. Br J Pharmacol 173: 2934‐2951 [PMID:26837045]5‐Hydroxytryptamine receptorsOverview5‐HT receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on 5‐HT receptors [828] and subsequently revised [742]) are, with the exception of the ionotropic 5‐HT3 class, GPCRs where the endogenous agonist is 5‐hydroxytryptamine. The diversity of metabotropic 5‐HT receptors is increased by alternative splicing that produces isoforms of the 5‐HT2A (non‐functional), 5‐HT2C (non‐functional), 5‐HT4, 5‐HT6 (non‐functional) and 5‐HT7 receptors. Unique amongst the GPCRs, RNA editing produces 5‐HT2C receptor isoforms that differ in function, such as efficiency and specificity of coupling to Gq/11 and also pharmacology [167, 2098]. Most 5‐HT receptors (except 5‐ht1e and 5‐ht5b) play specific roles mediating functional responses in different tissues (reviewed by [1625, 2037]).Nomenclature5‐HT1A receptor5‐HT1B receptorHGNC, UniProtHTR1A, P08908HTR1B, P28222AgonistsU92016A [1302], vilazodone (Partial agonist) [421], vortioxetine (Partial agonist) [96]L‐694,247 [671], naratriptan (Partial agonist) [1425], eletriptan [1425], frovatriptan [2158], zolmitriptan (Partial agonist) [1425], vortioxetine (Partial agonist) [96], rizatriptan (Partial agonist) [1425]Selective agonists8‐OH‐DPAT [431, 720, 939, 1143, 1338, 1451, 1453, 1454], NLX‐101 [1452]CP94253 [1022]Antagonists(S)‐UH 301 (pKi 7.9) [1451]–Selective antagonistsWAY‐100635 (pKi 7.9–9.2) [1451, 1453], robalzotan (pKi 9.2) [915]SB 224289 (Inverse agonist) (pKi 8.2–8.6) [614, 1449, 1768], SB236057 (Inverse agonist) (pKi 8.2) [1331], GR‐55562 (pKB 7.4) [830]Labelled ligands[3H]robalzotan (Antagonist) (pKd 9.8) [904], [3H]WAY100635 (Antagonist) (pKd 9.5) [978], [3H]8‐OH‐DPAT (Agonist) [160, 939, 1450, 1453], [3H]NLX‐112 (Agonist) [785], [11C]WAY100635 (Antagonist) [1991], p‐[18F]MPPF (Antagonist) [382][3H]N‐methyl‐AZ10419369 (Agonist, Partial agonist) [1245], [3H]GR 125,743 (Selective Antagonist) (pKd 8.6–9.2) [671, 2150], [3H]alniditan (Agonist) [1150], [125I]GTI (Agonist) [197, 237] – Rat, [3H]eletriptan (Agonist, Partial agonist) [1425], [3H]sumatriptan (Agonist, Partial agonist) [1425], [11C]AZ10419369 (Agonist, Partial agonist) [2029]Nomenclature5‐HT1D receptor5‐ht1e receptor5‐HT1F receptorHGNC, UniProtHTR1D, P28221HTR1E, P28566HTR1F, P30939Agonistsdihydroergotamine [719, 1150, 1157], ergotamine [648], L‐694,247 [2140], naratriptan [457, 1425, 1651], zolmitriptan [1425], frovatriptan [2158], rizatriptan [1425]BRL‐54443 [232]BRL‐54443 [232], eletriptan [1425], sumatriptan [12, 13, 1425, 2052]Selective agonistsPNU109291 [511] – Gorilla, eletriptan [1425]–lasmiditan [1439], LY334370 [2052], 5‐BODMT [1014], LY344864 [1572]Selective antagonistsSB 714786 (pKi 9.1) [2074]––Labelled ligands[3H]eletriptan (Agonist) [1425], [3H]alniditan (Agonist) [1150], [125I]GTI (Selective Agonist) [197, 237] – Rat, [3H]GR 125,743 (Selective Antagonist) (pKd 8.6) [2150], [3H]sumatriptan (Agonist) [1425][3H]5‐HT (Agonist) [1299, 1532][3H]LY334370 (Agonist) [2052], [125I]LSD (Agonist) [45] – MouseNomenclature5‐HT2A receptor5‐HT2B receptorHGNC, UniProtHTR2A, P28223HTR2B, P41595AgonistsDOI [210, 1438, 1825]methysergide (Partial agonist) [1018, 1679, 2053], DOI [1077, 1438, 1730]Selective agonists–BW723C86 [115, 1018, 1730], Ro 60‐0175 [1018]Antagonistsrisperidone (Inverse agonist) (pKi 9.3–10) [1032, 1055, 1746], mianserin (pKi 7.7–9.6) [1018, 1045, 1338], ziprasidone (pKi 8.8–9.5) [1032, 1055, 1746, 1782], volinanserin (pIC50 6.5–9.3) [1018, 1208, 1640], blonanserin (pKi 9.1) [1487], clozapine (Inverse agonist) (pKi 7.6–9) [1018, 1055, 1335, 1746, 2022]mianserin (pKi 7.9–8.8) [184, 1018, 2053]Selective antagonistsketanserin (pKi 8.1–9.7) [241, 1018, 1630], pimavanserin (Inverse agonist) (pKi 9.3) [603, 2022]BF‐1 (pKi 10.1) [1742], RS‐127445 (pKi 9–9.5) [184, 1018], EGIS‐7625 (pKi 9) [1045]Labelled ligands[3H]fananserin (Antagonist) (pKd 9.9) [1251] – Rat, [3H]ketanserin (Antagonist) (pKd 8.6–9.7) [1018, 1630], [11C]volinanserin (Antagonist) [712], [18F]altanserin (Antagonist) [1675][3H]LSD (Agonist) [1630], [3H]5‐HT (Agonist) [2051] – Rat, [3H]mesulergine (Antagonist, Inverse agonist) (pKd 7.9) [1018], [125I]DOI (Agonist)Nomenclature5‐HT2C receptor5‐HT4 receptorHGNC, UniProtHTR2C, P28335HTR4, Q13639AgonistsDOI [493, 1438, 1730], Ro 60‐0175 [999, 1018]cisapride (Partial agonist) [80, 132, 631, 1326, 1327, 2013]Selective agonistsWAY‐163909 [482], lorcaserin [1955]TD‐8954 [1312], ML 10302 (Partial agonist) [140, 164, 1326, 1327, 1328], RS67506 [765] – Rat, relenopride (Partial agonist) [641], velusetrag [1205, 1832], BIMU 8 [362]Antagonistsmianserin (Inverse agonist) (pKi 8.3–9.2) [551, 1018, 1338], methysergide (pKi 8.6–9.1) [493, 1018], ziprasidone (Inverse agonist) (pKi 7.9–9) [779, 1055, 1782], olanzapine (Inverse agonist) (pKi 8.1–8.4) [779, 1055, 1782], loxapine (Inverse agonist) (pKi 7.8–8) [779, 1055]–Selective antagonistsFR260010 (pKi 9) [735], SB 242084 (pKi 8.2–9) [974, 1018], RS‐102221 (pKi 8.3–8.4) [185, 1018]RS 100235 (pKi 8.7–12.2) [362, 1663], SB 204070 (pKi 9.8–10.4) [132, 1326, 1327, 2013], GR 113808 (pKi 9.3–10.3) [80, 132, 164, 362, 1327, 1663, 2013]Labelled ligands[3H]mesulergine (Antagonist, Inverse agonist) (pKd 8.7–9.3) [551, 1630], [125I]DOI (Agonist) [551], [3H]LSD (Agonist)[3H]GR 113808 (Antagonist) (pKd 9.7–10.3) [80, 132, 1328, 2013], [123I]SB 207710 (Antagonist) (pKd 10.1) [233] – Pig, [3H]RS 57639 (Selective Antagonist) (pKd 9.7) [183] – Guinea pig, [11C]SB207145 (Antagonist) (pKd 8.6) [1233]Nomenclature5‐HT5A receptor5‐ht5b receptor5‐HT6 receptor5‐HT7 receptorHGNC, UniProtHTR5A, P47898HTR5BP, –HTR6, P50406HTR7, P34969Selective agonists––WAY‐181187 [1734], E6801 (Partial agonist) [808], WAY‐208466 [139], EMD‐386088 [1291]LP‐12 [1148], LP‐44 [1148], LP‐211 [1149] – Rat, AS‐19 [993], E55888 [212]Antagonists–––lurasidone (pKi 9.3) [868], pimozide (pKi 9.3) [1678] – Rat, vortioxetine (pKi 6.3) [96]Selective antagonistsSB 699551 (pKi 8.2) [380]–SB399885 (pKi 9) [801], SB 271046 (pKi 8.9) [229], cerlapirdine (pKi 8.9) [371], SB357134 (pKi 8.5) [230], Ro 63‐0563 (pKi 7.9–8.4) [170, 1824]SB269970 (pKi 8.6–8.9) [1949], SB656104 (pKi 8.7) [558], DR‐4004 (pKi 8.7) [647, 985], JNJ‐18038683 (pKi 8.2) [181], SB 258719 (Inverse agonist) (pKi 7.5) [1950]Labelled ligands[125I]LSD (Agonist) [670], [3H]5‐CT (Agonist) [670][125I]LSD (Agonist) [1290] – Mouse, [3H]5‐CT (Agonist) [2049] – Mouse[11C]GSK215083 (Antagonist) (pKi 9.8) [1531], [125I]SB258585 (Selective Antagonist) (pKd 9) [801], [3H]LSD (Agonist) [169], [3H]Ro 63‐0563 (Antagonist) (pKd 8.3) [170], [3H]5‐CT (Agonist)[3H]5‐CT (Agonist) [1949], [3H]5‐HT (Agonist) [99, 1864], [3H]SB269970 (Selective Antagonist) (pKd 8.9) [1949], [3H]LSD (Agonist) [1864]CommentsTabulated pKi and KD values refer to binding to human 5‐HT receptors unless indicated otherwise. The nomenclature of 5‐HT1B/5‐HT1D receptors has been revised [742]. Only the non‐rodent form of the receptor was previously called 5‐HT1D: the human 5‐HT1B receptor (tabulated) displays a different pharmacology to the rodent forms of the receptor due to Thr335 of the human sequence being replaced by Asn in rodent receptors. Wang et al. (2013) report X‐ray structures which reveal the binding modality of ergotamine and dihydroergotamine to the 5‐HT1B receptor in comparison with the structure of the 5‐HT2B receptor [2064]. NAS181 is a selective antagonist of the rodent 5‐HT1B receptor. Fananserin and ketanserin bind with high affinity to dopamine D4 and histamine H1 receptors respectively, and ketanserin is a potent α1 adrenoceptor antagonist, in addition to blocking 5‐HT2A receptors. Lysergic acid(LSD) and ergotamine show a strong preference for arrestin recruitment over G protein coupling at the 5‐HT2B receptor, with no such preference evident at 5‐HT1B receptors, and they also antagonise 5‐HT7A receptors [2047]. DHE (dihydroergocryptine), pergolide and cabergoline also show significant preference for arrestin recruitment over G protein coupling at 5‐HT2B receptors [2047]. The serotonin antagonist mesulergine was key to the discovery of the 5‐HT2C receptor [1546]. The human 5‐HT5A receptor has been claimed to couple to several signal transduction pathways when stably expressed in C6 glioma cells [1472] and electrophysiological recordings from mice and rat prefrontal cortex (layer V pyramidal neurons) demonstrate 5‐HT‐elicited outward currents mediated via the 5‐HT5A receptor [660]. The human orthologue of the mouse 5‐ht5b receptor is non‐functional due to interruption of the gene by stop codons. The 5‐ht1e receptor appears not to have been cloned from mouse, or rat, impeding definition of its function. In addition to the receptors listed in the table, an 'orphan' receptor, unofficially termed 5‐HT1P, has been described [635]. .Further reading on 5‐Hydroxytryptamine receptorsBockaert J et al. (2011) 5‐HT(4) receptors, a place in the sun: act two. Curr Opin Pharmacol 11: 87‐93 [PMID:21342787]Hayes DJ et al. (2011) 5‐HT receptors and reward‐related behaviour: a review. Neurosci Biobehav Rev 35: 1419‐49 [PMID:21402098]Hoyer D et al. (1994) International Union of Pharmacology classification of receptors for 5‐hydroxytryptamine (Serotonin). Pharmacol. Rev. 46: 157‐203 [PMID:7938165]Leopoldo M et al. (2011) Serotonin 5‐HT7 receptor agents: Structure‐activity relationships and potential therapeutic applications in central nervous system disorders. Pharmacol. Ther. 129: 120‐48 [PMID:20923682]Meltzer HY et al. (2011) The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 11: 59‐67 [PMID:21420906]Roberts AJ et al. (2012) The 5‐HT(7) receptor in learning and memory. Hippocampus 22: 762‐71 [PMID:21484935]Acetylcholine receptors (muscarinic)OverviewMuscarinic acetylcholine receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Muscarinic Acetylcholine Receptors [288]) are GPCRs of the Class A, rhodopsin‐like family where the endogenous agonist is acetylcholine. In addition to the agents listed in the table, AC‐42, its structural analogues AC‐260584 and 77‐LH‐28‐1, N‐desmethylclozapine, TBPB and LuAE51090 have been described as functionally selective agonists of the M1 receptor subtype via binding in a mode distinct from that utilized by non‐selective agonists [74, 921, 1096, 1097, 1294, 1708, 1857, 1858, 1898]. There are two pharmacologically characterised allosteric sites on muscarinic receptors, one defined by it binding gallamine, strychnine and brucine, and the other defined by the binding of KT 5720, WIN 62,577, WIN 51,708 and staurosporine[1110, 1111].NomenclatureM1 receptorM2 receptorHGNC, UniProtCHRM1, P11229CHRM2, P08172Agonistscarbachol [350, 888, 2129], pilocarpine (Partial agonist) [888], bethanechol [888]bethanechol [888]Antagonistsglycopyrrolate (pIC50 9.9) [1874], umeclidinium (pKi 9.8) [1090, 1705], AE9C90CB (pKi 9.7) [1818], propantheline (pKi 9.7) [837], atropine (pKi 8.5–9.6) [350, 582, 797, 837, 1555, 1831], tiotropium (pKi 9.6) [452], 4‐DAMP (pKi 9.2) [486]tiotropium (pKi 9.9) [452], umeclidinium (pKi 9.8) [1090, 1705], propantheline (pKi 9.5) [837], glycopyrrolate (Full agonist) (pIC50 9.3) [1874], atropine (pKi 7.8–9.2) [245, 325, 797, 837, 1046, 1437, 1555], AE9C90CB (pKi 8.6) [1818], tolterodine (Inverse agonist) (pKi 8.4–8.6) [642, 1437, 1818]Selective antagonistsbiperiden (pKd 9.3) [175], VU0255035 (pKi 7.8) [1786], guanylpirenzepine (pKi 7.3–7.6) [23, 2050] – Rattripitramine (pKi 9.6) [1240]Allosteric modulatorsmuscarinic toxin 7 (Negative) (pKi 11–11.1) [1480], benzoquinazolinone 12 (Positive) (pKB 6.6) [4], KT 5720 (Positive) (pKd 6.4) [1110], brucine (Positive) (pKd 4.5–5.8) [888, 1109], BQCA (Positive) (pKB 4–4.8) [4, 5, 271, 1225], VU0029767 (Positive) [1270], VU0090157 (Positive) [1270]W‐84 (Negative) (pKd 6–7.5) [1353, 1983], C7/3‐phth (Negative) (pKd 7.1) [351], alcuronium (Negative) (pKd 6.1–6.9) [888, 1983], gallamine (Negative) (pKd 5.9–6.3) [363, 1107], LY2119620 (Positive) (pKd 5.7) [399, 1057], LY2033298 (Positive) (pKd 4.4) [2009]Labelled ligands[3H]QNB (Antagonist) (pKd 10.6–10.8) [352, 1555], Cy3B‐telenzepine (Antagonist) (pKd 10.5) [777], [3H]N‐methyl scopolamine (Antagonist) (pKd 9.4–10.3) [294, 350, 352, 797, 888, 889, 918, 977, 1107], [3H](+)telenzepine (Antagonist) (pKi 9.4) [526] – Rat, Alexa‐488‐telenzepine (Antagonist) (pKd 9.3) [777], [3H]pirenzepine (Antagonist) (pKd 7.9) [2083], BODIPY‐pirenzepine (Antagonist) (pKi 7) [860], [11C]butylthio‐TZTP (Agonist) [530], [11C]xanomeline (Agonist) [530], [18F](R,R)‐quinuclidinyl‐4‐fluoromethyl‐benzilate (Antagonist) [982] – Rat[3H]QNB (Antagonist) (pKd 10.1–10.6) [1555], Cy3B‐telenzepine (Antagonist) (pKi 10.4) [1444], [3H]tiotropium (Antagonist) (pKd 10.3) [1705], [3H]N‐methyl scopolamine (Antagonist) (pKd 9.3–9.9) [294, 325, 797, 888, 889, 918, 977, 1107, 2072], Alexa‐488‐telenzepine (Antagonist) (pKi 8.8) [1444], [3H]acetylcholine (Agonist) [1108], [3H]oxotremorine‐M (Agonist) [141], [3H]dimethyl‐W84 (Allosteric modulator, Positive) (pKd 8.5) [1983], [18F]FP‐TZTP (Agonist) [887] – MouseNomenclatureM3 receptorM4 receptorM5 receptorHGNC, UniProtCHRM3, P20309CHRM4, P08173CHRM5, P08912Agonistspilocarpine (Partial agonist) [888], carbachol [325, 888, 2129], bethanechol [888]pilocarpine (Partial agonist) [888], carbachol [888, 2129], bethanechol [888]pilocarpine (Partial agonist) [673], carbachol [2129]Antagoniststiotropium (pKi 9.5–11.1) [452, 469], umeclidinium (pKi 10.2) [1090, 1705], propantheline (pKi 10) [837], AE9C90CB (pKi 9.9) [1818], atropine (pKi 8.9–9.8) [245, 469, 797, 837, 1555, 1831], ipratropium (pKi 9.3–9.8) [469, 797], aclidinium (pIC50 9.8) [1601]umeclidinium (pKi 10.3) [1705], glycopyrrolate (pIC50 9.8) [1874], AE9C90CB (pKi 9.5) [1818], 4‐DAMP (pKi 8.9) [486], oxybutynin (pKi 8.7) [1818], biperiden (pKd 8.6) [175], UH‐AH 37 (pKi 8.3–8.4) [642, 2099]umeclidinium (pKi 9.9) [1705], glycopyrrolate (pIC50 9.7) [1874], AE9C90CB (pKi 9.5) [1818], 4‐DAMP (pKi 9) [486], tolterodine (pKi 8.5–8.8) [642, 1818], darifenacin (pKi 7.9–8.6) [642, 764, 797, 1818]Selective antagonists––ML381 (pKi 6.3) [625]Allosteric modulatorsWIN 62,577 (Positive) (pKd 5.1) [1111], N‐chloromethyl‐brucine (Positive) (pKd 3.3) [1109]muscarinic toxin 3 (Negative) (pKi 8.7) [918, 1512], VU0152100 (Positive) (pEC50 6.4) [207] – Rat, VU0152099 (Positive) (pEC50 6.4) [207] – Rat, LY2119620 (Positive) (pKd 5.7) [399], thiochrome (Positive) (pKd 4) [1108], LY2033298 (Positive) [301]ML380 (Positive) (pEC50 6.7) [627]Selective allosteric modulators––ML375 (Negative) (pIC50 6.5) [626]Labelled ligands[3H]tiotropium (Antagonist) (pKd 10.7) [1705], [3H]QNB (Antagonist) (pKd 10.4) [1555], [3H]N‐methyl scopolamine (Antagonist) (pKd 9.7–10.2) [294, 325, 797, 837, 888, 918, 977, 1107], [3H]darifenacin (Antagonist) (pKd 9.5) [1831][3H]QNB (Antagonist) (pKd 9.7–10.5) [352, 1555], [3H]N‐methyl scopolamine (Antagonist) (pKd 9.9–10.2) [294, 325, 352, 797, 888, 918, 977, 1107, 1512, 2072], [3H]acetylcholine (Agonist) [1108][3H]QNB (Antagonist) (pKd 10.2–10.7), [3H]N‐methyl scopolamine (Antagonist) (pKd 9.3–9.7) [294, 325, 797, 918, 977, 2072]CommentsLY2033298 and BQCA have also been shown to directly activate the M4 and M1 receptors, respectively, via an allosteric site [1119, 1121, 1427, 1428]. The allosteric site for gallamine and strychnine on M2 receptors can be labelled by [3H]dimethyl‐W84[1983]. McN‐A‐343 is a functionally selective partial agonist that appears to interact in a bitopic mode with both the orthosteric and an allosteric site on the M2 muscarinic receptor [2010]. THRX160209, hybrid 1 and hybrid 2, are multivalent (bitopic) ligands that also achieve selectivity for M2 receptors by binding both to the orthosteric and a nearby allosteric site [55, 1866].Although numerous ligands for muscarinic acetylcholine receptors have been described, relatively few selective antagonists have been described, so it is common to assess the rank order of affinity of a number of antagonists of limited selectivity (e.g. 4‐DAMP, darifenacin, pirenzepine) in order to identify the involvement of particular subtypes. It should be noted that the measured affinities of antagonists (and agonists) in radioligand binding studies are sensitive to ionic strength and can increase over 10‐fold at low ionic strength compared to their values at physiological ionic strengths [155].Further reading on Acetylcholine receptors (muscarinic)Caulfield MP et al. (1998) International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 50: 279‐290 [PMID:9647869]Eglen RM. (2012) Overview of muscarinic receptor subtypes. Handb Exp Pharmacol 3‐28 [PMID:22222692]Gregory KJ et al. (2007) Allosteric modulation of muscarinic acetylcholine receptors. Curr Neuropharmacol 5: 157‐67 [PMID:19305798]Kruse AC et al. (2014) Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat Rev Drug Discov 13: 549‐60 [PMID:24903776]Leach K et al. (2012) Structure‐function studies of muscarinic acetylcholine receptors. Handb Exp Pharmacol 29‐48 [PMID:22222693]Valant C et al. (2012) The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein‐coupled receptors. Annu. Rev. Pharmacol. Toxicol. 52: 153‐78 [PMID:21910627]Adenosine receptorsOverviewAdenosine receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Adenosine Receptors [569]) are activated by the endogenous ligand adenosine(potentially inosine also at A3 receptors). Crystal structures for the antagonist‐bound [374, 876, 1198, 1765], agonist‐bound [1126, 1127, 2154] and G protein‐bound A2A adenosine receptors [278] have been described.NomenclatureA1 receptorA2A receptorA2B receptorA3 receptorHGNC, UniProtADORA1, P30542ADORA2A, P29274ADORA2B, P29275ADORA3, P0DMS8Sub/family‐selective agonistsNECA [602, 913, 1665, 1980, 2166]NECA [193, 451, 602, 990, 1071, 2166]NECA [148, 193, 905, 1179, 1870, 2024, 2166]NECA [193, 602, 883, 1707, 2025, 2166]Selective agonistscyclopentyladenosine [404, 428, 602, 771, 880, 913, 1665], 5‐Cl‐5‐deoxy‐(±)‐ENBA [565], TCPA [150], CCPA [880, 1485]apadenoson [1548], UK‐432,097 [2154], compound 4g [374], CGS 21680 [193, 451, 602, 880, 990, 1016, 1071, 1485], regadenoson [880]BAY 60‐6583 [488]piclidenoson [537, 592, 1016, 2025], Cl‐IB‐MECA [208, 883, 987], MRS5698 [1977]Sub/family‐selective antagonistsCGS 15943 (pKi 8.5) [1513], xanthine amine congener (pKd 7.5) [565]CGS 15943 (pKi 7.7–9.4) [451, 990, 1016, 1513], xanthine amine congener (pKi 8.4–9) [451, 1016]xanthine amine congener (pKi 6.9–8.8) [148, 905, 906, 1016, 1179, 1870], CGS 15943 (pKi 6–8.1) [68, 905, 906, 1016, 1513, 1870]CGS 15943 (pKi 7–7.9) [995, 1016, 1513, 2025], xanthine amine congener (pKi 7–7.4) [1016, 1707, 2025]Selective antagonistsPSB36 (pKi 9.9) [6] – Rat, DPCPX (pKi 7.4–9.2) [428, 865, 1485, 1665, 2102], derenofylline (pKi 9) [939], WRC‐0571 (pKi 8.8) [1272], DU172 (pKi 7.4) [649]SCH442416 (pKi 8.4–10.3) [1796, 1969], ZM‐241385 (pKi 8.8–9.1) [1513]PSB‐0788 (pKi 9.4) [192], PSB603 (pKi 9.3) [192], MRS1754 (pKi 8.8) [905, 994], PSB1115 (pKi 7.3) [757]MRS1220 (pKi 8.2–9.2) [883, 995, 1892, 2177], VUF5574 (pKi 8.4) [2016], MRS1523 (pKi 7.7) [1158], MRS1191 (pKi 7.5) [883, 909, 1163]Allosteric modulatorsPD81723 (Positive) [239]––LUF6000 (Positive) [701], LUF6096 (Positive) [770]Labelled ligands[3H]CCPA (Agonist) [1016, 1665], [3H]DPCPX (Antagonist) (pKd 8.4–9.2) [404, 537, 1016, 1513, 1665, 1980][3H]ZM 241385 (Antagonist) (pKd 8.7–9.1) [36, 600], [3H]CGS 21680 (Agonist) [894, 2062][3H]MRS1754 (Antagonist) (pKd 9.8) [905][125I]AB‐MECA (Agonist) [1513, 2025]CommentsAdenosine inhibits many intracellular ATP‐utilising enzymes, including adenylyl cyclase (P‐site). A pseudogene exists for the A2B adenosine receptor (ADORA2BP1) with 79% identity to the A2B adenosine receptor cDNA coding sequence, but which is unable to encode a functional receptor [884]. DPCPX also exhibits antagonism at A2B receptors (pKi ca. 7,[34, 1016]). Antagonists at A3 receptors exhibit marked species differences, such that only MRS1523 and MRS1191 are selective at the rat A3 receptor. In the absence of other adenosine receptors, [3H]DPCPX and [3H]ZM 241385 can also be used to label A2B receptors (KD ca. 30 and 60 nM respectively). [125I]AB‐MECA also binds to A1 receptors [1016]. [3H]CGS 21680 is relatively selective for A2A receptors, but may also bind to other sites in cerebral cortex [400, 914]. [3H]NECA binds to other non‐receptor elements, which also recognise adenosine [1209]. XAC‐BY630 has been described as a fluorescent antagonist for labelling A1 adenosine receptors in living cells, although activity at other adenosine receptors was not examined [217].Further reading on Adenosine receptorsFredholm BB et al. (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors–an update. Pharmacol. Rev. 63: 1‐34 [PMID:21303899]Guo D et al. (2017) Kinetic Aspects of the Interaction between Ligand and G Protein‐Coupled Receptor: The Case of the Adenosine Receptors. Chem. Rev. 117: 38‐66 [PMID:27088232]Göblyös A et al. (2011) Allosteric modulation of adenosine receptors. Biochim. Biophys. Acta 1808: 1309‐18 [PMID:20599682]Headrick JP et al. (2011) Adenosine and its receptors in the heart: regulation, retaliation and adaptation. Biochim. Biophys. Acta 1808: 1413‐28 [PMID:21094127]Lasley RD. (2011) Adenosine receptors and membrane microdomains. Biochim. Biophys. Acta 1808: 1284‐9 [PMID:20888790]Mundell S et al. (2011) Adenosine receptor desensitization and trafficking. Biochim. Biophys. Acta 1808: 1319‐28 [PMID:20550943]Wei CJ et al. (2011) Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies. Biochim. Biophys. Acta 1808: 1358‐79 [PMID:21185258]Adhesion Class GPCRsOverviewAdhesion GPCRs are structurally identified on the basis of a large extracellular region, similar to the Class B GPCR, but which is linked to the 7TM region by a GPCR autoproteolysis‐inducing (GAIN) domain [56] containing a GPCR proteolytic site. The N‐terminus often shares structural homology with proteins such as lectins and immunoglobulins, leading to the term adhesion GPCR [571, 2187]. The nomenclature of these receptors was revised in 2015 as recommended by NC‐IUPHAR and the Adhesion GPCR Consortium [718].NomenclatureADGRA1ADGRA2ADGRA3ADGRB1ADGRB2ADGRB3CELSR1HGNC, UniProtADGRA1, Q86SQ6ADGRA2, Q96PE1ADGRA3, Q8IWK6ADGRB1, O14514ADGRB2, O60241ADGRB3, O60242CELSR1, Q9NYQ6Endogenous agonists–––phosphatidylserine [1530]–––Comments–––ADGRB1 is reported to respond to phosphatidylserine [1530].–––NomenclatureCELSR2CELSR3ADGRD1ADGRD2ADGRE1ADGRE2ADGRE3HGNC, UniProtCELSR2, Q9HCU4CELSR3, Q9NYQ7ADGRD1, Q6QNK2ADGRD2, Q7Z7M1ADGRE1, Q14246ADGRE2, Q9UHX3ADGRE3, Q9BY15Comments–––––A mutation destabilizing the GAIN domain sensitizes mast cells to IgE‐independent vibration‐induced degranulation [202].–NomenclatureADGRE4PADGRE5ADGRF1ADGRF2ADGRF3ADGRF4ADGRF5HGNC, UniProtADGRE4P, Q86SQ3ADGRE5, P48960ADGRF1, Q5T601ADGRF2, Q8IZF7ADGRF3, Q8IZF5ADGRF4, Q8IZF3ADGRF5, Q8IZF2NomenclatureADGRG1ADGRG2ADGRG3ADGRG4ADGRG5HGNC, UniProtADGRG1, Q9Y653ADGRG2, Q8IZP9ADGRG3, Q86Y34ADGRG4, Q8IZF6ADGRG5, Q8IZF4CommentsReported to bind tissue transglutaminase 2 [2155] and collagen, which activates the G12/13 pathway [1220].––––NomenclatureADGRG6ADGRG7ADGRL1ADGRL2ADGRL3ADGRL4ADGRV1HGNC, UniProtADGRG6, Q86SQ4ADGRG7, Q96K78ADGRL1, O94910ADGRL2, O95490ADGRL3, Q9HAR2ADGRL4, Q9HBW9ADGRV1, Q8WXG9Comments––––––Loss‐of‐function mutations are associated with Usher syndrome, a sensory deficit disorder [885].Further reading on Adhesion Class GPCRsHamann J et al. (2015) International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein‐coupled receptors. Pharmacol. Rev. 67: 338‐67 [PMID:25713288]Yona S et al. (2008) Adhesion‐GPCRs: emerging roles for novel receptors. Trends Biochem. Sci. 33: 491‐500 [PMID:18789697]AdrenoceptorsOverviewThe nomenclature of the Adrenoceptors has been agreed by the NC‐IUPHAR Subcommittee on Adrenoceptors [256], see also [789].Adrenoceptors, α1α1‐Adrenoceptors are activated by the endogenous agonists (‐)‐adrenaline and (‐)‐noradrenaline. Phenylephrine, methoxa‐mine and cirazoline are agonists and prazosin and cirazoline antagonists considered selective for α1‐ relative to α2‐adrenoceptors. [3H]prazosin and [125I]HEAT(BE2254) are relatively selective radioligands. S(+)‐niguldipine also has high affinity for L‐type Ca2+ channels. Fluorescent derivatives of prazosin(Bodipy PLprazosin‐ QAPB) are used to examine cellular localisation of α1‐adrenoceptors. Selective α1‐adrenoceptor agonists are used as nasal decongestants; antagonists to treat hypertension (doxazosin, prazosin) and benign prostatic hyperplasia (alfuzosin, tamsulosin). The α1‐ and β2‐adrenoceptor antagonist carvedilol is used to treat congestive heart failure, although the contribution of α1‐adrenoceptor blockade to the therapeutic effect is unclear. Several anti‐depressants and anti‐psychotic drugs are α1‐adrenoceptor antagonists contributing to side effects such as orthostatic hypotension and extrapyramidal effects.Nomenclatureα1A‐adrenoceptorα1B‐adrenoceptorα1D‐adrenoceptorHGNC, UniProtADRA1A, P35348ADRA1B, P35368ADRA1D, P25100Endogenous agonists(‐)‐adrenaline [819, 1789], (‐)‐noradrenaline [819, 1789, 1936]–(‐)‐noradrenaline [819, 1789], (‐)‐adrenaline [819, 1789]Agonistsoxymetazoline [819, 1486, 1789, 1936], phenylephrine [1936], methoxamine [1789, 1936]phenylephrine [559, 1345]–Selective agonistsA61603 [559, 1017], dabuzalgron [165]––Antagonistsprazosin (Inverse agonist) (pKi 9–9.9) [303, 405, 559, 1789, 2118], doxazosin (pKi 9.3) [724], terazosin (pKi 8.7) [1323], phentolamine (pKi 8.6) [1789], alfuzosin (pKi 8.1) [787]prazosin (Inverse agonist) (pKi 9.6–9.9) [559, 1789, 2118], tamsulosin (Inverse agonist) (pKi 9.5–9.7) [559, 1789, 2118], doxazosin (pKi 9.1) [724], alfuzosin (pKi 8.6) [788], terazosin (pKi 8.6) [1323], phentolamine (pKi 7.5) [1789]prazosin (Inverse agonist) (pKi 9.5–10.2) [559, 1789, 2118], tamsulosin (pKi 9.8–10.2) [559, 1789, 2118], doxazosin (pKi 9.1) [724], terazosin (pKi 9.1) [1323], alfuzosin (pKi 8.4) [787], dapiprazole (pKi 8.4) [71], phentolamine (Inverse agonist) (pKi 8.2) [1789], RS‐100329 (pKi 7.9) [2118], labetalol (pKi 6.6) [71]Selective antagoniststamsulosin (pKi 10–10.7) [303, 405, 559, 1789, 2118], silodosin (pKi 10.4) [1789], S(+)‐niguldipine (pKi 9.1–10) [559, 1789], RS‐100329 (pKi 9.6) [2118], SNAP5089 (pKi 8.8–9.4) [787, 1147, 2101], ρ‐Da1a (pKi 9.2–9.3) [1298, 1619], RS‐17053 (pKi 9.2–9.3) [303, 405, 556, 559]Rec 15/2615 (pKi 9.5) [1942], L‐765314 (pKi 7.7) [1537], AH 11110 (pKi 7.5) [1724]BMY‐7378 (pKi 8.7–9.1) [280, 2192]Adrenoceptors, α2α2‐Adrenoceptors are activated by (‐)‐adrenaline and with lower potency by (‐)‐noradrenaline. Brimonidine and talipexole are agonists and rauwolscine and yohimbine antagonists selective for α2‐ relative to α1‐adrenoceptors. [3H]rauwolscine, [3H]brimonidine and [3H]RX821002 are relatively selective radioligands. There is species variation in the pharmacology of the α2A‐adrenoceptor. Multiple mutations of α2‐adrenoceptors have been described, some associated with alterations in function. Presynaptic α2‐adrenoceptors regulate many functions in the nervous system. The α2‐adrenoceptor agonists clonidine, guanabenz and brimonidine affect central baroreflex control (hypotension and bradycardia), induce hypnotic effects and analgesia, and modulate seizure activity and platelet aggregation. Clonidine is an anti‐hypertensive and counteracts opioid withdrawal. Dexmedetomidine (also xylazine) is used as a sedative and analgesic in human and veterinary medicine with sympatholytic and anxiolytic properties. The α2‐adrenoceptor antagonist yohimbine has been used to treat erectile dysfunction and mirtazapine as an anti‐depressant. The α2B subtype appears to be involved in neurotransmission in the spinal cord and α2C in regulating catecholamine release from adrenal chromaffin cells.Nomenclatureα2A‐adrenoceptorα2B‐adrenoceptorα2C‐adrenoceptorHGNC, UniProtADRA2A, P08913ADRA2B, P18089ADRA2C, P18825Endogenous agonists(‐)‐adrenaline [896, 1573], (‐)‐noradrenaline [896, 1573](‐)‐noradrenaline (Partial agonist) [896, 1573], (‐)‐adrenaline [896](‐)‐noradrenaline [896, 1573], (‐)‐adrenaline [896]Agonistsdexmedetomidine (Partial agonist) [896, 1228, 1552, 1573], clonidine (Partial agonist) [896, 1552, 1573], brimonidine [896, 1228, 1552, 1573], apraclonidine [1399], guanabenz [71], guanfacine (Partial agonist) [896, 1231]dexmedetomidine [896, 1228, 1552, 1573], clonidine (Partial agonist) [896, 1552, 1573], brimonidine (Partial agonist) [896, 1552, 1573], guanabenz [71], guanfacine [896]dexmedetomidine [896, 1552, 1573], brimonidine (Partial agonist) [896, 1228, 1552, 1573], apraclonidine [1399], guanfacine (Partial agonist) [896], guanabenz [71]Selective agonistsoxymetazoline (Partial agonist) [896, 1228, 1998]––Antagonistsyohimbine (pKi 8.4–9.2) [255, 440, 1998]yohimbine (pKi 7.9–8.9) [255, 440, 1998], phenoxybenzamine (pKi 8.5) [2088], tolazoline (pKi 5.5) [896]yohimbine (pKi 8.5–9.5) [255, 440, 1998], WB 4101 (pKi 8.4–9.4) [255, 440, 1998], spiroxatrine (pKi 9) [1998], mirtazapine (pKi 7.7) [539], tolazoline (pKi 5.4) [896]Selective antagonistsBRL 44408 (pKi 8.2–8.8) [1998, 2194]imiloxan (pKi 7.3) [1329] – RatJP1302 (pKB 7.8) [1704]Labelled ligands––[3H]MK‐912 (Antagonist) (pKd 10.1) [1998]Adrenoceptors, ββ‐Adrenoceptors are activated by the endogenous agonists (‐)‐adrenaline and (‐)‐noradrenaline. Isoprenaline is selective for β‐adrenoceptors relative to α1‐ and α2‐adrenoceptors, while propranolol(pKi 8.2‐9.2) and cyanopindolol(pKi 10.0‐11.0) are relatively β1 and β2 adrenoceptor‐selective antagonists. (‐)‐noradrenaline, xamoterol and (‐)‐Ro 363 show selectivity for β1‐ relative to β2‐adrenoceptors. Pharmacological differences exist between human and mouse β3‐adrenoceptors, and the 'rodent selective' agonists BRL 37344 and CL316243 have low efficacy at the human β3‐adrenoceptor whereas CGP 12177 and L 755507 activate human β3‐adrenoceptors [88]. β3‐Adrenoceptors are resistant to blockade by propranolol, but can be blocked by high concentrations of bupranolol. SR59230A has reasonably high affinity at β3‐adrenoceptors, but does not discriminate well between the three β‐ subtypes whereas L 755507 is more selective. [125I]‐cyanopindolol, [125I]‐hydroxy benzylpindolol and [3H]‐alprenolol are high affinity radioligands that label β1‐ and β2‐ adrenoceptors and β3‐adrenoceptors can be labelled with higher concentrations (nM) of [125I]‐cyanopindolol together with β1‐ and β2‐adrenoceptor antagonists. [3H]‐L‐748337 is a β3‐selective radioligand [2020]. Fluorescent ligands such as BODIPY‐TMR‐CGP12177 can be used to track β‐adrenoceptors at the cellular level [8]. Somewhat selective β1‐adrenoceptor agonists (denopamine, dobutamine) are used short term to treat cardiogenic shock but, chronically, reduce survival. β1‐Adrenoceptor‐preferring antagonists are used to treat hypertension (atenolol, betaxolol, bisoprolol, metoprolol and nebivolol), cardiac arrhythmias (atenolol, bisoprolol, esmolol) and cardiac failure (metoprolol, nebivolol). Cardiac failure is also treated with carvedilol that blocks β1‐ and β2‐adrenoceptors, as well as α1‐adrenoceptors. Short (salbutamol, terbutaline) and long (formoterol, salmeterol) acting β2‐adrenoceptor‐selective agonists are powerful bronchodilators used to treat respiratory disorders. Many first generation β‐adrenoceptor antagonists (propranolol) block both β1‐ and β2‐adrenoceptors and there are no β2‐adrenoceptor‐selective antagonists used therapeutically. The β3‐adrenoceptor agonist mirabegron is used to control overactive bladder syndrome.Nomenclatureβ1‐adrenoceptorβ2‐adrenoceptorβ3‐adrenoceptorHGNC, UniProtADRB1, P08588ADRB2, P07550ADRB3, P13945Potency order of endogenous ligands(‐)‐noradrenaline>(‐)‐adrenaline(‐)‐adrenaline>(‐)‐noradrenaline(‐)‐noradrenaline = (‐)‐adrenalineEndogenous agonists(‐)‐adrenaline [579, 806], (‐)‐noradrenaline [579, 806], noradrenaline [579](‐)‐adrenaline [579, 806, 893], (‐)‐noradrenaline [579, 806](‐)‐noradrenaline [806, 1589, 1880], (‐)‐adrenaline [806]Agonistspindolol (Partial agonist) [1058], isoprenaline [579, 1723], dobutamine (Partial agonist) [870]pindolol (Partial agonist) [1058], arformoterol [37], isoprenaline [1723], dobutamine (Partial agonist) [1166], ephedrine (Partial agonist) [893]carazolol [1318]Selective agonists(‐)‐Ro 363 [1355], xamoterol (Partial agonist) [870], denopamine (Partial agonist) [870, 1903]formoterol [85], salmeterol [85], zinterol [85], vilanterol [1605], procaterol [85], indacaterol [114], fenoterol [59], salbutamol (Partial agonist) [87, 870], terbutaline (Partial agonist) [87], orciprenaline [1853]L 755507 [85], L742791 [2086], mirabegron [1922], CGP 12177 (Partial agonist) [163, 1210, 1318, 1355], SB251023 [850] – Mouse, BRL 37344 [163, 456, 806, 1318], CL316243 [2168]Antagonistscarvedilol (pKi 9.5) [272], bupranolol (pKi 7.3–9) [272, 1210], levobunolol (pKi 8.4) [71], labetalol (pKi 8.2) [71], metoprolol (pKi 7–7.6) [87, 272, 806, 1210], esmolol (pKi 6.9) [71], nadolol (pKi 6.9) [272], practolol (pKi 6.1–6.8) [87, 1210], propafenone (pKi 6.7) [71], sotalol (pKi 6.1) [71]carvedilol (pKi 9.4–9.9) [87, 272], timolol (pKi 9.7) [87], propranolol (pKi 9.1–9.5) [87, 90, 870, 1210], levobunolol (pKi 9.3) [71], bupranolol (pKi 8.3–9.1) [272, 1210], alprenolol (pKi 9) [87], nadolol (pKi 7–8.6) [87, 272], labetalol (pKi 8) [71], propafenone (pKi 7.4) [71], sotalol (pKi 6.5) [71]carvedilol (pKi 9.4) [272], SR59230A (pKi 6.9–8.4) [272, 430, 806], bupranolol (pKi 6.8–7.3) [163, 272, 1210, 1318], propranolol (pKi 6.3–7.2) [1210, 1589], levobunolol (pKi 6.8) [1589]Selective antagonistsCGP 20712A (pKi 8.5–9.2) [87, 272, 1210], levobetaxolol (pKi 9.1) [1785], betaxolol (pKi 8.8) [1210], nebivolol (pIC50 8.1–8.7) [1543] – Rabbit, atenolol (pKi 6.7–7.6) [87, 928, 1210], acebutolol (pKi 6.4) [71]ICI 118551 (Inverse agonist) (pKi 9.2–9.5) [87, 90, 1210]L‐748337 (pKi 8.4) [272], L748328 (pKi 8.4) [272]Labelled ligands[125I]ICYP (Selective Antagonist) (pKd 10.4–11.3) [870, 1210, 1723][125I]ICYP (Antagonist) (pKd 11.1) [1210, 1723][125I]ICYP (Agonist, Partial agonist) [1210, 1355, 1589, 1723, 1880]CommentsThe agonists indicated have less than two orders of magnitude selectivity [85].–Agonist SB251023 has a pEC50 of 6.9 for the splice variant of the mouse β3 receptor, β3b [850].CommentsAdrenoceptors, α1The α1C‐adrenoceptor corresponds to the pharmacologically defined α1A‐adrenoceptor [789]. Some tissues possess α1A‐adrenoceptors (α1L‐adrenoceptors [559, 1382]) that display relatively low affinity in functional and binding assays for prazosin indicative of different receptor states or locations. α1A‐adrenoceptor C‐terminal splice variants form homo‐ and heterodimers, but fail to generate a functional α1L‐adrenoceptor [1628]. α1D‐Adrenoceptors form heterodimers with α1B‐ or β2‐adrenoceptors that show increased cell‐surface expression [1993]. Recombinant α1D‐adrenoceptors have been shown in some heterologous systems to be mainly located intracellularly but cell‐surface localization is encouraged by truncation of the N‐terminus, or by co‐expression of α1B‐ or β2‐adrenoceptors [706, 1993]. In blood vessels all three α1‐adrenoceptor subtypes are located on the surface and intracellularly [1320, 1321]. Signalling is predominantly via Gq/11 but α1‐adrenoceptors also couple to Gi/o, Gs and G12/13. Several α1A‐adrenoceptor agonists display ligand directed signalling bias relative to noradrenaline [521]. There are also differences between subtypes in coupling efficiency to different pathways. In vascular smooth muscle, the potency of agonists is related to the predominant subtype, α1D‐ conveying greater agonist sensitivity than α1A‐adrenoceptors [553].Adrenoceptors, α2ARC‐239 and prazosin show selectivity for α2B‐ and α2C‐adrenoceptors over α2A‐adrenoceptors.Oxymetazoline is a reduced efficacy imidazoline agonist but also binds to non‐GPCR binding sites for imidazolines, classified as I1, I2 and I3sites [406]; catecholamines have a low affinity, while rilmenidine and moxonidine are selective ligands evoking hypotensive effects in vivo. I1‐imidazoline receptors cause central inhibition of sympathetic tone, I2‐imidazoline receptors are an allosteric binding site on monoamine oxidase B, and I3‐imidazoline receptors regulate insulin secretion from pancreatic β‐cells. α2A‐adrenoceptor stimulation reduces insulin secretion from β‐islets [2171], with a polymorphism in the 5'‐UTR of the ADRA2A gene being associated with increased receptor expression in β‐islets and heightened susceptibility to diabetes [1673]. α2A‐ and α2C‐adrenoceptors form homodimers [1829]. Heterodimers between α2A‐ and either the α2c‐adrenoceptor or μ opioid peptide receptor exhibit altered signalling and trafficking properties compared to the individual receptors [1829, 1931, 2036]. Signalling by α2‐adrenoceptors is primarily via Gi/o, although the α2A‐adrenoceptor also couples to Gs[487]. Imidazoline compounds display bias relative to each other at the α2A‐adrenoceptor [1544]. The noradrenaline reuptake inhibitor desipramine acts directly on the α2A‐adrenoceptor to promote internalisation via recruitment of arrestin [385].Adrenoceptors, β[125I]ICYP can be used to define β1‐ or β2‐adrenoceptors when conducted in the presence of a β1‐ or β2‐adrenoceptor‐selective antagonist. A fluorescent analogue of CGP 12177 can be used to study β2‐adrenoceptors in living cells [88]. [125I]ICYP at higher (nM) concentrations can be used to label β3‐adrenoceptors in systems with few if any other β‐adrenoceptor subtypes. The β3‐adrenoceptor has an intron in the coding region, but splice variants have only been described for the mouse [522], where the isoforms display different signalling characteristics [850]. There are 3 β‐adrenoceptors in turkey (termed the tβ, tβ3c and tβ4c) that have a pharmacology that differs from the human β‐adrenoceptors [86]. Numerous polymorphisms have been described for the β‐adrenoceptors; some are associated with signalling and trafficking, altered susceptibility to disease and/or altered responses to pharmacotherapy [1169]. All β‐adrenoceptors couple to Gs(activating adenylyl cyclase and elevating cAMP levels), but also activate Gi and β‐arrestin‐mediated signalling. Many β1‐ and β2‐adrenoceptor antagonists are agonists at β3‐adrenoceptors (CL316243, CGP 12177 and carazolol). Many ‘antagonists’ of cAMP accumulation, for example carvedilol and bucindolol, weakly activate MAP kinase pathways [89, 523, 589, 590, 1721, 1722] and thus display 'protean agonism'. Bupranolol acts as a neutral antagonist in most systems so far examined. Agonists also display biased signalling at the β2‐adrenoceptor via Gs or arrestins [470]. X‐ray crystal structures have been described of the agonist bound [2075] and antagonist bound forms of the β1‐ [2076], agonist‐bound [328] and antagonist‐bound forms of the β2‐adrenoceptor [1632, 1672], as well as a fully active agonist‐bound, Gs protein‐coupled β2‐adrenoceptor [1633]. Carvedilol and bucindolol bind to a site on the β1‐adrenoceptor involving contacts in TM2, 3, and 7 and extracellular loop 2 that may facilitate coupling to arrestins [2076]. Compounds displaying arrestin‐biased signalling at the β2‐adrenoceptor have a greater effect on the conformation of TM7, whereas full agonists for Gs coupling promote movement of TM5 and TM6 [1192]. Recent studies using NMR spectroscopy demonstrate significant conformational flexibility in the β2‐adrenoceptor that is stabilized by both agonist and G proteins highlighting the dynamic nature of interactions with both ligand and downstream signalling partners [992, 1260, 1479]. Such flexibility likely has consequences for our understanding of biased agonism, and for the future therapeutic exploitation of this phenomenon.Further reading on AdrenoceptorsBaker JG et al. (2011) Evolution of β‐blockers: from anti‐anginal drugs to ligand‐directed signalling. Trends Pharmacol. Sci. 32: 227‐34 [PMID:21429598]Bylund DB et al. (1994) International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 46: 121‐136 [PMID:7938162]Evans BA et al. (2010) Ligand‐directed signalling at beta‐adrenoceptors. Br. J. Pharmacol. 159: 1022‐38 [PMID:20132209]Jensen BC et al. (2011) Alpha‐1‐adrenergic receptors: targets for agonist drugs to treat heart failure. J. Mol. Cell. Cardiol. 51: 518‐28 [PMID:21118696]Kobilka BK. (2011) Structural insights into adrenergic receptor function and pharmacology. Trends Pharmacol. Sci. 32: 213‐8 [PMID:21414670]Langer SZ. (2015) α2‐Adrenoceptors in the treatment of major neuropsychiatric disorders. Trends Pharmacol. Sci. 36: 196‐202 [PMID:25771972]Michel MC et al. (2015) Selectivity of pharmacological tools: implications for use in cell physiology. A review in the theme: Cell signaling: proteins, pathways and mechanisms. Am. J. Physiol., Cell Physiol. 308: C505‐20 [PMID:25631871]Angiotensin receptorsOverviewThe actions of angiotensin II (AGT, P01019) (Ang II) are mediated by AT1 and AT2 receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Angiotensin receptors [423, 950]), which have around 30% sequence similarity. The decapeptide angiotensin I (AGT, P01019), the octapeptide angiotensin II(AGT, P01019) and the heptapeptide angiotensin III(AGT, P01019) are endogenous ligands. Losartan, candesartan, telmisartan, etc. are clinically used AT1 receptor blockers.NomenclatureAT1receptorAT2 receptorHGNC, UniProtAGTR1, P30556AGTR2, P50052Endogenous agonistsangiotensin II (AGT, P01019) [425, 2021], angiotensin III (AGT, P01019) [425]angiotensin III (AGT, P01019) [394, 425, 2105], angiotensin II (AGT, P01019) [425, 1838, 2105], angiotensin‐(1‐7) (AGT, P01019) [194]Selective agonistsL‐162,313 [1559]CGP42112 [194], [p‐aminoPhe6]ang II [425, 1860] – RatAntagoniststelmisartan (pIC50 8.4) [1303], olmesartan (pIC50 8.1) [1027]–Selective antagonistscandesartan (pIC50 9.5–9.7) [2021], EXP3174 (pIC50 7.4–9.5) [1965, 2021], eprosartan (pIC50 8.4–8.8) [492], irbesartan (pIC50 8.7–8.8) [2021], losartan (pIC50 7.4–8.7) [425, 1965], valsartan (pIC50 8.6) [424], azilsartan (pIC50 8.1–8.1) [1623, 1917]PD123177 (pIC50 8.5–9.5) [305, 336, 478] – Rat, EMA401 (pIC50 8.5–9.3) [543, 1656, 1836], PD123319 (pKd 8.7–9.2) [425, 477, 2115]Labelled ligands[3H]A81988 (Antagonist) (pKd 9.2) [725] – Rat, [3H]L158809 (Antagonist) (pKd 9.2) [320] – Rat, [3H]eprosartan (Antagonist) (pKd 9.1) [22] – Rat, [3H]valsartan (Antagonist) (pIC50 8.8–9) [2034], [125I]EXP985 (Antagonist) (pKd 8.8) [337] – Rat, [3H]losartan (Antagonist) (pKd 8.2) [309] – Rat[125I]CGP42112 (Agonist) [425, 2105, 2106]Commentstelmisartan and candesartan are also reported to be agonists of PPARγ [1877].–CommentsAT1 receptors are predominantly coupled to Gq/11, however they are also linked to arrestin recruitment and stimulate G protein‐independent arrestin signalling [1221]. Most species express a single AGTR1 gene, but two related agtr1a and agtr1b receptor genes are expressed in rodents. The AT2 receptor counteracts several of the growth responses initiated by the AT1 receptors. The AT2 receptor is much less abundant than the AT1 receptor in adult tissues and is upregulated in pathological conditions. AT1 receptor antagonists bearing substituted 4‐phenylquinoline moieties have been synthesized, which bind to AT1 receptors with nanomolar affinity and are slightly more potent than losartan in functional studies [275]. The antagonist activity of CGP42112 at the AT2 receptor has also been reported [1469]. The AT1 and bradykinin B2 receptors have been proposed to form a heterodimeric complex [3]. There is also evidence for an AT4 receptor that specifically binds angiotensin IV (AGT, P01019) and is located in the brain and kidney. An additional putative endogenous ligand for the AT4 receptor has been described (LVV‐hemorphin(HBB, P68871), a globin decapeptide) [1351]..1Further reading on Angiotensin receptorsde Gasparo M et al. (2000) International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52: 415‐472 [PMID:10977869]Karnik SS et al. (2015) International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. Pharmacol. Rev. 67: 754‐819 [PMID:26315714]Zhang H et al. (2015) Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor. J. Biol. Chem. 290: 29127‐39 [PMID:26420482]Zhang H et al. (2015) Structure of the Angiotensin receptor revealed by serial femtosecond crystallography. Cell 161: 833‐44 [PMID:25913193]Apelin receptorOverviewThe apelin receptor (nomenclature as agreed by the NC‐IUPHAR Subcommittee on the apelin receptor [1582]) responds to apelin, a 36 amino‐acid peptide derived initially from bovine stomach. Apelin‐36(APLN, Q9ULZ1), apelin‐13(APLN, Q9ULZ1) and [Pyr1]apelin‐13(APLN, Q9ULZ1) are the predominant endogenous ligands which are cleaved from a 77 amino‐acid precursor peptide (APLN, Q9ULZ1) by a so far unidentified enzymatic pathway [1938]. A second family of peptides discovered independently and named Elabela [338] or Toddler, that has little sequence similarity to apelin, has been proposed as a second endogenous apelin receptor ligand [1542]. Structure‐activity relationship Elabela analogues have been decsribed [1406].Nomenclatureapelin receptorHGNC, UniProtAPLNR, P35414Potency order of endogenous ligands[Pyr1]apelin‐13 (APLN, Q9ULZ1) ≥apelin‐13 (APLN, Q9ULZ1) >apelin‐36 (APLN, Q9ULZ1) [529, 1938]Endogenous agonistsapelin‐13 (APLN, Q9ULZ1) [529, 824, 1315], apelin receptor early endogenous ligand (APELA, P0DMC3) [436], apelin‐17 (APLN, Q9ULZ1) [496, 1315], [Pyr1]apelin‐13 (APLN, Q9ULZ1) [961, 1315], Elabela/Toddler‐21 (APELA, P0DMC3) [2174], Elabela/Toddler‐32 (APELA, P0DMC3) [2174], apelin‐36 (APLN, Q9ULZ1) [529, 824, 961, 1315], Elabela/Toddler‐11 (APELA, P0DMC3) [2174]Selective agonistsCMF‐019 (Biased agonist) [1639], MM07 (Biased agonist) [209]AntagonistsMM54 (pKi 8.2) [1227]Labelled ligands[125I][Nle75,Tyr77]apelin‐36 (human) (Agonist) [961], [125I][Glp65Nle75,Tyr77]apelin‐13 (Agonist) [824], [125I](Pyr1)apelin‐13 (Agonist) [955], [125I]apelin‐13 (Agonist) [529], [3H](Pyr1)[Met(0)11]‐apelin‐13 (Agonist) [1315]CommentsPotency order determined for heterologously expressed human apelin receptor (pD2 values range from 9.5 to 8.6). The apelin receptor may also act as a co‐receptor with CD4 for isolates of human immunodeficiency virus, with apelin blocking this function [293]. A modified apelin‐13 peptide, apelin‐13(F13A) was reported to block the hypotensive response to apelin in rat in vivo [1132], however, this peptide exhibits agonist activity in HEK293 cells stably expressing the recombinant apelin receptor [529].Further reading on Apelin receptorCheng B et al. (2012) Neuroprotection of apelin and its signaling pathway. Peptides 37: 171‐3 [PMID:22820556]Langelaan DN et al. (2009) Structural insight into G‐protein coupled receptor binding by apelin. Biochemistry 48: 537‐48 [PMID:19123778]O'Carroll AM et al. (2013) The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis. J. Endocrinol. 219: R13‐35 [PMID:23943882]Pitkin SL et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol. Rev. 62: 331‐42 [PMID:20605969]Yang P et al. (2015) Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. Trends Pharmacol. Sci. [PMID:26143239]Bile acid receptorOverviewThe bile acid receptor (GPBA) responds to bile acids produced during the liver metabolism of cholesterol. Selective agonists are promising drugs for the treatment of metabolic disorders, such as type II diabetes, obesity and atherosclerosis.NomenclatureGPBA receptorHGNC, UniProtGPBAR1, Q8TDU6Potency order of endogenous ligandslithocholic acid>deoxycholic acid>chenodeoxycholic acid, cholic acid [960, 1278]Selective agonistsS‐EMCA [1550] – Mouse, betulinic acid [621], oleanolic acid [1720]CommentsThe triterpenoid natural product betulinic acid has also been reported to inhibit inflammatory signalling through the NFκB pathway [1916]. Disruption of GPBA expression is reported to protect from cholesterol gallstone formation [2031]. A new series of 5‐phenoxy‐1,3‐dimethyl‐1H‐pyrazole‐4‐carboxamides have been reported as highly potent agonists [1204].Further reading on Bile acid receptorDuboc H et al. (2014) The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig Liver Dis 46: 302‐12 [PMID:24411485]Lefebvre P et al. (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89: 147‐91 [PMID:19126757]Lieu T et al. (2014) GPBA: a GPCR for bile acids and an emerging therapeutic target for disorders of digestion and sensation. Br. J. Pharmacol. 171: 1156‐66 [PMID:24111923]van Nierop FS et al. (2016) Clinical relevance of the bile acid receptor TGR5 in metabolism. Lancet Diabetes Endocrinol [PMID:27639537]Bombesin receptorsOverviewMammalian bombesin (Bn) receptors comprise 3 subtypes: BB1, BB2, BB3(nomenclature recommended by the NC‐IUPHAR Subcommittee on bombesin receptors, [900]). BB1 and BB2 are activated by the endogenous ligands gastrin‐releasing peptide(GRP, P07492) (GRP), neuromedin B(NMB, P08949) (NMB) and GRP‐(18‐27)(GRP, P07492) (previously named neuromedin C). Bombesin is a tetradecapeptide, originally derived from amphibians. The three Bn receptor subtypes couple primarily to the Gq/11 and G12/13 family of G proteins [900] (but see also [908, 1995]). Each of these receptors is widely distributed in the CNS and peripheral tissues [659, 900, 1590, 1626, 1626, 1715, 1715, 2208]. Activation of BB1 and BB2 receptors causes a wide range of physiological actions, including the stimulation of normal and neoplastic tissue growth, smooth‐muscle contraction, appetite and feeding behavior, secretion and many central nervous system effects [900, 901, 902, 1248, 1371, 1626, 1626]. A physiological role for the BB3 receptor has yet to be fully defined although recently studies using receptor knockout mice and newly described agonists/antagonists suggest an important role in glucose and insulin regulation, metabolic homeostasis, feeding, regulation of body temperature and other CNS behaviors, obesity, diabetes mellitus and growth of normal/neoplastic tissues [659, 1249, 1249, 1496, 1496, 2145].NomenclatureBB1 receptorBB2 receptorBB3 receptorHGNC, UniProtNMBR, P28336GRPR, P30550BRS3, P32247Endogenous agonistsneuromedin B (NMB, P08949) [900, 1626, 1995]neuromedin C [1995], gastrin releasing peptide(14‐27) (human) [1995]–Selective agonists––compound 8a [1194], compound 9g [1284], MK‐7725 [339], MK‐5046 [1375, 1759], [D‐Tyr6,Apa‐4Cl11,Phe13,Nle14]bombesin‐(6‐14) [1263], compound 17c [1283], compound 9f [1284], bag‐1 [692], compound 22e [761], bag‐2 [692]AntagonistsD‐Nal‐Cys‐Tyr‐D‐Trp‐Lys‐Val‐Cys‐Nal‐NH2 (pIC50 6.2–6.6) [658]––Selective antagonistsPD 176252 (pIC50 9.3–9.8) [658], PD 168368 (pIC50 9.3–9.6) [658], dNal‐cyc(Cys‐Tyr‐dTrp‐Orn‐Val)‐Nal‐NH2[D‐Phe6, Leu13, Cpa14,ψ13‐14]bombesin‐(6‐14) (pKi 9.8) [658], JMV641 (pIC50 9.3) [1970] – Mouse, [(3‐Ph‐Pr6), His7,D‐Ala11,D‐Pro13,ψ13‐14),Phe14]bombesin‐(6‐14) (pIC50 9.2) [658, 1125], JMV594 (pIC50 8.9) [1199, 1970] – Mouse, [D‐Tpi6, Leu13ψ(CH2NH)‐Leu14]bombesin‐(6‐14) (pIC50 8.9) [658], Ac‐GRP‐(20‐26)‐methylester (pIC50 8.7) [658]bantag‐1 (pIC50 8.6–8.7) [692, 1375], ML‐18 (pIC50 5.3) [1370]Labelled ligands[125I]BH‐NMB (human, mouse, rat) (Agonist), [125I][Tyr4]bombesin (Agonist)[125I][D‐Tyr6]bombesin‐(6‐13)‐methyl ester (Selective Antagonist) (pKd 9.3) [1262] – Mouse, [125I][Tyr4]bombesin (Agonist) [135], [125I]GRP (human) (Agonist)[3H]bag‐2 (Agonist) [692] – Mouse, [125I][D‐Tyr6,β‐Ala11,Phe13,Nle14]bombesin‐(6‐14) (Agonist) [1264, 1375]CommentsAll three human subtypes may be activated by [D‐Phe6,β‐Ala11,Phe13,Nle14]bombesin‐(6‐14)[1264]. [D‐Tyr6,Apa‐4Cl11,Phe13,Nle14]bombesin‐(6‐14) has more than 200‐fold selectivity for BB3 receptors over BB1 and BB2[1263, 1264, 1626, 1627].Further reading on Bombesin receptorsFerreira CA et al. (2017) Radiolabeled bombesin derivatives for preclinical oncological imaging. Biomed. Pharmacother. 87: 58‐72 [PMID:28040598]González N et al. (2015) Bombesin receptor subtype 3 as a potential target for obesity and diabetes. Expert Opin. Ther. Targets 1‐18 [PMID:26066663]Jensen RT et al. (2008) International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol. Rev. 60: 1‐42 [PMID:18055507]Jensen RT et al. (2013) Bombesin Peptides (Cancer). In Handbook of Biologically Active Peptides. 2nd Revised edition. Edited by Kastin AJ: Elsevier: 506‐511 [ISBN: 9780123850959]Ramos‐Álvarez I et al. (2015) Insights into bombesin receptors and ligands: Highlighting recent advances. Peptides [PMID:25976083]Sayegh AI. (2013) The role of bombesin and bombesin‐related peptides in the short‐term control of food intake. Prog Mol Biol Transl Sci 114: 343‐70 [PMID:23317790]Bradykinin receptorsOverviewBradykinin (or kinin) receptors (nomenclature as agreed by the NC‐IUPHAR subcommittee on Bradykinin (kinin) Receptors [1136]) are activated by the endogenous peptides bradykinin(KNG1, P01042) (BK), [des‐Arg9]bradykinin(KNG1, P01042), Lys‐BK (kallidin(KNG1, P01042)), [des‐Arg10]kallidin(KNG1, P01042), T‐kinin(KNG1, P01042) (Ile‐Ser‐BK), [Hyp3]bradykinin(KNG1, P01042) and Lys‐[Hyp3]‐bradykinin(KNG1, P01042). The variation in affinity or inactivity of B2 receptor antagonists could reflect the existence of species homologues of B2 receptors.NomenclatureB1 receptorB2 receptorHGNC, UniProtBDKRB1, P46663BDKRB2, P30411Potency order of endogenous ligands[des‐Arg10]kallidin (KNG1, P01042) >[des‐Arg9]bradykinin (KNG1, P01042) = kallidin (KNG1, P01042) >bradykinin (KNG1, P01042)kallidin (KNG1, P01042) >bradykinin (KNG1, P01042) ≫[des‐Arg9]bradykinin (KNG1, P01042), [des‐Arg10]kallidin (KNG1, P01042)Endogenous agonists[des‐Arg10]kallidin (KNG1, P01042) [72, 110, 919]–Selective agonists[Sar,D‐Phe8,des‐Arg9]bradykinin [919][Hyp3,Tyr(Me)8]BK, [Phe8,ψ(CH2‐NH)Arg9]BKAntagonists[Leu9,des‐Arg10]kallidin (pKi 9.1–9.3) [72, 110]–Selective antagonistsB‐9958 (pKi 9.2–10.3) [630, 1642], R‐914 (pA2 8.6) [650], R‐715 (pA2 8.5) [651]icatibant (pKi 10.2) [39], FR173657 (pA2 8.2) [1666], anatibant (pKi 8.2) [1608]Labelled ligands[125I]Hpp‐desArg10HOE140 (pKd 10), [3H]Lys‐[des‐Arg9]BK (Agonist), [3H]Lys‐[Leu8][des‐Arg9]BK (Antagonist)[3H]BK (human, mouse, rat) (Agonist) [2123] – Mouse, [3H]NPC17731 (Antagonist) (pKd 9.1–9.4) [2211, 2212], [125I][Tyr8]bradykinin (Agonist)Further reading on Bradykinin receptorsCampos MM et al. (2006) Non‐peptide antagonists for kinin B1 receptors: new insights into their therapeutic potential for the management of inflammation and pain. Trends Pharmacol. Sci. 27: 646‐51 [PMID:17056130]Duchene J et al. (2009) The kinin B(1) receptor and inflammation: new therapeutic target for cardiovascular disease. Curr Opin Pharmacol 9: 125‐31 [PMID:19124274]Marceau F et al. (2004) Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 3: 845‐52 [PMID:15459675]Paquet JL et al. (1999) Pharmacological characterization of the bradykinin B2 receptor: inter‐species variability and dissociation between binding and functional responses. Br. J. Pharmacol. 126: 1083‐90 [PMID:10204994]Thornton E et al. (2010) Kinin receptor antagonists as potential neuroprotective agents in central nervous system injury. Molecules 15: 6598‐618 [PMID:20877247]Calcitonin receptorsOverviewThis receptor family comprises a group of receptors for the calcitonin/CGRP family of peptides. The calcitonin (CT), amylin (AMY), calcitonin gene‐related peptide (CGRP) and adrenomedullin (AM) receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on CGRP, AM, AMY, and CT receptors [755, 1600]) are generated by the genes CALCR (which codes for the CT receptor) and CALCRL(which codes for the calcitonin receptor‐like receptor, CLR, previously known as CRLR). Their function and pharmacology are altered in the presence of RAMPs (receptor activity‐modifying proteins), which are single TM domain proteins of ca. 130 amino acids, identified as a family of three members; RAMP1, RAMP2 and RAMP3. There are splice variants of the CT receptor; these in turn produce variants of the AMY receptor [1600], some of which can be potently activated by CGRP. The endogenous agonists are the peptides calcitonin(CALCA, P01258), α‐CGRP(CALCA, P06881) (formerly known as CGRP‐I), β‐CGRP(CALCB, P10092) (formerly known as CGRP‐II), amylin(IAPP, P10997) (occasionally called islet‐amyloid polypeptide, diabetes‐associated polypeptide), adrenomedullin(ADM, P35318) and adrenomedullin 2/intermedin (ADM2, Q7Z4H4). There are species differences in peptide sequences, particularly for the CTs. CTR‐stimulating peptide {Pig} (CRSP) is another member of the family with selectivity for the CT receptor but it is not expressed in humans [952]. Olcegepant (also known as BIBN4096BS, pKi ˜ 10.5) and telcagepant (also known as MK0974, pKi ˜ 9) are the most selective antagonists available, showing selectivity for CGRP receptors, with a particular preference for those of primate origin.CLR (calcitonin receptor‐like receptor) by itself binds no known endogenous ligand, but in the presence of RAMPs it gives receptors for CGRP, adrenomedullin and adrenomedullin 2/intermedin.NomenclatureCT receptorAMY1 receptorAMY2 receptorAMY3 receptorHGNC, UniProtCALCR, P30988–––Subunits–CT receptor, RAMP1 (Accessory protein)CT receptor, RAMP2 (Accessory protein)CT receptor, RAMP3 (Accessory protein)Potency order of endogenous ligandscalcitonin (salmon)≥calcitonin (CALCA, P01258) ≥amylin (IAPP, P10997), α‐CGRP (CALCA, P06881) >adrenomedullin (ADM, P35318), adrenomedullin 2/intermedin (ADM2, Q7Z4H4)calcitonin (salmon)≥amylin (IAPP, P10997) ≥α‐CGRP (CALCA, P06881) >adrenomedullin 2/intermedin (ADM2, Q7Z4H4) ≥calcitonin (CALCA, P01258) >adrenomedullin (ADM, P35318)Poorly definedcalcitonin (salmon)≥amylin (IAPP, P10997) >α‐CGRP (CALCA, P06881) ≥adrenomedullin 2/intermedin (ADM2, Q7Z4H4) ≥calcitonin (CALCA, P01258) >adrenomedullin (ADM, P35318)Endogenous agonistscalcitonin (CALCA, P01258) [32, 62, 752, 1080, 1153, 1396]α‐CGRP (CALCA, P06881) [752, 1079, 1080, 1153, 2057], amylin (IAPP, P10997) [643]amylin (IAPP, P10997) [643]amylin (IAPP, P10997) [643]Sub/family‐selective agonistspramlintide [643]pramlintide [643]–pramlintide [643]Sub/family‐selective antagonistsCT‐(8‐32) (salmon) (pKd 9) [793], AC187 (pKi 7.2) [752]AC187 (pKi 8) [752], CT‐(8‐32) (salmon) (pKi 7.8) [752], olcegepant (pKd 7.2) [2057]–CT‐(8‐32) (salmon) (pKi 7.9) [752], AC187 (pKi 7.7) [752]Labelled ligands[125I]CT (human) (Agonist), [125I]CT (salmon) (Agonist)[125I]αCGRP (human) (Agonist), [125I]BH‐AMY (rat, mouse) (Agonist)[125I]BH‐AMY (rat,mouse) (Agonist)[125I]BH‐AMY (rat, mouse) (Agonist)Nomenclaturecalcitonin receptor‐like receptorCGRP receptorAM1 receptorAM2 receptorHGNC, UniProtCALCRL, Q16602–––Subunits–calcitonin receptor‐like receptor, RAMP1 (Accessory protein)calcitonin receptor‐like receptor, RAMP2 (Accessory protein)calcitonin receptor‐like receptor, RAMP3 (Accessory protein)Potency order of endogenous ligands–α‐CGRP (CALCA, P06881) >adrenomedullin (ADM, P35318) ≥adrenomedullin 2/intermedin (ADM2, Q7Z4H4) >amylin (IAPP, P10997) ≥calcitonin (salmon)adrenomedullin (ADM, P35318) >adrenomedullin 2/intermedin (ADM2, Q7Z4H4) >α‐CGRP (CALCA, P06881), amylin (IAPP, P10997) >calcitonin (salmon)adrenomedullin (ADM, P35318) ≥adrenomedullin 2/intermedin (ADM2, Q7Z4H4) ≥α‐CGRP (CALCA, P06881) >amylin (IAPP, P10997) >calcitonin (salmon)Endogenous agonists–β‐CGRP (CALCB, P10092) [21, 1313], α‐CGRP (CALCA, P06881) [21, 1313]adrenomedullin (ADM, P35318) [21, 1313]adrenomedullin (ADM, P35318) [21, 568]Antagonists–olcegepant (pKi 10.7–11) [462, 753, 754, 929, 1256], telcagepant (pKi 9.1) [1706]––Sub/family‐selective antagonists––AM‐(22‐52) (human) (pKi 7–7.8) [754]–Labelled ligands–[125I]αCGRP (human) (Agonist), [125I]αCGRP (mouse, rat) (Agonist)[125I]AM (rat) (Agonist)[125I]AM (rat) (Agonist)CommentsIt is important to note that a complication with the interpretation of pharmacological studies with AMY receptors in transfected cells is that most of this work has likely used a mixed population of receptors, encompassing RAMP‐coupled CTR as well as CTR alone. This means that although in binding assays human calcitonin(CALCA, P01258) has low affinity for 125I‐AMY binding sites, cells transfected with CTR and RAMPs can display potent CT functional responses. Transfection of human CTR with any RAMP can generate receptors with a high affinity for both salmon CT and AMY and varying affinity for different antagonists [353, 752, 753]. The major human CTR splice variant (hCT(a), which does not contain an insert) with RAMP1 (i.e. the AMY1(a) receptor) has a high affinity for CGRP [2057], unlike hCT(a)‐RAMP3 (i.e. AMY3(a) receptor) [353, 752]. Actions of CGRP at AMY (and the AM2) receptors led to proposals for a CGRP2 receptor in early literature [755]. However, the AMY receptor phenotype is RAMP‐type, splice variant and cell‐line‐dependent [1376, 1614, 1964].The ligands described have limited selectivity. Adrenomedullin has appreciable affinity for CGRP receptors. CGRP can show significant cross‐reactivity at AMY receptors and AM2 receptors. Adrenomedullin 2/intermedin also has high affinity for the AM2 receptor [818]. CGRP‐(8‐37) acts as an antagonist of CGRP (pKi˜ 8) and inhibits some AM and AMY responses (pKi˜ 6‐7). It is weak at CT receptors. Human AM‐(22‐52) has some selectivity towards AM receptors, but with modest potency (pKi˜ 7), limiting its use [754]. Olcegepant shows the greatest selectivity between receptors but still has significant affinity for AMY1 receptors [2057].Gs is a prominent route for effector coupling for CLR and CTR but other pathways (e.g. Ca2+, ERK, Akt), and G proteins can be activated [2056]. There is evidence that CGRP‐RCP (a 148 amino‐acid hydrophilic protein, ASL(P04424) is important for the coupling of CLR to adenylyl cyclase [524].[125I]‐Salmon CT is the most common radioligand for CT receptors but it has high affinity for AMY receptors and is also poorly reversible. [125I]‐Tyr0‐CGRP is widely used as a radioligand for CGRP receptors.Further reading on Calcitonin receptorsBooe JM et al. (2015) Structural Basis for Receptor Activity‐Modifying Protein‐Dependent Selective Peptide Recognition by a G Protein‐Coupled Receptor. Mol. Cell 58: 1040‐52 [PMID:25982113]Hay DL et al. (2015) Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacol. Rev. 67: 564‐600 [PMID:26071095]Hay DL et al. (2016) Receptor Activity‐Modifying Proteins (RAMPs): New Insights and Roles. Annu. Rev. Pharmacol. Toxicol. 56: 469‐87 [PMID:26514202]Kato J et al. (2015) Bench‐to‐bedside pharmacology of adrenomedullin. Eur. J. Pharmacol. 764: 140‐8 [PMID:26144371]Russell FA et al. (2014) Calcitonin gene‐related peptide: physiology and pathophysiology. Physiol. Rev. 94: 1099‐142 [PMID:25287861]Russo AF. (2015) Calcitonin gene‐related peptide (CGRP): a new target for migraine. Annu. Rev. Pharmacol. Toxicol. 55: 533‐52 [PMID:25340934]Calcium‐sensing receptorOverviewThe calcium‐sensing receptor (CaS, provisional nomenclature as recommended by NC‐IUPHAR[557]) responds to multiple endogenous ligands, including extracellular calcium and other divalent/trivalent cations, polyamines and polycationic peptides, L‐amino acids (particularly L‐Trp and L‐Phe), glutathione and various peptide analogues, ionic strength and extracellular pH (reviewed in [1122]). While divalent/trivalent cations, polyamines and polycations are CaS receptor agonists [234, 1618], L‐amino acids, glutamyl peptides, ionic strength and pH are allosteric modulators of agonist function [375, 557, 803, 1616, 1617]. Indeed, L‐amino acids have been identified as "co‐agonists", with both concomitant calcium and L‐amino acid binding required for full receptor activation [623, 2205]. The sensitivity of the CaS receptor to primary agonists is increased by elevated extracellular pH [270] or decreased extracellular ionic strength [1617]. This receptor bears no sequence or structural relation to the plant calcium receptor, also called CaS.NomenclatureCaS receptorHGNC, UniProtCASR, P41180Amino‐acid rank order of potencyL‐phenylalanine, L‐tryptophan, L‐histidine>L‐alanine>L‐serine, L‐proline, L‐glutamic acid>L‐aspartic acid (not L‐lysine, L‐arginine, L‐leucine and L‐isoleucine) [375]Cation rank order of potencyGd3+>Ca2+>Mg2+ [234]Glutamyl peptide rank order of potencyS‐methylglutathione ≈γGlu‐Val‐Gly > glutathione >γGlu‐Cys [226, 1498, 2068]Polyamine rank order of potencyspermine>spermidine>putrescine [1618]Allosteric modulatorsATF 936 (Negative) (pIC50 8.9) [2109], encaleret (Negative) (pIC50 7.9) [1795], SB‐423562 (Negative) (pIC50 7.1) [1074], ronacaleret (Negative) (pIC50 6.5–6.8) [92], NPS 2143 (Negative) (pKB 6.2–6.7) [418, 1120, 1123], cinacalcet (Positive) (pKB 5.9–6.6) [378, 418, 1120, 1123], tecalcet (Positive) (pKB 6.2–6.6) [378, 418], AC265347 (Positive) (pKB 6.3–6.4) [378, 1120], calhex 231 (Negative) (pIC50 6.4) [1569], calindol (Positive) (pKB 6.3) [378]CommentsThe CaS receptor has a number of physiological functions, but it is best known for its central role in parathyroid and renal regulation of extracellular calcium homeostasis [728]. This is seen most clearly in patients with loss‐of‐function CaS receptor mutations who develop familial hypocalciuric hypercalcaemia (heterozygous mutations) or neonatal severe hyperparathyroidism (heterozygous, compound heterozygous or homozygous mutations) [728] and in Casr null mice [307, 803], which exhibit similar increases in PTH secretion and blood calcium levels. Gain‐of‐function CaS mutations are associated with autosomal dominant hypocalcaemia and Bartter syndrome type V [728].The CaS receptor primarily couples to Gq/11, G12/13 and Gi/o[418, 634, 836, 1954], but in some cell types can couple to Gs[1258]. However, the CaS receptor can form heteromers with Class C GABAB [308, 327] and mGlu1/5 receptors [595], which may introduce further complexity in its signalling capabilities.Multiple other small molecule chemotypes are positive and negative allosteric modulators of the CaS receptor [980, 1441]. Further, etelcalcetide is a novel peptide agonist of the receptor [2059]. Agonists and positive allosteric modulators of the CaS receptor are termed Type I and II calcimimetics, respectively, and can suppress parathyroid hormone (PTH (PTH, P01270)) secretion [1443]. Negative allosteric modulators are called calcilytics and can act to increase PTH (PTH, P01270) secretion [1442].Where functional pKB values are provided for allosteric modulators, this refers to ligand affinity determined in an assay that measures a functional readout of receptor activity (i.e. a receptor signalling assay), as opposed to affinity determined in a radioligand binding assay. The functional pKB may differ depending on the signalling pathway studied. Consult the 'More detailed page' for the assay description, as well as other functional readouts.Further reading on Calcium‐sensing receptorBreitwieser GE. (2012) Minireview: the intimate link between calcium sensing receptor trafficking and signaling: implications for disorders of calcium homeostasis. Mol. Endocrinol. 26: 1482‐95 [PMID:22745192]Brown EM. (2013) Role of the calcium‐sensing receptor in extracellular calcium homeostasis. Best Pract. Res. Clin. Endocrinol. Metab. 27: 333‐43 [PMID:23856263]Conigrave AD et al. (2013) Calcium‐sensing receptor (CaSR): pharmacological properties and signaling pathways. Best Pract. Res. Clin. Endocrinol. Metab. 27: 315‐31 [PMID:23856262]Nemeth EF et al. (2013) Calcimimetic and calcilytic drugs for treating bone and mineral‐related disorders. Best Pract. Res. Clin. Endocrinol. Metab. 27: 373‐84 [PMID:23856266]Cannabinoid receptorsOverviewCannabinoid receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Cannabinoid Receptors [1564]) are activated by endogenous ligands that include N‐arachidonoylethanolamine (anandamide), N‐homo‐γ‐linolenoylethanolamine, N‐docosatetra‐7,10,13,16‐enoylethanolamine and 2‐arachidonoylglycerol. Potency determinations of endogenous agonists at these receptors are complicated by the possibility of differential susceptibility of endogenous ligands to enzymatic conversion [35].There are currently three licenced cannabinoid medicines each of which contains a compound that can activate CB1 and CB2 receptors [1562]. Two of these medicines were developed to suppress nausea and vomiting produced by chemotherapy. These are nabilone (Cesamet®), a synthetic CB1/CB2 receptor agonist, and synthetic Δ9‐tetrahydrocannabinol(Marinol®; dronabinol), which can also be used as an appetite stimulant. The third medicine, Sativex®, contains mainly Δ9‐tetrahydrocannabinol and cannabidiol, both extracted from cannabis, and is used to treat multiple sclerosis and cancer pain.NomenclatureCB1 receptorCB2 receptorHGNC, UniProtCNR1, P21554CNR2, P34972Agonistscannabinol (Partial agonist) [535, 1801]–Sub/family‐selective agonistsHU‐210 [535, 1801], CP55940 [535, 1676, 1801], WIN55212‐2 [535, 1798, 1801], Δ9‐tetrahydrocannabinol (Partial agonist) [535, 1801]HU‐210 [535, 1653, 1801], WIN55212‐2 [535, 1798, 1801], CP55940 [535, 1676, 1801], Δ9‐tetrahydrocannabinol (Partial agonist) [113, 535, 1653, 1801]Selective agonistsarachidonyl‐2‐chloroethylamide [791] – Rat, arachidonylcyclopropylamide [791] – Rat, O‐1812 [443] – Rat, R‐(+)‐methanandamide [976] – RatJWH‐133 [844, 1563], L‐759,633 [607, 1676], AM1241 [2175], L‐759,656 [607, 1676], HU‐308 [734]Selective antagonistsrimonabant (pKi 7.9–8.7) [534, 535, 1660, 1687, 1801], AM251 (pKi 8.1) [1094] – Rat, AM281 (pKi 7.9) [1093] – Rat, LY320135 (pKi 6.9) [534]SR144528 (pKi 8.3–9.2) [1661, 1676], AM‐630 (pKi 7.5) [1676]Allosteric modulatorsGAT100 (Negative) (pEC50 7.7) [1070], ZCZ011 (Positive) (pEC50 6.3) [857] – Mouse, cannabidiol (Negative) [1100]–Labelled ligands[3H]rimonabant (Antagonist) (pKd 8.9–10) [211, 799, 932, 1568, 1662, 1811, 1948] – Rat–CommentsBoth CB1 and CB2 receptors may be labelled with [3H]CP55940(0.5 nM; [1801]) and [3H]WIN55212‐2(2–2.4 nM; [1826, 1852]). Anandamide is also an agonist at vanilloid receptors (TRPV1) and PPARs[1484]. There is evidence for an allosteric site on the CB1 receptor [1603]. All of the compounds listed as antagonists behave as inverse agonists in some bioassay systems [1564]. For some cannabinoid receptor ligands, additional pharmacological targets that include GPR55 and GPR119 have been identified [1564]. Moreover, GPR18, GPR55 and GPR119, although showing little structural similarity to CB1 and CB2receptors, respond to endogenous agents that are structurally similar to the endogenous cannabinoid ligands [1564].Further reading on Cannabinoid receptorsHowlett AC et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54: 161‐202 [PMID:12037135]Pertwee RG. (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem. 17: 1360‐81 [PMID:20166927]Pertwee RG et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol. Rev. 62: 588‐631 [PMID:21079038]Chemerin receptorOverviewThe chemerin receptor (nomenclature as recommended by NC‐IUPHAR[414]) is activated by the lipid‐derived, anti‐inflammatory ligand resolvin E1 (RvE1), which is the result of sequential metabolism of EPA by aspirin‐modified cyclooxygenase and lipoxygenase [60, 61]. In addition, two GPCRs for resolvin D1 (RvD1) have been identified, FPR2/ALX, the lipoxin A4 receptor, and GPR32, an orphan receptor [1052].Nomenclaturechemerin receptorHGNC, UniProtCMKLR1, Q99788Potency order of endogenous ligandsresolvin E1>chemerin C‐terminal peptide>18R‐HEPE>EPA [60]Selective agonistsresolvin E1Labelled ligands[3H]resolvin E1 (Agonist) [60, 61]CommentsCCX832 (structure not disclosed) is a selective antagonist, pKi=9.2 [969].Chemokine receptorsOverviewChemokine receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Chemokine Receptors [81, 1402, 1403]) comprise a large subfamily of 7TM proteins that bind one or more chemokines, a large family of small cytokines typically possessing chemotactic activity for leukocytes. Chemokine receptors can be divided by function into two main groups: G protein‐coupled chemokine receptors, which mediate leukocyte trafficking, and "Atypical chemokine receptors", which may signal through non‐G protein‐coupled mechanisms and act as chemokine scavengers to downregulate inflammation or shape chemokine gradients [81].Chemokines in turn can be divided by structure into four subclasses by the number and arrangement of conserved cysteines. CC (also known as β‐chemokines; n= 28), CXC (also known as α‐chemokines; n= 17) and CX3C (n= 1) chemokines all have four conserved cysteines, with zero, one and three amino acids separating the first two cysteines respectively. C chemokines (n= 2) have only the second and fourth cysteines found in other chemokines. Chemokines can also be classified by function into homeostatic and inflammatory subgroups. Most chemokine receptors are able to bind multiple high‐affinity chemokine ligands, but the ligands for a given receptor are almost always restricted to the same structural subclass. Most chemokines bind to more than one receptor subtype. Receptors for inflammatory chemokines are typically highly promiscuous with regard to ligand specificity, and may lack a selective endogenous ligand. G protein‐coupled chemokine receptors are named acccording to the class of chemokines bound, whereas ACKR is the root acronym for atypical chemokine receptors [82]. Listed are those human agonists with EC50 values <50nM in either Ca2+ flux or chemotaxis assays at human recombinant G protein‐coupled chemokine receptors expressed in mammalian cell lines. There can be substantial cross‐species differences in the sequences of both chemokines and chemokine receptors, and in the pharmacology and biology of chemokine receptors. Endogenous and microbial non‐chemokine ligands have also been identified for chemokine receptors. Many chemokine receptors function as HIV co‐receptors, but CCR5 is the only one demonstrated to play an essential role in HIV/AIDS pathogenesis. The tables include both standard chemokine receptor names [2191] and aliases. Numerical data quoted are typically pKi or pIC50 values from radioligand binding to heterologously expressed receptors.NomenclatureCCR1CCR2CCR3HGNC, UniProtCCR1, P32246CCR2, P41597CCR3, P51677Endogenous agonistsCCL3 (CCL3, P10147) [342, 370, 783, 2228], CCL23 (CCL23, P55773) [342], CCL5 (CCL5, P13501) [370, 783], CCL7 (CCL7, P80098) [342, 703], CCL15 (CCL15, Q16663) [387], CCL14 (CCL14, Q16627) [342], CCL13 (CCL13, Q99616), CCL8 (CCL8, P80075)CCL2 (CCL2, P13500) [387, 1224, 1347, 1533, 1996], CCL13 (CCL13, Q99616) [1224, 1996], CCL7 (CCL7, P80098) [387, 1224, 1996], CCL11 (CCL11, P51671) (Partial agonist) [1224, 1533], CCL16 (CCL16, O15467)CCL13 (CCL13, Q99616) [1385, 1996], CCL24 (CCL24, O00175) [1385, 1533], CCL5 (CCL5, P13501) [409], CCL7 (CCL7, P80098) [409], CCL11 (CCL11, P51671) [480, 1009, 1385, 1700, 1996], CCL26 (CCL26, Q9Y258) [1009, 1385, 1533], CCL15 (CCL15, Q16663) [387], CCL28 (CCL28, Q9NRJ3), CCL8 (CCL8, P80075)Agonists––CCL11 {Mouse} [409]Endogenous antagonistsCCL4 (CCL4, P13236) (pKi 7.1–7.8) [342, 370]CCL26 (CCL26, Q9Y258) (pIC50 8.5) [1533]CXCL10 (CXCL10, P02778), CXCL11 (CXCL11, O14625), CXCL9 (CXCL9, Q07325)Selective antagonistsBX 471 (pKi 8.2–9) [1164], compound 2b‐1 (pIC50 8.7) [1429], UCB35625 (pIC50 8) [1700], CP‐481,715 (pKd 8) [646]GSK Compound 34 (pKi 7.6)banyu (I) (Inverse agonist) (pKi 8.5) [2063], SB328437 (pKi 8.4), BMS compound 87b (pKi 8.1) [2048]Labelled ligands[125I]CCL7 (human) (Agonist) [131], [125I]CCL3 (human) (Agonist) [131, 656, 1719], [125I]CCL5 (human) (Agonist) [1719][125I]CCL2 (human) (Agonist), [125I]CCL7 (human) (Agonist)[125I]CCL11 (human) (Antagonist) (pKd 8.3) [2063], [125I]CCL5 (human) (Agonist), [125I]CCL7 (human) (Agonist)NomenclatureCCR4CCR5CCR6CCR7CCR8CCR9CCR10HGNC, UniProtCCR4, P51679CCR5, P51681CCR6, P51684CCR7, P32248CCR8, P51685CCR9, P51686CCR10, P46092Endogenous agonistsCCL22 (CCL22, O00626) [862], CCL17 (CCL17, Q92583) [862]CCL5 (CCL5, P13501) [78, 1424, 1685], CCL4 (CCL4, P13236) [1424, 1685], CCL8 (CCL8, P80075) [1685], CCL3 (CCL3, P10147) [1424, 1685, 2228], CCL11 (CCL11, P51671) [161], CCL2 (CCL2, P13500) [1424], CCL14 (CCL14, Q16627) [1424], CCL16 (CCL16, O15467)CCL20 (CCL20, P78556) [20, 77, 1598], beta‐defensin 4A (DEFB4ADEFB4B, O15263) [2169]CCL21 (CCL21, O00585) [2189], CCL19 (CCL19, Q99731) [1517, 2188, 2189]CCL1 (CCL1, P22362) [403, 745, 863], CCL8 {Mouse} – MouseCCL25 (CCL25, O15444)CCL27 (CCL27, Q9Y4X3) [816], CCL28 (CCL28, Q9NRJ3)AgonistsvMIP‐IIIR5‐HIV‐1 gp120––vMIP‐I [403, 863]––Endogenous antagonists–CCL7 (CCL7, P80098) (pKi 7.5) [1424]–––––Antagonists–vicriviroc (pKi 9.1) [1879], ancriviroc (pKi 7.8–8.7) [1237, 1523, 1879]–––––Selective antagonistscompound 8ic (pIC50 7.7) [2186], plerixafor (pIC50 6.2) [577]E913 (pIC50 8.7) [1238], aplaviroc (pKi 8.5) [1237], maraviroc (pIC50 8.1) [1424], TAK‐779 (pKi 7.5) [1237], MRK‐1 [1073] – Rat––vMCC‐I (pIC50 9.4) [403]––Selective allosteric modulators–––––vercirnon (Antagonist) (pIC50 8.2) [2060]–Antibodiesmogamulizumab (Inhibition) [54, 1799]––––––Labelled ligands[125I]CCL17(human) (Agonist), [125I]CCL27(human) (Agonist)[125I]CCL4 (human) (Agonist) [1424], [125I]CCL3 (human) (Agonist), [125I]CCL5 (human) (Agonist), [125I]CCL8 (human) (Agonist)[125I]CCL20 (human) (Agonist) [675][125I]CCL19 (human) (Agonist), [125I]CCL21 (human) (Agonist) [899][125I]CCL1 (human) (Agonist) [863, 1671][125I]CCL25 (human) (Agonist)–NomenclatureCXCR1CXCR2CXCR3CXCR4CXCR5CXCR6CX3CR1HGNC, UniProtCXCR1, P25024CXCR2, P25025CXCR3, P49682CXCR4, P61073CXCR5, P32302CXCR6, O00574CX3CR1, P49238Endogenous agonistsCXCL8 (CXCL8, P10145) [145, 711, 1133, 2121, 2137], CXCL6 (CXCL6, P80162) [2141]CXCL1 (CXCL1, P09341) [711, 1133, 2137], CXCL8 (CXCL8, P10145) [145, 711, 1133, 2121, 2137], CXCL7 (PPBP, P02775) [18], CXCL3 (CXCL3, P19876) [18], CXCL2 (CXCL2, P19875) [18], CXCL5 (CXCL5, P42830) [18], CXCL6 (CXCL6, P80162) [2141]CXCL11 (CXCL11, O14625) [768], CXCL10 (CXCL10, P02778) [768, 2093], CXCL9 (CXCL9, Q07325) [768, 2093]CXCL12α (CXCL12, P48061) [782, 1202], CXCL12β (CXCL12, P48061) [782]CXCL13 (CXCL13, O43927) [103]CXCL16 (CXCL16, Q9H2A7) [2116]CX3CL1 (CX3CL1, P78423) [608]AgonistsvCXCL1 [1223], HIV‐1matrix protein p17 [637]vCXCL1 [1223], HIV‐1 matrix protein p17 [637]–––––Selective agonists–––ALX40‐4C (Partial agonist) [2213], X4‐HIV‐1 gp120–––Endogenous antagonists––CCL11 (CCL11, P51671) (pKi 7.2) [2093], CCL7 (CCL7, P80098) (pKi 6.6) [2093]––––Antagonists–––plerixafor (pKi 7) [2213]–––Selective antagonists–navarixin (pIC50 10.3) [81, 484], danirixin (pIC50 7.9) [1343], SB 225002 (pIC50 7.7) [2103], elubirixin (pIC50 7.7) [81], SX‐517 (pIC50 7.2) [1236]–T134 (pIC50 8.4) [1929], X4P‐001 (pIC50 7.9) [1819], HIV‐Tat–––Allosteric modulatorsreparixin (Negative) (pIC50 9) [145]reparixin (Negative) (pIC50 6.4) [145]–––––Labelled ligands[125I]CXCL8 (human) (Agonist) [711, 1658][125I]CXCL8 (human) (Agonist) [711, 1658], [125I]CXCL1 (human) (Agonist), [125I]CXCL5 (human) (Agonist), [125I]CXCL7 (human) (Agonist)[125I]CXCL10 (human) (Agonist), [125I]CXCL11 (human) (Agonist)[125I]CXCL12α(human) (Agonist) [444, 782][125I]CXCL13(mouse) (Agonist) [227] – Mouse[125I]CXCL16(human) (Agonist)[125I]CX3CL1(human) (Agonist)NomenclatureXCR1ACKR1ACKR2ACKR3ACKR4CCRL2HGNC, UniProtXCR1, P46094ACKR1, Q16570ACKR2, O00590ACKR3, P25106ACKR4, Q9NPB9CCRL2, O00421Endogenous ligands–CXCL5 (CXCL5, P42830), CXCL6 (CXCL6, P80162), CXCL8 (CXCL8, P10145), CXCL11 (CXCL11, O14625), CCL2 (CCL2, P13500), CCL5 (CCL5, P13501), CCL7 (CCL7, P80098), CCL11 (CCL11, P51671), CCL14 (CCL14, Q16627), CCL17 (CCL17, Q92583)–––chemerinC‐terminalpeptide, CCL19 (CCL19, Q99731) [101]Endogenous agonistsXCL1 (XCL1, P47992) [564], XCL2 (XCL2, Q9UBD3) [564]–CCL2 (CCL2, P13500), CCL3 (CCL3, P10147), CCL4 (CCL4, P13236), CCL5 (CCL5, P13501), CCL7 (CCL7, P80098), CCL8 (CCL8, P80075), CCL11 (CCL11, P51671), CCL13 (CCL13, Q99616), CCL14 (CCL14, Q16627), CCL17 (CCL17, Q92583), CCL22 (CCL22, O00626)CXCL12α (CXCL12, P48061) [674, 1854], CXCL11 (CXCL11, O14625)CCL19 (CCL19, Q99731) [2085], CCL25 (CCL25, O15444) [2085], CCL21 (CCL21, O00585) [2085]–CommentsXCL1 cannot be iodinated, but a secreted alkaline phophatase (SEAP)‐XCL1 fusion peptide can be used as a probe at XCR1.ACKR1 is used by Plasmodium vivax and Plasmodium knowlsei for entering erythrocytes.–Several lines of evidence have suggested that adrenomedullin is a ligand for ACKR3; however, classical direct binding to the receptor has not yet been convincingly demonstrated.––CommentsSpecific chemokine receptors facilitate cell entry by microbes, such as ACKR1 for Plasmodium vivax, and CCR5 and CXCR4 for HIV‐1. Virally encoded chemokine receptors are known (e.g. US28, a homologue of CCR1 from human cytomegalovirus and ORF74, which encodes a homolog of CXCR2 in Herpesvirus saimiri and gamma‐Herpesvirus‐68), but their role in viral life cycles is not established. Viruses can exploit or subvert the chemokine system by producing chemokine antagonists and scavengers. Two chemokine receptor antagonists have now been approved by the FDA: the CCR5 antagonist maraviroc (Pfizer) for treatment of HIV/AIDS in patients with CCR5‐using strains; and the CXCR4 antagonist plerixafor (Sanofi) for hematopoietic stem cell mobilization with G‐CSF(CSF3, P09919) in patients undergoing transplantation in the context of chemotherapy for Hodgkins' Disease and multiple myeloma.Further reading on Chemokine receptorsBachelerie F et al. (2015) An atypical addition to the chemokine receptor nomenclature: IUPHAR Review "15". Br. J. Pharmacol. [PMID:25958743]Koelink PJ et al. (2012) Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. Pharmacol. Ther. 133: 1‐18 [PMID:21839114]Murphy PM. (2002) International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol. Rev. 54: 227‐9 [PMID:12037138]Murphy PM et al. (2000) International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52: 145‐176 [PMID:10699158]Scholten DJ et al. (2012) Pharmacological modulation of chemokine receptor function. Br. J. Pharmacol. 165: 1617‐43 [PMID:21699506]Cholecystokinin receptorsOverviewCholecystokinin receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on CCK receptors [1471]) are activated by the endogenous peptides cholecystokinin‐8 (CCK‐8(CCK, P06307)), CCK‐33(CCK, P06307), CCK‐58(CCK, P06307) and gastrin (gastrin‐17(GAST, P01350)). There are only two distinct subtypes of CCK receptors, CCK1 and CCK2 receptors [1038, 2073], with some alternatively spliced forms most often identified in neoplastic cells. The CCK receptor subtypes are distinguished by their peptide selectivity, with the CCK1 receptor requiring the carboxyl‐terminal heptapeptide‐amide that includes a sulfated tyrosine for high affinity and potency, while the CCK2 receptor requires only the carboxyl‐terminal tetrapeptide shared by each CCK and gastrin peptides. These receptors have characteristic and distinct distributions, with both present in both the central nervous system and peripheral tissues.NomenclatureCCK1 receptorCCK2 receptorHGNC, UniProtCCKAR, P32238CCKBR, P32239Potency order of endogenous ligandsCCK‐8 (CCK, P06307) ≫gastrin‐17 (GAST, P01350), desulfated cholecystokinin‐8>CCK‐4 (CCK, P06307)CCK‐8 (CCK, P06307) ≥gastrin‐17 (GAST, P01350), desulfated cholecystokinin‐8, CCK‐4 (CCK, P06307)Endogenous agonists–desulfated cholecystokinin‐8 [1135], gastrin‐17 (GAST, P01350) [845] – Mouse, CCK‐4 (CCK, P06307) [871], desulfated gastrin‐14 (GAST, P01350), desulfated gastrin‐17 (GAST, P01350), desulfated gastrin‐34 (GAST, P01350), desulfated gastrin‐71 (GAST, P01350), gastrin‐14 (GAST, P01350), gastrin‐34 (GAST, P01350), gastrin‐71 (GAST, P01350)Selective agonistsA‐71623 [67] – Rat, JMV180 [971], GW‐5823 [772]RB‐400 [129] – Rat, PBC‐264 [886] – RatAntagonistslintitript (pIC50 8.3) [667]–Selective antagonistsdevazepide (pIC50 9.7) [845] – Rat, T‐0632 (pIC50 9.6) [1935] – Rat, PD‐140548 (pIC50 8.6) [1817] – Rat, lorglumide (pIC50 6.7–8.2) [845, 875] – RatYF‐476 (pIC50 9.7) [201, 1927], GV150013 (pIC50 9.4) [2006], L‐740093 (pIC50 9.2) [1464], YM‐022 (pIC50 9.2) [1464], JNJ‐26070109 (pIC50 8.5) [1390], L‐365260 (pIC50 8.4) [1135], RP73870 (pIC50 8) [1181] – Rat, LY262691 (pIC50 7.5) [1632] – RatLabelled ligands[3H]devazepide (Antagonist) (pKd 9.7) [306], [125I]DTyr‐Gly‐[(Nle28,31)CCK‐26‐33 (Agonist) [1599][3H]PD140376 (Antagonist) (pKi 9.7–10) [849] – Guinea pig, [125I]PD142308 (Antagonist) (pKd 9.6) [820] – Guinea pig, [125I]DTyr‐Gly‐[(Nle28,31)CCK‐26‐33 (Agonist) [1599], [125I]gastrin (Agonist), [3H]gastrin (Agonist), [3H]L365260 (Antagonist) (pKd 8.2–8.5) [1464], [125I]‐BDZ2 (Antagonist) (pKi 8.4) [25]CommentsWhile a cancer‐specific CCK receptor has been postulated to exist, which also might be responsive to incompletely processed forms of CCK (Gly‐extended forms), this has never been isolated. An alternatively spliced form of the CCK2 receptor in which intron 4 is retained, adding 69 amino acids to the intracellular loop 3 (ICL3) region, has been described to be present particularly in certain neoplasms where mRNA mis‐splicing has been commonly observed [1833], but it is not clear that this receptor splice form plays a special role in carcinogenesis. Another alternative splicing event for the CCK2 receptor was reported [1850], with alternative donor sites in exon 4 resulting in long (452 amino acids) and short (447 amino acids) forms of the receptor differing by five residues in ICL3, however, no clear functional differences have been observed.Further reading on Cholecystokinin receptorsCawston EE et al. (2010) Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor. Br. J. Pharmacol. 159: 1009‐21 [PMID:19922535]Dockray GJ. (2009) Cholecystokinin and gut‐brain signalling. Regul. Pept. 155: 6‐10 [PMID:19345244]Dufresne M et al. (2006) Cholecystokinin and gastrin receptors. Physiol. Rev. 86: 805‐47 [PMID:16816139]Miller LJ et al. (2008) Structural basis of cholecystokinin receptor binding and regulation. Pharmacol. Ther. 119: 83‐95 [PMID:18558433]Class Frizzled GPCRsOverviewReceptors of the Class Frizzled (FZD, nomenclature as agreed by the NC‐IUPHAR subcommittee on the Class Frizzled GPCRs [1747]), are GPCRs originally identified in Drosophila [300], which are highly conserved across species. While SMO shows structural resemblance to the 10 FZDs, it is functionally separated as it mediates effects in the Hedgehog signaling pathway [1747]. FZDs are activated by WNTs, which are cysteine‐rich lipoglycoproteins with fundamental functions in ontogeny and tissue homeostasis. FZD signalling was initially divided into two pathways, being either dependent on the accumulation of the transcription regulator β‐catenin(CTNNB1, P35222) or being β‐catenin‐independent (often referred to as canonical vs. non‐canonical WNT/FZD signalling, respectively). WNT stimulation of FZDs can, in cooperation with the low density lipoprotein receptors LRP5 (O75197) and LRP6(O75581), lead to the inhibition of a constitutively active destruction complex, which results in the accumulation of β‐catenin and subsequently its translocation to the nucleus. β‐Catenin, in turn, modifies gene transcription by interacting with TCF/LEF transcription factors. β‐Catenin‐independent FZD signalling is far more complex with regard to the diversity of the activated pathways. WNT/FZD signalling can lead to the activation of heterotrimeric G proteins [447], the elevation of intracellular calcium [1828], activation of cGMP‐specific PDE6 [19] and elevation of cAMP as well as RAC‐1, JNK, Rho and Rho kinase signalling [730]. Furthermore, the phosphoprotein Dishevelled constitutes a key player in WNT/FZD signalling. As with other GPCRs, members of the Frizzled family are functionally dependent on the arrestin scaffolding protein for internalization [321], as well as for β‐catenin‐dependent [242] and ‐independent [243, 986] signalling. The pattern of cell signalling is complicated by the presence of additional ligands, which can enhance or inhibit FZD signalling (secreted Frizzled‐related proteins (sFRP), Wnt‐inhibitory factor(WIF1, Q9Y5W5) (WIF), sclerostin(SOST, Q9BQB4) or Dickkopf (DKK)), as well as modulatory (co)‐receptors with Ryk, ROR1, ROR2 and Kremen, which may also function as independent signalling proteins.NomenclatureFZD1FZD2FZD3FZD4FZD5FZD6FZD7HGNC, UniProtFZD1, Q9UP38FZD2, Q14332FZD3, Q9NPG1FZD4, Q9ULV1FZD5, Q13467FZD6, O60353FZD7, O75084NomenclatureFZD8FZD9FZD10SMOHGNC, UniProtFZD8, Q9H461FZD9, O00144FZD10, Q9ULW2SMO, Q99835Antagonists–––saridegib (pIC50 8.9) [1981], glasdegib (pIC50 8.3) [1398], sonidegib (pKi 8.2) [2065]Selective antagonists–––vismodegib (pKi 7.8) [2065]CommentsThere is limited knowledge about WNT/FZD specificity and which molecular entities determine the signalling outcome of a specific WNT/FZD pair. Understanding of the coupling to G proteins is incomplete (see [447]). There is also a scarcity of information on basic pharmacological characteristics of FZDs, such as binding constants, ligand specificity or concentration‐response relationships [984].Ligands associated with FZD signallingWNTs: Wnt‐1(WNT1, P04628), Wnt‐2(WNT2, P09544) (also known as Int‐1‐related protein), Wnt‐2b(WNT2B, Q93097) (also known as WNT‐13), Wnt‐3(WNT3, P56703) , Wnt‐3a(WNT3A, P56704), Wnt‐4(WNT4, P56705), Wnt‐5a(WNT5A, P41221) , Wnt‐5b(WNT5B, Q9H1J7), Wnt‐6(WNT6, Q9Y6F9), Wnt‐7a(WNT7A, O00755), Wnt‐7b(WNT7B, P56706), Wnt‐8a(WNT8A, Q9H1J5), Wnt‐8b(WNT8B, Q93098), Wnt‐9a(WNT9A, O14904) (also known as WNT‐14), Wnt‐9b(WNT9B, O14905) (also known as WNT‐15 or WNT‐14b), Wnt‐10a(WNT10A, Q9GZT5), Wnt‐10b(WNT10B, O00744) (also known as WNT‐12), Wnt‐11(WNT11, O96014) and Wnt‐16(WNT16, Q9UBV4).Extracellular proteins that interact with FZDs: norrin(NDP, Q00604), R‐spondin‐1(RSPO1, Q2MKA7), R‐spondin‐2(RSPO2, Q6UXX9) , R‐spondin‐3(RSPO3, Q9BXY4), R‐spondin‐4(RSPO4, Q2I0M5), sFRP‐1(SFRP1, Q8N474), sFRP‐2(SFRP2, Q96HF1), sFRP‐3(FRZB, Q92765), sFRP‐4(SFRP4, Q6FHJ7), sFRP‐5(SFRP5, Q6FHJ7).Extracellular proteins that interact with WNTs or LRPs: Dickkopf 1(DKK1, O94907), WIF1 (Q9Y5W5), sclerostin(SOST, Q9BQB4), kremen 1(KREMEN1, Q96MU8) and kremen 2 (KREMEN2, Q8NCW0)Small exogenous ligands: Foxy‐5 [1910], Box‐5, UM206 [1086], and XWnt8 (P28026) also known as mini‐Wnt8.Further reading on Class Frizzled GPCRsAngers S et al. (2009) Proximal events in Wnt signal transduction. Nat. Rev. Mol. Cell Biol. 10: 468‐77 [PMID:19536106]Schulte G. (2015) Frizzleds and WNT/β‐catenin signaling–The black box of ligand‐receptor selectivity, complex stoichiometry and activation kinetics. Eur. J. Pharmacol. 763: 191‐5 [PMID:26003275]van Amerongen R. (2012) Alternative Wnt pathways and receptors. Cold Spring Harb Perspect Biol 4: [PMID:22935904]Wang Y et al. (2016) Frizzled Receptors in Development and Disease. Curr. Top. Dev. Biol. 117: 113‐39 [PMID:26969975]Complement peptide receptorsOverviewComplement peptide receptors (nomenclature as agreed by the NC‐IUPHAR subcommittee on Complement peptide receptors [1015]) are activated by the endogenous ˜ 75 amino‐acid anaphylatoxin polypeptides C3a(C3, P01024) and C5a(C5, P01031), generated upon stimulation of the complement cascade.NomenclatureC3a receptorC5a1 receptorC5a2 receptorHGNC, UniProtC3AR1, Q16581C5AR1, P21730C5AR2, Q9P296Potency order of endogenous ligandsC3a (C3, P01024) >C5a (C5, P01031) [41]C5a (C5, P01031), C5a des‐Arg (C5) >C3a (C3, P01024) [41]–Endogenous agonists–ribosomal protein S19 (RPS19, P39019) [2160]–AgonistsE7 [43], compound 17 [1644], compound 21 [1643], Ac‐RHYPLWR [707]N‐methyl‐Phe‐Lys‐Pro‐D‐Cha‐Cha‐D‐Arg‐CO2H [959, 1035]–Selective agonists––P59 (Biased agonist) [396], P32 (Biased agonist) [396]AntagonistsSB290157 (pIC50 7.6) [40], compound 4 (pIC50 5.9) [1643]avacopan (pIC50 9.7) [125], W54011 (pKi 8.7) [1893], DF2593A (pIC50 8.3) [1380], AcPhe‐Orn‐Pro‐D‐Cha‐Trp‐Arg (pIC50 7.9) [2128], N‐methyl‐Phe‐Lys‐Pro‐D‐Cha‐Trp‐D‐Arg‐CO2H (pIC50 7.2) [1035]–Labelled ligands[125I]C3a (human) (Agonist) [310][125I]C5a (human) (Agonist) [843][125I]C5a (human) (Agonist)CommentsSB290157 has also been reported to have agonist properties at the C3a receptor [1282]. The putative chemoattractant receptor termed C5a2 (also known as GPR77, C5L2) binds [125I]C5a with no clear signalling function, but has a putative role opposing inflammatory responses [267, 599, 616]. Binding to this site may be displaced with the rank order C5a des‐Arg(C5)>C5a(C5, P01031) [267, 1508] while there is controversy over the ability of C3a(C3, P01024) and C3a des Arg(C3, P01024) to compete [817, 936, 937, 1508]. C5a2 appears to lack G protein signalling and has been termed a decoy receptor [1753]. However, C5a2 does recruit arrestin after ligand binding, which might provide a signaling pathway for this receptor [94, 2015], and forms heteromers with C5a1. C5a, but not C5a‐des Arg, induces upregulation of heteromer formation between complement C5a receptors C5a1 and C5a2[395]. There are also reports of pro‐inflammatory activity of C5a2, mediated by HMGB1, but the signaling pathway that underlies this is currently unclear (reviewed in [1161]). More recently, work in T cells has shown that C5a1 and C5a2 act in opposition to each other and that altering the equilibrium between the two receptors, by differential expression or production of C5a‐des Arg (which favours C5a2), can affect the final cellular response [57].Further reading on Complement peptide receptorsArbore G et al. (2016) A novel "complement‐metabolism‐inflammasome axis" as a key regulator of immune cell effector function. Eur. J. Immunol. 46: 1563‐73 [PMID:27184294]Klos A et al. (2013) International Union of Pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol. Rev. 65: 500‐43 [PMID:23383423]Li R et al. (2013) C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J. 27: 855‐64 [PMID:23239822]Monk PN et al. (2007) Function, structure and therapeutic potential of complement C5a receptors. Br. J. Pharmacol. 152: 429‐48 [PMID:17603557]Corticotropin‐releasing factor receptorsOverviewCorticotropin‐releasing factor (CRF, nomenclature as agreed by the NC‐IUPHAR subcommittee on Corticotropin‐releasing Factor Receptors [750]) receptors are activated by the endogenous peptides corticotrophin‐releasing hormone (CRH, P06850), a 41 amino‐acid peptide, urocortin 1(UCN, P55089), 40 amino‐acids, urocortin 2 (UCN2, Q96RP3), 38 amino‐acids and urocortin 3 (UCN3, Q969E3), 38 amino‐acids. CRF1 and CRF2 receptors are activated non‐selectively by corticotrophin‐releasing hormone (CRH, P06850) and urocortin 1 (UCN, P55089). Binding to CRF receptors can be conducted using [125I]Tyr0‐CRF or [125I]Tyr0‐sauvagine with Kd values of 0.1‐0.4 nM. CRF1 and CRF2 receptors are non‐selectively antagonized by α‐helical CRF, D‐Phe‐CRF‐(12‐41) and astressin.NomenclatureCRF1 receptorCRF2 receptorHGNC, UniProtCRHR1, P34998CRHR2, Q13324Endogenous agonists–urocortin 2 (UCN2, Q96RP3) [410], urocortin 3 (UCN3, Q969E3) [410]AntagonistsSSR125543A (pKi 8.7) [698]–Selective antagonistsCP 154,526 (pIC50 9.3–10.4) [1218] – Rat, DMP696 (pKi 8.3–9) [760], NBI27914 (pKi 8.3–9) [314], R121919 (pKi 8.3–9) [2227], antalarmin (pKi 8.3–9) [2087], CP376395 (pIC50 8.3) [322] – Rat, CRA1000 (pIC50 6.4–7.1) [298]antisauvagine (pKd 8.8–9.6) [412], K41498 (pKi 9.2) [1105], K31440 (pKi 8.7–8.8) [1697]CommentsA CRF binding protein has been identified (CRHBP, P24387) to which both corticotrophin‐releasing hormone(CRH, P06850) and urocortin 1(UCN, P55089) bind with high affinities, which has been suggested to bind and inactivate circulating corticotrophin‐releasing hormone(CRH, P06850) [1558].Further reading on Corticotropin‐releasing factor receptorsGrammatopoulos DK. (2012) Insights into mechanisms of corticotropin‐releasing hormone receptor signal transduction. Br. J. Pharmacol. 166: 85‐97 [PMID:21883143]Gysling K. (2012) Relevance of both type‐1 and type‐2 corticotropin releasing factor receptors in stress‐induced relapse to cocaine seeking behaviour. Biochem. Pharmacol. 83: 1‐5 [PMID:21843515]Hauger RL et al. (2003) International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin‐releasing factor and their ligands. Pharmacol Rev. 55: 21‐26 [PMID:12615952]Valentino RJ et al. (2013) Sex‐biased stress signaling: the corticotropin‐releasing factor receptor as a model. Mol. Pharmacol. 83: 737‐45 [PMID:23239826]Zhu H et al. (2011) Corticotropin‐releasing factor family and its receptors: pro‐inflammatory or anti‐inflammatory targets in the periphery? Inflamm. Res. 60: 715‐21 [PMID:21476084]Dopamine receptorsOverviewDopamine receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Dopamine Receptors [1748]) are commonly divided into D1‐like (D1 and D5) and D2‐like (D2, D3 and D4) families, where the endogenous agonist is dopamine.NomenclatureD1 receptorD2 receptorHGNC, UniProtDRD1, P21728DRD2, P14416Sub/family‐selective labelled ligands[125I]SCH23982 (Antagonist) (pKd 9.5) [433], [3H]SCH‐23390 (Antagonist) (pKd 9.5) [2221][3H]spiperone (Antagonist) (pKd 10.2) [246, 805, 2219] – RatEndogenous agonistsdopamine [1897, 1962]dopamine [252, 573, 1725]Agonistsfenoldopam [1962]rotigotine [448], cabergoline (Partial agonist) [1337], aripiprazole (Partial agonist) [2199], bromocriptine [573, 1337, 1725], MLS1547 (Biased agonist) [572], ropinirole [766], apomorphine (Partial agonist) [252, 573, 1337, 1725, 1844], pramipexole [1332, 1725], benzquinamide [677]Sub/family‐selective agonistsA68930 [1445], SKF‐38393 (Partial agonist) [1897, 1962]quinpirole [252, 1332, 1539, 1844, 1846, 2019]Selective agonistsSKF‐83959 (Biased agonist) [377], SKF‐81297 [47] – Ratsumanirole [1301]Antagonistsflupentixol (pKi 7–8.4) [1897, 1962]blonanserin (pKi 9.9) [1487], pipotiazine (pKi 9.7) [1845], perphenazine (pKi 8.9–9.6) [1055, 1761], risperidone (pKi 9.4) [64], perospirone (pKi 9.2) [1762], trifluoperazine (pKi 8.9–9) [1055, 1763]Sub/family‐selective antagonistsSCH‐23390 (pKi 7.4–9.5) [1897, 1962], SKF‐83566 (pKi 9.5) [1897], ecopipam (pKi 8.3) [1963]haloperidol (pKi 7.4–8.8) [573, 1230, 1332, 1844, 1963]Selective antagonists–L‐741,626 (pKi 7.9–8.5) [688, 1069], domperidone (pKi 7.9–8.4) [573, 1844], raclopride (pKi 8) [1339], ML321 (pKi 7) [2147, 2148]Labelled ligands–[3H]raclopride (Antagonist) (pKd 8.9) [1081] – RatNomenclatureD3 receptorD4 receptorD5 receptorHGNC, UniProtDRD3, P35462DRD4, P21917DRD5, P21918Sub/family‐selective labelled ligands–[3H]spiperone (Antagonist) (pKd 9.5) [786, 2019][3H]SCH‐23390 (Antagonist) (pKd 9.2) [1654]Endogenous agonistsdopamine [252, 573, 1725, 1846]dopamine [2019]dopamine [1897]Agonistspramipexole [1332, 1725], bromocriptine (Partial agonist) [573, 1337, 1725], ropinirole [766], apomorphine (Partial agonist) [252, 573, 1337, 1725, 1844]apomorphine (Partial agonist) [1337]–Sub/family‐selective agonistsquinpirole [252, 1332, 1339, 1539, 1725, 1844, 1846, 2019]quinpirole [1337, 1539, 2019]A68930 [1445]Selective agonistsPD 128907 [1610, 1725]PD168,077 (Partial agonist) [1040] – Rat, A412997 [1373] – Rat, A412997 [1373]–Antagonistsperospirone (pKi 9.6) [1844], sertindole (pKi 8–8.8) [64, 1746, 1761], prochlorperazine (pKi 8.4) [71], (‐)‐sulpiride (pKi 6.7–7.7) [573, 1844, 1934], loxapine (pKi 7.7) [1761], domperidone (pKi 7.1–7.6) [573, 1844], promazine (pKi 6.8) [253]perospirone (pKi 10.1) [1764], sertindole (pKi 7.8–9.1) [253, 1761, 1763, 1764], sonepiprazole (pKi 8.9) [1739], loxapine (pKi 8.1) [1763]–Sub/family‐selective antagonistshaloperidol (pKi 7.5–8.6) [573, 1782, 1844, 1963]haloperidol (pKi 8.7–8.8) [1088, 1782, 1963]SCH‐23390 (pKi 7.5–9.5) [1897], SKF‐83566 (pKi 9.4) [1897], ecopipam (pKi 8.3) [1897]Selective antagonistsS33084 (pKi 9.6) [1336], nafadotride (pKi 9.5) [1726], PG01037 (pKi 9.2) [689], NGB 2904 (pKi 8.8) [2143], SB 277011‐A (pKi 8) [1641], (+)‐S‐14297 (pKi 6.9–7.9) [1334, 1339]L745870 (pKi 9.4) [1069], A‐381393 (pKi 8.8) [1420], L741742 (pKi 8.5) [1683], ML398 (pKi 7.4) [142]–Selective allosteric modulatorsSB269652 (Negative) (pKi∼9) [588]––Labelled ligands[3H]spiperone (Antagonist) (pKd 9.9) [805, 2219] – Rat, [3H]7‐OH‐DPAT (Agonist) [1655], [3H]PD128907 (Agonist) [27][125I]L750667 (Antagonist) (pKd 9.8) [1539], [3H]NGD941 (Antagonist) (pKd 8.3) [1604][125I]SCH23982 (Antagonist) (pKd 9.1)CommentsThe selectivity of many of these agents is less than two orders of magnitude. [3H]raclopride exhibits similar high affinity for D2 and D3 receptors (low affinity for D4), but has been used to label D2 receptors in the presence of a D3‐selective antagonist. [3H]7‐OH‐DPAT has similar affinity for D2 and D3 receptors, but labels only D3 receptors in the absence of divalent cations. The pharmacological profile of the D5 receptor is similar to, yet distinct from, that of the D1 receptor. The splice variants of the D2 receptor are commonly termed D2S and D2L (short and long). The DRD4 gene encoding the D4 receptor is highly polymorphic in humans, with allelic variations of the protein from amino acid 387 to 515.Further reading on Dopamine receptorsBeaulieu JM et al. (2015) Dopamine receptors ‐ IUPHAR Review 13. Br. J. Pharmacol. 172: 1‐23 [PMID:25671228]Beaulieu JM et al. (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 63: 182‐217 [PMID:21303898]Cumming P. (2011) Absolute abundances and affinity states of dopamine receptors in mammalian brain: A review. Synapse 65: 892‐909 [PMID:21308799]Maggio R et al. (2010) Dopamine D2‐D3 receptor heteromers: pharmacological properties and therapeutic significance. Curr Opin Pharmacol 10: 100‐7 [PMID:19896900]Ptácek R et al. (2011) Dopamine D4 receptor gene DRD4 and its association with psychiatric disorders. Med. Sci. Monit. 17: RA215‐20 [PMID:21873960]Schwartz J‐C et al.. (1998) Dopamine Receptors. In The IUPHAR Compendium of Receptor Characterization and Classification Edited by Girdlestone D: IUPHAR Media: 141‐151Undieh AS. (2010) Pharmacology of signaling induced by dopamine D(1)‐like receptor activation. Pharmacol. Ther. 128: 37‐60 [PMID:20547182]Endothelin receptorsOverviewEndothelin receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Endothelin Receptors [413]) are activated by the endogenous 21 amino‐acid peptides endothelins 1‐3 (endothelin‐1(EDN1, P05305), endothelin‐2(EDN2, P20800) and endothelin‐3(EDN3, P14138)).NomenclatureETA receptorETB receptorHGNC, UniProtEDNRA, P25101EDNRB, P24530Family selective agonists–endothelin‐1 (EDN1, P05305) = endothelin‐2 (EDN2, P20800), endothelin‐3 (EDN3, P14138)Potency order of endogenous ligandsendothelin‐1 (EDN1, P05305) = endothelin‐2 (EDN2, P20800) >endothelin‐3 (EDN3, P14138) [1242]–Selective agonists–sarafotoxin S6c [1062, 1690], BQ 3020 [1650], [Ala1,3,11,15]ET‐1 [1354], IRL 1620 [2078]Sub/family‐selective antagonistsSB209670 (pKB 9.4) [502] – Rat, TAK 044 (pA2 8.4) [2081] – Rat, bosentan (pA2 7.2) [367] – RatSB209670 (pKB 9.4) [502] – Rat, TAK 044 (pA2 8.4) [2081] – Rat, bosentan (pKi 7.1) [1405]Selective antagonistsmacitentan (pIC50 9.3) [177], sitaxsentan (pA2 8) [2135], FR139317 (Inverse agonist) (pIC50 7.3–7.9) [1242], BQ123 (pA2 6.9–7.4) [1242], ambrisentan (pA2 7.1) [178]A192621 (pKd 8.1) [2043], BQ788 (pKd 7.9–8) [1690], IRL 2500 (pKd 7.2) [1690], Ro 46‐8443 (pIC50 7.2) [215]Labelled ligands[125I]PD164333 (Antagonist) (pKd 9.6–9.8) [416], [3H]S0139 (Antagonist) (pKd 9.2), [125I]PD151242 (Antagonist) (pKd 9–9.1) [417], [3H]BQ123 (Antagonist) (pKd 8.5) [858][125I]IRL1620 (Agonist) [1421], [125I]BQ3020 (Agonist) [737, 1354, 1565], [125I][Ala1,3,11,15]ET‐1 (Agonist) [1354]CommentsSplice variants of the ETA receptor have been identified in rat pituitary cells; one of these, ETAR‐C13, appeared to show loss of function with comparable plasma membrane expression to wild type receptor [748]. Subtypes of the ETB receptor have been proposed, although gene disruption studies in mice suggest that only a single gene product exists [1350].Further reading on Endothelin receptorsClozel M et al. (2013) Endothelin receptor antagonists. Handb Exp Pharmacol 218: 199‐227 [PMID:24092342]Davenport AP. (2002) International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol. Rev. 54: 219‐26 [PMID:12037137]Davenport AP et al. (2016) Endothelin. Pharmacol. Rev. 68: 357‐418 [PMID:26956245]Maguire JJ et al. (2014) Endothelin@25 ‐ new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12. Br. J. Pharmacol. 171: 5555‐72 [PMID:25131455]G protein‐coupled estrogen receptorOverviewThe G protein‐coupled estrogen receptor (GPER, nomenclature as agreed by the NC‐IUPHAR Subcommittee on the G protein‐coupled estrogen receptor [1607]) was identified following observations of estrogen‐evoked cyclic AMP signalling in breast cancer cells [65], which mirrored the differential expression of an orphan 7‐transmembrane receptor GPR30 [276]. There are observations of both cell‐surface and intracellular expression of the GPER receptor [1647, 1953].NomenclatureGPERHGNC, UniProtGPER1, Q99527Agonistsraloxifene [1570]Selective agonistsG1 [179]Selective antagonistsG36 (pIC50 6.8–6.9) [438], G15 (pIC50 6.7) [437]Labelled ligands[3H]17β‐estradiol (Agonist) [1953]CommentsAntagonists at the nuclear estrogen receptor, such as fulvestrant, tamoxifen[540] and raloxifene[1570], as well as the flavonoid ‘phytoestrogens’ genistein and quercetin[1241], are agonists at GPER receptors. A complete review of GPER pharmacology has been recently published [1607].Further reading on G protein‐coupled estrogen receptorProssnitz ER et al. (2015) International Union of Basic and Clinical Pharmacology. XCVII. G Protein‐Coupled Estrogen Receptor and Its Pharmacologic Modulators. Pharmacol. Rev. 67: 505‐40 [PMID:26023144]Prossnitz ER et al. (2015) What have we learned about GPER function in physiology and disease from knockout mice? J. Steroid Biochem. Mol. Biol. 153: 114‐26 [PMID:26189910]Formylpeptide receptorsOverviewThe formylpeptide receptors (nomenclature agreed by the NC‐IUPHAR Subcommittee on the formylpeptide receptor family [2180]) respond to exogenous ligands such as the bacterial product fMet‐Leu‐Phe (fMLP) and endogenous ligands such as annexin I(ANXA1, P04083) , cathepsin G(CTSG, P08311), amyloid β42, serum amyloid A and spinorphin, derived from β‐haemoglobin(HBB, P68871).NomenclatureFPR1FPR2/ALXFPR3HGNC, UniProtFPR1, P21462FPR2, P25090FPR3, P25089Potency order of endogenous ligandsfMet‐Leu‐Phe>cathepsin G (CTSG, P08311) >annexin I (ANXA1, P04083) [1118, 1895]LXA4 = aspirin triggered lipoxin A4 = ATLa2 = resolvin D1>LTC4 = LTD4≫15‐deoxy‐LXA4≫fMet‐Leu‐Phe [365, 544, 546, 684, 1919]–Endogenous agonists–LXA4 [1052], resolvin D1 [1052], aspirin‐triggered resolvin D1 [1051], aspirin triggered lipoxin A4F2L (HEBP1, Q9NRV9) [1333]AgonistsfMet‐Leu‐Phe [575, 1802]––Selective agonists–ATLa2 [697]–Endogenous antagonistsspinorphin (pIC50 4.3) [1165, 1404]––Antagonistst‐Boc‐FLFLF (pKi 6–6.5) [2095]––Selective antagonistscyclosporin H (pKi 6.1–7.1) [2095, 2167]WRWWWW (pIC50 6.6) [83], t‐Boc‐FLFLF (pIC50 4.3–6) [574, 1867, 2061]–Labelled ligands[3H]fMet‐Leu‐Phe (Agonist) [1036][3H]LXA4 (Agonist) [544, 545]–CommentsA FITC‐conjugated fMLP analogue has been used for binding to the mouse recombinant receptor [758].––CommentsNote that the data for FPR2/ALX are also reproduced on the leukotriene receptor page.Further reading on Formylpeptide receptorsDorward DA et al. (2015) The Role of Formylated Peptides and Formyl Peptide Receptor 1 in Governing Neutrophil Function during Acute Inflammation. Am. J. Pathol. 185: 1172‐1184 [PMID:25791526]Dufton N et al. (2010) Therapeutic anti‐inflammatory potential of formyl‐peptide receptor agonists. Pharmacol. Ther. 127: 175‐88 [PMID:20546777]Liu M et al. (2012) G protein‐coupled receptor FPR1 as a pharmacologic target in inflammation and human glioblastoma. Int. Immunopharmacol. 14: 283‐8 [PMID:22863814]Rabiet MJ et al. (2011) N‐formyl peptide receptor 3 (FPR3) departs from the homologous FPR2/ALX receptor with regard to the major processes governing chemoattractant receptor regulation, expression at the cell surface, and phosphorylation. J. Biol. Chem. 286: 26718‐31 [PMID:21543323]Yazid S et al. (2012) Anti‐inflammatory drugs, eicosanoids and the annexin A1/FPR2 anti‐inflammatory system. Prostaglandins Other Lipid Mediat. 98: 94‐100 [PMID:22123264]Ye RD et al. (2009) International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol. Rev. 61: 119‐61 [PMID:19498085]Free fatty acid receptorsOverviewFree fatty acid receptors (FFA, nomenclature as agreed by the NC‐IUPHAR Subcommittee on free fatty acid receptors [414, 1876]) are activated by free fatty acids. Long‐chain saturated and unsaturated fatty acids (C14.0 (myristic acid), C16:0 (palmitic acid), C18:1 (oleic acid), C18:2 (linoleic acid), C18:3, (α‐linolenic acid), C20:4 (arachidonic acid), C20:5,n‐3 (EPA) and C22:6,n‐3 (docosahexaenoic acid)) activate FFA1 [223, 872, 1043] and FFA4 receptors [795, 852, 1494], while short chain fatty acids (C2 (acetic acid), C3 (propanoic acid), C4 (butyric acid) and C5 (pentanoic acid)) activate FFA2 [231, 1117, 1465] and FFA3 [231, 1117] receptors. The crystal structure for agonist bound FFA1 has been described [1862].NomenclatureFFA1 receptorFFA2 receptorHGNC, UniProtFFAR1, O14842FFAR2, O15552Endogenous agonistsdocosahexaenoic acid [223, 872], α‐linolenic acid [223, 872, 1043], oleic acid [223, 872, 1043], myristic acid [223, 872, 1043]propanoic acid [231, 1117, 1465, 1741], acetic acid [231, 1117, 1465, 1741], butyric acid [231, 1117, 1465, 1741], trans‐2‐methylcrotonic acid [1741], 1‐methylcyclopropanecarboxylic acid [1741]Selective agonistsAMG‐837 [1176], compound 4 [347], TUG‐770 [346], TUG‐905 [345], GW9508 (Partial agonist) [222], fasiglifam [935, 1434, 1862, 1985]compound 1 [840] – RatSelective antagonistsGW1100 (pIC50 6) [222, 1875]GLPG0974 (pIC50 8.1) [1423, 1584], CATPB (pIC50 6.5) [841]CommentsAntagonist GW1100 is also an oxytocin receptor antagonist [222]. Fasiglifam, TUG‐770 and GW9508 are approximately 100 fold selective for FFA1 over FFA4 [222, 346, 1434]. AMG‐837 and the related analogue AM6331 have been suggested to have an allosteric mechanism of action at FFA1, with respect to the orthosteric fatty acid binding site [1176, 2153].–NomenclatureFFA3 receptorFFA4 receptorGPR42HGNC, UniProtFFAR3, O14843FFAR4, Q5NUL3GPR42, O15529Endogenous agonistspropanoic acid [231, 1117, 1741, 2152], butyric acid [231, 1117, 1741, 2152], 1‐methylcyclopropanecarboxylic acid [1741]α‐linolenic acid [1794], myristic acid [2084], α‐linolenic acid [1932] – Rat, oleic acid [2084]–Agonistsacetic acid [231, 1117, 1741, 2152]––Selective agonists–compound A [1493], TUG‐891 [1794], NCG21 [1902]–CommentsBeta‐hydroxybutyrate has been reported to antagonise FFA3 responses to short chain fatty acids [997]. A range of FFA3 selective molecules with agonist and antagonist properties, but which bind at sites distinct from the short chain fatty acid binding site (i.e. allosteric modulators), have recently been described [180, 839, 1226].A wide range of both saturated and unsaturated fatty acids containing from 6 to 22 carbons have been shown to act as agonists at FFA4 [348] with a small subset listed above. Compound A [PMID 24997608] exhibits more than 1000 fold selectivity [1493], and TUG‐891 50‐1000 fold selectivity for FFA4 over FFA1 [1794], dependent on the assay. NGC21 exhibits approximately 15 fold selectivity for FFA4 over FFA1 [1894].–CommentsShort (361 amino acids) and long (377 amino acids) splice variants of human FFA4 have been reported [1372], which differ by a 16 amino acid insertion in intracellular loop 3, and exhibit differences in intracellular signalling properties in recombinant systems [2084]. The long FFA4 splice variant has not been identified in other primates or rodents to date [795, 1372].GPR42 was originally described as a pseudogene within the family (ENSFM00250000002583), but the discovery of several polymorphisms suggests that some versions of GPR42 may be functional [1167]. GPR84 is a structurally‐unrelated G protein‐coupled receptor which has been found to respond to medium chain fatty acids [2067].Further reading on Free fatty acid receptorsBolognini D et al. (2016) The Pharmacology and Function of Receptors for Short‐Chain Fatty Acids. Mol. Pharmacol. 89: 388‐98 [PMID:26719580]Mancini AD et al. (2013) The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends Endocrinol. Metab. 24: 398‐407 [PMID:23631851]Moniri NH. (2016) Free‐fatty acid receptor‐4 (GPR120): Cellular and molecular function and its role in metabolic disorders. Biochem. Pharmacol. 110‐111: 1‐15 [PMID:26827942]Stoddart LA et al. (2008) International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, ‐2, and ‐3: pharmacology and pathophysiological functions. Pharmacol. Rev. 60: 405‐17 [PMID:19047536]Talukdar S et al. (2011) Targeting GPR120 and other fatty acid‐sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol. Sci. 32: 543‐50 [PMID:21663979]Watterson KR et al. (2014) Treatment of type 2 diabetes by free Fatty Acid receptor agonists. Front Endocrinol (Lausanne) 5: 137 [PMID:25221541]GABAB receptorsOverviewFunctional GABAB receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on GABAB receptors [199, 1579]) are formed from the heterodimerization of two similar 7TM subunits termed GABAB1 and GABAB2[199, 506, 1578, 1579, 2002]. GABAB receptors are widespread in the CNS and regulate both pre‐ and postsynaptic activity. The GABAB1 subunit, when expressed alone, binds both antagonists and agonists, but the affinity of the latter is generally 10‐100‐fold less than for the native receptor. Co‐expression of GABAB1 and GABAB2 subunits allows transport of GABAB1 to the cell surface and generates a functional receptor that can couple to signal transduction pathways such as high‐voltage‐activated Ca2+ channels (Cav2.1, Cav2.2), or inwardly rectifying potassium channels (Kir3) [147, 199, 200]. The GABAB1 subunit harbours the GABA (orthosteric)‐binding site within an extracellular domain (ECD) venus flytrap module (VTM), whereas the GABAB2 subunit mediates G protein‐coupled signalling [199, 622, 624, 1578]. The two subunits interact by direct allosteric coupling [1367], such that GABAB2 increases the affinity of GABAB1 for agonists and reciprocally GABAB1 facilitates the coupling of GABAB2 to G proteins [622, 1060, 1578]. GABAB1 and GABAB2 subunits assemble in a 1:1 stoichiometry by means of a coiled‐coil interaction between α‐helices within their carboxy‐termini that masks an endoplasmic reticulum retention motif (RXRR) within the GABAB1 subunit but other domains of the proteins also contribute to their heteromerization [147, 250, 1578]. Recent evidence indicates that higher order assemblies of GABABreceptor comprising dimers of heterodimers occur in recombinant expression systems and in vivo and that such complexes exhibit negative functional cooperativity between heterodimers [373, 1577]. Adding further complexity, KCTD (potassium channel tetramerization proteins) 8, 12, 12b and 16 associate as tetramers with the carboxy terminus of the GABAB2 subunit to impart altered signalling kinetics and agonist potency to the receptor complex [108, 1751, 1990] and are reviewed by [1580]. The molecular complexity of GABAB receptors is further increased through association with trafficking and effector proteins [Schwenk et al., 2016, Nature Neuroscience 19(2): 233‐42] and reviewed by [1576]. Four isoforms of the human GABAB1 subunit have been cloned. The predominant GABAB1a and GABAB1b isoforms, which are most prevalent in neonatal and adult brain tissue respectively, differ in their ECD sequences as a result of the use of alternative transcription initiation sites. GABAB1a‐containing heterodimers localise to distal axons and mediate inhibition of glutamate release in the CA3‐CA1 terminals, and GABA release onto the layer 5 pyramidal neurons, whereas GABAB1b‐containing receptors occur within dendritic spines and mediate slow postsynaptic inhibition [1613, 2035]. Only the 1a and 1b variants are identified as components of native receptors [199]. Additional GABAB1 subunit isoforms have been described in rodents and humans [1130] and reviewed by [147].NomenclatureGABAB receptorSubunitskctd12b (Accessory protein), KCTD16 (Accessory protein), KCTD12 (Accessory protein), GABAB2, GABAB1, KCTD8 (Accessory protein)AgonistsCGP 44532 [581] – Rat, (‐)‐baclofen [581] – Rat, 3‐APPA [800], baclofen [800, 2130], 3‐APMPA [2130]AntagonistsCGP 62349 (pKi 8.5–8.9) [800, 2130], CGP 55845 (pKi 7.8) [2130], SCH 50911 (pKi 5.5–6) [800, 2130], CGP 35348 (pKi 4.4) [2130], 2‐hydroxy‐saclofen (pIC50 4.1) [957] – RatLabelled ligands[3H]CGP 54626 (Antagonist) (pKi 9.1) [922] – Rat, [3H]CGP 62349 (Antagonist) (pKd 9.1) [964] – Rat, [125I]CGP 64213 (Antagonist) (pKd 9) [594] – Rat, [125I]CGP 71872 (Antagonist) (pKd 9) [957] – Rat, [3H](R)‐(‐)‐baclofen (Agonist)SubunitsNomenclatureGABAB1GABAB2HGNC, UniProtGABBR1, Q9UBS5GABBR2, O75899CommentsPotencies of agonists and antagonists listed in the table, quantified as IC50 values for the inhibition of [3H]CGP27492 binding to rat cerebral cortex membranes, are from [199, 580, 581]. Radioligand KD values relate to binding to rat brain membranes. CGP 71872 is a photoaffinity ligand for the GABAB1 subunit [128]. CGP27492 (3‐APPA), CGP35024 (3‐APMPA) and CGP 44532 act as antagonists at human GABAAρ1 receptors, with potencies in the low micromolar range [580]. In addition to the ligands listed in the table, Ca2+ binds to the VTM of the GABAB1 subunit to act as a positive allosteric modulator of GABA[594]. Synthetic positive allosteric modulators with low, or no, intrinsic activity include CGP7930, GS39783, BHF‐177[2040] and (+)‐BHFF[9, 147, 154, 580]. The site of action of CGP7930 and GS39783 appears to be on the heptahelical domain of the GABAB2 subunit [483, 1578]. In the presence of CGP7930 or GS39783, CGP 35348 and 2‐hydroxy‐saclofen behave as partial agonists [580]. A negative allosteric modulator of GABAB activity has been reported [318]. Knock‐out of the GABAB1 subunit in C57B mice causes the development of severe tonic‐clonic convulsions that prove fatal within a month of birth, whereas GABAB1‐/‐ BALB/c mice, although also displaying spontaneous epileptiform activity, are viable. The phenotype of the latter animals additionally includes hyperalgesia, hyperlocomotion (in a novel, but not familiar, environment), hyperdopaminergia, memory impairment and behaviours indicative of anxiety [510, 2008]. A similar phenotype has been found for GABAB2‐/‐ BALB/c mice [613].Further reading on GABAB receptorsBowery NG et al. (2002) International Union of Pharmacology. XXXIII. Mammalian gamma‐aminobutyricacid(B) receptors: structure and function. Pharmacol Rev. 54: 247‐264 [PMID:12037141]Froestl W. (2011) An historical perspective on GABAergic drugs. Future Med Chem 3: 163‐75 [PMID:21428811]Gassmann M et al. (2012) Regulation of neuronal GABA(B) receptor functions by subunit composition. Nat. Rev. Neurosci. 13: 380‐94 [PMID:22595784]Pin JP et al. (2016) Organization and functions of mGlu and GABAB receptor complexes. Nature 540: 60‐68 [PMID:27905440]Galanin receptorsOverviewGalanin receptors (provisional nomenclature as recommended by NC‐IUPHAR[557]) are activated by the endogenous peptides galanin(GAL, P22466) and galanin‐like peptide(GALP, Q9UBC7). Human galanin(GAL, P22466) is a 30 amino‐acid non‐amidated peptide [525]; in other species, it is 29 amino acids long and C‐terminally amidated. Amino acids 1–14 of galanin are highly conserved in mammals, birds, reptiles, amphibia and fish. Shorter peptide species (e.g. human galanin‐1–19 [143] and porcine galanin‐5–29 [1809]) and N‐terminally extended forms (e.g. N‐terminally seven and nine residue elongated forms of porcine galanin [144, 1809]) have been reported.NomenclatureGAL1 receptorGAL2 receptorGAL3 receptorHGNC, UniProtGALR1, P47211GALR2, O43603GALR3, O60755Potency order of endogenous ligandsgalanin (GAL, P22466) >galanin‐like peptide (GALP, Q9UBC7) [1500]galanin‐like peptide (GALP, Q9UBC7) ≥galanin (GAL, P22466) [1500]galanin‐like peptide (GALP, Q9UBC7) >galanin (GAL, P22466) [1095]Agonists–galanin(2‐29) (rat/mouse) [1526, 2069, 2070, 2071] – Rat–Selective agonists–[D‐Trp2]galanin‐(1‐29) [1834] – Rat–Selective antagonists2,3‐dihydro‐1,4‐dithiin‐1,1,4,4‐tetroxide (pIC50 5.6) [1758]M871 (pKi 7.9) [1848]SNAP 398299 (pKi 8.3) [1033, 1034, 1906], SNAP 37889 (pKi 7.8–7.8) [1033, 1034, 1906]Selective allosteric modulators–CYM2503 (Positive) (pEC50 9.2) [1213] – Rat–Labelled ligands[125I][Tyr26]galanin (human) (Agonist) [552], [125I][Tyr26]galanin (human) (Agonist) [552][125I][Tyr26]galanin (human) (Agonist) [2070] – Rat[125I][Tyr26]galanin (pig) (Agonist) [191, 1835]Comments–The CYM2503 PAM potentiates the anticonvulsant activity of endogenous galanin in mouse seizure models [1213].–Commentsgalanin‐(1‐11) is a high‐affinity agonist at GAL1/GAL2(pKi 9), and galanin(2‐11) is selective for GAL2 and GAL3 compared with GAL1[1212]. [125I]‐[Tyr26]galanin binds to all three subtypes with Kd values generally reported to range from 0.05 to 1 nM, depending on the assay conditions used [552, 1821, 1834, 1835, 2070]. Porcine galanin‐(3‐29) does not bind to cloned GAL1, GAL2 or GAL3 receptors, but a receptor that is functionally activated by porcine galanin‐(3–29) has been reported in pituitary and gastric smooth muscle cells [691, 2142]. Additional galanin receptor subtypes are also suggested from studies with chimeric peptides (e.g. M15, M35 and M40), which act as antagonists in functional assays in the cardiovascular system [2000], spinal cord [2114], locus coeruleus, hippocampus [106] and hypothalamus [107, 1142], but exhibit agonist activity at some peripheral sites [107, 691]. The chimeric peptides M15, M32, M35, M40 and C7 are agonists at GAL1 receptors expressed endogenously in Bowes human melanoma cells [1500], and at heterologously expressed recombinant GAL1, GAL2 and GAL3 receptors [552, 1834, 1835]. Recent studies have described the synthesis of a series of novel, systemically‐active, galanin analogues, with modest preferential binding at the GAL2 receptor. Specific chemical modifications to the galanin backbone increased brain levels of these peptides after i.v. injection and several of these peptides exerted a potent antidepressant‐like effect in mouse models of depression [1698].Further reading on Galanin receptorsFoord SM et al. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. Pharmacol Rev 57: 279‐288 [PMID:15914470]Lang R et al. (2015) Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol. Rev. 67: 118‐75 [PMID:25428932]Lang R et al. (2011) The galanin peptide family in inflammation. Neuropeptides 45: 1‐8 [PMID:21087790]Lawrence C et al. (2011) Galanin‐like peptide (GALP) is a hypothalamic regulator of energy homeostasis and reproduction. Front Neuroendocrinol 32: 1‐9 [PMID:20558195]Webling KE et al. (2012) Galanin receptors and ligands. Front Endocrinol (Lausanne) 3: 146 [PMID:23233848]Ghrelin receptorOverviewThe ghrelin receptor (nomenclature as agreed by the NC‐IUPHAR Subcommittee for the Ghrelin receptor [415]) is activated by a 28 amino‐acid peptide originally isolated from rat stomach, where it is cleaved from a 117 amino‐acid precursor (GHRL, Q9UBU3). The human gene encoding the precursor peptide has 83% sequence homology to rat prepro‐ghrelin, although the mature peptides from rat and human differ by only two amino acids [1285]. Alternative splicing results in the formation of a second peptide, [des‐Gln14]ghrelin(GHRL, Q9UBU3) with equipotent biological activity [822]. A unique post‐translational modification (octanoylation of Ser3, catalysed by ghrelin O‐acyltransferase (MBOAT4, Q96T53) [2170] occurs in both peptides, essential for full activity in binding to ghrelin receptors in the hypothalamus and pituitary, and for the release of growth hormone from the pituitary [1029]. Structure activity studies showed the first five N‐terminal amino acids to be the minimum required for binding [122], and receptor mutagenesis has indicated overlap of the ghrelin binding site with those for small molecule agonists and allosteric modulators of ghrelin(GHRL, Q9UBU3) function [814]. In cell systems, the ghrelin receptor is constitutively active [815], but this is abolished by a naturally occurring mutation (A204E) that results in decreased cell surface receptor expression and is associated with familial short stature [1527].Nomenclatureghrelin receptorHGNC, UniProtGHSR, Q92847Potency order of endogenous ligandsghrelin (GHRL, Q9UBU3) = [des‐Gln14]ghrelin (GHRL, Q9UBU3) [121, 1285]Selective antagonistsGSK1614343 (pIC50 8.4) [1699], GSK1614343 (pKB 8) [1556] – RatLabelled ligands[125I][His9]ghrelin (human) (Agonist) [956], [125I][Tyr4]ghrelin (human) (Agonist) [1394]Comments[des‐octanoyl]ghrelin(GHRL, Q9UBU3) has been shown to bind (as [125I]Tyr4‐des‐octanoyl‐ghrelin) and have effects in the cardiovascular system [121], which raises the possible existence of different receptor subtypes in peripheral tissues and the central nervous system. A potent inverse agonist has been identified ([D‐Arg1,D‐Phe5,D‐Trp7,9,Leu11]substance P, pD2 8.3; [812]). Ulimorelin, described as a ghrelin receptor agonist (pKi 7.8 and pD2 7.5 at human recombinant ghrelin receptors), has been shown to stimulate ghrelin receptor mediated food intake and gastric emptying but not elicit release of growth hormone, or modify ghrelin stimulated growth hormone release, thus pharmacologically discriminating the orexigenic and gastrointestinal actions of ghrelin(GHRL, Q9UBU3) from the release of growth hormone [567]. A number of selective antagonists have been reported, including peptidomimetic [1393] and non‐peptide small molecules including GSK1614343[1556, 1699].Further reading on Ghrelin receptorAndrews ZB. (2011) The extra‐hypothalamic actions of ghrelin on neuronal function. Trends Neurosci. 34: 31‐40 [PMID:21035199]Angelidis G et al. (2010) Current and potential roles of ghrelin in clinical practice. J. Endocrinol. Invest. 33: 823‐38 [PMID:21293171]Briggs DI et al. (2011) Metabolic status regulates ghrelin function on energy homeostasis. Neuroendocrinology 93: 48‐57 [PMID:21124019]Callaghan B et al. (2014) Novel and conventional receptors for ghrelin, desacyl‐ghrelin, and pharmacologically related compounds. Pharmacol. Rev. 66: 984‐1001 [PMID:25107984]Davenport AP et al. (2005) International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol. Rev. 57: 541‐6 [PMID:16382107]Glucagon receptor familyOverviewThe glucagon family of receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on the Glucagon receptor family [1296]) are activated by the endogenous peptide (27‐44 aa) hormones glucagon(GCG, P01275), glucagon‐like peptide 1(GCG, P01275), glucagon‐like peptide 2 (GCG, P01275), glucose‐dependent insulinotropic polypeptide (also known as gastric inhibitory polypeptide(GIP, P09681)), GHRH(GHRH, P01286) and secretin(SCT, P09683). One common precursor (GCG) generates glucagon(GCG, P01275), glucagon‐like peptide 1(GCG, P01275) and glucagon‐like peptide 2(GCG, P01275) peptides [866].NomenclatureGHRH receptorGIP receptorGLP‐1 receptorHGNC, UniProtGHRHR, Q02643GIPR, P48546GLP1R, P43220Endogenous agonists–gastric inhibitory polypeptide (GIP, P09681) [2042]glucagon‐like peptide 1‐(7‐36) amide (GCG, P01275) [927], glucagon‐like peptide 1‐(7‐37) (GCG, P01275) [449]AgonistsJI‐38 [265], sermorelin–liraglutide [1020], lixisenatide [2097], WB4‐24 [528]Selective agonistsBIM28011 [393], tesamorelin–exendin‐4 [1346], exendin‐4 [927], exendin‐3 (P20394) [1635]Selective antagonistsJV‐1‐36 (pKi 10.1–10.4) [1733, 2026, 2027] – Rat, JV‐1‐38 (pKi 10.1) [1733, 2026, 2027] – Rat[Pro3]GIP [615] – Mouseexendin‐(9‐39) (pKi 8.1) [927], GLP‐1‐(9‐36) (pIC50 6.9) [1368] – Rat, T‐0632 (pIC50 4.7) [1961]Labelled ligands[125I]GHRH (human) (Agonist) [196] – Rat[125I]GIP (human) (Agonist) [593] – Rat[125I]GLP‐1‐(7‐36)‐amide (Agonist) [927], [125I]exendin‐(9‐39) (Antagonist) (pKd 8.3) [927], [125I]GLP‐1‐(7‐37) (human) (Agonist)NomenclatureGLP‐2 receptorglucagon receptorsecretin receptorHGNC, UniProtGLP2R, O95838GCGR, P47871SCTR, P47872Endogenous agonistsglucagon‐like peptide 2 (GCG, P01275) [1958]glucagon (GCG, P01275) [1587]secretin (SCT, P09683) [343]Agoniststeduglutide [1310]––Selective antagonists–L‐168,049 (pIC50 8.4) [282], adomeglivant (pKi 8.2) [963, 967], des‐His1‐[Glu9]glucagon‐NH2 (pA2 7.2) [2004, 2005] – Rat, NNC 92‐1687 (pKi 5) [1234], BAY27‐9955 [1566][(CH2NH)4,5]secretin (pKi 5.3) [704]Labelled ligands–[125I]glucagon (human, mouse, rat) (Agonist)[125I](Tyr10)secretin‐27 (rat) (Agonist) [2001] – RatCommentsThe glucagon receptor has been reported to interact with receptor activity modifying proteins (RAMPs), specifically RAMP2, in heterologous expression systems [349], although the physiological significance of this has yet to be established.Further reading on Glucagon receptor familyAhrén B. (2015) Glucagon–Early breakthroughs and recent discoveries. Peptides 67: 74‐81 [PMID:25814364]Campbell JE et al. (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17: 819‐37 [PMID:23684623]Donnelly D. (2012) The structure and function of the glucagon‐like peptide‐1 receptor and its ligands. Br. J. Pharmacol. 166: 27‐41 [PMID:21950636]Kazda CM et al. (2016) Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12‐ and 24‐Week Phase 2 Studies. Diabetes Care 39: 1241‐9 [PMID:26681715]Mayo KE et al. (2003) International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol. Rev. 55: 167‐94 [PMID:12615957]Trujillo JM et al. (2014) GLP‐1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy 34: 1174‐86 [PMID:25382096]Glycoprotein hormone receptorsOverviewGlycoprotein hormone receptors (provisional nomenclature [557]) are activated by a non‐covalent heterodimeric glycoprotein made up of a common α chain (glycoprotein hormone common alpha subunit (CGA, P01215) CGA, P01215), with a unique β chain that confers the biological specificity to FSH(CGAFSHB, P01215P01225), LH(CGALHB, P01215P01229), hCG(CGACGB3, P01215P01233) or TSH(CGATSHB, P01215P01222). There is binding cross‐reactivity across the endogenous agonists for each of the glycoprotein hormone receptors. The deglycosylated hormones appear to exhibit reduced efficacy at these receptors [1701].NomenclatureFSH receptorLH receptorTSH receptorHGNC, UniProtFSHR, P23945LHCGR, P22888TSHR, P16473Potency order of endogenous ligandsFSH (CGAFSHB, P01215P01225)LH (CGALHB, P01215P01229), hCG (CGACGB3, P01215P01233)TSH (CGATSHB, P01215P01222)Endogenous agonistsFSH (CGAFSHB, P01215P01225)hCG (CGACGB3, P01215P01233) [907, 1411], LH (CGALHB, P01215P01229) [907, 1411]TSH (CGATSHB, P01215P01222)Labelled ligands[125I]FSH (human) (Agonist)[125I]LH (Agonist), [125I]chorionic gonadotropin (human) (Agonist)[125I]TSH (human) (Agonist)Further reading on Glycoprotein hormone receptorsJiang X et al. (2012) Structure of follicle‐stimulating hormone in complex with the entire ectodomain of its receptor. Proc. Natl. Acad. Sci. U.S.A. 109: 12491‐6 [PMID:22802634]Kleinau G et al. TSH receptor mutations and disease. Accessed on 2017‐02‐23. Thyroid Disease Manager.Tao YX et al. (2009) Follicle stimulating hormone receptor mutations and reproductive disorders. Prog Mol Biol Transl Sci 89: 115‐31 [PMID:20374735]Troppmann B et al. (2013) Structural and functional plasticity of the luteinizing hormone/choriogonadotrophin receptor. Hum. Reprod. Update 19: 583‐602 [PMID:23686864]Gonadotrophin‐releasing hormone receptorsOverviewGnRH1 and GnRH2 receptors (provisonal nomenclature [557], also called Type I and Type II GnRH receptor, respectively [1342]) have been cloned from numerous species, most of which express two or three types of GnRH receptor [1341, 1342, 1810]. GnRH I (GNRH1, P01148) (p‐Glu‐His‐Trp‐Ser‐Tyr‐Gly‐Leu‐Arg‐Pro‐Gly‐NH2) is a hypothalamic decapeptide also known as luteinizing hormone‐releasing hormone, gonadoliberin, luliberin, gonadorelin or simply as GnRH. It is a member of a family of similar peptides found in many species [1341, 1342, 1810] including GnRH II(GNRH2, O43555) (pGlu‐His‐Trp‐Ser‐His‐Gly‐Trp‐Tyr‐Pro‐Gly‐NH2(which is also known as chicken GnRH‐II). Receptors for three forms of GnRH exist in some species but only GnRH I and GnRH II and their cognate receptors have been found in mammals [1341, 1342, 1810]. GnRH1 receptors are expressed by pituitary gonadotrophs, where they mediate the effects of GnRH on gonadotropin hormone synthesis and secretion that underpin central control of mammalian reproduction. GnRH analogues are used in assisted reproduction and to treat steroid hormone‐dependent conditions [981]. Notably, agonists cause desensitization of GnRH‐stimulated gonadotropin secretion and the consequent reduction in circulating sex steroids is exploited to treat hormone‐dependent cancers of the breast, ovary and prostate [981]. GnRH1 receptors are selectively activated by GnRH I and all lack the COOH‐terminal tails found in other GPCRs. GnRH2 receptors do have COOH‐terminal tails and (where tested) are selective for GnRH II over GnRH I. GnRH2 receptors are expressed by some primates but not by humans [1377]. Phylogenetic classifications divide GnRH receptors into three [1342] or five groups [2117] and highlight examples of gene loss through evolution, with humans retaining only one ancient gene.NomenclatureGnRH1 receptorGnRH2 receptorHGNC, UniProtGNRHR, P30968GNRHR2, Q96P88Potency order of endogenous ligandsGnRH I (GNRH1, P01148) >GnRH II (GNRH2, O43555) [1342]GnRH II (GNRH2, O43555) >GnRH I (GNRH1, P01148) (Monkey) [1340]Endogenous agonistsGnRH I (GNRH1, P01148) [1214], GnRH II (GNRH2, O43555) [550, 1214, 1869]GnRH II (GNRH2, O43555) [1340] – Monkey, GnRH I (GNRH1, P01148) [1340] – MonkeySelective agonistsbuserelin [1432], buserelin [1431], buserelin [1431], triptorelin [118], leuprolide [1881], goserelin, histrelin, nafarelin–Antagonistsiturelix (pKi 9.5) [1664]–Selective antagonistscetrorelix (pKi 9.3–10) [119, 120, 1881], abarelix (pKi 9.1–9.5) [1881], degarelix (pKi 8.8) [2017], ganirelixtrptorelix‐1 [1246] – MonkeyLabelled ligands[125I]cetrorelix (Antagonist) (pKd 9.7) [807], [125I]triptorelin (Agonist) [435] – Rat, [125I]buserelin (Agonist) [1076] – Rat, [125I]GnRH I (human, mouse, rat) (Agonist)–CommentsGnRH1 and GnRH2 receptors couple primarily to Gq/11[686] but coupling to Gs and Gi is evident in some systems [1056, 1076]. GnRH2 receptors may also mediate (heterotrimeric) G protein‐independent signalling to protein kinases [289]. There is increasing evidence for expression of GnRH receptors on hormone‐dependent cancer cells where they can exert antiproliferative and/or proapoptotic effects and mediate effects of cytotoxins conjugated to GnRH analogues [324, 741, 1174, 1732]. In some human cancer cell models GnRH II(GNRH2, O43555) is more potent than GnRH I (GNRH1, P01148), implying mediation by GnRH2 receptors [690], but GnRH2 receptors are not expressed by humans because the human GNRHR2 gene contains a frame shift and internal stop codon [1377]. The possibility remains that this gene generates GnRH2 receptor'related proteins (other than the full‐length receptor) that mediate responses to GnRH II(GNRH2, O43555) (see [1436]). Alternatively, evidence for multiple active GnRH receptor conformations [289, 290, 541, 1293, 1342] raises the possibility that GnRH1 receptor‐mediated proliferation inhibition in hormone‐dependent cancer cells is dependent upon different conformations than effects on Gq/11 in pituitary cells [290, 1293]. Loss‐of‐function mutations in the GnRH1 receptor and deficiency of GnRH I (GNRH1, P01148) are associated with hypogonadotropic hypogonadism although some 'loss of function' mutations may actually prevent trafficking of 'functional' GnRH1 receptors to the cell surface, as evidenced by recovery of function by nonpeptide antagonists [1124]. Human GnRH1 receptors are poorly expressed at the cell surface because of failure to meet structural quality control criteria for endoplasmic reticulum exit [542, 1124], and this increase susceptibility to point mutations that further impair trafficking [542, 1124]. GnRH receptor signalling may require receptor oligomerisation [376, 1054].Further reading on Gonadotrophin‐releasing hormone receptorsLimonta P et al. (2012) GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr. Rev. 33: 784‐811 [PMID:22778172]McArdle CA and Roberson MS.. (2015) Gonadotropes and gonadotropin‐releasing hormone signaling. In Knobil and Neill's Physiology of Reproduction (4th edition). Edited by Plant TM and Zeleznik AJ.: Elsevier Inc.: [ISBN: 9780123971753]Millar RP et al. (2004) Gonadotropin‐releasing hormone receptors. Endocr Rev 25: 235‐275 [PMID:15082521]Tao YX et al. (2014) Chaperoning G protein‐coupled receptors: from cell biology to therapeutics. Endocr. Rev. 35: 602‐47 [PMID:24661201]GPR18, GPR55 and GPR119OverviewGPR18, GPR55 and GPR119 (provisional nomenclature), although showing little structural similarity to CB1 and CB2 cannabinoid receptors, respond to endogenous agents analogous to the endogenous cannabinoid ligands, as well as some natural/synthetic cannabinoid receptor ligands [1564]. Although there are multiple reports to indicate that GPR18, GPR55 and GPR119 can be activated in vitro by N‐arachidonoylglycine, lysophosphatidylinositol and N‐oleoylethanolamide, respectively, there is a lack of evidence for activation by these lipid messengers in vivo. As such, therefore, these receptors retain their orphan status.NomenclatureGPR18GPR55GPR119HGNC, UniProtGPR18, Q14330GPR55, Q9Y2T6GPR119, Q8TDV5Potency order of endogenous ligands––N‐oleoylethanolamide, N‐palmitoylethanolamine>SEA (anandamide is ineffective) [1520]Endogenous agonistsN‐arachidonoylglycine [1026]lysophosphatidylinositol [773, 1502, 1854], 2‐arachidonoylglycerolphosphoinositol [1504]N‐oleoylethanolamide [354, 1520, 1854], N‐palmitoylethanolamine, SEASelective agonists–AM251 [773, 948, 1695]AS1269574 [2190], PSN632408 [1520], PSN375963 [1520]Selective antagonists–CID16020046 (pA2 7.3) [949]–CommentsThe pairing of N‐arachidonoylglycine with GPR18 was not replicated in two studies based on arrestin assays [1854, 2182]. See [414] for discussion.See reviews [414] and [1800].In addition to those shown above, further small molecule agonists have been reported [722].CommentsGPR18 failed to respond to a variety of lipid‐derived agents in an in vitro screen [2182], but has been reported to be activated by Δ9‐tetrahydrocannabinol[1308]. GPR55 responds to AM251 and rimonabant at micromolar concentrations, compared to their nanomolar affinity as CB1 receptor antagonists/inverse agonists [1564]. It has been reported that lysophosphatidylinositol acts at other sites in addition to GPR55 [2164]. N‐Arachidonoylserine has been suggested to act as a low efficacy agonist/antagonist at GPR18 in vitro [1306]. It has also been suggested oleoyl‐lysophosphatidylcholine acts, at least in part, through GPR119 [1466]. Although PSN375963 and PSN632408 produce GPR119‐dependent responses in heterologous expression systems, comparison with N‐oleoylethanolamide‐mediated responses suggests additional mechanisms of action [1466].Further reading on GPR18, GPR55 and GPR119Davenport AP et al. (2013) International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein‐coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol. Rev. 65: 967‐86 [PMID:23686350]Hassing HA et al. (2016) Biased signaling of lipids and allosteric actions of synthetic molecules for GPR119. Biochem Pharmacol 119: 66‐75 [PMID:27569424]Liu B et al. (2015) GPR55: from orphan to metabolic regulator? Pharmacol Ther 145: 35‐42 [PMID:24972076]Pertwee RG et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB_1 and CB_2. Pharmacol. Rev. 62: 588‐631 [PMID:21079038]Histamine receptorsOverviewHistamine receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Histamine Receptors [790, 1528]) are activated by the endogenous ligand histamine. Marked species differences exist between histamine receptor orthologues [790]. The human and rat H3 receptor genes are subject to significant splice variance [91]. The potency order of histamine at histamine receptor subtypes is H3 = H4> H2> H1[1528]. Some agonists at the human H3 receptor display significant ligand bias [1659]. Antagonists of all 4 histamine receptors have clinical uses: H1 antagonists for allergies (e.g. cetirizine), H2 antagonists for acid‐reflux diseases (e.g. ranitidine), H3 antagonists for narcolepsy (e.g. pitolisant/WAKIX; Registered) and H4 antagonists for atopic dermatitis (e.g. ZPL‐3893787; Phase IIa) [1528].NomenclatureH1 receptorH2 receptorH3 receptorH4 receptorHGNC, UniProtHRH1, P35367HRH2, P25021HRH3, Q9Y5N1HRH4, Q9H3N8Selective agonistsmethylhistaprodifen [1766], histaprodifen [1173]amthamine [1048]immethridine [1011], methimepip [1010], MK‐0249 (Inverse agonist) [1413]clobenpropit (Partial agonist) [517, 1173, 1188, 1189, 1389], 4‐methylhistamine [617, 1173], ST‐1006 [1528], VUF 8430 [1172]Antagonistscyproheptadine (pKi 10.2) [1352], promethazine (pKi 9.6) [636], pyrilamine (Inverse agonist) (pKi 8.7–9) [188, 1634], cetirizine (Inverse agonist) (pKi 8.2) [1352], diphenhydramine (pKi 7.9) [188]–iodophenpropit (pKi 8.2–8.7) [2112, 2139]–Sub/family‐selective antagonists––thioperamide (Selective for H3/H4 compared to H1 and H3.) (pKi 7.1–7.7) [368, 516, 517, 1170, 1211, 2112, 2139]thioperamide (Selective for H3/H4 compared to H1 and H3.) (pKi 6.3–7.6) [516, 517, 1188, 1189, 1389, 2226]Selective antagonistsclemastine (pKi 10.3) [71], desloratadine (pKi 9) [1156], triprolidine (pKi 8.5–9) [188, 1352], azelastine (pKi 8.9) [1606], astemizole (pKi 8.5) [1547]tiotidine (pKi 7.5) [149] – Rat, ranitidine (pKi 7.1) [1152], cimetidine (pKi 6.8) [274]pitolisant (pKi 8.1–8.6) [1528, 2254], A331440 (pKi 8.5) [723], conessine (pKi 8.3) [1528], MK‐0249 (pKi 8.2) [1528], ciproxifan (pKi 6.7–7.3) [368, 516, 517, 1170, 1528, 2139]ZPL‐3893787 (pKi 8.3) [1528], INCB‐38579 (pKi 8.3) [1528], JNJ 7777120 (pKi 7.8–8.3) [1173, 1839, 1959], JNJ‐39758979 (pKi 7.9) [1528, 1727]Labelled ligands[3H]pyrilamine (Antagonist, Inverse agonist) (pKd 8.4–9.1) [422, 1352, 1746, 1766], [11C]doxepin (Antagonist) (pKd 9) [869], [11C]pyrilamine (Antagonist, Inverse agonist)[125I]iodoaminopotentidine (Antagonist) (pKd 8.7) [1082] – Rat, [3H]tiotidine (Antagonist) (pKd 7.7–8.7) [1363][123I]iodoproxyfan (Antagonist) (pKd 10.2) [1170], [125I]iodophenpropit (Antagonist) (pKd 9.2) [891] – Rat, [3H](R)‐α‐methylhistamine (Agonist) [1188], N‐[3H]α‐methylhistamine (Agonist) [317] – Mouse[3H]JNJ 7777120 (Antagonist) (pKd 8.4) [1959]Commentshistaprodifen and methylhistaprodifen are reduced efficacy agonists. The H4 receptor appears to exhibit broadly similar pharmacology to the H3 receptor for imidazole‐containing ligands, although (R)‐α‐methylhistamine and N‐α‐methylhistamine are less potent, while clobenpropit acts as a reduced efficacy agonist at the H4 receptor and an antagonist at the H3 receptor [1188, 1419, 1455, 1489, 2226]. Moreover, 4‐methylhistamine is identified as a high affinity, full agonist for the human H4 receptor [1173]. [3H]histamine has been used to label the H4 receptor in heterologous expression systems.Further reading on Histamine receptorsGbahou F et al. (2012) The histamine autoreceptor is a short isoform of the H_3 receptor. Br. J. Pharmacol. 166: 1860‐71 [PMID:22356432]Nieto‐Alamilla G et al. (2016) The Histamine H3 Receptor: Structure, Pharmacology, and Function. Mol. Pharmacol. 90: 649‐673 [PMID:27563055]Panula P et al. (2015) International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. Pharmacol. Rev. 67: 601‐55 [PMID:26084539]van Rijn RM et al. (2008) Cloning and characterization of dominant negative splice variants of the human histamine H4 receptor. Biochem. J. 414: 121‐31 [PMID:18452403]Hydroxycarboxylic acid receptorsOverviewThe hydroxycarboxylic acid family of receptors (ENSFM00500000271913, nomenclature as agreed by the NC‐IUPHAR Subcommittee on Hydroxycarboxylic acid receptors [414, 1491]) respond to organic acids, including the endogenous hydroxy carboxylic acids 3‐hydroxy butyric acid and L‐lactic acid, as well as the lipid lowering agents nicotinic acid (niacin), acipimox and acifran[1842, 1989, 2125]. These receptors were provisionally described as nicotinic acid receptors, although nicotinic acid shows submicromolar potency at HCA2receptors only and is unlikely to be the natural ligand [1989, 2125].NomenclatureHCA1 receptorHCA2 receptorHCA3 receptorHGNC, UniProtHCAR1, Q9BXC0HCAR2, Q8TDS4HCAR3, P49019Potency order of endogenous ligands–β‐D‐hydroxybutyric acid>butyric acid–Endogenous agonistsL‐lactic acid [16, 266, 1190, 1854]β‐D‐hydroxybutyric acid [1912], butyric acid3‐hydroxyoctanoic acid [15]Agonists3,5‐dihydroxybenzoic acid [1187]SCH 900271 [1522], GSK256073 [1861]–Selective agonists–MK 6892 [1788], MK 1903 [166], nicotinic acid [1842, 1989, 2125], acipimox [1842, 2125], monomethylfumarate [1933]compound 6o [1820], IBC 293 [1769]Labelled ligands–[3H]nicotinic acid (Agonist) [1842, 1989, 2125]–CommentsFurther closely‐related GPCRs include the 5‐oxoeicosanoid receptor (OXER1, Q8TDS5) and GPR31(O00270). Lactate activates HCA1 on adipocytes in an autocrine manner. It inhibits lipolysis and thereby promotes anabolic effects. HCA2 and HCA3 regulate adipocyte lipolysis and immune functions under conditions of increased FFA formation through lipolysis (e.g., during fasting). HCA2 agonists acting mainly through the receptor on immune cells exert antiatherogenic and anti‐inflammatory effects. HCA2 is also a receptor for butyrate and mediates some of the beneficial effects of short‐chain fatty acids produced by gut microbiota.Further reading on Hydroxycarboxylic acid receptorsBoatman PD et al. (2008) Nicotinic acid receptor agonists. J. Med. Chem. 51: 7653‐62 [PMID:18983141]Graff EC et al. (2016) Anti‐inflammatory effects of the hydroxycarboxylic acid receptor 2. Metab. Clin. Exp. 65: 102‐13 [PMID:26773933]Kamanna VS et al. (2013) Recent advances in niacin and lipid metabolism. Curr. Opin. Lipidol. 24: 239‐45 [PMID:23619367]Offermanns S. (2017) Hydroxy‐Carboxylic Acid Receptor Actions in Metabolism. Trends Endocrinol. Metab. [PMID:28087125]Offermanns S et al. (2011) International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy‐carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B). Pharmacol. Rev. 63: 269‐90 [PMID:21454438]Offermanns S et al. (2015) Nutritional or pharmacological activation of HCA(2) ameliorates neuroinflammation. Trends Mol Med 21: 245‐55 [PMID:25766751]Kisspeptin receptorOverviewThe kisspeptin receptor (nomenclature as agreed by the NC‐IUPHAR Subcommittee on the kisspeptin receptor [1004]), like neuropeptide FF (NPFF), prolactin‐releasing peptide (PrP) and QRFP receptors (provisional nomenclature) responds to endogenous peptides with an arginine‐phenylalanine‐amide (RFamide) motif. Kisspeptin‐54(KISS1, Q15726) (KP54, originally named metastin), kisspeptin‐13(KISS1, Q15726) (KP13) and kisspeptin‐10(KISS1) (KP10) are biologically‐active peptides cleaved from the KISS1(Q15726) gene product. Kisspeptins have roles in, for example, cancer metastasis, fertility/puberty regulation and glucose homeostasis.Nomenclaturekisspeptin receptorHGNC, UniProtKISS1R, Q969F8Endogenous agonistskisspeptin‐10 (KISS1) [1041, 1501], kisspeptin‐54 (KISS1, Q15726) [1041, 1501], kisspeptin‐14 (KISS1, Q15726) [1041], kisspeptin‐13 (KISS1, Q15726) [1041]Selective agonists4‐fluorobenzoyl‐FGLRW‐NH2 [1973], [dY]1KP‐10 [401] – MouseSelective antagonistspeptide 234 [1674]Labelled ligands[125I]Tyr45‐kisspeptin‐15 (Agonist) [1501], [125I]kisspeptin‐13 (human) (Agonist) [1314], [125I]kisspeptin‐10 (human) (Agonist) [1041], [125I]kisspeptin‐14 (human) (Agonist) [1314]Further reading on Kisspeptin receptorKanda S et al. (2013) Structure, synthesis, and phylogeny of kisspeptin and its receptor. Adv. Exp. Med. Biol. 784: 9‐26 [PMID:23550000]Kirby HR et al. (2010) International Union of Basic and Clinical Pharmacology. LXXVII. Kisspeptin receptor nomenclature, distribution, and function. Pharmacol. Rev. 62: 565‐78 [PMID:21079036]Millar RP et al. (2010) Kisspeptin antagonists: unraveling the role of kisspeptin in reproductive physiology. Brain Res. 1364: 81‐9 [PMID:20858467]Oakley AE et al. (2009) Kisspeptin signaling in the brain. Endocr. Rev. 30: 713‐43 [PMID:19770291]Pasquier J et al. (2014) Molecular evolution of GPCRs: Kisspeptin/kisspeptin receptors. J. Mol. Endocrinol. 52: T101‐17 [PMID:24577719]Leukotriene receptorsOverviewThe leukotriene receptors (nomenclature as agreed by the NC‐IUPHAR subcommittee on Leukotriene Receptors [257, 258]) are activated by the endogenous ligands leukotrienes (LT), synthesized from lipoxygenase metabolism of arachidonic acid. The human BLT1 receptor is the high affinity LTB4 receptor whereas the BLT2 receptor in addition to being a low‐affinity LTB4 receptor also binds several other lipoxygenase‐products, such as 12S‐HETE, 12S‐HPETE, 15S‐HETE, and the thromboxane synthase product 12‐hydroxyheptadecatrienoic acid. The BLT receptors mediate chemotaxis and immunomodulation in several leukocyte populations and are in addition expressed on non‐myeloid cells, such as vascular smooth muscle and endothelial cells. In addition to BLT receptors, LTB4 has been reported to bind to the peroxisome proliferator activated receptor (PPAR) α[1178] and the vanilloid TRPV1 ligand‐gated nonselective cation channel [1307]. The receptors for the cysteinyl‐leukotrienes (i.e. LTC4, LTD4 and LTE4) are termed CysLT1 and CysLT2 and exhibit distinct expression patterns in human tissues, mediating for example smooth muscle cell contraction, regulation of vascular permeability, and leukocyte activation. There is also evidence in the literature for additional CysLT receptor subtypes, derived from functional in vitro studies, radioligand binding and in mice lacking both CysLT1 and CysLT2 receptors [258]. Cysteinyl‐leukotrienes have also been suggested to signal through the P2Y12 receptor [570, 1473, 1534], GPR17 [359] and GPR99 [943].NomenclatureBLT1 receptorBLT2 receptorCysLT1 receptorCysLT2 receptorHGNC, UniProtLTB4R, Q15722LTB4R2, Q9NPC1CYSLTR1, Q9Y271CYSLTR2, Q9NS75Potency order of endogenous ligandsLTB4>20‐hydroxy‐LTB4≫12R‐HETE [2185]12‐hydroxyheptadecatrienoicacid>LTB4>12S‐HETE = 12S‐HPETE>15S‐HETE>12R‐HETE>20‐hydroxy‐LTB4 [1510, 2185]LTD4>LTC4>LTE4 [1222, 1716]LTC4≥LTD4≫LTE4 [767, 1477, 1920]Endogenous agonists–12S‐HETE (Partial agonist) [2185]––Antagonists––ICI198615 (pKi 9.7) [591] – Guinea pigBAYu9773 (pA2 6.8–7.7) [1988] – RatSelective antagonistsBIIL 260 (pKi 8.8) [156, 485], CP105696 (pIC50 8.1) [1803], U75302 (pKi 6.4) [174]LY255283 (pIC50 6–7.1) [780, 2185]zafirlukast (pIC50 8.6–8.7) [1222, 1716], SR2640 (pKi 8.7), montelukast (pIC50 8.3–8.6) [1222, 1716], sulukast (pKi 8.3), pobilukast (pIC50 7.5) [1716]BayCysLT2 (pIC50 6.6–7.3) [1456]Labelled ligands[3H]LTB4 (Agonist) [2184], [3H]CGS23131 (Antagonist) (pKd 7.9) [877][3H]LTB4 (pKd 7.6–9.7)[3H]LTD4 (Agonist), [3H]ICI‐198615 (Antagonist) (pKd 10.6) [1682][3H]LTD4 (Agonist) [767]NomenclatureOXE receptorFPR2/ALXHGNC, UniProtOXER1, Q8TDS5FPR2, P25090Potency order of endogenous ligands5‐oxo‐ETE, 5‐oxo‐C20:3, 5‐oxo‐ODE>5‐oxo‐15‐HETE>5S‐HPETE>5S‐HETE [823, 920, 1538]LXA4 = aspirin triggeredlipoxin A4 = ATLa2 = resolvin D1>LTC4 = LTD4≫15‐deoxy‐LXA4≫fMet‐Leu‐Phe [365, 544, 546, 684, 1919]Endogenous agonists5‐oxo‐ETE [672, 1483, 1538, 1597, 1752]LXA4 [1052], resolvin D1 [1052], aspirin‐triggered resolvinD1 [1051], aspirin triggeredlipoxin A4Selective agonists–ATLa2 [697]Endogenous antagonists5‐oxo‐12‐HETE (pIC50 6.3) [1596]–Selective antagonists–WRWWWW (pIC50 6.6) [83], t‐Boc‐FLFLF (pIC50 4.3–6) [574, 1867, 2061]Labelled ligands[3H]5‐oxo‐ETE (Agonist) [1483][3H]LXA4 (Agonist) [544, 545]CommentsThe FPR2/ALX receptor (nomenclature as agreed by the NC‐IUPHAR subcommittee on Leukotriene and Lipoxin Receptors [258]) is activated by the endogenous lipid‐derived, anti‐inflammatory ligands lipoxin A4(LXA4) and 15‐epi‐LXA4(aspirin triggered lipoxin A4, ATL). The FPR2/ALX receptor also interacts with endogenous peptide and protein ligands, such as MHC binding peptide [330] as well as annexin I (ANXA1, P04083) (ANXA1) and its N‐terminal peptides [379, 1560]. In addition, a soluble hydrolytic product of protease action on the urokinase‐type plasminogen activator receptor has been reported to activate the FPR2/ALX receptor [1646]. Furthermore, FPR2/ALX has been suggested to act as a receptor mediating the proinflammatory actions of the acute‐phase reactant, serum amyloid A [1840, 1883]. The agonist activity of the lipid mediators described has been questioned [732, 1585], which may derive from batch‐to‐batch differences, partial agonism or biased agonism. Recent results from Cooray et al. (2013) [379] have addressed this issue and the role of homodimers and heterodimers in intracellular signaling. A receptor selective for LXB4 has been suggested from functional studies [58, 1232, 1670]. Note that the data for FPR2/ALX are also reproduced on the Formylpeptide receptor pages.Oxoeicosanoid receptors (OXE, nomenclature agreed by the NC‐IUPHAR subcommittee on Oxoeicosanoid Receptors [219]) are activated by endogenous chemotactic eicosanoid ligands oxidised at the C‐5 position, with 5‐oxo‐ETE the most potent agonist identified for this receptor. Initial characterization of the heterologously expressed OXE receptor suggested that polyunsaturated fatty acids, such as docosahexaenoic acid and EPA, acted as receptor antagonists [823].Further reading on Leukotriene receptorsBäck M et al. (2011) International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol. Rev. 63: 539‐84 [PMID:21771892]Bäck M et al. (2014) Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br. J. Pharmacol. 171: 3551‐74 [PMID:24588652]Brink C et al. (2004) International Union of Pharmacology XLIV. Nomenclature for the Oxoeicosanoid Receptor. Pharmacol. Rev. 56: 149‐157 [PMID:15001665]Brink C et al. (2003) International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol. Rev. 55: 195‐227 [PMID:12615958]Lysophospholipid (LPA) receptorsOverviewLysophosphatidic acid (LPA) receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Lysophospholipid Receptors [414, 983]) are activated by the endogenous phospholipid metabolite LPA. The first receptor, LPA1, was identified as ventricular zone gene‐1 (vzg‐1), leading to deorphanisation of members of the endothelial differentiation gene (edg) family as other LPA receptors along with sphingosine 1‐phosphate (S1P) receptors. Additional LPA receptor GPCRs were later identified. Gene names have been codified as LPAR1, etc. to reflect the receptor function of proteins. The crystal structure of LPA1 was recently solved and demonstrates extracellular LPA access to the binding pocket, consistent with proposed delivery via autotaxin. These studies have also implicated cross‐talk with endocannabinoids via phosphorylated intermediates that can also activate these receptors. The identified receptors can account for most, although not all, LPA‐induced phenomena in the literature, indicating that a majority of LPA‐dependent phenomena are receptor‐mediated. Radioligand binding has been conducted in heterologous expression systems using [3H]LPA(e.g. [586]). In native systems, analysis of binding data is complicated by metabolism and high levels of nonspecific binding, and therefore the relationship between recombinant and endogenously expressed receptors is unclear. Targeted deletion of LPA receptors has clarified signalling pathways and identified physiological and pathophysiological roles. Independent validation by multiple groups has been reported in the peer‐reviewed literature for all six LPA receptors described in the tables, including further validation using a distinct read‐out via a novel TGFα"shedding" assay [864]. LPA has also been described as an agonist for the transient receptor potential (Trp) ion channel TRPV1 [1461] and TRPA1 [1012]. In addition, orphan GPCRs (PSP24 [547] and GPR87 [1488]) are proposed as LPA receptors. LPA was originally proposed to be a ligand for GPCR35, but recent data shows that in fact it is a receptor for CXCL17(CXCL17, Q6UXB2) [1266]. Further, the nuclear hormone receptor PPARγ[1309, 1812], has been reported as an LPA receptor. All of these proposed entities require confirmation and are not currently recognized as bona fide LPA receptors.NomenclatureLPA1 receptorLPA2 receptorLPA3 receptorLPA4 receptorLPA5 receptorLPA6 receptorHGNC, UniProtLPAR1, Q92633LPAR2, Q9HBW0LPAR3, Q9UBY5LPAR4, Q99677LPAR5, Q9H1C0LPAR6, P43657Selective agonists–dodecylphosphate [2038], decyl dihydrogen phosphate [2038], GRI977143 [1007]OMPT [744]–––Sub/family‐selective antagonistsKi16425 (pIC50 6.6–6.9) [1499] – Mouse, VPC12249 (pKi 5.2–6.9) [769] – Mouse, VPC32179 [763]–Ki16425 (pKi 6.4) [1499], VPC12249 (pKi 6.4) [769], VPC32179 [763]–––Selective antagonistsBMS‐986020 (pIC50 8.9), AM966 (pIC50 6.7–7.8) [1905], ONO‐7300243 (pIC50 6.8) [1940], AM095 (pIC50 6–6.1) [1905]–dioctanoylglycerolpyrophosphate (pKi 5.5–7) [548, 1499]–TCLPA5 (pIC50 6.1) [1047]–CommentsKi16425[1499], VPC12249[769] and VPC32179[763] have dual antagonist activity at LPA1 and LPA3 receptors. There is growing evidence for in vivo efficacy of these chemical antagonists in several disorders, including fetal hydrocephalus [2197], fetal hypoxia [778], lung fibrosis [1495], systemic sclerosis [1495] and atherosclerosis progression [1053]. Virtual screening experiments have shown H2L5186303 to be a potent antagonist of LPA2[536]. Dodecylphosphate is also an antagonist at LPA3 receptors [2038].Further reading on Lysophospholipid (LPA) receptorsChun J et al. (2010) International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol. Rev. 62: 579‐87 [PMID:21079037]Kihara Y et al. (2014) Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br. J. Pharmacol. 171: 3575‐94 [PMID:24602016]Yung YC et al. (2014) LPA receptor signaling: pharmacology, physiology, and pathophysiology. J. Lipid Res. 55: 1192‐1214 [PMID:24643338]Yung YC et al. (2015) Lysophosphatidic Acid signaling in the nervous system. Neuron 85: 669‐82 [PMID:25695267]Lysophospholipid (S1P) receptorsOverviewSphingosine 1‐phosphate (S1P) receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Lysophospholipid receptors [983]) are activated by the endogenous lipid sphingosine 1‐phosphate (S1P) and with lower apparent affinity, sphingosylphosphorylcholine(SPC). Originally cloned as orphan members of the endothelial differentiation gene (edg) family, deorphanisation as lysophospholipid receptors for S1P was based on sequence homology to LPA receptors. Current gene names have been codified as S1P1R, etc. to reflect the receptor function of these proteins. Most cellular phenomena ascribed to S1P can be explained by receptor‐mediated mechanisms; S1P has also been described to act at intracellular sites [1915], and awaits precise definition. Previously‐proposed SPC (or lysophophosphatidylcholine) receptors‐ G2A, TDAG8, OGR1 and GPR4‐ continue to lack confirmation of these roles [414]. The relationship between recombinant and endogenously expressed receptors is unclear. Radioligand binding has been conducted in heterologous expression systems using [32P]S1P(e.g [1505]). In native systems, analysis of binding data is complicated by metabolism and high levels of nonspecific binding. Targeted deletion of several S1P receptors and key enzymes involved in S1P biosynthesis or degradation has clarified signalling pathways and physiological roles. A crystal structure of an S1P1‐T4 fusion protein has been described [733].The S1P receptor modulator, fingolimod(FTY720, Gilenya), has received world‐wide approval as the first oral therapy for relapsing forms of multiple sclerosis. This drug has a novel mechanism of action involving modulation of S1P receptors in both the immune and nervous systems [340, 369, 687], although the precise nature of its interaction requires clarification.NomenclatureS1P1 receptorS1P2 receptorS1P3 receptorS1P4 receptorS1P5 receptorHGNC, UniProtS1PR1, P21453S1PR2, O95136S1PR3, Q99500S1PR4, O95977S1PR5, Q9H228Potency order of endogenous ligandssphingosine 1‐phosphate>dihydrosphingosine1‐phosphate>sphingosylphosphorylcholine [46, 1505]sphingosine 1‐phosphate>dihydrosphingosine1‐phosphate>sphingosylphosphorylcholine [46, 1505]sphingosine 1‐phosphate>dihydrosphingosine1‐phosphate>sphingosylphosphorylcholine [1505]sphingosine 1‐phosphate>dihydrosphingosine1‐phosphate>sphingosylphosphorylcholine [2012]sphingosine 1‐phosphate>dihydrosphingosine1‐phosphate>sphingosylphosphorylcholine [861]Agonistsamiselimod phosphate [1887], FTY720‐phosphate [220, 560, 1525], siponimod [1524], AUY954 [1525], AFD(R) [220], etrasimod [254], fingolimod [708]––––Selective agonistsozanimod [657, 1274, 1757], ponesimod [176], KRP 203‐phosphate [1851] – Mouse, CYM5181 [657], SEW2871 [1713] – Mouse––––AntagonistsVPC23019 (pKi 7.9) [419], VPC03090‐P (pKi 7.6–7.7) [972], VPC44116 (pIC50 7.6) [561]–VPC44116 (pKi 6.5) [561], VPC23019 (pKi 5.9) [419]––Selective antagonistsNIBR‐0213 (pIC50 8.6) [1615], W146 (pKi 7.1) [1714]JTE‐013 (pIC50 7.8) [1515]–––CommentsThe FDA‐approved immunomodulator fingolimod(FTY720) can be phosphorylated in vivo [31] to generate a relatively potent agonist with activity at S1P1, S1P3, S1P4 and S1P5 receptors [220, 1259]. The physiological consequences of FTY720‐phosphate administration, as well as those of other S1P1 agonists, may involve functional antagonism via ubiquitination and subsequent degradation of S1P1[1514].Further reading on Lysophospholipid (S1P) receptorsChew WS et al. (2016) To fingolimod and beyond: The rich pipeline of drug candidates that target S1P signaling. Pharmacol. Res. 113: 521‐532 [PMID:27663260]Chun J et al. (2010) International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol. Rev. 62: 579‐87 [PMID:21079037]Pyne NJ et al. (2017) Sphingosine 1‐Phosphate Receptor 1 Signaling in Mammalian Cells. Molecules 22: [PMID:28241498]Rosen H et al. (2013) Sphingosine‐1‐phosphate and its receptors: structure, signaling, and influence. Annu. Rev. Biochem. 82: 637‐62 [PMID:23527695]Melanin‐concentrating hormone receptorsOverviewMelanin‐concentrating hormone (MCH) receptors (provisional nomenclature as recommended by NC‐IUPHAR [557]) are activated by an endogenous nonadecameric cyclic peptide identical in humans and rats (DFDMLRCMLGRVYRPCWQV) generated from a precursor (PMCH, P20382), which also produces neuropeptide EI(PMCH, P20382) and neuropeptide GE (PMCH, P20382).NomenclatureMCH1 receptorMCH2 receptorHGNC, UniProtMCHR1, Q99705MCHR2, Q969V1Selective antagonistsGW803430 (pIC50 9.3) [781], SNAP‐7941 (pA2 9.2) [190], T‐226296 (pIC50 8.3) [1926], ATC0175 (pIC50 7.9–8.1) [297]–Labelled ligands[125I]S36057 (Antagonist) (pKd 9.2–9.5) [69], [125I][Phe13,Tyr19]MCH (Agonist) [249], [3H]MCH (human, mouse, rat) (Agonist) [249]–CommentsThe MCH2 receptor appears to be a non‐functional pseudogene in rodents [1930].Further reading on Melanin‐concentrating hormone receptorsChung S et al. (2011) Recent updates on the melanin‐concentrating hormone (MCH) and its receptor system: lessons from MCH1R antagonists. J. Mol. Neurosci. 43: 115‐21 [PMID:20582487]Eberle AN et al. (2010) Cellular models for the study of the pharmacology and signaling of melanin‐concentrating hormone receptors. J. Recept. Signal Transduct. Res. 30: 385‐402 [PMID:21083507]Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. Pharmacol Rev 57: 279‐288 [PMID:15914470]Takase K et al. (2014) Meta‐analysis of melanin‐concentrating hormone signaling‐deficient mice on behavioral and metabolic phenotypes. PLoS ONE 9: e99961 [PMID:24924345]Melanocortin receptorsOverviewMelanocortin receptors (provisional nomenclature as recommended by NC‐IUPHAR[557]) are activated by members of the melanocortin family (α‐MSH(POMC, P01189), β‐MSH(POMC, P01189) and γ‐MSH(POMC, P01189) forms; δ form is not found in mammals) and adrenocorticotrophin (ACTH(POMC, P01189)). Endogenous antagonists include agouti(ASIP, P42127) and agouti‐related protein (AGRP, O00253). ACTH(1‐24) was approved by the US FDA as a diagnostic agent for adrenal function test. At least 2 synthetic melanocortin receptor agonists are under clinical development as of 2017.NomenclatureMC1 receptorMC2 receptorMC3 receptorMC4 receptorMC5 receptorHGNC, UniProtMC1R, Q01726MC2R, Q01718MC3R, P41968MC4R, P32245MC5R, P33032Potency order of endogenous ligandsα‐MSH (POMC, P01189) >β‐MSH (POMC, P01189) >ACTH (POMC, P01189), γ‐MSH (POMC, P01189)ACTH (POMC, P01189)γ‐MSH (POMC, P01189), β‐MSH (POMC, P01189) >ACTH (POMC, P01189), α‐MSH (POMC, P01189)β‐MSH (POMC, P01189) >α‐MSH (POMC, P01189), ACTH (POMC, P01189) >γ‐MSH (POMC, P01189)α‐MSH (POMC, P01189) >β‐MSH (POMC, P01189) >ACTH (POMC, P01189) >γ‐MSH (POMC, P01189)Selective agonists–corticotropin zinchydroxide[D‐Trp8]γ‐MSH [679]THIQ [1760]–Antagonists––PG‐106 (pIC50 6.7) [680]––Selective antagonists–––MBP10 (pIC50 10) [123], HS014 (pKi 8.5) [1738]–Labelled ligands[125I]NDP‐MSH (Agonist) [1037][125I]ACTH‐(1‐24) (Agonist)[125I]NDP‐MSH (Agonist) [1037], [125I]SHU9119 (Antagonist) [1457][125I]SHU9119 (Antagonist) (pKd 9.2) [1457], [125I]NDP‐MSH (Agonist) [1037, 1736][125I]NDP‐MSH (Agonist) [1037]CommentsPolymorphisms of the MC1 receptor have been linked to variations in skin pigmentation. Defects of the MC2 receptor underlie familial glucocorticoid deficiency. Polymorphisms of the MC4 receptor have been linked to obesity [296, 531].Further reading on Melanocortin receptorsCaruso V et al. (2014) Synaptic changes induced by melanocortin signalling. Nat. Rev. Neurosci. 15: 98‐110 [PMID:24588018]Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. Pharmacol Rev 57: 279‐288 [PMID:15914470]Renquist BJ et al. (2011) Physiological roles of the melanocortin MC_3 receptor. Eur. J. Pharmacol. 660: 13‐20 [PMID:21211527]Melatonin receptorsOverviewMelatonin receptors (nomenclature as agreed by the NC‐IUPHARSubcommittee on Melatonin Receptors [474]) are activated by the endogenous ligands melatonin and clinically used drugs like ramelteon and agomelatine.NomenclatureMT1 receptorMT2 receptorHGNC, UniProtMTNR1A, P48039MTNR1B, P49286Endogenous agonistsmelatonin [70, 473, 475]melatonin [70, 473, 475]Agonistsramelteon [954], agomelatine [70, 136]agomelatine [70, 136], ramelteon [954, 1636]Selective agonists–UCM1014 [1855], IIK7 [532, 1888], 5‐methoxy‐luzindole (Partial agonist) [475]Selective antagonists–4P‐PDOT (pKi 8.8–9.4) [70, 475, 476], K185 (pKi 9.3) [532, 1888], DH97 (pKi 8) [1939]Labelled ligands[125I]SD6 (Agonist) [1138], 2‐[125I]melatonin (Agonist) [70, 475], [3H]melatonin (Agonist) [235][125I]SD6 (Agonist) [1138], 2‐[125I]melatonin (Agonist) [70, 475], [125I]DIV880 (Agonist, Partial agonist) [1138], [3H]melatonin (Agonist) [235]Commentsmelatonin, 2‐iodo‐melatonin, agomelatine, GR 196429, LY 156735 and ramelteon[954] are nonselective agonists for MT1 and MT2 receptors. (‐)‐AMMTC displays an ~400‐fold greater agonist potency than (+)‐AMMTC at rat MT1 receptors (see AMMTC for structure) [1966]. Luzindole is an MT1/MT2 non‐selective competitive melatonin receptor antagonist with about 15‐25 fold selectivity for the MT2 receptor [476]. MT1/MT2 heterodimers present different pharmacological profiles from MT1 and MT2 receptors [75].The MT3 binding site of hamster brain and peripheral tissues such as kidney and testis, also termed the ML2 receptor, binds selectively 2‐iodo‐[125I]5MCA‐NAT[1356]. Pharmacological investigations of MT3 binding sites have primarily been conducted in hamster tissues. At this site, The endogenous ligand N‐acetylserotonin[495, 1215, 1356, 1588] and 5MCA‐NAT[1588] appear to function as agonists, while prazosin[1215] functions as an antagonist. The MT3 binding site of hamster kidney was also identified as the hamster homologue of human quinone reductase 2 (NQO2, P16083[1474, 1475]). The MT3 binding site activated by 5MCA‐NAT in eye ciliary body is positively coupled to adenylyl cyclase and regulates chloride secretion [842]. Xenopus melanophores and chick brain express a distinct receptor (x420, P49219; c346, P49288, initially termed Mel1C) coupled to the Gi/o family of G proteins, for which GPR50 has recently been suggested to be a mammalian counterpart [479] although melatonin does not bind to GPR50 receptors. Several variants of the MTNR1B gene have been associated with increased type 2 diabetes risk.Further reading on Melatonin receptorsDubocovich ML et al. (2010) International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein‐coupled melatonin receptors. Pharmacol. Rev. 62: 343‐80 [PMID:20605968]Jockers R et al. (2016) Update on melatonin receptors: IUPHAR Review 20. Br. J. Pharmacol. 173: 2702‐25 [PMID:27314810]Liu J et al. (2016) MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu. Rev. Pharmacol. Toxicol. 56: 361‐83 [PMID:26514204]Zlotos DP et al. (2013) MT1 and MT2 Melatonin Receptors: Ligands, Models, Oligomers, and Therapeutic Potential. J. Med. Chem. [PMID:24228714]Metabotropic glutamate receptorsOverviewMetabotropic glutamate (mGlu) receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Metabotropic Glutamate Receptors [1743]) are a family of G‐protein coupled receptors activated by the neurotransmitter glutamate. The mGlu family is composed of eight members (named mGlu1 to mGlu8) which are divided in three groups based on similarities of agonist pharmacology, primary sequence and G protein coupling to effector: Group‐I (mGlu1 and mGlu5), Group‐II (mGlu2 and mGlu3) and Group‐III (mGlu4, mGlu6, mGlu7 and mGlu8) (see Further reading).Structurally, mGlu are composed of three juxtaposed domains: a core G‐protein‐activating seven‐transmembrane domain (TM), common to all GPCRs, is linked via a rigid cysteine‐rich domain (CRD) to the Venus Flytrap domain (VFTD), a large bi‐lobed extracellular domain where glutamate binds. The structures of the VFTD of mGlu1, mGlu2, mGlu3, mGlu5 and mGlu7 have been solved [1075, 1364, 1408, 1984]. The structure of the 7 transmembrane (TM) domains of both mGlu1 and mGlu5 have been solved, and confirm a general helical organization similar to that of other GPCRs, although the helices appear more compacted [465, 2136]. mGlu form constitutive dimers crosslinked by a disulfide bridge. Although mGlu receptors have been thought to only form homodimers, recent studies revealed the possible formation of heterodimers between either group‐I receptors, or within and between group‐II and ‐III receptors [468]. Although well characterized in transfected cells, co‐localization and specific pharmacological properties also suggest the existence of such heterodimers in the brain [2183].The endogenous ligands of mGlu are L‐glutamic acid, L‐serine‐O‐phosphate, N‐acetylaspartylglutamate (NAAG) and L‐cysteine sulphinic acid. Group‐I mGlu receptors may be activated by 3,5‐DHPG and (S)‐3HPG[204] and antagonized by (S)‐hexylhomoibotenic acid[1235]. Group‐II mGlu receptors may be activated by LY389795[1365], LY379268[1365], eglumegad[1744, 2138], DCG‐IV and (2R,3R)‐APDC[1745], and antagonised by eGlu[890] and LY307452[518, 2096]. Group‐III mGlu receptors may be activated by L‐AP4 and (R,S)‐4‐PPG[610]. An example of an antagonist selective for mGlu receptors is LY341495, which blocks mGlu2 and mGlu3 at low nanomolar concentrations, mGlu8 at high nanomolar concentrations, and mGlu4, mGlu5, and mGlu7 in the micromolar range [1001]. In addition to orthosteric ligands that directly interact with the glutamate recognition site, allosteric modulators that bind within the TM domain have been described. Negative allosteric modulators are listed separately. The positive allosteric modulators most often act as ‘potentiators’ of an orthosteric agonist response, without significantly activating the receptor in the absence of agonist.NomenclaturemGlu1 receptormGlu2 receptormGlu3 receptormGlu4 receptormGlu5 receptorHGNC, UniProtGRM1, Q13255GRM2, Q14416GRM3, Q14832GRM4, Q14833GRM5, P41594Endogenous agonistsL‐glutamic acid [1574]L‐glutamic acid [1574]L‐glutamic acid [1574], NAAG [1750]L‐glutamic acid [1574]L‐glutamic acid [1574]Agonists–––L‐AP4 [2138], L‐serine‐O‐phosphate [2138]–Selective agonists–––LSP4‐2022 [666](S)‐(+)‐CBPG (Partial agonist) [1261] – Rat, CHPG [1407]AntagonistsLY367385 (pIC50 5.1) [364]––MAP4 (pKi 4.6) [721] – Rat–Selective antagonists3‐MATIDA (pIC50 5.2) [1386] – Rat, (S)‐(+)‐CBPG (pIC50 4.2) [1261] – Rat, (S)‐TBPG (pIC50 4.2) [381] – Rat, AIDA (pA2 4.2) [1387]PCCG‐4 (pIC50 5.1) [1551] – Rat––ACDPP (pIC50 6.9) [186]Allosteric modulators–CBiPES (Positive) (pEC50 7) [917], 4‐MPPTS (Positive) (pIC50 5.8) [100, 916, 917, 1731]–SIB‐1893 (Positive) (pEC50 6.3–6.8) [1281], MPEP (Positive) (pEC50 6.3–6.6) [1281], PHCCC (Positive) (pEC50 4.5) [1247]3,3'‐difluorobenzaldazine (Positive) (pIC50 5.6–8.5) [1481, 1482], alloswitch‐1 (Negative) (pIC50 8.1) [1583] – Rat, CDPPB (Positive) (pEC50 7.6–8) [1002, 1180], MTEP (Negative) (pKi 7.8) [228], MPEP (Negative) (pIC50 7.4–7.7) [609, 611], fenobam (Negative) (pIC50 7.2) [1592], SIB‐1893 (Negative) (pIC50 5.9–6.5) [609, 2028], SIB‐1757 (Negative) (pIC50 6–6.4) [609, 2028], CPPHA (Positive) (pIC50 6.3) [1482]Selective allosteric modulatorsBAY 367620 (Negative) (pKi 9.5) [279] – Rat, JNJ16259685 (Negative) (pIC50 8.9) [1104], Ro01‐6128 (Positive) (pKi 7.5–7.7) [1019] – Rat, LY456236 (Negative) (pIC50 6.9) [1160], CPCCOEt (Negative) (pIC50 5.2–5.8) [1183]Ro64‐5229 (Negative) (pIC50 7) [1031] – Rat, biphenylindanone A (Positive) (pEC50 7) [187]–VU0361737 (Positive) (pEC50 6.6) [508], VU0155041 (Positive) (pEC50 6.1) [1468]VU‐1545 (Positive) (pEC50 8) [429]NomenclaturemGlu6 receptormGlu7 receptormGlu8 receptorHGNC, UniProtGRM6, O15303GRM7, Q14831GRM8, O00222Endogenous agonistsL‐glutamic acid [1574]L‐glutamic acid [1574]L‐serine‐O‐phosphate [1254, 2138], L‐glutamic acid [1574]Agonists–LSP4‐2022 [666], L‐serine‐O‐phosphate [2138], L‐AP4 [2138](S)‐3,4‐DCPG [1952], L‐AP4 [1254]Selective agonists1‐benzyl‐APDC [1987] – Rat, homo‐AMPA [244]––AntagonistsMAP4 (pIC50 3.5) [1575] – Rat, THPG [1956]–MPPG (pIC50 4.3) [2138]Allosteric modulators–MMPIP (Negative) (pIC50 6.1–7.6) [1467, 1900] – Rat, ADX71743 (Negative) (pIC50 7.2) [938], AMN082 (Positive) (pEC50 6.5–6.8) [1349], XAP044 (Negative) (pIC50 5.6) [618]–CommentsThe activity of NAAG as an agonist at mGlu3 receptors was questioned on the basis of contamination with glutamate [341, 576], but this has been refuted [1430].Radioligand binding using a variety of radioligands has been conducted on recombinant receptors (for example, [3H]R214127[1103] and [3H]YM298198[1025] at mGlu1 receptors and [3H]M‐MPEP[609] and [3H]methoxymethyl‐MTEP[48] at mGlu5 receptors. Although a number of radioligands have been used to examine binding in native tissues, correlation with individual subtypes is limited. Many pharmacological agents have not been fully tested across all known subtypes of mGlu receptors. Potential differences linked to the species (e.g. human versus rat or mouse) of the receptors and the receptor splice variants are generally not known. The influence of receptor expression level on pharmacology and selectivity has not been controlled for in most studies, particularly those involving functional assays of receptor coupling.(S)‐(+)‐CBPG is an antagonist at mGlu1, but is an agonist (albeit of reduced efficacy) at mGlu5 receptors. DCG‐IV also exhibits agonist activity at NMDA glutamate receptors [2007], and is an antagonist at all Group‐III mGluRs with an IC50 of 30μM. A potential novel metabotropic glutamate receptor coupled to phosphoinositide turnover has been observed in rat brain; it is activated by 4‐methylhomoibotenic acid (ineffective as an agonist at recombinant Group I metabotropic glutamate receptors), but is resistant to LY341495[356]. There are also reports of a distinct metabotropic glutamate receptor coupled to phospholipase D in rat brain, which does not readily fit into the current classification [1013, 1549]A related class C receptor composed of two distinct subunits, T1R1 + T1R3 is also activated by glutamate and is responsible for umami taste detection.All selective antagonists at metabotropic glutamate receptors are competitive.Further reading on Metabotropic glutamate receptorsConn PJ et al. (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37: 205‐237 [PMID:9131252]Ferraguti F et al. (2006) Metabotropic glutamate receptors. Cell Tissue Res. 326: 483‐504 [PMID:16847639]Nicoletti F et al. (2011) Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology 60: 1017‐41 [PMID:21036182]Niswender CM et al. (2010) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 50: 295‐322 [PMID:20055706]Pin JP et al. (2016) Organization and functions of mGlu and GABAB receptor complexes. Nature 540: 60‐68 [PMID:27905440]Rondard P et al. (2011) The complexity of their activation mechanism opens new possibilities for the modulation of mGlu and GABAB class C G protein‐coupled receptors. Neuropharmacology 60: 82‐92 [PMID:20713070]Motilin receptorOverviewMotilin receptors (provisional nomenclature) are activated by motilin(MLN, P12872), a 22 amino‐acid peptide derived from a precursor (MLN, P12872), which may also generate a motilin‐associated peptide (MLN, P12872). These receptors promote gastrointestinal motility and are suggested to be responsible for the gastrointestinal prokinetic effects of certain macrolide antibiotics (often called motilides; e.g. erythromycin), although for many of these molecules the evidence is sparse.Nomenclaturemotilin receptorHGNC, UniProtMLNR, O43193Endogenous agonistsmotilin (MLN, P12872) [386, 1286, 1287, 1288]Agonistsalemcinal [1947], erythromycin‐A [533, 1947], azithromycin [225]Selective agonistscamicinal [105, 1712], mitemcinal [1023, 1918] – RabbitSelective antagonistsMA‐2029 (pA2 9.2) [1884], GM‐109 (pIC50 8) [736] – RabbitLabelled ligands[125I]motilin (human) (Agonist) [533]CommentsIn terms of structure, the motilin receptor has closest homology with the ghrelin receptor. Thus, the human motilin receptor shares 52% overall amino acid identity with the ghrelin receptor and 86% in the transmembrane regions [759, 1918, 1947]. However, differences between the N‐terminus regions of these receptors means that their cognate peptide ligands do not readily activate each other [408, 1712]. In laboratory rodents, the gene encoding the motilin percursor appears to be absent, while the receptor appears to be a pseudogene [759, 1710]. Functions of motilin(MLN, P12872) are not usually detected in rodents, although brain and other responses to motilin and the macrolide alemcinal have been reported and the mechanism of these actions is obscure [1311, 1462]. Notably, in some non‐laboratory rodents (e.g. the North American kangaroo rat (Dipodomys) and mouse (Microdipodops) a functional form of motilin may exist but the motilin receptor is non‐functional [1159]. Marked differences in ligand affinities for the motilin receptor in dogs and humans may be explained by significant differences in receptor structure [1711]. Note that for the complex macrolide structures, selectivity of action has often not been rigorously examined and other actions are possible (e.g. P2X inhibition by erythromycin; [2216]). Small molecule motilin receptor agonists are now described [1159, 1712, 2100]. The motilin receptor does not appear to have constitutive activity [812]. Although not proven, the existence of biased agonism at the receptor has been suggested [1288, 1348, 1709]. A truncated 5‐transmembrane structure has been identified but this is without activity when transfected into a host cell [533]. Receptor dimerisation has not been reported.Further reading on Motilin receptorDe Smet B et al. (2009) Motilin and ghrelin as prokinetic drug targets. Pharmacol. Ther. 123: 207‐23 [PMID:19427331]Sanger GJ et al. (2016) Ghrelin and motilin receptors as drug targets for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 13: 38‐48 [PMID:26392067]Neuromedin U receptorsOverviewNeuromedin U receptors (provisional nomenclature as recommended by NC‐IUPHAR[557]) are activated by the endogenous 25 amino acid peptide neuromedin U (neuromedin U‐25 (NMU, P48645), NmU‐25), a peptide originally isolated from pig spinal cord [1344]. In humans, NmU‐25 appears to be the sole product of a precursor gene (NMU, P48645) showing a broad tissue distribution, but which is expressed at highest levels in the upper gastrointestinal tract, CNS, bone marrow and fetal liver. Much shorter versions of NmU are found in some species, but not in human, and are derived at least in some instances from the proteolytic cleavage of the longer NmU. Despite species differences in NmU structure, the C‐terminal region (particularly the C‐terminal pentapeptide) is highly conserved and contains biological activity. Neuromedin S (neuromedin S‐33 (NMS, Q5H8A3)) has also been identified as an endogenous agonist [1378]. NmS‐33 is, as its name suggests, a 33 amino‐acid product of a precursor protein derived from a single gene and contains an amidated C‐terminal heptapeptide identical to NmU. NmS‐33 appears to activate NMU receptors with equivalent potency to NmU‐25.NomenclatureNMU1 receptorNMU2 receptorHGNC, UniProtNMUR1, Q9HB89NMUR2, Q9GZQ4Antagonists–R‐PSOP (pKB 7) [1193]CommentsNMU1 and NMU2 couple predominantly to Gq/11 although there is evidence of good coupling to Gi/o[218, 825, 833]. NMU1 and NMU2 can be labelled with [125I]‐NmU and [125I]‐NmS (of various species, e.g. [1319]), BODIPY® TMR‐NMU or Cy3B‐NMU‐8[218]. A range of radiolabelled (125I‐), fluorescently labelled (e.g. Cy3, Cy5, rhodamine and FAM) and biotin labelled versions of neuromedin U‐25(NMU, P48645) and neuromedin S‐33 (NMS, Q5H8A3) are now commercially available.Further reading on Neuromedin U receptorsBrighton PJ et al. (2004) Neuromedin U and its receptors: structure, function, and physiological roles. Pharmacol. Rev. 56: 231‐48 [PMID:15169928]Budhiraja S et al. (2009) Neuromedin U: physiology, pharmacology and therapeutic potential. Fundam Clin Pharmacol 23: 149‐57 [PMID:19645813]Mitchell JD et al. (2009) Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S. Br. J. Pharmacol. 158: 87‐103 [PMID:19519756]Novak CM. (2009) Neuromedin S and U. Endocrinology 150: 2985‐7 [PMID:19549882]Neuropeptide FF/neuropeptide AF receptorsOverviewThe Neuropeptide FF receptor family contains two subtypes, NPFF1 and NPFF2 (provisional nomenclature [557]), which exhibit high affinities for neuropeptide FF (NPFF, O15130) and RFamide related peptides (RFRP: precursor gene symbol NPVF, Q9HCQ7). NPFF1 is broadly distributed in the central nervous system with the highest levels found in the limbic system and the hypothalamus. NPFF2 is present in high density in the superficial layers of the mammalian spinal cord where it is involved in nociception and modulation of opioid functions.NomenclatureNPFF1 receptorNPFF2 receptorHGNC, UniProtNPFFR1, Q9GZQ6NPFFR2, Q9Y5X5Potency order of endogenous ligandsRFRP‐1 (NPVF, Q9HCQ7) >RFRP‐3 (NPVF, Q9HCQ7) > FMRFneuropeptide FF (NPFF, O15130) >neuropeptide AF (NPFF, O15130) >neuropeptide SF (NPFF, O15130), QRFP43 (QRFP, P83859), PrRP‐31 (PRLH, P81277) [663]neuropeptide AF (NPFF, O15130), neuropeptide FF (NPFF, O15130) >PrRP‐31 (PRLH, P81277) > FMRF, QRFP43 (QRFP, P83859) >neuropeptide SF (NPFF, O15130) [663]Endogenous agonistsneuropeptide FF (NPFF, O15130) [663, 664, 1359], RFRP‐3 (NPVF, Q9HCQ7) [664, 665, 1359]neuropeptide FF (NPFF, O15130) [664, 1358]Selective agonists–dNPA [1681], AC263093 [1092]AntagonistsRF9 (pKi 7.2) [1814]–Selective antagonistsAC262620 (pKi 7.7–8.1) [1092], AC262970 (pKi 7.4–8.1) [1092]–Labelled ligands[125I]Y‐RFRP‐3 (Agonist) [664], [3H]NPVF (Agonist) [1928], [125I]NPFF (Agonist) [663][125I]EYF (Agonist) [1359], [3H]EYF (Agonist) [1928], [125I]NPFF (Agonist) [663]CommentsAn orphan receptor GPR83(Q9NYM4) shows sequence similarities with NPFF1, NPFF2, PrRP and QRFP receptors. The antagonist RF9 is selective for NPFF receptors, but does not distinguish between the NPFF1 and NPFF2 subtypes (pKi 7.1 and 7.2, respectively, [1814]).Further reading on Neuropeptide FF/neuropeptide AF receptorsMoulédous L et al. (2010) Opioid‐modulating properties of the neuropeptide FF system. Biofactors 36: 423‐9 [PMID:20803521]Vyas N et al. (2006) Structure‐activity relationships of neuropeptide FF and related peptidic and non‐peptidic derivatives. Peptides 27: 990‐6 [PMID:16490282]Yang HY et al. (2008) Modulatory role of neuropeptide FF system in nociception and opiate analgesia. Neuropeptides 42: 1‐18 [PMID:17854890]Neuropeptide S receptorOverviewThe neuropeptide S receptor (NPS, provisional nomenclature [557]) responds to the 20 amino‐acid peptide neuropeptide S derived from a precursor (NPS, P0C0P6).NomenclatureNPS receptorHGNC, UniProtNPSR1, Q6W5P4Endogenous agonistsneuropeptide S (NPS, P0C0P6) [2159]Selective agonistsPWT1‐NPS [1692] – MouseSelective antagonistsNCGC 84 (pA2 9) [1957], SHA 68 (pA2 8.1) [1693] – Mouse, RTI‐118 [2214]Labelled ligands[125I]Tyr10NPS (human) (Agonist) [2159]CommentsMultiple single‐nucleotide polymorphisms (SNP) and several splice variants have been identified in the human NPS receptor. The most interesting of these is an Asn‐Ile exchange at position 107 (Asn107Ile). The human NPS receptor Asn107Ile displayed similar binding affinity but higher NPS potency (by approx. 10‐fold) than human NPS receptor Asn107 [1645]. Several epidemiological studies reported an association between Asn107Ile receptor variant and susceptibility to panic disorders [458, 460, 1506, 1621]. The SNP Asn107Ile has also been linked to sleep behavior [662], inflammatory bowel disease [402], schizophrenia [1145], increased impulsivity and ADHD symptoms [1083]. Interestingly, a carboxy‐terminal splice variant of human NPS receptor was found to be overexpressed in asthmatic patients [1091].Further reading on Neuropeptide S receptorGuerrini R et al. (2010) Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. Med Res Rev 30: 751‐77 [PMID:19824051]Xu YL et al. (2004) Neuropeptide S: a neuropeptide promoting arousal and anxiolytic‐like effects. Neuron 43: 487‐497 [PMID:15312648]Neuropeptide W/neuropeptide B receptorsOverviewThe neuropeptide BW receptor 1 (NPBW1, provisional nomenclature [557]) is activated by two 23‐amino‐acid peptides, neuropeptide W (neuropeptide W‐23 (NPW, Q8N729)) and neuropeptide B (neuropeptide B‐23 (NPB, Q8NG41)) [584, 1792]. C‐terminally extended forms of the peptides (neuropeptide W‐30(NPW, Q8N729) and neuropeptide B‐29 (NPB, Q8NG41)) also activate NPBW1 [216]. Unique to both forms of neuropeptide B is the N‐terminal bromination of the first tryptophan residue, and it is from this post‐translational modification that the nomenclature NPB is derived. These peptides were first identified from bovine hypothalamus and therefore are classed as neuropeptides. Endogenous variants of the peptides without the N‐terminal bromination, des‐Br‐neuropeptide B‐23(NPB, Q8NG41) and des‐Br‐neuropeptide B‐29 (NPB, Q8NG41), were not found to be major components of bovine hypothalamic tissue extracts. The NPBW2 receptor is activated by the short and C‐terminal extended forms of neuropeptide W and neuropeptide B [216].NomenclatureNPBW1 receptorNPBW2 receptorHGNC, UniProtNPBWR1, P48145NPBWR2, P48146Potency order of endogenous ligandsneuropeptide B‐29 (NPB, Q8NG41) >neuropeptide B‐23 (NPB, Q8NG41) >neuropeptide W‐23 (NPW, Q8N729) >neuropeptide W‐30 (NPW, Q8N729) [216]neuropeptide W‐23 (NPW, Q8N729) >neuropeptide W‐30 (NPW, Q8N729) >neuropeptide B‐29 (NPB, Q8NG41) >neuropeptide B‐23 (NPB, Q8NG41) [216]Selective agonistsAva3 [945], Ava5 [945]–Labelled ligands[125I]NPW‐23 (human) (Agonist) [1816][125I]NPW‐23 (human) (Agonist) [1792]CommentsPotency measurements were conducted with heterologously‐expressed receptors with a range of 0.14‐0.57 nM (NPBW1) and 0.98‐21 nM (NPBW2). NPBW1‐/‐ mice show changes in social behavior, suggesting that the NPBW1 pathway may have an important role in the emotional responses of social interaction [1414]. For a review of the contribution of neuropeptideB/W to social dominance, see [2080]. It has been reported that neuropeptide W may have a key role in the gating of stressful stimuli when mice are exposed to novel environments [1392]. Two antagonists have been discovered and reported to have affinity for NPBW1, ML181 and ML250, the latter exhibiting improved selectivity ( ∼ 100 fold) for NPBW1 compared to MCH1 receptors [694, 695]. Computational insights into the binding of antagonists to this receptor have also been described [1541].Further reading on Neuropeptide W/neuropeptide B receptorsSakurai T. (2013) NPBWR1 and NPBWR2: Implications in Energy Homeostasis, Pain, and Emotion. Front Endocrinol (Lausanne) 4: 23 [PMID:23515889]Singh G et al. (2006) Neuropeptide B and W: neurotransmitters in an emerging G‐protein‐coupled receptor system. Br. J. Pharmacol. 148: 1033‐41 [PMID:16847439]Neuropeptide Y receptorsOverviewNeuropeptide Y (NPY) receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Neuropeptide Y Receptors [1330]) are activated by the endogenous peptides neuropeptide Y (NPY, P01303), neuropeptide Y‐(3‐36), peptide YY(PYY, P10082), PYY‐(3‐36) and pancreatic polypeptide (PPY, P01298) (PP). The receptor originally identified as the Y3 receptor has been identified as the CXCR4 chemokine recepter (originally named LESTR, [1201]). The y6 receptor is a functional gene product in mouse, absent in rat, but contains a frame‐shift mutation in primates producing a truncated non‐functional gene [676]. Many of the agonists exhibit differing degrees of selectivity dependent on the species examined. For example, the potency of PP is greater at the rat Y4receptor than at the human receptor [513]. In addition, many agonists lack selectivity for individual subtypes, but can exhibit comparable potency against pairs of NPY receptor subtypes, or have not been examined for activity at all subtypes. [125I]‐PYY or [125I]‐NPY can be used to label Y1, Y2, Y5 and y6 subtypes non‐selectively, while [125I][cPP(1‐7), NPY(19‐23), Ala31, Aib32, Gln34]hPP may be used to label Y5 receptors preferentially (note that cPP denotes chicken peptide sequence and hPP is the human sequence).NomenclatureY1 receptorY2 receptorY4 receptorY5 receptory6 receptorHGNC, UniProtNPY1R, P25929NPY2R, P49146NPY4R, P50391NPY5R, Q15761NPY6R, Q99463Potency order of endogenous ligandsneuropeptide Y = peptide YY ≫ pancreatic polypeptidepeptide YY = peptide YY(3‐36) = neuropeptide Y = neuropeptide Y(3‐36) ≫ pancreatic polypeptidepancreatic polypeptide ≫ neuropeptide Y = peptide YYneuropeptide Y > peptide YY > pancreatic polypeptideneuropeptide Y = peptide YY > pancreatic polypeptideEndogenous agonistsneuropeptide Y (NPY, P01303), peptide YY (PYY, P10082)PYY‐(3‐36) (PYY, P10082) [619, 633], neuropeptide Y (NPY, P01303), neuropeptide Y‐(3‐36) (NPY, P01303), peptide YY (PYY, P10082)pancreatic polypeptide (PPY, P01298) [98, 1217, 1978, 2165]––Agonists[Leu31,Pro34]NPY [392], [Leu31,Pro34]PYY (human), [Pro34]NPY, [Pro34]PYY (human)––––Selective agonists–––[Ala31,Aib32]NPY (pig) [264]–Selective antagonistsBIBO3304 (pIC50 9.5) [2110], BIBP3226 (pKi 8.1–9.3) [463, 2111]BIIE0246 (pIC50 8.5) [461], JNJ‐5207787 (pIC50 6.9–7.1) [182]–L‐152,804 (pKi 7.6) [944]–Selective allosteric modulators––niclosamide (Positive) [1827]––Labelled ligands[3H]BIBP3226 (Antagonist) (pKd 8.7), [125I][Leu31,Pro34]NPY (Agonist)[125I]PYY‐(3‐36) (human) (Agonist)[125I]PP (human) (Agonist)[125I][cPP(1‐7), NPY(19‐23),Ala31, Aib32, Gln34]hPP (Agonist) [481] – Rat–CommentsNote that Pro34‐containing NPY and PYY can also bind Y4 and Y5 receptors, so strictly speaking are not selective, but are the 'preferred' agonists.––––CommentsThe Y1 agonists indicated are selective relative to Y2 receptors. BIBP3226 is selective relative to Y2, Y4 and Y5 receptors [632]. NPY‐(13‐36) is Y2 selective relative to Y1 and Y5 receptors. PYY‐(3‐36) is Y2 selective relative to Y1 receptors. Note that Pro34‐containing NPY and PYY can also bind Y4 and Y5, thus they are selective only relative to Y2. The y6 receptor is a pseudogene in humans, but is functional in mouse, rabbit and some other mammals.Further reading on Neuropeptide Y receptorsBowers ME et al. (2012) Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y. Physiol. Behav. 107: 699‐710 [PMID:22429904]Michel MC et al. (1998) XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY and pancreatic polypeptide receptors. Pharmacol. Rev. 50: 143‐150 [PMID:9549761]Pedragosa‐Badia X et al. (2013) Neuropeptide Y receptors: how to get subtype selectivity. Front Endocrinol (Lausanne) 4: 5 [PMID:23382728]Zhang L et al. (2011) The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacol. Ther. 131: 91‐113 [PMID:21439311]Neurotensin receptorsOverviewNeurotensin receptors (nomenclature as recommended by NC‐IUPHAR[557]) are activated by the endogenous tridecapeptide neurotensin (pGlu‐Leu‐Tyr‐Glu‐Asn‐Lys‐Pro‐Arg‐Arg‐Pro‐Tyr‐Ile‐Leu) derived from a precursor (NTS, 30990), which also generates neuromedin N, an agonist at the NTS2 receptor. [3H]neurotensin (human, mouse, rat) and [125I]neurotensin (human, mouse, rat) may be used to label NTS1 and NTS2 receptors at 0.1‐0.3 and 3‐5 nM concentrations respectively.NomenclatureNTS1 receptorNTS2 receptorHGNC, UniProtNTSR1, P30989NTSR2, O95665Potency order of endogenous ligandsneurotensin (NTS, P30990) >neuromedin N {Mouse, Rat} [776]neurotensin (NTS, P30990) = neuromedin N {Mouse, Rat} [1297]Selective agonistsJMV449 [1822] – Ratlevocabastine [1297, 1657]Selective antagonistsmeclinertant (pIC50 7.5–8.2) [699]–Labelled ligands[3H]meclinertant (Antagonist) (pKd 8.5) [1085] – Rat–Commentsneurotensin(NTS, P30990) appears to be a low‐efficacy agonist at the NTS2 receptor [2039], while the NTS1 receptor antagonist meclinertant is an agonist at NTS2 receptors [2039]. An additional protein, provisionally termed NTS3 (also known as NTR3, gp95 and sortilin; ENSG00000134243), has been suggested to bind lipoprotein lipase and mediate its degradation [1460]. It has been reported to interact with the NTS1 receptor [1273] and the NTS2 receptor [260], and has been implicated in hormone trafficking and/or neurotensin uptake. A splice variant of the NTS2 receptor bearing 5 transmembrane domains has been identified in mouse [195] and later in rat [1561].Further reading on Neurotensin receptorsBoules M et al. (2013) Diverse roles of neurotensin agonists in the central nervous system. Front Endocrinol (Lausanne) 4: 36 [PMID:23526754]Mazella J et al. (2012) Neurotensin and its receptors in the control of glucose homeostasis. Front Endocrinol (Lausanne) 3: 143 [PMID:23230428]Myers RM et al. (2009) Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors. ACS Chem. Biol. 4: 503‐25 [PMID:19462983]Tanganelli S et al. (2012) Relevance of dopamine D(2)/neurotensin NTS1 and NMDA/neurotensin NTS1 receptor interaction in psychiatric and neurodegenerative disorders. Curr. Med. Chem. 19: 304‐16 [PMID:22335510]Opioid receptorsOverviewOpioid and opioid‐like receptors are activated by a variety of endogenous peptides including [Met]enkephalin(PENK, P01210) (met), [Leu]enkephalin(PENK, P01210) (leu), β‐endorphin(POMC, P01189) (β‐end), α‐neodynorphin(PDYN, P01213), dynorphin A(PDYN, P01213) (dynA), dynorphin B(PDYN, P01213) (dynB), big dynorphin(PDYN, P01213) (Big dyn), nociceptin/orphanin FQ(PNOC, Q13519) (N/OFQ); endomorphin‐1 and endomorphin‐2 are also potential endogenous peptides. The Greek letter nomenclature for the opioid receptors, μ, δ and κ, is well established, and NC‐IUPHAR considers this nomenclature appropriate, along with the symbols spelled out (mu, delta, and kappa), and the acronyms, MOP, DOP, and KOP. [390, 441, 557]. The human N/OFQ receptor, NOP, is considered 'opioid‐related' rather than opioid because, while it exhibits a high degree of structural homology with the conventional opioid receptors [1361], it displays a distinct pharmacology. Currently there are numerous clinically used drugs, such as morphine and many other opioid analgesics, as well as antagonists such as naloxone, however only for the μ receptor.Nomenclatureδ receptorκ receptorμ receptorNOP receptorHGNC, UniProtOPRD1, P41143OPRK1, P41145OPRM1, P35372OPRL1, P41146Principal endogenous agonistsβ‐endorphin (POMC, P01189), [Leu]enkephalin (PENK, P01210), [Met]enkephalin (PENK, P01210)big dynorphin (PDYN, P01213), dynorphin A (PDYN, P01213)β‐endorphin (POMC, P01189), [Met]enkephalin (PENK, P01210), [Leu]enkephalin (PENK, P01210)nociceptin/orphanin FQ (PNOC, Q13519) [11, 153, 1507]Potential endogenous agonists––endomorphin‐1, endomorphin‐2–AgonistsDADLE [1972], etorphine [1972], ethylketocyclazocine [1972]–levorphanol [727], hydromorphone [2094], fentanyl [1972], buprenorphine (Partial agonist) [1972], methadone [1595], codeine [1972], tapentadol [1992], pethidine [1595]–Sub/family‐selective agonistsBU08028 (Partial agonist) [979]BU08028 [979]BU08028 (Partial agonist) [979]cebranopadol [1182], BU08028 (Partial agonist) [979]Selective agonistsUFP‐512 [2033], BW373U86 [1115], ADL5859 [1115], DPDPE [1391, 1972], [D‐Ala2]deltorphin II [515], ADL5747 [1116], SNC80 [268, 1620]U50488 [313, 1545, 1813, 1972, 2046, 2222, 2224], enadoline [848, 1447], U69593 [1089, 1972], salvinorin A [259, 1677]sufentanil [2041], DAMGO [726, 1972], loperamide [323], morphine [653, 1972], PL017 [304, 1972]N/OFQ‐(1‐13)‐NH2 [153, 696, 1304, 1507], Ac‐RYYRWK‐NH2 (Partial agonist) [464, 1304], SCH221510 [2030], Ro64‐6198 [898, 2108]Antagonistsnaltrexone (pKi 8) [1972], naloxone (pKi 7.2) [1972]buprenorphine (pKi 9.1–10.2) [1972, 2224], nalmefene (pKi 9.5) [1972], naltrexone (pKi 8.4–9.4) [1545, 1813, 1972], naloxone (pKi 7.6–8.6) [1545, 1813, 1972, 2222, 2224]naltrexone (pKi 9.1–9.7) [965, 1972], nalmefene (pKi 9.5) [1972], nalorphine (pKi 8.9) [1972], naloxone (pKi 8.9) [1972], methylnaltrexone (pKi 8.7) [2094]–Sub/family‐selective antagonistsAT‐076 (pKi 7.7) [1972, 2201]AT‐076 (pKi 8.9) [1972, 2202]AT‐076 (pKi 8.8) [1972, 2202]AT‐076 (pKi 8.8) [2202]Selective antagonistsnaltriben (pKi 10) [1841, 1972], naltrindole (pKi 9.7) [1594, 1972], TIPPψ (Inverse agonist) (pKi 9) [1735, 1972]nor‐binaltorphimine (pKi 8.9–11) [1545, 1593, 1813, 1972, 2222, 2224], 5'‐guanidinonaltrindole (pKi 9.7–9.9) [924, 1545, 1868], JDTic (pKi 9–9.4) [1400, 1951, 2202]alvimopan (pKi 9.3) [1114], levallorphan (pKi 8.8–9.3) [1250], CTAP (pKi 8.6) [304, 1972]UFP‐101 (pKi 10.2) [269], LY2940094 (pKi 10) [1971], compound 24 (pKi 9.6) [549], SB 612111 (pKi 9.2–9.5) [1856, 2200], J‐113397 (pIC50 8.3) [962]Allosteric modulators––BMS‐986123 (Neutral) (pKB 6) [247], BMS‐986121 (Positive) (pKB 5.7) [247], BMS‐986124 (Neutral) (pKB 5.7) [247], BMS‐986122 (Positive) (pKB 5.3) [247]–Labelled ligands[3H]naltrindole (Antagonist) (pKd 10.4) [2161] – Rat, [3H][D‐Ala2]deltorphin I (Selective Agonist) [1865], [3H]diprenorphine (Agonist) [52, 1972], [3H]DPDPE (Agonist) [26], [3H]deltorphin II (Agonist) [261], [3H]naltriben (Antagonist) [1154][3H]diprenorphine (Antagonist) (pKd 9.1) [52, 1813], [3H]U69593 (Agonist) [1089, 1545, 1813], [3H]enadoline (Agonist) [1815][3H]diprenorphine (Antagonist) (pKd 10.1) [1638] – Mouse, [3H]DAMGO (Agonist) [1638] – Rat, [3H]PL017 (Agonist) [751] – Rat[3H]N/OFQ (Agonist) [464, 1360]CommentsThree naloxone‐sensitive opioid receptor genes have been identified in humans, and while the μ‐receptor in particular may be subject to extensive alternative splicing [1535], these putative isoforms have not been correlated with any of the subtypes of receptor proposed in years past. Opioid receptors may heterodimerize with each other or with other 7TM receptors [926], and give rise to complexes with a unique pharmacology, however, evidence for such heterodimers in native cells is equivocal and the consequences of this heterodimerization for signalling remains largely unknown. For μ‐opioid receptors at least, dimerization does not seem to be required for signalling [1078]. A distinct met‐enkephalin receptor lacking structural resemblance to the opioid receptors listed has been identified (OGFR, 9NZT2) and termed an opioid growth factor receptor [2198].Endomorphin‐1 and endomorphin‐2 have been identified as highly selective, putative endogenous agonists for the μ‐opioid receptor. At present, however, the mechanisms for endomorphin synthesis in vivo have not been established, and there is no gene identified that encodes for either. Thus, the status of these peptides as endogenous ligands remains unproven.Two areas of increasing importance in defining opioid receptor function are the presence of functionally relevant single nucleotide polymorphisms in human μ‐receptors [1490] and the identification of biased signalling by opioid receptor ligands, in particular, compounds previously characterized as antagonists [236]. Pathway bias for agonists makes general rank orders of potency and efficacy somewhat obsolete, so these do not appear in the table. As ever, the mechanisms underlying the acute and long term regulation of opiod receptor function are the subject of intense investigation and debate.The richness of opioid receptor pharmacology has been enhanced with the recent discovery of allosteric modulators of μ and δ receptors, notably the positive allosteric modulators and silent allosteric "antagonists" outlined in [247, 248]. Negative allosteric modulation of opioid receptors has been previously suggested [953], whether all compounds are acting at a similar site remains to be established.Further reading on Opioid receptorsButelman ER et al. (2012) κ‐opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci. 35: 587‐96 [PMID:22709632]Cox BM et al. (2015) Challenges for opioid receptor nomenclature: IUPHAR Review 9. Br. J. Pharmacol. 172: 317‐23 [PMID:24528283]Pradhan AA et al. (2011) The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol. Sci. 32: 581‐90 [PMID:21925742]Williams JT et al. (2013) Regulation of μ‐opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol. Rev. 65: 223‐54 [PMID:23321159]Orexin receptorsOverviewOrexin receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Orexin receptors [557]) are activated by the endogenous polypeptides orexin‐A(HCRT, O43612) and orexin‐B(HCRT, O43612) (also known as hypocretin‐1 and ‐2; 33 and 28 aa) derived from a common precursor, preproorexin or orexin precursor, by proteolytic cleavage [1703].NomenclatureOX1 receptorOX2 receptorHGNC, UniProtHCRTR1, O43613HCRTR2, O43614Potency order of endogenous ligandsorexin‐A (HCRT, O43612) >orexin‐B (HCRT, O43612)orexin‐A (HCRT, O43612) = orexin‐B (HCRT, O43612)Selective agonists–[Ala11, D‐Leu15]orexin‐B [66, 1612]Selective antagonistssuvorexant (pKi 9.3) [391], SB‐649868 (pKi 9.1) [442], SB‐674042 (pKi 8.7–9.1) [1098, 1253, 1255], filorexant (pKi 8.6) [2124], almorexant (pIC50 7.9) [221], SB‐408124 (pKi 7.2–7.6) [1098, 1253], SB‐334867 (pKi 7.4–7.5) [1253, 1591]filorexant (pKi 9.5) [2124], suvorexant (pKi 9.5) [391], EMPA (pKi 9) [1252], SB‐649868 (pKi 8.9) [442], JNJ‐10397049 (pKi 8–8.6) [1300], almorexant (pIC50 8.1) [221], TCS‐OX2‐29 (pKi 7.4) [798]Labelled ligands–[3H]‐almorexant (Selective Antagonist) (pKd 8.9–9.8) [1253, 1255], [3H]Cp‐1 (Selective Antagonist) (pKd 9.2–9.4) [1253], [3H]EMPA (Selective Antagonist) (pKd 8.6–9) [1252, 1255], [125I]‐orexin‐A (Agonist) [1066, 1611, 1703]CommentsThe primary coupling of orexin receptors to Gq/11 proteins is rather speculative and based on the strong activation of phospholipase C, though recent studies in recombinant CHO cells also stress the importance of Gq/11[1065]. Coupling of both receptors to Gi/o and Gs has also been reported [951, 1068, 1146, 1629] for most cellular responses observed, the G protein pathway is unknown. The potency order of endogenous ligands may depend on the cellular signal transduction machinery. Most of the OX2 receptor selective antagonists listed are weakly selective (≤10‐fold), or selectivity may be less than 100‐fold or not unequivocally determined. [Ala11, D‐Leu15]orexin‐B may show poor OX2 receptor selectivity [1612].Orexin receptors have been reported to be able to form complexes with each other and some other GPCRs as well as CRF receptors [1067, 1426], which might affect the signaling and pharmacology. Recently a promising synthetic orexin receptor ligand (compound 26) has been reported but not thoroughly characterized [1412]. Loss‐of‐function mutations in the gene encoding the OX2 receptor underlie canine hereditary narcolepsy [1177]. Antagonists of the orexin receptors are the focus of major drug discovery effort for their potential to treat insomnia and other disorders of wakefulness [1668], while agonists would likely be useful in human narcolepsy.Further reading on Orexin receptorsBaimel C et al. (2015) Orexin/hypocretin role in reward: implications for opioid and other addictions. Br. J. Pharmacol. 172: 334‐48 [PMID:24641197]Kukkonen JP. (2013) Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am. J. Physiol., Cell Physiol. 304: C2‐32 [PMID:23034387]Li SB et al. (2016) Hypocretins, Neural Systems, Physiology, and Psychiatric Disorders. Curr Psychiatry Rep 18: 7 [PMID:26733323]Mahler SV et al. (2014) Motivational activation: a unifying hypothesis of orexin/hypocretin function. Nat. Neurosci. 17: 1298‐303 [PMID:25254979]Oxoglutarate receptorOverviewNomenclature as recommended by NC‐IUPHAR[414].Nomenclatureoxoglutarate receptorHGNC, UniProtOXGR1, Q96P68Endogenous agonistsα‐ketoglutaric acid [762, 1854]P2Y receptorsOverviewP2Y receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on P2Y Receptors [1, 2]) are activated by the endogenous ligands ATP, ADP, uridine triphosphate, uridine diphosphate and UDP‐glucose. The relationship of many of the cloned receptors to endogenously expressed receptors is not yet established and so it might be appropriate to use wording such as 'uridine triphosphate‐preferring (or ATP‐, etc.) P2Y receptor' or 'P2Y1‐like', etc., until further, as yet undefined, corroborative criteria can be applied [251, 514, 878, 2044, 2089].Clinically used drugs acting on these receptors include the dinucleoside polyphosphate diquafosol, agonist of the P2Y2 receptor subtype, approved in Japan for the management of dry eye disease [1101], and the P2Y12 receptor antagonists prasugrel, ticagrelor and cangrelor, all approved as antiplatelet drugs [273, 1602].NomenclatureP2Y1 receptorP2Y2 receptorP2Y4 receptorP2Y6 receptorHGNC, UniProtP2RY1, P47900P2RY2, P41231P2RY4, P51582P2RY6, Q15077Potency order of endogenous ligandsADP>ATPuridine triphosphate>ATP [1112]uridine triphosphate>ATP (at rat recombinant receptors, UTP = ATP)uridine diphosphate≫uridine triphosphate>ADPEndogenous agonists–uridine triphosphate [989, 1112]––AgonistsADPβS [1921], 2MeSADP [1729, 2054]–––Sub/family‐selective agonists–diquafosol [1554], denufosol [1113, 1554, 2181], UTPγS [1112]diquafosol [240], denufosol [2181], UTPγS [1113]–Selective agonistsMRS2365 [329], 2‐Cl‐ADP(α‐BH3) [76]MRS2698 [874], 2‐thioUTP [498], PSB1114 (EC50 value determined using an IP3 functional assay) [498, 499, 873]MRS4062 [1276], MRS2927 [1276], (N)methanocarba‐UTP [989]Rp‐5‐OMe‐UDPαB [644, 702], MRS2957 [1275], MRS2693 [146]Antagonistssuramin (pKi 5.3) [2054], PPADS (pKi 5.2) [2054]–ATP (pKd 6.2) [970]–Sub/family‐selective antagonists–reactive blue‐2 (pIC50 6) [892], suramin (pIC50 4.3) [892, 1729]PPADS (pEC50 2–5) [881], reactive blue‐2 (pIC50 4.7) [171] – Ratreactive blue‐2 (pKB 6) [2045], PPADS (pKB 4) [2045], suramin (pKB 4) [2045]Selective antagonistsMRS2500 (pKi 8.8–9.1) [286, 988], MRS2279 (pKi 7.9) [2054], MRS2179 (pKi 7–7.1) [203, 2054]AR‐C118925XX (pIC50∼6) [968], AR‐C126313 (pEC50 6) [874], PSB‐416 (pIC50 4.7) [792]ATP (pKd 6.2) [970]MRS2578 (pIC50 7.4) [1257], MRS2567 (pIC50 6.9) [1257]Allosteric modulators2,2'‐pyridylisatogen tosylate (Negative) (pIC50 7.8) [601]–––Selective allosteric modulatorsBMS compound 16 (Negative) (pKi 6.9) [2206]–––Labelled ligands[3H]MRS2279 (Antagonist) (pKd 8.1) [2054], [3H]2MeSADP (Agonist) [1921], [35S]ADPβS (Agonist)––MRS4162 (Selective Antagonist) (pEC50 7.6) [897]NomenclatureP2Y11 receptorP2Y12 receptorP2Y13 receptorP2Y14 receptorHGNC, UniProtP2RY11, Q96G91P2RY12, Q9H244P2RY13, Q9BPV8P2RY14, Q15391Potency order of endogenous ligandsATPADP [775]ADP≫ATPuridine diphosphate [281]Sub/family‐selective agonists–2MeSADP [775], ADPβS [1921]2MeSADP [1271], 2MeSATP [1271], ADPβS [1271]–Selective agonistsAR‐C67085 [93, 372], NF546 [1317], ATPγS [372]––α.β‐methylene‐2‐thio‐UDP [407], MRS2905 [879], 2‐thio‐UDP [407]Antagonists–PSB‐0739 (pKi 7.6) [97]––Sub/family‐selective antagonistssuramin (pIC50 4.8–6) [372], reactive blue‐2 (pIC50 5) [372]cangrelor (pIC50 9.4) [882], Ap4A (pIC50 6) [1271], 2MeSAMP (pIC50 5.4) [1921]cangrelor (pIC50 8.3) [1271], Ap4A (pIC50 6.7) [1271], 2MeSAMP (pIC50 5.6) [1271]–Selective antagonistsNF157 (pKi 7.3) [1999], NF340 (pIC50 6.4–7.1) [1317]AZD1283 (pKi 8) [79, 2207], ARL66096 (pIC50 7.9) [846, 847], ticagrelor (pKi 7.8) [2203]MRS2603 (pIC50 6.2) [996], MRS2211 (pIC50 6) [996]PPTN (pKi 10.1) [102]Labelled ligands–[3H]2MeSADP (Agonist) [1921], [3H]PSB‐0413 (Antagonist) (pKd 8.3–8.5) [497, 1497][33P]2MeSADP (Agonist) [1271]MRS4174 (Selective Antagonist) (pKi 10.1) [1006], MRS4183 (Selective Agonist) [1005]CommentsA series of 4‐alkyloxyimino derivatives of uridine‐5'‐triphosphate which could be useful for derivatization as fluorescent P2Y2/4/6 receptor probes has been recently synthesized [897].Single nucleotide polymorphisms of the P2YR1 gene are associated with different platelet reactivity to ADP ADP[784]. Three frequent nonsynonymous P2Y2 receptor polymorphisms have been identified, one of which was significantly more common in cystic fibrosis patients. This polymorphism is linked to increases in Ca2+ influx in transfected cells, and might therefore play a role in disease development [263]. Although uridine triphosphate (UTP) was also shown to be a biased agonist at P2Y11, this is still under debate [1388, 2104]. A group of single nucleotide polymorphisms in the P2Y12 gene, forming the so called P2Y12 H2 haplotype, has been associated with increased platelet responsiveness to ADP, increased risk of peripheral arterial disease and with coronary artery disease [291]. The platelet‐type bleeding disorder due to P2Y12 receptor defects is an autosomal recessive condition characterized by mild to moderate mucocutaneous bleeding and excessive bleeding after surgery or trauma. The defect is due to the inability of ADP to induce platelet aggregation [287]. The P2Y13 receptor Met‐158‐Thr polymorphism, which is in linkage disequilibrium with the P2Y12 locus, is not associated with acute myocardial infarction, diabetes mellitus or related risk factors [44]. The P2Y14 receptor was previously considered to exclusively bind sugar nucleotides such as UDP‐glucose and UDP‐galactose[299]. However, more recent evidence with several cell lines has demonstrated that uridine diphosphate (UDP) is 5‐fold more potent than UDP‐glucose[281]. UDP was also shown to competitively antagonise the UDP‐glucose response at the human recombinant P2Y14 receptor [578].Further reading on P2Y receptorsAbbracchio MP et al. (2006) International Union of Pharmacology LVIII: update on the P2Y G protein‐coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev. 58: 281‐341 [PMID:16968944]Jacobson KA et al. (2015) Nucleotides Acting at P2Y Receptors: Connecting Structure and Function. Mol. Pharmacol. 88: 220‐30 [PMID:25837834]von Kügelgen I et al. (2016) Pharmacology and structure of P2Y receptors. Neuropharmacology 104: 50‐61 [PMID:26519900]Parathyroid hormone receptorsOverviewThe parathyroid hormone receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Parathyroid Hormone Receptors [606]) are family B G protein‐coupled receptors. The parathyroid hormone (PTH)/parathyroid hormone‐related peptide (PTHrP) receptor (PTH1 receptor) is activated by precursor‐derived peptides: PTH(PTH, P01270) (84 amino acids), and PTHrP(PTHLH, P12272) (141 amino‐acids) and related peptides (PTH‐(1‐34), PTHrP‐(1‐36)(PTHLH, P12272)). The parathyroid hormone 2 receptor (PTH2 receptor) is activated by the precursor‐derived peptide TIP39(PTH2, Q96A98) (39 amino acids). [125I]PTH may be used to label both PTH1 and PTH2 receptors.NomenclaturePTH1 receptorPTH2 receptorHGNC, UniProtPTH1R, Q03431PTH2R, P49190Potency order of endogenous ligandsPTH (PTH, P01270) = PTHrP (PTHLH, P12272)TIP39 (PTH2, Q96A98), PTH (PTH, P01270) ≫PTHrP (PTHLH, P12272)Agoniststeriparatide [604]TIP39 (PTH2, Q96A98) [661, 804]Selective agonistsPTHrP‐(1‐34) (human) [605] – Rat–CommentsThe parathyroid hormone type 1 receptor (PTHR) is the canonical GPCR for PTH and PTHrP. It is coupled to Gs and Gq and regulates the development of bone, heart, mammary glands and other tissues in response to PTHrP, and blood concentrations of calcium and phosphate ions, as well as vitamin D, in response to PTH. Another important action of the PTH/PTHR system is to stimulate bone formation when the hormone is intermittently administrated (daily injection). Although PTH(PTH, P01270) is an agonist at human PTH2 receptors, it fails to activate the rodent orthologues. TIP39(PTH2, Q96A98) is a weak antagonist at PTH1 receptors [925].Further reading on Parathyroid hormone receptorsCheloha RW et al. (2015) PTH receptor‐1 signalling‐mechanistic insights and therapeutic prospects. Nat Rev Endocrinol [PMID:26303600]Gardella TJ et al. (2015) International Union of Basic and Clinical Pharmacology. XCIII. The Parathyroid Hormone Receptors‐Family B G Protein‐Coupled Receptors. Pharmacol. Rev. 67: 310‐37 [PMID:25713287]Vilardaga JP et al. (2014) Endosomal generation of cAMP in GPCR signaling. Nat. Chem. Biol. 10: 700‐6 [PMID:25271346]Platelet‐activating factor receptorOverviewPlatelet‐activating factor (PAF, 1‐O‐alkyl‐2‐acetyl‐sn‐glycero‐3‐phosphocholine) is an ether phospholipid mediator associated with platelet coagulation, but also subserves inflammatory roles. The PAF receptor (provisional nomenclature recommended by NC‐IUPHAR [557]) is activated by PAF and other suggested endogenous ligands are oxidized phosphatidylcholine [1265] and lysophosphatidylcholine[1492]. It may also be activated by bacterial lipopolysaccharide [1417].NomenclaturePAF receptorHGNC, UniProtPTAFR, P25105Selective agonistsmethylcarbamyl PAFSelective antagonistsforopafant (pKi 10.3) [774], ABT‐491 (pKi 9.2) [30], CV‐6209 (pIC50 8.1–8.3) [652, 1416], L659989 (pKi 7.8) [851], apafant (pKi 5.2–7.5) [1529, 1904]Labelled ligands[3H]PAF (Agonist) [585, 1416]CommentsNote that a previously recommended radioligand ([3H]apafant; Kd44.6 nM) is currently unavailable.Further reading on Platelet‐activating factor receptorFoord SM et al. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. Pharmacol Rev 57: 279‐288 [PMID:15914470]Ishii S et al. (2000) Platelet‐activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog. Lipid Res. 39: 41‐82 [PMID:10729607]Prescott SM et al. (2000) Platelet‐activating factor and related lipid mediators. Annu. Rev. Biochem. 69: 419‐45 [PMID:10966465]Prokineticin receptorsOverviewProkineticin receptors, PKR1 and PKR2(provisional nomenclature as recommended by NC‐IUPHAR[557]) respond to the cysteine‐rich 81‐86 amino‐acid peptides prokineticin‐1(PROK1, Q9HC23) (also known as endocrine gland‐derived vascular endothelial growth factor, mambakine) and prokineticin‐2(PROK2, Q9HC23) (protein Bv8 homologue). An orthologue of PROK1 from black mamba (Dendroaspis polylepis) venom, mamba intestinal toxin 1 (MIT1, [1749]) is a potent, non‐selective agonist at prokineticin receptors [1279], while Bv8, an orthologue of PROK2 from amphibians (Bombina sp., [1357]), is equipotent at recombinant PKR1 and PKR2[1435], and has high potency in macrophage chemotaxis assays, which are lost in PKR1‐null mice.NomenclaturePKR1PKR2HGNC, UniProtPROKR1, Q8TCW9PROKR2, Q8NFJ6Potency order of endogenous ligandsprokineticin‐2 (PROK2, Q9HC23) >prokineticin‐1 (PROK1, Q9HC23) >prokineticin‐2β (PROK2) [1175, 1279, 1843]prokineticin‐2 (PROK2, Q9HC23) >prokineticin‐1 (PROK1, Q9HC23) >prokineticin‐2β (PROK2) [1175, 1279, 1843]Endogenous agonistsprokineticin‐2 (PROK2, Q9HC23) [316, 1279], prokineticin‐1 (PROK1, Q9HC23) [316, 1279], prokineticin‐2β (PROK2) [316]prokineticin‐2 (PROK2, Q9HC23) [316, 1279], prokineticin‐1 (PROK1, Q9HC23) [316, 1279], prokineticin‐2β (PROK2) [316]AgonistsMIT1 [1279]MIT1 [1279]Selective agonistsIS20 [612], IS1 [612]–Labelled ligands[125I]BH‐MIT1 (Agonist) [1279][125I]BH‐MIT1 (Agonist) [1279]CommentsGenetic mutations in PROKR1 are associated with Hirschsprung's disease [1688], while genetic mutations in PROKR2 are associated with hypogonadotropic hypogonadism with anosmia [455], hypopituitarism with pituitary stalk interruption [1649] and Hirschsprung's disease [1688].Further reading on Prokineticin receptorsBoulberdaa M et al. (2011) Prokineticin receptor 1 (PKR1) signalling in cardiovascular and kidney functions. Cardiovasc. Res. 92: 191‐8 [PMID:21856786]Negri L et al. (2012) Bv8/PK2 and prokineticin receptors: a druggable pronociceptive system. Curr Opin Pharmacol 12: 62‐6 [PMID:22136937]Negri L et al. (2007) Bv8/Prokineticin proteins and their receptors. Life Sci. 81: 1103‐16 [PMID:17881008]Ngan ES et al. (2008) Prokineticin‐signaling pathway. Int. J. Biochem. Cell Biol. 40: 1679‐84 [PMID:18440852]Prolactin‐releasing peptide receptorOverviewThe precursor (PRLH, P81277) for PrRP generates 31 and 20‐amino‐acid versions. QRFP43(QRFP, P83859) (named after a pyroglutamylated arginine‐phenylalanine‐amide peptide) is a 43 amino acid peptide derived from QRFP(P83859) and is also known as P518 or 26RFa. RFRP is an RF amide‐related peptide [794] derived from a FMRFamide‐related peptide precursor (NPVF, Q9HCQ7), which is cleaved to generate neuropeptide SF(NPFF, O15130), neuropeptide RFRP‐1(NPVF, Q9HCQ7), neuropeptide RFRP‐2(NPVF, Q9HCQ7) and neuropeptide RFRP‐3(NPVF, Q9HCQ7) (neuropeptide NPVF).NomenclaturePrRP receptorHGNC, UniProtPRLHR, P49683Potency order of endogenous ligandsPrRP‐20 (PRLH, P81277) = PrRP‐31 (PRLH, P81277) [1099]Endogenous agonistsPrRP‐20 (PRLH, P81277) [509, 1099], PrRP‐31 (PRLH, P81277) [509, 1099]Endogenous antagonistsneuropeptide Y (NPY, P01303) (pKi 5.4) [1087]Labelled ligands[125I]PrRP‐20 (human) (Agonist) [1099], [125I]PrRP31 (Agonist) [501]CommentsThe orphan receptor GPR83(Q9NYM4) shows sequence similarities with NPFF1, NPFF2, PrRP and QRFP receptors.Further reading on Prolactin‐releasing peptide receptorSamson WK et al. (2006) Prolactin releasing peptide (PrRP): an endogenous regulator of cell growth. Peptides 27: 1099‐103 [PMID:16500730]Takayanagi Y et al. (2010) Roles of prolactin‐releasing peptide and RFamide related peptides in the control of stress and food intake. FEBS J. 277: 4998‐5005 [PMID:21126313]Prostanoid receptorsOverviewProstanoid receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Prostanoid Receptors [2132]) are activated by the endogenous ligands prostaglandins PGD2, PGE1, PGE2 , PGF2α, PGH2, prostacyclin [PGI2] and thromboxane A2. Measurement of the potency of PGI2 and thromboxane A2 is hampered by their instability in physiological salt solution; they are often replaced by cicaprost and U46619, respectively, in receptor characterization studies.NomenclatureDP1 receptorDP2 receptorHGNC, UniProtPTGDR, Q13258PTGDR2, Q9Y5Y4Potency order of endogenous ligandsPGD2>PGE1≫PGE2>PGF2α>PGI2, thromboxane A2PGD2≫PGF2α, PGE2>PGI2, thromboxane A2Selective agonistsBW 245C [173, 2133, 2134], L‐644,698 [2133, 2134]15(R)‐15‐methyl‐PGD2 [747, 1366, 1889]Antagonists–fevipiprant (pKd 9) [1908, 1909], ramatroban (pKi 7.4) [1889]Selective antagonistslaropiprant (pKi 10.1) [1882], BWA868C (pKi 8.6–9.3) [173, 640, 2133], ONO‐AE3‐237 (pKi 7.7) [796, 1974, 1976]CAY 10471 (pIC50 8.9) [1684, 2003]Labelled ligands[3H]PGD2 (Agonist) [2119, 2133][3H]PGD2 (Agonist) [1280, 1790]NomenclatureEP1 receptorEP2 receptorEP3 receptorEP4 receptorHGNC, UniProtPTGER1, P34995PTGER2, P43116PTGER3, P43115PTGER4, P35408Potency order of endogenous ligandsPGE2>PGE1>PGF2α, PGI2>PGD2, thromboxane A2PGE2 = PGE1>PGF2α, PGI2>PGD2, thromboxane A2PGE2, PGE1>PGF2α, PGI2>PGD2, thromboxane A2PGE2 = PGE1>PGF2α, PGI2>PGD2, thromboxane A2Endogenous agonists–PGE2 [7, 1871, 2119]PGE2 (EP3‐III isoform) [7]–Agonists17‐phenyl‐ω‐trinor‐PGE2 [1783]PGE1 [111]misoprostol (methyl ester) (EP3‐III isoform) [7]–Selective agonistsONO‐DI‐004 [1899] – MouseONO‐AE1‐259 [1899] – Mouse, butaprost (free acid form) [7, 1871]sulprostone (EP3‐III isoform) [7], ONO‐AE‐248 [562, 1206]L902688 [563, 1129], ONO‐AE1‐329 [562, 563]Antagonists–––EP4A (pKi 7.6–8.5) [1229, 2195]Selective antagonistsONO‐8711 (pKi 9.2) [2079], SC‐51322 (pKi 7.9) [7]PF‐04418948 (PF‐04418948 has weaker affinity at the EP2‐receptor in guinea‐pigs) (pKB 8.3) [14, 157], TG6‐129 (pKB 8.1) [598]L‐826266 (EP3‐III isoform (pKi=8.04 in the presence of HSA)) (pKi 9.1) [933], ONO‐AE3‐240 (pIC50 8.8) [38] – Mouse, DG‐041 (pKi 8.4) [931]ONO‐AE3‐208 (pKi 8.5), GW 627368 (pKi 7–7.1) [2119, 2120]Labelled ligands[3H]PGE2 (Agonist) [7, 1783, 2119][3H]PGE2 (Agonist) [7, 2119][3H]PGE2 (Agonist) [7, 2119][3H]PGE2 (Agonist) [7, 420, 2107, 2119]NomenclatureFP receptorIP receptorTP receptorHGNC, UniProtPTGFR, P43088PTGIR, P43119TBXA2R, P21731Potency order of endogenous ligandsPGF2α>PGD2>PGE2>PGI2, thromboxane A2PGI2≫PGE1>PGD2, PGF2α>thromboxane A2thromboxane A2 = PGH2≫PGD2, PGE2, PGF2α, PGI2Endogenous agonists–PGI2 [1804], PGE1 [1277, 1873]–Agonists–iloprost [7, 2119], treprostinil [2107]–Selective agonistsfluprostenol [7], latanoprost (free acid form) [7]cicaprost [7]U46619 [7]Antagonists––ramatroban (pKi 8) [1944]Selective antagonistsAS604872 (pKi 7.5) [361]RO1138452 (pKi 8.7) [162], RO3244794 (pA2 8.5) [162]vapiprost (pKi 8.3–9.4) [63, 1216], SQ‐29548 (pKi 8.1–9.1) [7, 1907, 2119]Labelled ligands[3H]PGF2α (Agonist) [7, 8, 2119], [3H](+)‐fluprostenol (Agonist)[3H]iloprost (Agonist) [7, 172, 2107, 2119][125I]SAP (Antagonist) (pKd 7.7–9.3) [1415], [125I]BOP (Agonist) [1381], [3H]SQ‐29548 (Antagonist) (pKd 7.4–8.2) [7, 2119]CommentsWhilst cicaprost is selective for IP receptors, it does exhibit moderate agonist potency at EP4 receptors [7]. Apart from IP receptors, iloprost also binds to EP1 receptors. The IP receptor agonist treprostinil binds also to human EP2 and DP1 receptors with high affinity (pKi 8.44 and 8.36, respectively) [2107]. The EP1 agonist 17‐phenyl‐ω‐trinor‐PGE2 also shows agonist activity at EP3 receptors. Butaprost and SC46275 may require de‐esterification within tissues to attain full agonist potency. There is evidence for subtypes of FP [1171] and TP receptors [1050, 1637]. mRNA for the EP3 receptor undergoes alternative splicing to produce variants which can interfere with signalling [1509] or generate complex patterns of G‐protein (Gi/o, Gq/11, Gs and G12,13) coupling (e.g. [1042, 1433]). The number of EP3 receptor (protein) variants are variable depending on species, with five in human, three in rat and three in mouse. Putative receptor(s) for prostamide F (which as yet lack molecular correlates) and which preferentially recognize PGF2‐1‐ethanolamide and its analogues (e.g. Bimatoprost) have been identified, together with moderate‐potency antagonists (e.g. AGN 211334) [2131]. The free acid form of AL‐12182, AL12180, used in in vitro studies, has a EC50 of 15nM which is the concentration of the compound giving half‐maximal stimulation of inositol phosphate turnover in HEK‐293 cells expressing the human FP receptor [1784]. References given alongside the TP receptor agonists I‐BOP [1295] and STA2[63] use human platelets as the source of TP receptors for competition radio‐ligand binding assays to determine the indicated activity values. Pharmacological evidence for a second IP receptor, denoted IP2, in the central nervous system [1924, 2082] and in the BEAS‐2B human airway epithelial cell line [2122] is available. This receptor is selectively activated by 15R‐17,18,19, 20‐tetranor‐16‐m‐tolyl‐isocarbacyclin (15R‐TIC) and 15R‐Deoxy 17,18,19,20‐tetranor‐16‐m‐tolyl‐isocarbacyclin (15‐deoxy‐TIC). However, molecular biological evidence for an IP2 subtype is currently lacking.Further reading on Prostanoid receptorsWoodward DF et al. (2011) International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol. Rev. 63: 471‐538 [PMID:21752876]Proteinase‐activated receptorsOverviewProteinase‐activated receptors (PARs, nomenclature as agreed by the NC‐IUPHAR Subcommittee on Proteinase‐activated Receptors [809]) are unique members of the GPCR superfamily activated by proteolytic cleavage of their amino terminal exodomains. Agonist proteinase‐induced hydrolysis unmasks a tethered ligand (TL) at the exposed amino terminus, which acts intramolecularly at the binding site in the body of the receptor to effect transmembrane signalling. TL sequences at human PAR1‐4 are SFLLRN‐NH2, SLIGKV‐NH2, TFRGAP‐NH2 and GYPGQV‐NH2, respectively. With the exception of PAR3, these synthetic peptide sequences (as carboxyl terminal amides) are able to act as agonists at their respective receptors. Several proteinases, including neutrophil elastase, cathepsin G and chymotrypsin can have inhibitory effects at PAR1 and PAR2 such that they cleave the exodomain of the receptor without inducing activation of Gαq‐coupled calcium signalling, thereby preventing activation by activating proteinases but not by agonist peptides. Neutrophil elastase (NE) cleavage of PAR1 and PAR2 can however activate MAP kinase signaling by exposing a TL that is different from the one revealed by trypsin [1624]. PAR2 ectivation by NE regulates inflammation and pain responses [1397, 2217] and triggers mucin secretion from airway epithelial cells [2220].NomenclaturePAR1PAR2PAR3PAR4HGNC, UniProtF2R, P25116F2RL1, P55085F2RL2, O00254F2RL3, Q96RI0Agonist proteasesthrombin (F2, P00734), activated protein C (PROC, P04070), matrix metalloproteinase 1 (MMP1, P45452), matrix metalloproteinase 13 (MMP13, P45452) [73]Trypsin, tryptase, TF/VIIa, Xathrombin (F2, P00734)thrombin (F2, P00734), trypsin, cathepsin G (CTSG, P08311)AgonistsF16357–––Selective agonistsTFLLR‐NH2 [355]AC264613 [1767], AY77 [2178], AC‐55541 [1767], GB110 [104], 2‐furoyl‐LIGRLO‐amide [1305], SLIGKV‐NH2 [1134], SLIGRL‐NH2 [1134]–AYPGKF‐NH2, GYPGKF‐NH2, GYPGQV‐NH2Selective antagonistsvorapaxar (pKi 8.1) [295], atopaxar (pIC50 7.7) [1024], RWJ‐56110 (pIC50 6.4) [49]GB88 (pIC50 5.7) [1886], P2pal18s [1776]–YD‐3 (pIC50 6.9) [2091], ML354 (pIC50 6.8) [2091]Labelled ligands[3H]haTRAP (Agonist) [17]2‐furoyl‐LIGRL[N‐(Alexa Fluor 594)‐O]‐NH2 (Agonist) [810], 2‐furoyl‐LIGRL[N[3H]propionyl]‐O‐NH2 (Agonist) [810], [3H]2‐furoyl‐LIGRL‐NH2 (Selective Agonist) [946], trans‐cinnamoyl‐LIGRLO [N‐[3H]propionyl]‐NH2 (Agonist) [28]––CommentsTFLLR‐NH2 is selective relative to the PAR2 receptor [159, 958].2‐Furoyl‐LIGRLO‐NH2 activity was measured via calcium mobilisation in HEK 293 cells which constitutively coexpress human PAR1 and PAR2.––CommentsEndogenous serine proteases (EC 3.4.21.) active at the proteinase‐activated receptors include: thrombin(F2, P00734), generated by the action of Factor X (F10, P00742) on liver‐derived prothrombin (F2, P00734); trypsin, generated by the action of enterokinase (TMPRSS15, P98073) on pancreatic‐derived trypsinogen (PRSS1, P07477); tryptase, a family of enzymes (α/β1 TPSAB1, Q15661 ; γ1 TPSG1, Q9NRR2; δ1 TPSD1, Q9BZJ3) secreted from mast cells; cathepsin G (CTSG, P08311) generated from leukocytes; liver‐derived protein C (PROC, P04070) generated in plasma by thrombin(F2, P00734) and matrix metalloproteinase 1 (MMP1, P45452).Further reading on Proteinase‐activated receptorsAdams MN et al. (2011) Structure, function and pathophysiology of protease activated receptors. Pharmacol. Ther. 130: 248‐82 [PMID:21277892]Canto I et al. (2012) Allosteric modulation of protease‐activated receptor signaling. Mini Rev Med Chem 12: 804‐11 [PMID:22681248]García PS et al. (2010) The role of thrombin and protease‐activated receptors in pain mechanisms. Thromb. Haemost. 103: 1145‐51 [PMID:20431855]Hollenberg MD et al. (2002) International Union of Pharmacology. XXVIII. Proteinase‐activated receptors. Pharmacol. Rev. 54: 203‐17 [PMID:12037136]Ramachandran R et al. (2012) Targeting proteinase‐activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov 11: 69‐86 [PMID:22212680]Soh UJ et al. (2010) Signal transduction by protease‐activated receptors. Br. J. Pharmacol. 160: 191‐203 [PMID:20423334]QRFP receptorOverviewThe human gene encoding the QRFP receptor (QRFPR, also known as the peptide P518 receptor), previously designated as an orphan GPCR receptor was identified in 2001 by Lee et al. from a hypothalamus cDNA library [1131]. However, the reported cDNA (AF411117) is a chimera with bases 1‐127 derived from chromosome 1 and bases 155‐1368 derived from chromosome 4. When corrected, QRFPR (also referred to as SP9155 or AQ27) encodes a 431 amino acid protein that shares sequence similarities in the transmembrane spanning regions with other peptide receptors. These include neuropeptide FF2 (38%), neuropeptide Y2 (37%) and galanin Gal1(35%) receptors.NomenclatureQRFP receptorHGNC, UniProtQRFPR, Q96P65Endogenous agonistsQRFP43 (QRFP, P83859) [311, 587, 1923] – Rat, QRFP26 (QRFP) [311, 910]AgonistsLV‐2172 [1448]Selective antagonistscompound 25e (pIC50 7.3) [628, 629]Labelled ligands[125I]QRFP43 (human) (Agonist) [587, 1063, 1923]CommentsThe orphan receptor GPR83(9NYM4) shows sequence similarities with the QRFP receptor, as well as with the NPFF1, NPFF2, and PrRP receptors.Further reading on QRFP receptorFukusumi S et al. (2006) Recent advances in mammalian RFamide peptides: the discovery and functional analyses of PrRP, RFRPs and QRFP. Peptides 27: 1073‐86 [PMID:16500002]Relaxin family peptide receptorsOverviewRelaxin family peptide receptors (RXFP, nomenclature as agreed by the NC‐IUPHAR Subcommittee on Relaxin family peptide receptors [112, 713]) may be divided into two pairs, RXFP1/2 and RXFP3/4. Endogenous agonists at these receptors are a number of heterodimeric peptide hormones structurally related to insulin: relaxin‐1(RLN1, P04808), relaxin(RLN2, P04090), relaxin‐3(RLN3, Q8WXF3) (also known as INSL7), insulin‐like peptide 3 (INSL3(INSL3, P51460)) and INSL5(INSL5, Q9Y5Q6).Species homologues of relaxin have distinct pharmacology – relaxin(RLN2, P04090) interacts with RXFP1, RXFP2 and RXFP3, whereas mouse and rat relaxin selectively bind to and activate RXFP1 [1755] and porcine relaxin may have a higher efficacy than human relaxin(RLN2, P04090) [714]. Relaxin‐3(RLN3, Q8WXF3) has differential affinity for RXFP2 between species; mouse and rat RXFP2 have a higher affinity for relaxin‐3(RLN3, Q8WXF3) [1754]. At least two binding sites have been identified on RXFP1 and RXFP2: a high‐affinity site in the leucine‐rich repeat region of the ectodomain and a somewhat lower‐affinity site located in the surface loops of the transmembrane domain [714, 1885]. The unique N‐terminal LDLa module of RXFP1 and RXFP2 is essential for receptor signalling [1756].NomenclatureRXFP1RXFP2RXFP3RXFP4HGNC, UniProtRXFP1, Q9HBX9RXFP2, Q8WXD0RXFP3, Q9NSD7RXFP4, Q8TDU9Potency order of endogenous ligandsrelaxin (RLN2, P04090) = relaxin‐1 (RLN1, P04808) >relaxin‐3 (RLN3, Q8WXF3) [1885]INSL3 (INSL3, P51460) >relaxin (RLN2, P04090) ≫relaxin‐3 (RLN3, Q8WXF3) [1072, 1885]relaxin‐3 (RLN3, Q8WXF3) >relaxin‐3 (B chain) (RLN3, Q8WXF3) >relaxin (RLN2, P04090) [1186]INSL5 (INSL5, Q9Y5Q6) = relaxin‐3 (RLN3, Q8WXF3) >relaxin‐3 (B chain) (RLN3, Q8WXF3) [1184, 1185]Endogenous antagonists––INSL5 (INSL5, Q9Y5Q6) (pKi 7) [2223]–AntagonistsB‐R13/17K H2 relaxin (pEC50 5.7–6.7) [827, 1446]–R3(BΔ23‐27)R/I5 chimeric peptide (pIC50 9.2) [1064]R3(BΔ23‐27)R/I5 chimeric peptide (pIC50 8–8.6) [749, 1064]Selective antagonists–A(9‐26)INSL3 (pKi 9.1) [826], A(10‐24)INSL3 (pKi 8.7) [826], A(C10/15S)INSL3 (pKi 8.6) [2210], INSL3 B chain dimer analogue 8 (pKi 8.5) [1781], A(Δ10/15C)INSL3 (pKi 8.3) [2210], cyclic INSL3 B‐chain analogue 6 (pKi 6.7) [1779], INSL3 B‐chain analogue (pKi 5.1) [434], (des 1‐8) A‐chain INSL3 analogue [262]minimised relaxin‐3 analogue 3 (pKi 7.6) [1777], R3‐B1‐22R (pKi 7.4) [749]minimised relaxin‐3 analogue 3 (pIC50 6.6) [1777]Allosteric modulatorsML290 (Agonist) (pEC50 7) [2146, 2149]–––Labelled ligands[33P]relaxin (human) (Agonist) [714, 1885], europium‐labelled relaxin (Agonist) [1778], [125I]relaxin (human) (Agonist)[125I]INSL3 (human) (Agonist) [1395], [33P]relaxin (human) (Agonist) [714, 1885][125I]relaxin‐3 (human) (Agonist) [1186], [125I]relaxin‐3‐B/INSL5 A chimera (Agonist) [1184], europium‐labelledrelaxin‐3‐B/INSL5 A chimera (Agonist) [749][125I]relaxin‐3 (human) (Agonist) [1185], [125I]relaxin‐3‐B/INSL5 A chimera (Agonist) [1184], europium‐labelled mouse INSL5 (Agonist) [126], europium‐labelled relaxin‐3‐B/INSL5A chimera (Agonist) [749], europium‐labelled INSL5 (pKd 8.3) [749]Comments–europium‐labelled INSL3 is a fluorescent ligand for this receptor (Kd=1nM) [1780].––CommentsRelaxin is the cognate peptide ligand for RXFP1 and is in extended Phase III clinical trials for the treatment of acute heart failure [1322]. Relaxin has vasodilatory, anti‐fibrotic, angiogenic, anti‐apoptotic and anti‐inflammatory effects. Small molecule allosteric agonists such as ML290 have been developed [1787, 2149]. The antifibrotic actions of relaxin are dependent on the angiotensin receptor AT2[344]. RXFP2 and its cognate ligand INSL3 have a more specialized role with mutations reported in patients with cryptorchidism [538]. cAMP elevation is the major signalling pathway for RXFP1 and RXFP2 [834, 835], but RXFP1 also activates MAP kinases, nitric oxide signalling, tyrosine kinase phosphorylation and relaxin can interact with glucocorticoid receptors [716]. RXFP1 signalling involves lipid rafts, residues in the C‐terminus of the receptor and activation of phosphatidylinositol‐3‐kinase [717] and pre‐assembled protein complexes [715]. Receptor expression profiles suggest that RXFP3 is a brain neuropeptide receptor and RXFP4 a gut hormone receptor with the relaxin‐3/RXFP3 system modulating feeding [596, 597, 749, 1777, 1830], anxiety [1694, 2204], and reward and motivated goal‐directed behaviours [821, 1694, 2055]. Relaxin‐3(RLN3, Q8WXF3) is an agonist at RXFP3 and RXFP4 whereas INSL5(INSL5, Q9Y5Q6) is an agonist at RXFP4 and a weak antagonist at RXFP3. Unlike RXFP1 and RXFP2, both RXFP3 and RXFP4 are encoded by a single exon. INSL5 is secreted from enteroendocrine L cells and the INSL5/RXFP4 system controls food intake and glucose homeostasis [685]. RXFP3 and RXFP4 couple to Gi/o and inhibit adenylyl cyclase [1186, 2014], and also cause Erk1/2 phosphorylation [2014]. RXFP4 also causes phosphorylation of p38MAPK, Akt and S6RP [51]. There is evidence that at RXFP3, relaxin(RLN2, P04090) is a biased ligand compared to the cognate ligand relaxin‐3.Further reading on Relaxin family peptide receptorsBathgate RA et al. (2013) Relaxin family peptides and their receptors. Physiol. Rev. 93: 405‐80 [PMID:23303914]Du XJ et al. (2010) Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol 7: 48‐58 [PMID:19935741]Halls ML et al. (2015) International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1‐4, the receptors for relaxin family peptides. Pharmacol. Rev. 67: 389‐440 [PMID:25761609]Ivell R et al. (2011) Relaxin family peptides in the male reproductive system–a critical appraisal. Mol. Hum. Reprod. 17: 71‐84 [PMID:20952422]Somatostatin receptorsOverviewSomatostatin (somatotropin release inhibiting factor) is an abundant neuropeptide, which acts on five subtypes of somatostatin receptor (SST1‐SST5; nomenclature as agreed by the NC‐IUPHAR Subcommittee on Somatostatin Receptors [829]). Activation of these receptors produces a wide range of physiological effects throughout the body including the inhibition of secretion of many hormones. Endogenous ligands for these receptors are somatostatin‐14 (SRIF‐14(SST, P61278)) and somatostatin‐28 (SRIF‐28(SST, P61278)). Cortistatin‐14{Mouse, Rat} has also been suggested to be an endogenous ligand for somatostatin receptors [427].NomenclatureSST1 receptorSST2 receptorSST3 receptorSST4 receptorSST5 receptorHGNC, UniProtSSTR1, P30872SSTR2, P30874SSTR3, P32745SSTR4, P31391SSTR5, P35346Agonistspasireotide [1740]pasireotide [1740]pasireotide [1740], vapreotide [238, 1540, 1807]NNC269100 [1197]pasireotide [1740]Selective agonistsL‐797,591 [1669], Des‐Ala1,2,5‐[D‐Trp8,IAmp9]SRIF [512]L‐054,522 [2172], BIM 23027 [283], octreotide [238, 1540, 1805, 1806, 1807, 2172]L‐796,778 [1669]L‐803,087 [1669]BIM 23052 [1325, 1805, 1806, 1807], L‐817,818 [1669]Selective antagonistsSRA880 (pKd 8–8.1) [831][D‐Tyr8]CYN 154806 (pKd 8.1–8.9) [1478]NVP ACQ090 (pKi 7.9) [832]––Labelled ligands–[125I]Tyr3 SMS 201‐995 (Agonist) [1805, 1806], [125I]BIM23027 (Agonist) [811] – Rat––[125I]Tyr3 SMS 201‐995 (Agonist) [1805, 1806]Comments[125I]Tyr11‐SRIF‐14, [125I]LTT‐SRIF‐28, [125I]CGP 23996 and [125I]Tyr10‐CST14 may be used to label somatostatin receptors nonselectively. A number of nonpeptide subtype‐selective agonists have been synthesised [1669]. Octreotide and lanreotide are being used in the treatment of SST2‐expressing neuroendocrine tumors and pasireotide for SST5‐expressing neuroendocrine tumors. A novel peptide somatostatin analogue, veldoreotide (somatoprim), has affinity for SST2, SST4 and SST5 receptors and is a potent inhibitor of GH secretion [1586, 1793].Further reading on Somatostatin receptorsColao A et al. (2011) Resistance to somatostatin analogs in acromegaly. Endocr. Rev. 32: 247‐71 [PMID:21123741]Hoyer D et al. (2000) Somatostatin receptors. In The IUPHAR Compendium of Receptor Characterization and Classification, 2nd edn. Edited by Watson SP, Girdlestone D: IUPHAR Media: 354‐364Schulz S et al. (2014) Fine‐tuning somatostatin receptor signalling by agonist‐selective phosphorylation and dephosphorylation: IUPHAR Review 5. Br. J. Pharmacol. 171: 1591‐9 [PMID:24328848]Weckbecker G et al. (2003) Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2: 999‐1017 [PMID:14654798]Succinate receptorOverviewNomenclature as recommended by NC‐IUPHAR[414]. The Succinate receptor has been identified as being activated by physiological levels of the Krebs' cycle intermediate succinate and other dicarboxylic acids such as maleate in 2004. Since its pairing with its endogenous ligand, the receptor has been the focus of intensive research and its role has been evidenced in various (patho)physiological processes such as regulation of renin production, retinal angiogenesis or immune response.Nomenclaturesuccinate receptorHGNC, UniProtSUCNR1, Q9BXA5Endogenous agonistssuccinic acid [762, 1854]CommentsIn humans, there is the possibility of two open‐reading frames (ORFs) for SUCNR1, allowing the generation of 330 or 334 amino acid proteins Wittenberger et al.[2127] noted that the 330‐AA protein was more likely to be expressed given the Kozak sequence surrounding the second ATG. Some databases report SUCNR1 as being 334‐AA long.Further reading on Succinate receptorAriza AC et al. (2012) The succinate receptor as a novel therapeutic target for oxidative and metabolic stress‐related conditions. Front Endocrinol (Lausanne) 3: 22. [PMID:22649411]de Castro Fonseca M et al. (2016) GPR91: expanding the frontiers of Krebs cycle intermediates. Cell Commun. Signal 14: 3 [PMID:26759054]Gilissen J et al. (2016) Insight into SUCNR1 (GPR91) structure and function. Pharmacol. Ther. 159: 56‐65 [PMID:26808164]Peti‐Peterdi J. (2010) High glucose and renin release: the role of succinate and GPR91. Kidney Int. 78 (12): 1214‐7. [PMID:20861827]Tachykinin receptorsOverviewTachykinin receptors (provisional nomenclature as recommended by NC‐IUPHAR[557]) are activated by the endogenous peptides substance P(TAC1, P20366) (SP), neurokinin A (TAC1, P20366) (NKA; previously known as substance K, neurokinin α, neuromedin L), neurokinin B (TAC3, Q9UHF0) (NKB; previously known as neurokinin β, neuromedin K), neuropeptide K(TAC1, P20366) and neuropeptide γ(TAC1, P20366) (N‐terminally extended forms of neurokinin A). The neurokinins (A and B) are mammalian members of the tachykinin family, which includes peptides of mammalian and nonmammalian origin containing the consensus sequence: Phe‐x‐Gly‐Leu‐Met. Marked species differences in in vitro pharmacology exist for all three receptors, in the context of nonpeptide ligands. Antagonists such as aprepitant and fosaprepitant were approved by FDA and EMA, in combination with other antiemetic agents, for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy.NomenclatureNK1 receptorNK2 receptorNK3 receptorHGNC, UniProtTACR1, P25103TACR2, P21452TACR3, P29371Potency order of endogenous ligandssubstance P (TAC1, P20366) >neurokinin A (TAC1, P20366) >neurokinin B (TAC3, Q9UHF0)neurokinin A (TAC1, P20366) >neurokinin B (TAC3, Q9UHF0) ≫substance P (TAC1, P20366)neurokinin B (TAC3, Q9UHF0) >neurokinin A (TAC1, P20366) >substance P (TAC1, P20366)Agonistssubstance P‐OMe [1960]––Selective agonists[Sar9,Met(O2)11]SP [1960], septide [130, 746], [Pro9]SP [1975] – Rat[Lys5,Me‐Leu9,Nle10]NKA‐(4‐10) [1292] – Rat, GR64349 [432] – Rat, [βAla8]neurokinin A‐(4‐10) [505][Phe(Me)7]neurokinin B [1717, 1718], senktide [1717, 1718, 1960]Selective antagonistsaprepitant (pKi 10.1) [709, 710], CP 99994 (pKi 9.3–9.7) [53, 1718], RP67580 (pIC50 7.7) [555]GR94800 (pKi 9.8) [206], saredutant (pKi 9.4–9.7) [53, 505, 1718], GR 159897 (pKd 7.8–9.5) [137, 505, 1837], MEN10627 (pKi 9.2) [638], nepadutant (pKi 8.5–8.7) [284, 358]osanetant (pKi 8.4–9.7) [53, 116, 357, 504, 941, 1518, 1717, 1718, 1960], talnetant (pKi 7.4–9) [133, 639, 1717, 1718], PD157672 (pIC50 7.8–7.9) [168, 1960]Labelled ligands[125I]L703,606 (Antagonist) (pKd 9.5) [566], [125I]BH‐[Sar9,Met(O2)11]SP (Agonist) [1979] – Rat, [3H]SP (human, mouse, rat) (Agonist) [84], [125I]SP (human, mouse, rat) (Agonist), [18F]SPA‐RQ (Antagonist) [332][3H]saredutant (Antagonist) (pKd 9.7) [683] – Rat, [125I]NKA (human, mouse, rat) (Agonist) [2077], [3H]GR100679 (Antagonist) (pKd 9.2) [705][3H]osanetant (Antagonist) (pKd 9.9), [3H]senktide (Agonist) [693] – Guinea pig, [125I][MePhe7]NKB (Agonist)CommentsThe NK1 receptor has also been described to couple to G proteins other than Gq/11[1680]. The hexapeptide agonist septide appears to bind to an overlapping but non‐identical site to substance P(TAC1, P20366) on the NK1 receptor. There are suggestions for additional subtypes of tachykinin receptor; an orphan receptor (SwissProt P30098) with structural similarities to the NK3 receptor was found to respond to NKB when expressed in Xenopus oocytes or Chinese hamster ovary cells [459, 1049].Further reading on Tachykinin receptorsDouglas SD et al. (2011) Neurokinin‐1 receptor: functional significance in the immune system in reference to selected infections and inflammation. Ann. N. Y. Acad. Sci. 1217: 83‐95 [PMID:21091716]Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. Pharmacol Rev 57: 279‐288 [PMID:15914470]Jones S et al. (2008) The neurokinin 1 receptor: a potential new target for anti‐platelet therapy? Curr Opin Pharmacol 8: 114‐9 [PMID:18296119]Rance NE et al. (2010) Neurokinin B and the hypothalamic regulation of reproduction. Brain Res. 1364: 116‐28 [PMID:20800582]Rojas C et al. (2012) Pharmacological mechanisms of 5‐HT_3 and tachykinin NK_1 receptor antagonism to prevent chemotherapy‐induced nausea and vomiting. Eur. J. Pharmacol. 684: 1‐7 [PMID:22425650]Steinhoff MS et al. (2014) Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol. Rev. 94: 265‐301 [PMID:24382888]Thyrotropin‐releasing hormone receptorsOverviewThyrotropin‐releasing hormone (TRH) receptors (provisional nomenclature as recommended by NC‐IUPHAR[557]) are activated by the endogenous tripeptide TRH(TRH, P20396) (pGlu‐His‐ProNH2). TRH(TRH, P20396) and TRH analogues fail to distinguish TRH1 and TRH2 receptors [1896]. [3H]TRH (human, mouse, rat) is able to label both TRH1 and TRH2 receptors with Kd values of 13 and 9 nM respectively. Synthesis and biology of ring‐modified L‐Histidine containing TRH analogues has been reported [1316].NomenclatureTRH1 receptorTRH2 receptorHGNC, UniProtTRHR, P34981–Antagonistsdiazepam (pKi 5.2) [471] – Rat–Selective antagonistsmidazolam (pKi 5.5) [471] – Rat, chlordiazepoxide (pKi 4.8) [471] – Rat, chlordiazepoxide (pKi 4.7) [1878] – Mouse–Comments–A class A G protein‐coupled receptor: not present in manFurther reading on Thyrotropin‐releasing hormone receptorsBílek R et al. (2011) TRH‐like peptides. Physiol Res 60: 207‐15 [PMID:21114375]Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. Pharmacol Rev 57: 279‐288 [PMID:15914470]Nillni EA. (2010) Regulation of the hypothalamic thyrotropin releasing hormone (TRH) neuron by neuronal and peripheral inputs. Front Neuroendocrinol 31: 134‐56 [PMID:20074584]Trace amine receptorOverviewTrace amine‐associated receptors were discovered from a search for novel 5‐HT receptors [189], where 15 mammalian orthologues were identified and divided into two families. The TA1 receptor (nomenclature as agreed by the NC‐IUPHAR Subcommittee for the Trace amine receptor [1244]) has affinity for the endogenous trace amines tyramine, β‐phenylethylamine and octopamine in addition to the classical amine dopamine[189]. Emerging evidence suggests that TA1 is a modulator of monoaminergic activity in the brain [2151] with TA1 and dopamine D2 receptors shown to form constitutive heterodimers when co‐expressed [519]. In addition to trace amines, receptors can be activated by amphetamine‐like psychostimulants, and endogenous thyronamines.NomenclatureTA1 receptorHGNC, UniProtTAAR1, Q96RJ0Potency order of endogenous ligandstyramine>β‐phenylethylamine>octopamine = dopamine [189]AgonistsRO5166017 [1648]AntagonistsEPPTB (Inverse agonist) (pIC50 5.1) [205]Labelled ligands[3H]tyramine (Agonist) [189]CommentsIn addition to TA1, in man there are up to 5 functional TAAR genes (TAAR2,5,6,8,9). See [189] for detailed discussion. The product of the gene TAAR2 (also known as GPR58) appears to respond to β‐phenylethylamine>tyramine and to couple through Gs[189]. TAAR3, in some individuals, and TAAR4 are pseudogenes in man, although functional in rodents. The signalling characteristics and pharmacology of TAAR5(PNR, Putative Neurotransmitter Receptor: TAAR5, O14804), TAAR6(Trace amine receptor 4, TaR‐4: TAAR6, 96RI8), TAAR8(Trace amine receptor 5, GPR102: TAAR8, Q969N4) and TAAR9(trace amine associated receptor 9: TAAR9, 96RI9) are lacking. The thyronamines, endogenous derivatives of thyroid hormone, have affinity for rodent cloned trace amine receptors, including TA1[1728]. An antagonist EPPTB has recently been described with a pKi of 9.1 at the mouse TA1 but >5.3 for human TA1[1863].Further reading on Trace amine receptorMaguire JJ et al. (2009) International Union of Pharmacology. LXXII. Recommendations for trace amine receptor nomenclature. Pharmacol. Rev. 61: 1‐8 [PMID:19325074]Pei Y et al. (2016) Trace Amines and the Trace Amine‐Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications. Front Neurosci 10: 148 [PMID:27092049]Urotensin receptorOverviewThe urotensin‐II (U‐II) receptor (UT, nomenclature as agreed by the NC‐IUPHAR Subcommittee on the Urotensin receptor [466, 557, 2032]) is activated by the endogenous dodecapeptide urotensin‐II(UTS2, O95399), originally isolated from the urophysis, the endocrine organ of the caudal neurosecretory system of teleost fish [138]. Several structural forms of U‐II exist in fish and amphibians. The goby orthologue was used to identify U‐II as the cognate ligand for the predicted receptor encoded by the rat gene gpr14 [389, 1195, 1379, 1476]. Human urotensin‐II(UTS2, O95399), an 11‐amino‐acid peptide [389], retains the cyclohexapeptide sequence of goby U‐II that is thought to be important in ligand binding [224, 1003]. This sequence is also conserved in the deduced amino‐acid sequence of rat urotensin‐II {Rat} (14 amino‐acids) and mouse urotensin‐II{Mouse} (14 amino‐acids), although the N‐terminal is more divergent from the human sequence [388]. A second endogenous ligand for the UT has been discovered in rat [1890]. This is the urotensin II‐related peptide (UTS2B, Q765I0), an octapeptide that is derived from a different gene, but shares the C‐terminal sequence (CFWKYCV) common to U‐II from other species. Identical sequences to rat urotensin II‐related peptide (UTS2B, Q765I0) are predicted for the mature mouse and human peptides [472]. UT exhibits relatively high sequence identity with somatostatin, opioid and galanin receptors [2032].NomenclatureUT receptorHGNC, UniProtUTS2R, Q9UKP6Endogenous agonistsurotensin II‐related peptide (UTS2B, Q765I0) [472, 1243], urotensin‐II (UTS2, O95399) [467, 503, 681]Selective agonists[Pen5]U‐(4‐11) (human) [681], U‐II‐(4‐11) (human) [681], [3‐iodo‐Tyr6]U‐II‐(4‐11) (human) [1084], Urolinin [95], FL104 [1139, 1141], AC‐7954 [398, 1140]Selective antagonistsJNJ‐39319202 (pKi 8.4) [1106], urantide (pKi 8.3) [1536], SB‐706375 (pKi 8) [467], [Orn5]URP (pKi 7.2) [445] – Rat, palosuran (pIC50 7.1) [366], SB‐436811 (pKi 6.7) [912] – Rat, SB‐611812 (pKi 6.6) [1622], S6716 (Inverse agonist) (pIC50 6.4) [554], [Cha6]U‐II‐(4‐11) (pKi 6.4) [312] – RatLabelled ligands[125I]U‐II (human) (Agonist) [42, 198, 312, 1243], [125I]N‐biotin‐[Ahx0, Bpa3]U‐II (human) [454]CommentsIn the human vasculature, human urotensin‐II(UTS2, O95399) elicits both vasoconstrictor (pD2 9.3‐10.1, [1243]) and vasodilator (pIC50 10.3‐10.4, [1872]) responses.Further reading on Urotensin receptorFoord SM et al. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. Pharmacol Rev 57: 279‐288 [PMID:15914470]Hunt BD et al. (2010) A rat brain atlas of urotensin‐II receptor expression and a review of central urotensin‐II effects. Naunyn Schmiedebergs Arch. Pharmacol. 382: 1‐31 [PMID:20422157]Maryanoff BE et al. (2010) Urotensin‐II receptor modulators as potential drugs. J. Med. Chem. 53: 2695‐708 [PMID:20043680]Ross B et al. (2010) Role of urotensin II in health and disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298: R1156‐72 [PMID:20421634]Vasopressin and oxytocin receptorsOverviewVasopressin (AVP) and oxytocin (OT) receptors (nomenclature as recommended by NC‐IUPHAR[557]) are activated by the endogenous cyclic nonapeptides vasopressin(AVP, P01185) and oxytocin(OXT, P01178). These peptides are derived from precursors which also produce neurophysins (neurophysin I for oxytocin; neurophysin II for vasopressin).NomenclatureV1A receptorV1B receptorHGNC, UniProtAVPR1A, P37288AVPR1B, P47901Potency order of endogenous ligandsvasopressin (AVP, P01185) >oxytocin (OXT, P01178)vasopressin (AVP, P01185) >oxytocin (OXT, P01178)Endogenous agonistsvasopressin (AVP, P01185) [24, 326, 383, 439, 1418, 1571, 1702, 1913, 1914, 1945, 1946, 2162]vasopressin (AVP, P01185) [24, 326, 439, 682, 1418, 1702, 1913, 1914, 1946, 2162]Selective agonistsF180 [50, 383]d[Leu4]LVP [1553], d[Cha4]AVP [439, 682]Antagonistsconivaptan (pKi 8.2–8.4) [1913, 1914]nelivaptan (pKi 8.4–9.3) [678, 682, 1773]Selective antagonistsrelcovaptan (pKi 8.1–9.3) [24, 383, 682, 1571, 1771, 1913, 1945, 1946, 1986], d(CH2)5[Tyr(Me)2,Arg8]VP (pKi 9)–Labelled ligands[125I]OH‐LVA (Antagonist) (pKd 10.3–10.4) [334, 383, 1571], [3H]AVP (human, mouse, rat) (Agonist) [214, 334, 383, 384, 1418, 1571, 1702, 1913, 1914, 1945, 1946, 1986, 2162], [3H]d(CH2)5[Tyr(Me)2]AVP (Antagonist) (pKd 9)[3H]AVP (human, mouse, rat) (Agonist) [214, 334, 383, 384, 1418, 1571, 1702, 1913, 1914, 1945, 1946, 1986, 2162]NomenclatureV2 receptorOT receptorHGNC, UniProtAVPR2, P30518OXTR, P30559Potency order of endogenous ligandsvasopressin (AVP, P01185) >oxytocin (OXT, P01178)oxytocin (OXT, P01178) >vasopressin (AVP, P01185)Endogenous agonistsvasopressin (AVP, P01185) [24, 326, 334, 439, 1418, 1702, 1771, 1913, 1914, 1946, 2162]oxytocin (OXT, P01178) [24, 334, 335, 360, 682, 895]Selective agonistsVNA932 [527], OPC‐51803 [1418], d[Val4,DArg8]VP[Thr4,Gly7]OT [335, 500, 895]Antagonists–L‐371,257 (pKi 8.8) [682]Selective antagonistsconivaptan (pKi 9.4) [397], tolvaptan (pKi 9.4) [2162], satavaptan (pKi 8.4–9.3) [24, 383, 384, 1770, 1771, 1913, 1986], lixivaptan (Inverse agonist) (pKi 8.9–9.2) [33, 1771], d(CH2)5[D‐Ile2,Ile4]AVP (pKi 6.9–8.4) [1771], mozavaptan (Inverse agonist) (pKi 7.4–8.1) [384, 1771, 1913, 1946, 2162, 2163]SSR126768A (pKi 8.8–9.1) [1772], desGlyNH2‐d(CH2)5[Tyr(Me)2,Thr4,Orn8]OT (pKi 8.5), L‐372662 (pKi 8.4) [127]Labelled ligands[3H]AVP (human, mouse, rat) (Agonist) [334, 383, 384, 1418, 1702, 1913, 1914, 1946, 1986, 2162], [3H]dDAVP (Agonist) [334, 384, 1946], [3H]desGly‐NH2[D‐Ile2,Ile4]VP (pKd 8.6)[125I]d(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr‐NH29]OVT (Antagonist) (pKd 10), [3H]OT (human, mouse, rat) (Agonist) [334, 583, 895, 998], [111In]DOTA‐dLVT (pKd 8.3) [333]CommentsThe V2 receptor exhibits marked species differences, such that many ligands (d(CH2)5[D‐Ile2,Ile4]AVP and [3H]desGly‐NH2[D‐Ile2,Ile4]VP) exhibit low affinity at human V2 receptors [29]. Similarly, [3H]d[D‐Arg8]VP is V2 selective in the rat, not in the human [1702]. The gene encoding the V2 receptor is polymorphic in man, underlying nephrogenic diabetes insipidus [152]. D[Cha4]AVP is selective only for the human and bovine V1B receptors [439], while d[Leu4]LVP has high affinity for the rat V1B receptor [1553].Further reading on Vasopressin and oxytocin receptorsBartz JA et al. (2011) Social effects of oxytocin in humans: context and person matter. Trends Cogn. Sci. (Regul. Ed.) 15: 301‐9 [PMID:21696997]Knepper MA. (2012) Systems biology in physiology: the vasopressin signaling network in kidney. Am. J. Physiol., Cell Physiol. 303: C1115‐24 [PMID:22932685]Koshimizu TA et al. (2012) Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol. Rev. 92: 1813‐64 [PMID:23073632]Manning M et al. (2012) Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J. Neuroendocrinol. 24: 609‐28 [PMID:22375852]Meyer‐Lindenberg A et al. (2011) Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat. Rev. Neurosci. 12: 524‐38 [PMID:21852800]Neumann ID et al. (2012) Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci. 35: 649‐59 [PMID:22974560]VIP and PACAP receptorsOverviewVasoactive intestinal peptide (VIP) and pituitary adenylate cyclase‐activating peptide (PACAP) receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Vasoactive Intestinal Peptide Receptors [739, 740]) are activated by the endogenous peptides VIP(VIP, P01282), PACAP‐38(ADCYAP1, P18509), PACAP‐27(ADCYAP1, P18509), peptide histidine isoleucineamide (PHI {Mouse, Rat}), peptide histidine methionineamide (PHM(VIP, P01282)) and peptide histidine valine (PHV(VIP, P01282)). VPAC1 and VPAC2 receptors display comparable affinity for the PACAP peptides, PACAP‐27(ADCYAP1, P18509) and PACAP‐38(ADCYAP1, P18509), and VIP(VIP, P01282), whereas PACAP‐27(ADCYAP1, P18509) and PACAP‐38(ADCYAP1, P18509) are >100 fold more potent than VIP(VIP, P01282) as agonists of most isoforms of the PAC1 receptor. However, one splice variant of the human PAC1 receptor has been reported to respond to PACAP‐38(ADCYAP1, P18509), PACAP‐27(ADCYAP1, P18509) and VIP(VIP, P01282) with comparable affinity [411]. PG 99‐465[1374] has been used as a selective VPAC2receptor antagonist in a number of physiological studies, but has been reported to have significant activity at VPAC1 and PAC1 receptors [446]. The selective PAC1 receptor agonist maxadilan, was extracted from the salivary glands of sand flies (Lutzomyia longipalpis) and has no sequence homology to VIP(VIP, P01282) or the PACAP peptides [1383]. Two deletion variants of maxadilan, M65[1994] and Max.d.4[1384] have been reported to be PAC1 receptor antagonists, but these peptides have not been extensively characterised.NomenclaturePAC1 receptorVPAC1 receptorVPAC2 receptorHGNC, UniProtADCYAP1R1, P41586VIPR1, P32241VIPR2, P41587Potency order of endogenous ligandsPACAP‐27 (ADCYAP1, P18509), PACAP‐38 (ADCYAP1, P18509) ≫VIP (VIP, P01282)VIP (VIP, P01282), PACAP‐27 (ADCYAP1, P18509), PACAP‐38 (ADCYAP1, P18509) ≫GHRH (GHRH, P01286), PHI {Pig}, secretin (SCT, P09683)VIP (VIP, P01282), PACAP‐38 (ADCYAP1, P18509), PACAP‐27 (ADCYAP1, P18509) >PHI {Pig} ≫GHRH (GHRH, P01286), secretin (SCT, P09683)Selective agonistsmaxadilan [446], maxadilan [446][Lys15,Arg16,Leu27]VIP‐(1‐7)/GRF‐(8‐27)‐NH2 [1369], [Ala11,22,28]VIP [1458]Ro 25‐1553 [669, 930, 1369], Ro 25‐1392 [2144]Selective antagonists–PG 97‐269 (pIC50 8.7) [668, 930]–Labelled ligands[125I]PACAP‐27 (Agonist) [1581][125I]VIP (human, mouse, rat) (Agonist) [1458], [125I]PACAP‐27 (Agonist)[125I]VIP (human, mouse, rat) (Agonist) [1458], [125I]PACAP‐27 (Agonist)CommentsSubtypes of PAC1 receptors have been proposed based on tissue differences in the potencies of PACAP‐27(ADCYAP1, P18509) and PACAP‐38(ADCYAP1, P18509); these might result from differences in G protein coupling and second messenger mechanisms [2018], or from alternative splicing of PAC1 receptor mRNA [1859].Further reading on VIP and PACAP receptorsHarmar AJ et al. (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide. Pharmacol Rev 50: 265‐270 [PMID:9647867]Harmar AJ et al. (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide: IUPHAR review 1. Br. J. Pharmacol. 166: 4‐17 [PMID:22289055]Reglodi D et al. (2012) Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney. Neuropeptides 46: 61‐70 [PMID:21621841]Smith CB et al. (2012) Is PACAP the major neurotransmitter for stress transduction at the adrenomedullary synapse? J. Mol. Neurosci. 48: 403‐12 [PMID:22610912]ReferencesAbbracchio MP et al. (2003) [12559763].Abbracchio MP et al. (2006) [16968944].AbdAlla S et al. (2000) [10993080].Abdul‐Ridha A et al. (2014) [25326383].Abdul‐Ridha A et al. (2014) [24443568].Abo‐Salem OM et al. (2004) [14563788].Abramovitz M et al. (2000) [10634944].Abramovitz M et al. (1994) [8300593].Adams CL et al. (2007) [17894647].Adams JW et al. (2008) [18539757].Adapa ID et al. (1997) [9413015].Adham N et al. (1997) hrefhttp://www.ncbi.nlm.nih.gov/pubmed/9225282?dopt=AbstractPlus[9225282].Adham N et al. (1993) [8380639].af Forselles KJ et al. (2011) [21595651].Ahmed K et al. (2009) [19561068].Ahmed K et al. (2010) [20374963].Ahn HS et al. (1997) [9203642].Ahuja SK et al. (1996) [8702798].Ahumada A et al. (2002) [12471263].Ai LS et al. (2002) [12081481].Aiyar N et al. (2001) [11693189].Aiyar N et al. (1993) [8463997].Akbulut H et al. (1999) [10323493].Akerlund M et al. (1999) [10519430].Akgün E et al. (2009) [19271701].Akiyama K et al. (1985) [2986120].Akunne HC et al. (1995) [7674830].Al‐Ani B et al. (1999) [10411588].Ala Y et al. (1998) [9773787].Albert DH et al. (1997) [9151941].Albert R et al. (2005) [16078855].Albrandt K et al. (1995) [7588285].Albright JD et al. (1998) [9651149].Alexander SP et al. (1996) [8937736].Alexander SP et al. (2007) [17876303].Alexander SP et al. (2001) [11164377].Alikhani V et al. (2004) [15324892].Amano H et al. (2003) [12538661].Amblard M et al. (1999) [10514288].Ames RS et al. (2001) [11342658].Ames RS et al. (1996) [8898085].Ames RS et al. (1999) [10499587].Ames RS et al. (1997) [9476119].Amisten S et al. (2008) [18213371].Amlaiky N et al. (1992) [1328180].Ancellin N et al. (1999) [10383399].Andersen PH et al. (1990) [1973652].Anderson JJ et al. (2002) [12438526].Andrade‐Gordon P et al. (1999) [10535908].Andres M et al. (2002) [11934825].Ang SY et al. (2016) [27243554].Ann DK et al. (1992) [1313812].Anthes JC et al. (2002) [12206858].Antoniu SA (2010) [21154168].Antony J et al. (2009) [18842964].Araç D et al. (2012) [22333914].Arbore G et al. (2016) [27313051].Ariel A et al. (2003) [12794159].Aristotelous T et al. (2013) [24454993].Arita M et al. (2005) [15753205].Arita M et al. (2007) [17339491].Armour SL et al. (1999) [11033437].Armstrong RA et al. (1993) [8242228].Arnt J et al. (1998) [9430133].Aronica SM et al. (1994) [8078914].Asahi S et al. (2003) [12467628].Asin KE et al. (1992) [1636779].Auchampach JA et al. (2009) [19141710].Audinot V et al. (2001) [11375253].Audinot V et al. (2003) [12764576].Auerbach SS et al.National Toxicology Program: Dept of Health and Human Services. Accessed on 02/05/2014. DrugMatrix.Austin CE et al. (1997) [9111052].Austin KM et al. (2013) [23086754].Avlani VA et al. (2010) [20413650].Ayoub MA et al. (2004) [15266022].Azran S et al. (2013) [23751098].Baba M et al. (1997) [9169459].Baba M et al. (1999) [10318947].Bach P et al. (2013) [24215345].Bach T et al. (2001) [11218067].Bachelerie F et al. (2014) [24218476].Bachelerie F et al. (2015) [25958743].Bae YS et al. (2004) [15210823].Bahouth SW et al. (1985) [2410593].Baker JG (2010) [20590599].Baker JG (2010) [21152092].Baker JG (2005) [15655528].Baker JG et al. (2003) [12770928].Baker JG et al. (2003) [14645666].Baker JG et al. (2003) [12920204].Bakker RA et al. (2006) [16415177].Balan G et al. (2009) [19442519].Balogh J et al. (2005) [15893764].Bamberg CE et al. (2010) [20044484].Bandholtz S et al. (2016) [27791374].Bang‐Andersen B et al. (2011) [21486038].Baqi Y et al. (2009) [19463000].Bard JA et al. (1995) [7592911].Bard JA et al. (1993) [8226867].Barda DA et al. (2004) [15149652].Barnea G et al. (2008) [18165312].Barrett MO et al. (2013) [23592514].Barroso R et al. (2012) [22913878].Barry GD et al. (2010) [20873792].Barshop K et al. (2015) [25341626].Bartfai T et al. (1991) [1720557].Bartfai T et al. (1993) [7504301].Bartoi T et al. (2010) [20406808].Bassi MT et al. (1995) [7647783].Bastian S et al. (1997) [9313952].Bastien L et al. (1994) [8163486].Bathgate RA et al. (2006) [16507880].Bayewitch M et al. (1996) [8626625].Beattie D et al. (2012) [22932315].Beattie DT et al. (2004) [15466450].Beaujouan JC et al. (1997) [9042606].Bechtold DA et al. (2012) [22197240].Beckers T et al. (2001) [11726197].Beckers T et al. (1995) [7649152].Beckers T et al. (1997) [9300077].Bedendi I et al. (2003) [12969753].Bednarek MA et al. (2000) [11087562].Bednarek MA et al. (2001) [11606131].Behrens M et al. (2004) [15178431].Bekker P et al. (2016) [27768695].Belgi A et al. (2011) [21866895].Bell IM et al. (1998) [9622556].Belley M et al. (1999) [10658574].Bellier B et al. (2004) [14698161].Bellucci F et al. (2002) [11786503].Ben‐Baruch A et al. (1995) [7545673].Bender E et al. (2000) [10646498].Bennacef I et al. (2004) [15265501].Benned‐Jensen T et al. (2010) [20148890].Benya RV et al. (1995) [7838118].Beresford IJ et al. (1998) [9618428].Beresford IJ et al. (1995) [7713168].Bern HA et al. (1985) [2864726].Bernotas RC et al. (2009) [19523834].Berque‐Bestel I et al. (2003) [12801225].Berrie CP et al. (1984) [6478115].Berry CB et al. (2014) [25221667].Bersani M et al. (1991) [1710578].Bersani M et al. (1991) [1718731].Bertini R et al. (2004) [15282370].Besada P et al. (2006) [16942026].Bettler B et al. (2004) [15269338].Beukers MW et al. (2000) [11093773].Beukers MW et al. (1997) [9384502].Beukers MW et al. (2003) [12672250].Bi Y et al. (2015) [25754495].Bichet DG et al. (1998) [9756088].Bigoni R et al. (2002) [12070757].Binet V et al. (2004) [15126507].Birdsall NJ et al. (1979) [497538].Birke FW et al. (2001) [11259574].Birrell MA et al. (2013) [22747912].Bjursell M et al. (2006) [16887097].Blackhart BD et al. (1996) [8663335].Blair JB et al. (2000) [11101361].Blanpain C et al. (1999) [10477718].Bley KR et al. (2006) [16331286].Blin N et al. (1993) [7903415].Blondel O et al. (1998) [9603189].Blue DR et al. (2004) [14678390].Boatman PD et al. (2012) [22435740].Bockaert J et al. (2006) [16896947].Boden P et al. (1996) [8648606].Boess FG et al. (1997) [9284367].Boess FG et al. (1998) [9730917].Bogdanov YD et al. (1998) [9647463].Boie Y et al. (1994) [7512962].Boie Y et al. (1995) [7642548].Boie Y et al. (1999) [10513580].Bolden C et al. (1992) [1346637].Bolli MH et al. (2010) [20446681].Bolli MH et al. (2012) [22862294].Bolli MH et al. (2004) [15139756].Bologa CG et al. (2006) [16520733].Bolognini D et al. (2016) [27385588].Bonaventure P et al. (2012) [22570363].Bonaventure P et al. (2004) [14617685].Bonhaus DW et al. (1997) [9225293].Bonhaus DW et al. (1999) [10455251].Bonhaus DW et al. (1977) [9225287].Bonnefous C et al. (2005) [15686941].Bonnefous C et al. (2005) [16046122].Booth RG et al. (2002) [12065734].Borowsky B et al. (2001) [11459929].Borowsky B et al. (2002) [12118247].Borowsky B et al. (1998) [9880084].Borrmann T et al. (2009) [19569717].Bosch MP et al. (2004) [15267242].Bosnyak S et al. (2011) [21542804].Botto JM et al. (1997) [9001400].Boulanger L et al. (2002) [11814616].Boulenguez P et al. (1992) [1738002].Bourguignon‐Bellefroid C et al. (1992) [1546952].Bowery NG et al. (2002) [12037141].Bowery NG et al. (2000) [10604925].Boyce M et al. (2012) [22607579].Boyden SE et al. (2016) [26841242].Boyer JL et al. (1996) [8913364].Brabet I et al. (1995) [8532171].Bradaia A et al. (2009) [19892733].Bradshaw CG et al. (1994) [8027981].Brady AE et al. (2008) [18772318].Brambilla R et al. (2000) [10731034].Brame AL et al. (2015) [25712721].Branchek T et al. (1990) [2233697].Breivogel CS et al. (1997) [9316881].Brenchat A et al. (2009) [19118950].Brennan et al. (2007) Patent number: US2007/0074299.Breton C et al. (2001) [11337500].Breu V et al. (1996) [8612786].Brezillon S et al. (2003) [12401809].Briddon SJ et al. (2004) [15070776].Brighton PJ et al. (2004) [15331768].Brink C et al. (2004) [15001665].Brinkmann V et al. (2002) [11967257].Brisbare‐Roch C (2007) [17259994].Briscoe CP et al. (2006) [16702987].Briscoe CP et al. (2003) [12496284].Brkovic A et al. (2003) [12807997].Broad J et al. (2013) [23190027].Broadhead GK et al. (2011) [21187282].Brodfuehrer J et al. (2014) [24190631].Brodkin J et al. (2002) [12473093].Bromidge SM et al. (1999) [9925723].Bromidge SM et al. (2001) [11140733].Brown AJ et al. (2003) [12496283].Brown AM et al. (1998) British Journal of Pharmacology 123: 233.Brown AM et al. (1993) Br J Pharmacol 110: 10.Brown EM et al. (1993) [8255296].Browning C et al. (2000) [10696085].Bruchas MR et al. (2007) [17702750].Bruinvels AT et al. (1993) [8361548].Bruns C et al. (1996) [8769372].Bruns RF et al. (1990) [2174510].Brunschweiger A et al. (2006) [16475938].Bryant HU et al. (1996) [8845011].Bryja V et al. (2007) [17426148].Bryja V et al. (2008) [18953287].Bräuner‐Osborne H et al. (1996) [8759641].Buckley NJ et al. (1989) [2704370].Bunzow JR et al. (1988) [2974511].Burford NT et al. (2013) [23754417].Burford NT et al. (2015) [25901762].Burgaud JL et al. (1997) [9434758].Burmakina S et al. (2014) [24778228].Burnstock G et al. (2012) Purinergic signalling and the nervous system, pp. 1–715: Springer.Burris KD et al. (1995) [7576010].Burstein ES et al. (2005) [16135699].Buzard DJ et al. (2014) [25516790].Bylund DB et al. (1992) [1353247].Bylund DB et al. (1994) [7938162].Bäck M et al. (2011) [21771892].Bäck M et al. (2014) [24588652].Béguin C et al. (2005) [15869877].Béraud‐Dufour S et al. (2009) [19891061].Búzás B et al. (1992) [1313131].Büllesbach EE et al. (2005) [15708846].Büscher R et al. (2006) [16495779].Cabrele C et al. (2002) [12069595].Cai R et al. (2014) [24373935].Cai TQ et al. (2008) [18952058].Cain SA et al. (2002) [11773063].Calderon SN et al. (1994) [8035418].Calo G et al. (2002) [12010780].Campion KL et al. (2015) [25556167].Canals M et al. (2012) [22086918].Candelore MR et al. (1999) [10411574].Capodanno D et al. (2013) [23809135].Cappelli A et al. (2013) [23466604].Cappelli A et al. (2004) [15115399].Carmeci C et al. (1997) [9367686].Carmon KS et al. (2011) [21693646].Carpenter B et al. (2016) [27462812].Carroll FY et al. (2001) [11306677].Carroll WA et al. (2001) [11354357].Carter RL et al. (2009) [19759354].Cascieri MA et al. (1999) [10085108].Castro SW et al. (1996) [8646408].Catalioto RM et al. (1998) [9484857].Catalán V et al. (2007) [17371481].Cattaneo M et al. (2004) [15476670].Cattaneo M et al. (2003) [12578987].Caulfield MP et al. (1998) [9647869].Caunt CJ et al. (2004) [15059960].Caunt CJ et al. (2012) [22808094].Cavallari U et al. (2007) [17803810].Cavanaugh DJ et al. (2009) [19451647].Cayabyab M et al. (2000) [11090199].Cembala TM et al. (1998) [9846649].Chackalamannil S et al. (2008) [18447380].Chagnon YC et al. (1997) [9392003].Chaki S et al. (2005) [15677346].Chaki S et al. (1999) [10357258].Chambers JK et al. (2000) [10753868].Chan SD et al. (1992) [1334084].Chan WY et al. (2008) [18678919].Chandrashekar J et al. (2000) [10761935].Chang DJ et al. (1998) [9490024].Chang KJ et al. (1983) [6313901].Chang RS et al. (1990) [2314387].Chang RS et al. (1986) [3018478].Chang W et al. (2008) [18765830].Chang W et al. (2007) [17591780].Chansel D et al. (1993) [8282008].Chao TH et al. (1999) [10092660].Chartrel N et al. (2003) [14657341].Chatenet D et al. (2006) [17125276].Chavkin C et al. (2004) [14718611].Chen C et al. (1996) [8893829].Chen H et al. (2004) [15163697].Chen J et al. (2005) [15772293].Chen J et al. (2003) [12706455].Chen LH et al. (2014) [25050158].Chen Q et al. (2012) [22697179].Chen TB et al. (1992) [1480133].Chen W et al. (2003) [12958365].Chen YL et al. (2008) [18288792].Chen Z et al. (2004) [15454210].Cheng CK et al. (2005) [15561800].Cheng K et al. (2002) [12235229].Cheng LL et al. (2004) [15084136].Cheng Z et al. (2007) [17615148].Cherezov V et al. (2007) [17962520].Chhatriwala M et al. (2004) [15345752].Chiang N et al. (2000) [10748237].Chiang N et al. (2012) [22538616].Chin FT et al. (2006) Journal of labelled compounds and radiopharmaceuticals 17‐31.Chini B et al. (2003) [12942128].Chini B et al. (1995) [7774575].Chini B et al. (1996) [8955347].Chiu AT et al. (1989) [2590220].Chiu AT et al. (1992) [1445340].Chng SC et al. (2013) [24316148].Chobanian HR et al. (2012) [24900461].Choi JW et al. (2011) [21177428].Chopra M et al. (2009) [19389924].Chou CC et al. (2002) [12381680].Chow BK (1995) [7612008].Chow BS et al. (2014) [24429402].Christiansen E et al. (2012) [22724451].Christiansen E et al. (2013) [23687558].Christiansen E et al. (2016) [27074625].Christiansen E et al. (2015) [25916176].Christopoulos A et al. (2003) [12446722].Christopoulos A et al. (1998) [9614217].Christopoulos A et al. (1999) [9890565].Christopoulos A et al. (2001) [11578621].Christopoulos G et al. (1999) [10385705].Chu ZL et al. (2010) [19901198].Chung AW et al. (2002) [11877318].Chung DS et al. (1997) [9353394].Chung FZ et al. (1995) [7476898].Cialdai C et al. (2006) [16979621].Ciana P et al. (2006) [16990797].Cirillo R et al. (2003) [12660315].Cirillo R et al. (2007) [17618756].Claeysen S et al. (1997) [9351641].Clark AL et al. (1976) [990587].Clark BP et al. (1997) Bioorganic & Medicinal Chemistry Letters 7: 2777‐2780.Clish CB et al. (1999) [10393980].Clozel M et al. (2004) [15146030].Clozel M et al. (1994) [8035319].Cogé F et al. (2001) [11284713].Cohen JA et al. (2011) [21520239].Combadiere C et al. (1995) [8530354].Commery TA (2010) Alzheimer's & Dementia 6: S548‐S549.Communi D et al. (1999) [10578132].Comps‐Agrar L et al. (2011) [21552208].Congreve M et al. (2012) [22220592].Conigrave AD et al. (2000) [10781086].Conn PM et al. (1982) [6282571].Conroy JL et al. (2015) [25660762].Cook AE et al. (2015) [25220431].Cooray SN et al. (2013) [24108355].Corbett DF et al. (2005) [16002289].Costantino G et al. (2001) [11249114].Costes N et al. (2005) [16330560].Cotte N et al. (2000) [10866830].Cotte N et al. (1998) [9792651].Cottingham C et al. (2011) [21859713].Coulie B et al. (2001) [11461914].Coulin F et al. (1997) [9346309].Coulouarn Y et al. (1999) [10486557].Coulouarn Y et al. (1998) [9861051].Cox BM et al. (2015) [24528283].Cox CD et al. (2010) [20565075].Cox HM et al. (1995) [8590988].Coy DH et al. (1996) [8993400].Criscione L et al. (1993) [8242249].Croker DE et al. (2013) [24060963].Croker DE et al. (2016) [27108698].Crombie AL et al. (2010) [20471258].Croston GE et al. (2002) [12408704].Croy CH et al. (2014) [24807965].Cunha RA et al. (1996) [8692280].Curtis AE et al. (2010) [19934405].D'Amato M et al. (2007) [17854592].Dairaghi DJ et al. (1999) [10419462].Dalpiaz A et al. (1998) [9827575].Daniels DV et al. (1999) [10334511].Dardonville C et al. (2004) [15224384].Das A et al. (2010) [19902968].Dass NB et al. (2003) [14504130].Daugherty BL et al. (1996) [8642344].Dautzenberg FM et al. (2004) [15450949].Dautzenberg FM et al. (1999) [10583729].Dautzenberg FM et al. (2001) [11123370].Davenport AP (2002) [12037137].Davenport AP et al. (2013) [23686350].Davenport AP et al. (2005) [16382107].Davenport AP et al. (1998) [9489609].Davenport AP et al. (1994) [8012722].Davey AE et al. (2012) [22210744].Davis MD et al. (2005) [15590668].Davis TL et al. (2000) [10952683].Dawson LA et al. (2009) [19499624].De Backer MD et al. (1998) [9794809].deGasparo M et al. (2000) [10977869].deGasparo M et al. (1995) [8577935].deGasparo M et al. (1994) In Medicinal Chemistry of the Renin‐Angiotensin System. Edited by Timmermanns PBMWM, Wexler RR: Elsevier: 269‐294 [ISBN: 0444820531].deLau W et al. (2011) [21727895].De Lecea L et al. (1996) [8622767].deLigt RA et al. (2005) [15740718].dePaulis T et al. (2006) [16722652].De Ponti F et al. (1996) [8730727].De Vry J et al. (1998) [9495870].Deal MJ et al. (1992) [1331460].Dearry A et al. (1990) [2144334].Del Borgo MP et al. (2006) [16547350].Delahaye R et al. (1997) [9484907].Deng C et al. (2015) [25995451].Dennis MK et al. (2009) [19430488].Dennis MK et al. (2011) [21782022].Derick S et al. (2002) [12446593].Devedjian JC et al. (1994) [7908642].Dhawan BN et al. (1996) [8981566].Di Fabio R et al. (2011) [21831639].Di Marzo V et al. (2001) [11181068].Di Salvo J et al. (2000) [11104827].Diallo M et al. (2008) [18082287].Dickson L et al. (2006) [16930633].Dijksterhuis JP et al. (2013) [24032637].Dijkstra D et al. (2002) [12086487].Dillon JS et al. (1993) [8404634].Dinter J et al. (2015) [25706283].Dionisotti S et al. (1997) [9179373].Disse B et al. (1993) [8441333].Divorty N et al. (2015) [25805994].Doan ND et al. (2012) [22044114].Dodé C et al. (2013) [23596439].Dolan JA et al. (1994) [7912272].Domenech T et al. (1997) [9303569].Domschke K et al. (2011) [20603625].Donaldson LF et al. (1996) [8947459].Donner J et al. (2010) [20705147].Doods H et al. (1999) [10611450].Doods H et al. (2000) [10711339].Doods HN et al. (1995) [7562541].Dooley CT et al. (1997) [9353393].Doré AS et al. (2014) [25042998].Douglas SA, & Ohlstein EH (2000) Urotensin receptors. In The IUPHAR Receptor Compendium of Receptor Characterization and Classification. Edited by Girdlestone D: IUPHAR Media Ltd: 365‐372.Douglas SA et al. (2005) [15852036].Doumazane E et al. (2011) [20826542].Dowling MR et al. (2006) [16847442].Drake MT et al. (2008) [18086673].Drummond AH et al. (1989) [2566295].Dubessy C et al. (2008) [18710417].Dubocovich ML (1985) [2991499].Dubocovich ML et al. (2010) [20605968].Dubocovich ML et al. (1997) [9089668].Dubocovich ML et al. (1998) [9737724].Dudley DT et al. (1990) [2402226].Dudley DT et al. (1993) [8469774].Dufourny L et al. (2008) [18400093].Duggal P et al. (2003) [12761559].Dumont Y et al. (2004) [15337369].Dunlop J et al. (2005) [15705738].Dupuis DS et al. (2006) [16966477].Dwyer MP et al. (2006) [17181143].Díaz‐González F et al. (2007) [17170051].Dörje F et al. (1991) [1994002].Eason MG et al. (1995) [7559592].Eckle T et al. (2007) [17353435].Edgar AJ (2007) [17454009].Edinger AL et al. (1997) [9405683].Edson MA et al. (2010) [19887567].Edwards RM et al. (1992) [1309870].Egan C et al. (2000) [10611640].Eggerickx D et al. (1995) [7639700].Eison AS et al. (1993) [8246675].El Messari S et al. (2004) [15341513].El‐Tayeb A et al. (2005) [16213725].El‐Tayeb A et al. (2006) [17125260].El‐Tayeb A et al. (2011) [21417463].Elands J et al. (1988) [2827511].Ellacott KL et al. (2005) [15752583].Elliott JD et al. (1994) [8201588].Elshourbagy NA et al. (2002) [11976263].Emonds‐Alt X et al. (1995) [7830490].Emonds‐Alt X et al. (1993) [7682062].Emson PC (2007) [17499108].Engel KM et al. (2011) [22216272].Engers DW et al. (2009) [19469556].Engstrom M et al. (2003) [12606605].Enna SJ et al. (2004) [15451397].Ennis MD et al. (1998) [9632349].Erchegyi J et al. (2005) [15658864].Eriksson H et al. (1998) [9802391].Erlinge D (2011) [21586366].Erspamer V et al. (1989) [2544892].Esbenshade TA et al. (2004) [15294456].Esbenshade TA et al. (2003) [12606603].Escribano A et al. (1998) [9871538].Espinoza S et al. (2011) [21670104].Evangelou E et al. (2011) [21068099].Evans BA et al. (2011) [20978120].Evans BA et al. (1999) [10455305].Evans BA et al. (2010) [20132209].Evans BN et al. (2000) [10903324].Evans HF et al. (1991) [1714839].Eveleigh P et al. (1989) [2704371].Failli AA et al. (2006) [16297621].Fan H et al. (2015) [25176008].Fan X et al. (2003) [12939143].Farde L et al. (1996) [8835881].Farooqi IS et al. (2008) [18779842].Faust R et al. (2000) [10737738].Feighner SD et al. (1999) [10381885].Felder CC et al. (1998) [9435190].Felder CC et al. (1995) [7565624].Fells JI et al. (2008) [18467108].Feoktistov I et al. (2001) [11705449].Ferlin A et al. (2009) [19416191].Fernández J et al. (2005) [15771415].Filardo EJ et al. (2000) [11043579].Finch AR et al. (2010) [20009083].Finch AR et al. (2010) [19888967].Finnerup NB et al. (2014) [24507378].Fiore S et al. (1994) [8006586].Fiore S et al. (1992) [1322894].Fiore S et al. (1995) [8527441].Fischer DJ et al. (1998) [9855625].Fischer DJ et al. (2001) [11562440].Fischetti C et al. (2009) [19445927].Fister S et al. (2009) [19638591].Fitzgerald LW et al. (1999) [10217294].Fitzgerald LW et al. (1998) [9808667].Flacco N et al. (2013) [23373597].Flohr S et al. (2002) [11960491].Fong TM et al. (1992) [1281470].Foord APDW et al. (1996) [8632751].Foord SM et al. (2005) [15914470].Forbes IT et al. (2002) [12392747].Ford APDW et al. (1997) [9249248].Forrest M et al. (2004) [14747617].Foss FW et al. (2007) [17113298].Foudi N et al. (2011) [21323896].Foudi N et al. (2008) [18516068].Fox JC et al. (2015) [25497737].Franchetti P et al. (2009) [19317449].Francis BE et al. (1994) [8287060].Fraser GL et al. (2008) [18719021].Fraser NJ et al. (1999) [10347248].Fredholm BB et al. (2001) [11734617].Fredman G et al. (2010) [20702811].Fredriksson R et al. (2003) [12761335].Free RB et al. (2014) [24755247].Freedman SB et al. (1994) [8301582].Freer RJ et al. (1982) [6280748].Freer RJ et al. (1980) [7387981].Fricker AC et al. (2009) [19285517].Fricker SP et al. (2006) [16815309].Fricks IP et al. (2008) [18252808].Frielle T et al. (1988) [2849109].Froestl W (2011) [21428811].Froestl W et al. (1997) In Enna SJ (Ed.), The GABA Receptors. Bowery, NG: Humana Press, pp. 271–296. [ISBN: 0896034585].Fruchart‐Gaillard C et al. (2006) [16439611].Fuchs AR et al. (1982) [6278592].Fujii R et al. (2002) [12118011].Fukunaga K et al. (2001) [11560941].Fukushima N et al. (1998) [9600933].Fukusumi S et al. (2003) [12960173].Furman CA et al. (2014) [25583363].Galandrin S et al. (2006) [16901982].Galandrin S et al. (2008) [18403719].Galemmo RAJr et al. (1990) J Med Chem, 33, 2828–41.Gallo‐Rodriguez C et al. (1994) [8126704].Gallwitz B et al. (1996) [8795084].Galvez T et al. (2000) [10692480].Gama L et al. (2001) [11489900].Ganella DE et al. (2013) [23135160].Ganella DE et al. (2012) [22854307].Ganesh T et al. (2013) [23914286].Gao H et al. (2005) [15784721].Gao ZG et al. (2000) [10927024].Gao ZG et al. (2004) [15193995].Gao ZG et al. (2004) [15476669].Gardell LR et al. (2007) [17519387].Gardella TJ et al. (1996) [8702701].Gardella TJ et al. (1995) [7896796].Gardella TJ et al. (2015) [25713287].Gareau Y et al. (1996) Bioorg. Med. Chem. Lett., 6, 189–194.Garin A et al. (2003) [14607932].Gasparini F et al. (2002) [11814808].Gasparini F et al. (1999) [10336568].Gasparini F et al. (1999) [10530811].Gasser A et al. (2015) [25831128].Gassmann M et al. (2004) [15240800].Gaster LM et al. (1998) [9548813].Gault VA et al. (2003) [12627321].Gavrilyuk V et al. (2005) [15715664].Gbahou F et al. (2006) [16432504].Gee CE et al. (2014) [24596089].Gehlert DR et al. (1996) [8632753].Gembardt F et al. (2008) [18636314].Genet C et al. (2010) [19911773].Geng Y et al. (2013) [24305054].Geng Y et al. (2016) [27434672].Geng Y et al. (2012) [22660477].Gentry PR et al. (2014) [24692176].Gentry PR et al. (2013) [24164599].Gentry PR et al. (2014) [25147929].Georgsson J et al. (2014) [24937104].Georgsson J et al. (2015) [25875054].Gera L et al. (2006) [16368899].Gerald C et al. (1995) [7796807].Gerald C et al. (1996) [8700207].Gerald C et al. (1995) [7592910].Gerbino A et al. (2005) [16247029].Gershon MD (1999) [10429737].Ghoneim OM et al. (2006) [16782354].Giagulli C et al. (2012) [22262769].Giannotti D et al. (2000) [11063600].Giardina GA et al. (1996) [8691422].Giles H et al. (1989) [2924081].Gilet M et al. (2014) [25316608].Gillberg PG et al. (1998) [9671109].Gingell JJ et al. (2014) [24169554].Ginsburg‐Shmuel T et al. (2012) [22901672].Gironacci MM et al. (2011) [21670420].Gladue RP et al. (2003) [12909630].Glennon RA (2003) [12825922].Glennon RA et al. (2000) [10715164].Glukhova A et al. (2017) [28235198].Gobeil F et al. (1999) [10082494].Gobeil F et al. (1996) [8901831].Goldring WP et al. (2005) [15922596].Goldstein A et al. (1989) [2549383].Gomes I et al. (2013) [24043826].Gomes I et al. (2016) [27117253].Gong X et al. (1997) [9115216].Gonzalez‐Cabrera PJ et al. (2008) [18708635].González N et al. (2009) [19463875].González N et al. (2015) [26066663].Goodfellow NM et al. (2012) [22539842].Goold CP et al. (2001) [11602681].Gottlieb DJ et al. (2007) [17903308].Gouardères C et al. (2007) [17011599].Gouardères C et al. (2002) [12421602].Gouardères C et al. (2007) [17337079].Goudet C et al. (2012) [22223752].Gouldson P et al. (2000) [10988332].Gourlet P et al. (1997) [9437716].Gourlet P et al. (1997) [9145428].Grailhe R et al. (2001) [11343685].Granas C et al. (1999) [10513577].Grant GE et al. (2009) [19450703].Grant MK et al. (2005) [16002459].Gravel S et al. (2010) [20956518].Greaves DR et al. (1997) [9294138].Gregor P et al. (1996) [8641440].Gregori‐Puigjané E et al. (2012) [22711801].Griebel G et al. (2002) [11959912].Grieco P et al. (2000) [11150170].Grieco P et al. (2007) [17482720].Grieco P et al. (2002) [12238917].Griffante C et al. (2005) [16158071].Grisshammer R et al. (1994) [7719707].Gronert K et al. (2001) [11141472].Grosse J et al. (2014) [25028498].Grosse R et al. (2000) [10734055].Groves A et al. (2013) [23518370].Grundt P et al. (2007) [17095222].Grundt P et al. (2007) [17672446].Gründker C et al. (2002) [12237622].Gu ZF et al. (1995) [7529309].Guan XM et al. (2010) [20096642].Guard S et al. (1990) [1694464].Guerrero M et al. (2010) [23762933].Guerrero M et al. (2010) [22834040].Guerrini R et al. (1997) [9191955].Guilford WJ et al. (2004) [15056011].Gully D et al. (2002) [11907190].Gully D et al. (1997) [9023294].Guo Y et al. (2011) [21712392].Göblyös A et al. (2006) [16722654].Haas M et al. (2014) [24970757].Habasque C et al. (2002) [11994538].Haffar BM et al. (1991) [1702423].Hagan RM et al. (1993) [8210508].Hague C et al. (2004) [14718583].Halai R et al. (2014) [25446428].Hale JJ et al. (2004) [15615513].Hale JJ et al. (2000) [10737756].Hale JJ et al. (1998) [9804700].Hall DA et al. (1999) [10188995].Hall H et al. (2000) [11044889].Halls ML et al. (2015) [25761609].Halls ML et al. (2005) [15649866].Halls ML et al. (2010) [20664520].Halls ML et al. (2007) [17293890].Halls ML et al. (2009) [19029286].Hamann J et al. (2015) [25713288].Hamblin MW et al. (1991) [1652050].Hameg A et al. (2003) [12527336].Han G et al. (1999) [10187777].Han S et al. (2015) [26048791].Hancock AA et al. (2004) [15033391].Hancock AA et al. (1998) Drug Development Research, 44, 140–162.Hancock AA et al. (1994) [8206129].Handa BK et al. (1981) [6263640].Hanessian S et al. (2003) [12502358].Hannan FM et al. (2016) [27647839].Hannedouche S et al. (2011) [21796212].Hansen C et al. (2009) [19651774].Hansen W et al. (2010) [20200545].Hanson J et al. (2013) [23643932].Hanson MA et al. (2012) [22344443].Hanus L et al. (1999) [10588688].Harada K et al. (2006) [17074317].Haramura M et al. (2002) [11806718].Harland SP et al. (1995) [8587429].Harmar AJ (2001) [11790261].Harmar AJ et al. (1998) [9647867].Harmar AJ et al. (2012) [22289055].Harrison GS et al. (2004) [15613448].Hartig PR et al. (1996) [8936345].Hase M et al. (2008) [18347022].Hasegawa Y et al. (2003) [12554733].Haskell CA et al. (2006) [16221874].Hastrup H et al. (1996) [8985159].Hata AN et al. (2003) [12721327].Hatae N et al. (2007) [17312275].Haugaard‐Kedström LM et al. (2011) [21384867].Hauger RL et al. (2003) [12615952].Hawkins KN et al. (1987) [3030778].Hay DL et al. (2005) [15692146].Hay DL et al. (2006) [16959943].Hay DL et al. (2003) [12970090].Hay DL et al. (2008) [18552275].Hay DL et al. (2011) [21051558].Hayallah AM et al. (2002) [11906291].He HQ et al. (2013) [23160941].He J et al. (2010) [19696113].He L et al. (2000) [10669572].He S et al. (2010) [20167483].He W et al. (2004) [15141213].Heasley BH et al. (2004) [15125924].Hegde SS et al. (1997) [9113359].Hegde SS et al. (1996) [8903510].Heier RF et al. (1997) [9057850].Heise CE et al. (2000) [10851239].Heise CE et al. (2005) [15761110].Heise CE et al. (2001) [11723223].Heitman LH et al. (2009) [19161279].Heitman LH et al. (2006) [16444290].Henke BR et al. (1997) [9276016].Henstridge CM et al. (2010) [20136841].Herbert JM et al. (1993) [8395255].Herbert JM et al. (2003) [15199474].Hermans E et al. (1997) [9283723].Hern JA et al. (2010) [20133736].Herr KJ et al. (2011) [21878565].Herrick‐Davis K et al. (2000) [10991983].Herron DK et al. (1992) [1316967].Hertzog DL et al. (2006) [16870432].Hesselgesser J et al. (1998) [9551924].Hesselgesser J et al. (1998) [9624164].Hetherington SL et al. (2005) [15514209].Heusler P et al. (2010) [20799027].Hidaka K et al. (1995) [7777184].Hieble JP (2000) [10812954].Hieble JP et al. (1995) [7658428].Hieble JP et al. (1995) [7568329].Hill SJ et al. (1997) [9311023].Hillard CJ et al. (1999) [10336536].Hillmann P et al. (2009) [19419204].Hilton JM et al. (2000) [10856900].Hinuma S et al. (2000) [11025660].Hirasawa A et al. (2005) [15619630].Hirata T et al. (2011) [21819041].Hirose H et al. (2001) [11303071].Hirose M et al. (2003) [14643355].Hirst RA et al. (1996) [8981483].Hirst WD et al. (2003) [12663046].Hirst WD et al. (2006) [17069795].Hisatsune C et al. (2007) [17925404].Ho C et al. (1995) [7493018].Hoare SR et al. (2000) [10854439].Hoare SR et al. (2000) [10882389].Hoffmann C et al. (2004) [14730417].Hoffmann SH et al. (2000) [10894158].Holenz J et al. (2005) [15771424].Hollenberg MD et al. (2002) [12037136].Hollenberg MD et al. (2008) [18477767].Holloway S et al. (1996) [9121614].Holst B et al. (2003) [12907757].Holst B et al. (2007) [16959833].Holst B et al. (2009) [18923064].Holst B et al. (2004) [15383539].Homey B et al. (2000) [10725697].Honczarenko M et al. (2005) [15990859].Hong Y et al. (2012) [21658025].Horie K et al. (1995) [8564227].Horwell DC et al. (1995) Bioorganic and Medicinal Chemistry Letters, 5, 2501–2506.Hosken IT et al. (2015) [25257104].Hosoda H et al. (2000) [10801861].Hosoi T et al. (2002) [12065583].Hosoya M et al. (2000) [10777510].Hosoya M et al. (2000) [10887190].Hossain MA et al. (2008) [18434306].Hossain MA et al. (2010) [20043231].Hoyer D et al. (1994) [7938165].Hoyer D et al. (2000) In The IUPHAR Compendium of Receptor Characterization and Classification, pp. 354–364.Hoyer D et al. (2002) [11888546].Hoyer D et al. (2004) [15135911].Hoyer D et al. (2004) Soc Neuroscience Abs ‐.Hsu SH et al. (2007) [17652154].Hsu SY et al. (2000) [10935549].Hsu SY et al. (2002) [11809971].Huang C et al. (2004) [12954603].Huang F et al. (2001) [12049493].Huang XP et al. (2015) [26550826].Hudson BD et al. (2014) [24870406].Hudson BD et al. (2013) [23589301].Hudson BD et al. (2012) [23066016].Huete‐Toral F et al. (2015) [25344385].Huey R et al. (1985) [4020139].Huffman JW et al. (1999) [10658595].Hughes J et al. (1990) [1975695].Humphries RG et al. (1995) [7582510].Humphries RG et al. (1994) [7858849].Hunter JC et al. (1990) [2178014].Hunter JC et al. (1993) [8474432].Hutchinson DS et al. (2002) [11959793].Hwang SB et al. (1988) [2841449].Ichimura A et al. (2012) [22343897].Ignatov A et al. (2004) [15111018].Ignatov A et al. (2003) [12574419].Ignatov A et al. (2003) [14592418].Ignatov A et al. (2006) [17001303].Ignatowska‐Jankowska BM et al. (2015) [26052038].Ihara M et al. (1995) [7768260].Ikubo M et al. (2015) [25970039].Ilien B et al. (2009) [19451648].Im DS et al. (2000) [10799507].Imai T et al. (1998) [9430724].Inngjerdingen M et al. (2001) [11154210].Inoue A et al. (2012) [22983457].Iredale PA et al. (1994) [8032613].Irwin DM (2001) [11179772].Isberg V et al. (2014) [24826842].Ishibashi T et al. (2010) [20404009].Ishiwata K et al. (2004) [15093820].Isogaya M et al. (1999) [10531390].Ito M et al. (1993) [8349705].Itoh Y et al. (2003) [12629551].Ivanov AA et al. (2007) [17088057].Ivanov AA et al. (2007) [17302398].Iwamoto Y et al. (1987) [2437574].Jaakola VP et al. (2008) [18832607].Jackson RH et al. (1992) [1320692].Jacobson KA (2013) [23597047].Jacobson KA et al. (2011) [21484092].Jacobson KA et al. (2006) [16518376].Jacobson KA et al. (2009) [18600475].Jacobson KA et al. (2002) [12213051].Jacobson KA et al. (1997) [9364471].Jacobson MA et al. (1995) [7558011].Jacobson SG et al. (2008) [18463160].Jagerschmidt A et al. (1996) [8720482].Jagoda EM et al. (2003) [12668051].Jakubik J et al. (1997) [9224827].Jakubik J et al. (2006) [16675658].Jane DE et al. (1996) [9121605].Jansen FP et al. (1994) [7834183].Janssens R et al. (1999) [10401562].January B et al. (1997) [9295336].Jarvis MF et al. (1989) [2600819].Jasper JR et al. (1995) [7475979].Jasper JR et al. (1998) [9605427].Jayasekara PS et al. (2014) [24712832].Jenck F et al. (2000) [10758169].Jenh CH et al. (1999) [10201891].Jensen RT et al. (2008) [18055507].Jensen RT et al. (2013) In Kastin AJ (Ed.), Handbook of Biologically Active Peptides: Elsevier, pp. 118–96. [ISBN: 9780123850959].Jensen RT et al. (2013) In Kastin AJ (Ed.), Handbook of Biologically Active Peptides: Elsevier, pp. 506–11. [ISBN: 9780123850959].Jensen T et al. (2014) [25442311].Jerning E et al. (1998) [9851589].Ji X et al. (2001) [11266650].Ji XD et al. (1999) [10624567].Jia XC et al. (1991) [1922095].Jian X et al. (1999) [10206964].Jiang JL et al. (1996) [8917655].Jiang Y et al. (2003) [12714592].Jin C et al. (2008) [18487371].Jin J et al. (2005) [15936190].Jockers R et al. (1994) [7798201].Johansson B et al. (1995) [7566470].Johansson L et al. (1997) [9336327].Johnson MP et al. (2003) [12852748].Johnson MP et al. (2005) [15717213].Jolkkonen M et al. (1994) [7925952].Jones C et al. (1999) [10422787].Jones CE et al. (2003) [12606753].Jones CK et al. (2008) [18842902].Jones KA et al. (1998) [9872315].Jones PG et al. (2007) [17363172].Jones RM et al. (2000) [10822054].Jonsson KB et al. (2001) [11159842].Jordan BA et al. (1999) [10385123].Jorgensen R et al. (2005) [15528268].Joseph SS et al. (2004) [15060759].Joshi P et al. (2014) [24405707].Juarranz MG et al. (1999) [10570056].Jugus MJ et al. (2009) [19486006].Jung M et al. (1997) [8978752].Juteau H et al. (2001) [11504634].Kabarowski JH et al. (2001) [11474113].Kaku K et al. (2015) [25787200].Kalant D et al. (2003) [12540846].Kalant D et al. (2005) [15833747].Kalinichev M et al. (2013) [23257312].Kalipatnapu S et al. (2004) [15628665].Kalk P et al. (2007) [17558436].Kamali F (2001) [11757797].Kamohara M et al. (2005) [15823563].Kanaoka Y et al. (2013) [23504326].Kanatani A et al. (2000) [10872822].Kanesaka M et al. (2007) [17486669].Kanke T et al. (2005) [15765104].Kapas S et al. (1995) [7592696].Kapur A et al. (2009) [19723626].Kargl J et al. (2013) [23639801].Karnik SS et al. (2015) [26315714].Karteris E et al. (2005) [15687100].Katafuchi T et al. (2003) [12556539].Kathmann M et al. (2006) [16489449].Kato K et al. (2005) [15695169].Katugampola SD et al. (2001) [11250876].Katugampola SD et al. (2001) [11522606].Kaupmann K et al. (1997) [9069281].Kawabata A et al. (1999) [9862790].Kawai M et al. (1992) [1732540].Kawamata Y et al. (2003) [12524422].Kawamata Y et al. (2001) [11336787].Kawamoto H et al. (1999) [10602690].Kazda CM et al. (2016) [26681715].Keir MJ et al. (1999) [10521582].Kelly E et al. (2015) [24973897].Kelly LM et al. (2011) [21844396].Kelly RP et al. (2015) [25656305].Kemp PA et al. (2004) [15231488].Kennedy AJ et al. (2016) [27742615].Kennedy C et al. (2000) [10779375].Kennedy K et al. (1995) [7654246].Kennedy PC et al. (2011) [21632869].Kennedy SP et al. (1998) [9535752].Kennett GA et al. (1997) [9225286].Kerkhof HJ et al. (2010) [20112360].Khanolkar AD et al. (1996) [8893848].Khattar SK et al. (2006) [16369696].Khawaja X et al. (1997) [9048968].Khroyan TV et al. (2011) [21177476].Kiefer L et al. (2011) [21406038].Kiesel LA et al. (2002) [12072036].Kiesewetter DO et al. (1997) [9313861].Kihara Y et al. (2014) [24602016].Kikuchi A et al. (2009) [19208479].Kikuchi C et al. (1999) [10052959].Kim GH et al. (2007) [17476309].Kim HO et al. (1994) [7932588].Kim HS et al. (2003) [14584948].Kim HS et al. (2002) [11754592].Kim J et al. (1995) [7775460].Kim SV et al. (2013) [23661644].Kim TH et al. (2013) [23721409].Kim Y et al. (2013) [23541835].Kim YC et al. (2000) [10737749].Kim YC et al. (1996) [8863790].Kim YC et al. (2005) [15913566].Kimura I et al. (2011) [21518883].Kimura T et al. (1994) [7921228].Kimura Y et al. (2004) [14709324].Kinghorn AD et al. (2011) [21650152].Kingston AE et al. (1998) [9680254].Kinney GG et al. (2005) [15608073].Kinney WA et al. (2002) [12203418].Kirby HR et al. (2010) [21079036].Kiselev E et al. (2015) [26303895].Kiselev E et al. (2014) [25299434].Kiss GN et al. (2012) [22968304].Kitamura H et al. (2012) [22343749].Kitaura M et al. (1999) [10488147].Kitbunnadaj R et al. (2005) [15771452].Kitbunnadaj R et al. (2004) [15115383].Kittaka H et al. (2017) [28176353].Klein J et al. (1997) [9175608].Klein MT et al. (2011) [21422162].Klos A et al. (2013) [23383423].Klotz K‐N et al. (1998) [9459566].Knepper SM et al. (1995) [7616455].Knight AR et al. (2004) [15322733].Knoflach F et al. (2001) [11606768].Knudsen LB et al. (2000) [10794683].Kobilka B (2013) [23650120].Koe BK et al. (1992) Drug Development Research 26: 241‐250.Koga H et al. (1994) Bioorganic and Medicinal Chemistry Letters 4: 1347‐1352.Kogushi M et al. (2011) [21300059].Kohara A et al. (2005) [15976016].Kohno M et al. (2006) [16844083].Koike H et al. (2001) [11451212].Kojima D et al. (2011) [22043319].Kojima M et al. (1999) [10604470].Kolakowski Jr LF (1994) [8081729].Kolczewski S et al. (1999) [10465539].Kongsamut S et al. (2002) [12176106].Konkel MJ et al. (2006) [16789730].Konkel MJ et al. (2006) [16730981].Konteatis ZD et al. (1994) [7930622].Koo C et al. (1982) [6285921]., et al. (2005) [15840392].Kopin AS et al. (1992) [1373504].Korstanje R et al. (2008) [18796533].Kortagere S et al. (2004) [15448188].Kotani M et al. (2001) [11457843].Kotani M et al. (1995) [7476918].Kotarsky K et al. (2003) [12565875].Kottyan LC et al. (2009) [19641187].Kovacs A et al. (2003) [15107597].Kovacs I et al. (1998) [9454790].Kozian DH et al. (2012) [22801643].Kraus A et al. (2009) [19072936].Krause JE et al. (1997) [8990205].Krauss AH et al. (1996) [8882612].Krishnamoorthy S et al. (2012) [22449948].Krishnamoorthy S et al. (2010) [20080636].Kritikou E et al. (2016) [27883026].Kroeger KM et al. (2001) [11278883].Kroeze WK et al. (2003) [12629531].Krsmanovic LZ et al. (2003) [12591945].Kruse AC et al. (2013) [24256733].Krushinski Jr JH et al. (2007) [17804228].Ku GM et al. (2012) [22253604].Kubo Y et al. (2005) [15922585].Kuc D et al. (2008) [18235993].Kuc RE et al. (1995) [8587419].Kuc RE et al. (2006) Proceedings of the British Pharmacological Society 4: abst186.Kuei C et al. (2007) [17606621].Kukkonen JP (2016) [27237973].Kukkonen JP (2016) [26582739].Kukkonen JP (2016) [27909990].Kukkonen JP et al. (2014) [23902572].Kulagowski JJ et al. (1996) [8642550].Kulkarni PM et al. (2016) [26529344].Kull B et al. (1999) [9920286].Kumagai J et al. (2002) [12114498].Kumar S et al. (2003) [12604693].Kumar S et al. (2010) [19786130].Kunishima N et al. (2000) [11069170].Kuphal D et al. (1994) [8013367].Kursar JD et al. (1994) [8078486].Kuszak AJ et al. (2009) [19542234].Kuwasako K et al. (2004) [14722252].Kuwasako K et al. (2003) [12565884].Köhler C et al. (1985) [4015674].Kühn B et al. (1996) [8961278].Laas K et al. (2013) [23325374].Labarrere P et al. (2003) [12943190].Labbé‐Jullié C et al. (1995) [7746272].Laeremans H et al. (2011) [21931076].Lagerström MC et al. (2005) [15885496].Lahti RA et al. (1993) [8102973].Lahti RA et al. (1985) [2986999].Lainé DI et al. (2009) [19317446].Laitinen T et al. (2004) [15073379].Lameh J et al. (2010) [20354177].Lan R et al. (1999) [11741201].Lan R et al. (1999) [10052983].Lang R et al. (2005) [15944009].Langmead CJ et al. (2008) [18454168].Langmead CJ et al. (2006) [16207821].Langmead CJ et al. (2004) [14691055].Langmead CJ et al. (2000) [11030716].Laprairie RB et al. (2015) [26218440].Lau OC et al. (2014) [24511227]., et al. (2013) [23446738].Lavreysen H et al. (2003) [12695537].Lavreysen H et al. (2004) [15555631].Lawrence AJ et al. (2002) [12110614].Lawson EC et al. (2009) [19731961].Lazareno S et al. (1995) [7651370].Lazareno S et al. (2004) [14722259].Lazareno S et al. (1998) [9495826].Lazareno S et al. (2000) [10860942].Lazareno S et al. (2002) [12435818].Lazarowski ER et al. (1995) [8564228].Lazarowski ER et al. (1996) [8825364].Le Bourdonnec B et al. (2008) [18313920].Le Bourdonnec B et al. (2008) [18788723].Le Bourdonnec B et al. (2009) [19694468].Le Poul E et al. (2003) [12711604].Le Y et al. (2002) [12401407].Leach K et al. (2011) [21300722].Leach K et al. (2016) [27002221].Leach K et al. (2010) [19940843].Leach K et al. (2014) [24111791].Leach K et al. (2013) [23372019].Leaños‐Miranda A et al. (2003) [12843188].Leban JJ et al. (1993) [8446610].Lebon G et al. (2015) [25762024].Lebon G et al. (2011) [21593763].Ledent C et al. (2005) [15956199].Leduc M et al. (2009) [19584306].Lee C et al. (2010) [21124972].Lee DK et al. (2001) [11574155].Lee DK et al. (2005) [15486224].Lee J et al. (1992) [1379593].Lee MC et al. (2008) [18179608].Lee YM et al. (1993) [7681836].Leeb‐Lundberg LM et al. (2005) [15734727].Lefkowitz RJ (2013) [23650015].Legros C et al. (2013) [23698757].Lehmann F et al. (2009) [19481466].Lehmann F et al. (2005) [15781415].Lehmann F et al. (2007) [17112638].Leibowitz SF et al. (1992) [1283559].Lejeune F et al. (1997) [9067310].Lembo PM et al. (2002) [11850634].Lennertz L et al. (2012) [22078257].Leonard CS et al. (2014) [23848055].Leonardi A et al. (1997) [9190863].Leopoldo M et al. (2007) [17649988].Leopoldo M et al. (2008) [18800769].Lesage AS et al. (1998) [9605573].Leung T et al. (2008) [18755178].Leurs R et al. (1994) [7921611].Leuthauser K et al. (2000) [11023820].Lever JR et al. (1998) [9696425].Levoye A et al. (2006) [16778767].Lewis TA et al. (2004) [15482930].Leysen JE et al. (1996) [8967979].Li AH et al. (1998) [9703464].Li JJ et al. (2004) [15027861].Li L et al. (2002) Neuropharmacology 43: 295.Li R et al. (2013) [23239822].Li X et al. (2002) [12013525].Liang BT, Urso R, Sambraski E, et al. (2010) In Adenosine Receptors from Cell Biology to Pharmacology Edited by Borea P: Springer: 257‐280 [ISBN: 9789048131440].Liang M et al. (2000) [10748002].Liang TS et al. (2001) [11714831].Liapakis G et al. (2004) [15102946].Liaw CW et al. (2009) [19630535].Liebscher I et al. (2011) [21097509].Liggett SB (2003) [15090197].Ligneau X et al. (2000) [11090094].Liljebris C et al. (1995) [7830272].Lim HD et al. (2006) [17154494].Lim HD et al. (2005) [15947036].Limonta P et al. (2003) [14726258].Lin DC et al. (2002) [11886876].Lin DC et al. (2012) [22859723].Lin L et al. (1999) [10458611].Lin Q et al. (1999) [9890897].Linden J et al. (1999) [10496952].Lindsley CW et al. (2004) [15537338].Lindström E et al. (1999) [10385255].Linz K et al. (2014) [24713140].Litschig S et al. (1999) [10051528].Liu C et al. (2005) [15465925].Liu C et al. (2003) [14522967].Liu C et al. (2003) [14522968].Liu C et al. (2012) [22434674].Liu C et al. (2001) [11179434].Liu C et al. (2001) [11561071].Liu C et al. (2009) [19047060].Liu C et al. (2011) [21796211].Liu JJ et al. (2012) [22267580].Liu JJ et al. (2009) [19369576].Liu P et al. (2011) [24900283].Liu Q et al. (1999) [10581185].Liu Q et al. (2009) [20004959].Liu S et al. (1998) [9822540].Liu W et al. (2012) [22798613].Llinares M et al. (1999) [10231715].Lobo MK et al. (2007) [17934457].Loetscher M et al. (1994) [8276799].Loetscher P et al. (1998) [9712844].Logue SF et al. (2009) [19796684].Londregan AT et al. (2013) [23337601].Long DD et al. (2012) [22959244].Longrois D et al. (2012) [22342278].Lopez VM et al. (2008) [18828673].Lopez‐Gimenez JF et al. (2001) [11562430].Lorenzen A et al. (1996) [8937447].Louis SN et al. (1999) [10079020].Lovenberg TW et al. (2000) [10869375].Lu X et al. (2005) [15944007].Lu X et al. (2010) [20660766].Lu ZL et al. (2007) [17452338].Lucchelli A et al. (1997) [9283717].Lumley P et al. (1989) [2527074].Lundell I et al. (1995) [7493937].Lundkvist J et al. (1996) [8874139].Luo J et al. (2009) [19605502].Luo R et al. (2011) [21768377].Luttrell LM et al. (2010) [20427692].Lynch KR et al. (1999) [10391245].Lüttichau HR (2010) [20044480].Lüttichau HR et al. (2003) [12554737].Ma L et al. (2009) [19717450].Ma L et al. (2016) [26808470].Macaluso NJ et al. (2011) [21560248].MacDonald E et al. (1997) [9227000].Machwate M et al. (2001) [11408598].MacKenzie RG et al. (1994) [7907989].MacLennan SJ et al. (1997) [9283709].Maddox JF et al. (1996) [8551217].Madsen K et al. (2011) [21831646].Madsen P et al. (1998) [9857085].Madsen U et al. (2005) [15996690].Maeda DY et al. (2014) [25254640].Maeda K et al. (2006) [16476734].Maeda K et al. (2001) [11454872].Maekawa A et al. (2009) [19561298].Maggio R et al. (1994) [7805774].Maggiolini M et al. (2004) [15090535].Maguire JJ et al. (1995) [7647976].Maguire JJ et al. (2000) [11015293].Maguire JJ et al. (2009) [19325074].Maier DL et al. (2009) [19401496].Maiti K et al. (2003) [14651258].Maj M et al. (2003) [14573382].Majumdar ID et al. (2011) [21042212].Majumdar ID et al. (2012) [22157398].Majumdar S et al. (2011) [21621410].Malgouris C et al. (1993) [8472747].Malherbe P et al. (2009) [19751316].Malherbe P et al. (2009) [19542319].Malherbe P et al. (1999) [10216218].Malherbe P et al. (2010) [20404073].Mallee JJ et al. (2002) [11847213].Mamedova LK et al. (2004) [15081875].Mamillapalli R et al. (2010) [20032198].Mandala S et al. (2002) [11923495].Manglik A et al. (2015) [25981665].Mannaioni G et al. (1999) [10428410].Mantey S et al. (1993) [7684815].Mantey SA et al. (2004) [15102928].Mantey SA et al. (1997) [9325344].Marathe GK et al. (1999) [10497200].Maravillas‐Montero JL et al. (2015) [25411203].Marazziti D et al. (2009) [19398891].Marazziti D et al. (2011) [21372109].Marazziti D et al. (2007) [17519329].Marlo JE et al. (2009) [19047481].Marteau F et al. (2003) [12815166].Martin PL et al. (1996) [8632314].Martin S et al. (2002) [12360476].Martinborough E et al. (2011) Patent number: US20110172202 A1.Maruoka H et al. (2010) [20446735].Maruoka H et al. (2011) [21528910].Maruyama T et al. (2001) [11454473].Maruyama T et al. (2002) [12419312].Masuda Y et al. (2002) [12054613].Mathiesen JM et al. (2006) [16418339].Mathiesen JM et al. (2003) [12684257].Mathieu MC et al. (2005) [16154494].Matsufuji T et al. (2015) [25497965].Matsufuji T et al. (2014) [24412111].Matsumoto M et al. (2001) [11549267].Matsuura B et al. (2005) [15677347].Matsuura B et al. (2002) [11781320].Matsuura B et al. (2006) [16531413].Matteson PG et al. (2008) [18250320].Matthes H et al. (1993) [8450829].Mattsson C et al. (2005) [16055331].Matuszek MA et al. (1998) [9718274].Maudsley S et al. (2004) [15492280].May LT et al. (2007) [17525129].Mayeux PR et al. (1991) [1830308].Mayo KE et al. (2003) [12615957].Mazella J et al. (1996) [8795617].Maïga A et al. (2013) [23935897].McAllister G et al. (1992) [1608964].McAtee LC et al. (2004) [15261275].McCall RB et al. (2005) [15980060].McCall RB et al. (1994) [7965808].McClellan KJ et al. (1998) [9878991].McDonald J et al. (2003) [12967935].McGuire JJ et al. (2004) [14976230].McHugh D et al. (2010) [20346144].McHugh D et al. (2006) [16207832].McHugh D et al. (2012) [21595653].McIntyre TM et al. (2003) [12502787].McKeage K (2015) [25859983].McKee KK et al. (1997) [9441746].McKinnell RM et al. (2013) [23756062].McLatchie LM et al. (1998) [9620797].Mead EJ et al. (2007) [17023533].Medhurst AD et al. (2003) [12603839].Meena CL et al. (2016) [26854379].Meis S et al. (2010) [19815812].Mejean A et al. (1995) [8719421].Meng T et al. (2008) [18358099].Methven L et al. (2009) [19572943].Methven L et al. (2009) [19888965].Metra M et al. (2013) [23273292].Meyer MD et al. (1997) [9379432].Meyer RC et al. (2013) [23690594].Meyerhof W (1998) [9600011].Mialet J et al. (2000) [10683202].Mialet J et al. (2000) [11030734].Mialet J et al. (2000) [10821780].Michel AD et al. (1990) [1970500].Michel MC et al. (1998) [9549761].Middlemiss DN et al. (1999) [10443589].Mierau J et al. (1995) [7664822].Migeotte I et al. (2005) [15623572].Millan MJ et al. (1994) [7988633].Millan MJ et al. (1998) [9732398].Millan MJ et al. (2000) [10869410].Millan MJ et al. (2002) [12388666].Millan MJ et al. (2000) [10611634].Millan MJ et al. (1995) [7473180].Millar R et al. (2001) [11493674].Millar RP (2005) [16140177].Millar RP et al. (2004) [15082521].Miller BE et al. (2015) [26092545].Minamino N et al. (1985) [3839674].Minneman KP et al. (1994) [7969082].Miranda LP et al. (2008) [18412318].Mirzadegan T et al. (2000) [10770925].Mitselos A et al. (2007) [17074305].Mitsukawa K et al. (2005) [16339898].Mizuguchi T et al. (1997) [9113361].Moeller I et al. (1997) [9166749].Moguilevsky N et al. (1994) [7925364].Mohr M et al. (2004) [15163212].Molenaar P et al. (1992) [1472961].Molenaar P et al. (1997) [9117106].Molinari EJ et al. (1996) [8773460].Mollay C et al. (1999) [10422759].Mollereau C et al. (2001) [11325787].Mollereau C et al. (2002) [12242085].Mollereau C et al. (1996) [8849681].Mollereau C et al. (1994) [8137918].Mombaerts P (2004) [15034552].Monczor F et al. (2003) [12869657].Monn JA et al. (2015) [25602126].Monn JA et al. (1999) [10090786].Monneret G et al. (2003) [12490611].Monnier C et al. (2011) [21063387].Montrose‐Rafizadeh C et al. (1997) [9261127].Moody TW et al. (2002) [11931347].Moody TW et al. (2015) [25554218].Moody TW et al. (2004) [15134870].Moore K et al. (2009) [19723586].Moreland RB et al. (2005) [16153699].Moreno D et al. (2000) [11068102].Moreno P et al. (2013) [23892571].Morfis M et al. (2008) [18599553].Morgan K et al. (2003) [12538601].Mori K et al. (2005) [15635449].Mori M et al. (1999) [10548501].Moriconi A et al. (2014) [25385614].Morinelli TA et al. (1989) [2530338].Morishima S et al. (2007) [17162094].Moro O et al. (1997) [8995389].Moro O et al. (1999) [10438479].Morokata T et al. (2005) [16339911].Moroni F et al. (2002) [12015200].Moroni F et al. (1997) [9152378].Morrow GB et al. (2014) [25015314].Morse KL et al. (2001) [11181941].Morton MF et al. (2011) [21493750].Mosberg HI et al. (1983) [6310598].Motoike T et al. (2016) [27140610].Moulin A et al. (2013) [22798076].Muccioli G et al. (2001) [11314756].Muda M et al. (2005) [16051677].Muff R et al. (1999) [10342886].Muley MM et al. (2016) [26140667].Munchhof MJ et al. (2012) [24900436].Munk SA et al. (1996) [8784451].Munro TA et al. (2013) [23976952].Murakami M et al. (2008) [18466763].Murphy PM (2002) [12037138].Murphy PM et al. (2000) [10699158].Murphy PM et al. (1992) [1373134].Murugesan N et al. (2003) [12502366].Murza A et al. (2016) [26986036].Mutel V et al. (2000) [11080213].Muto T et al. (2007) [17360426].Müller A et al. (2013) [23335960].Müller A et al. (2014) [25516095].Müller T et al. (2003) [12727981].Nagahara T et al. (2015) [26267383].Nagase T et al. (2008) [18598020].Nagata‐Kuroiwa R et al. (2011) [21390312].Naka M et al. (1992) [1386885].Nakamura M et al. (1991) [1657923].Nakamura M et al. (1992) [1333988].Nakamura S et al. (2000) [10780976].Nakamura T et al. (2000) [11118334].Nakane M et al. (2005) [15992586].Nambi P et al. (1994) [8301559].Nambu H et al. (2011) [21971119].Namour F et al. (2016) [26852904].Napier C et al. (2005) [16298345].Napier C et al. (1999) [10193663].Navarro G et al. (2015) [25926444].Nawaratne V et al. (2010) [20406819].Nawaratne V et al. (2008) [18628403].Naya A et al. (2003) [12614873].Neale JH (2011) [21740441].Nederpelt I et al. (2016) [26398856].Nederpelt I et al. (2016) [26774084].Negishi M et al. (1995) [7608175].Negoro N et al. (2010) [24900210].Negri L et al. (2005) [16113687].Neill JD (2002) [11861490].Nelson CP et al. (2006) [16188951].Nelson DL et al. (1999) [9933142].Nelson DL et al. (2010) [20855361].Nelson G et al. (2001) [11509186].Nemeth EF (2013) [24050279].Nemeth EF et al. (2001) [11561095].Nemeth EF et al. (1998) [9520489].Nenasheva TA et al. (2013) [23357106].Nergårdh R et al. (2005) [16318870].Neschadim A et al. (2014) [24812057].Neumeyer JL et al. (2003) [14613319].Neveu C et al. (2012) [22800498].Newman‐Tancredi A et al. (2000) [11040052].Newman‐Tancredi A et al. (1999) [10431754].Newman‐Tancredi A et al. (1998) [9760039].Newman‐Tancredi A et al. (2009) [19154445].Newman‐Tancredi A et al. (1998) [9550290].Newman‐Tancredi A et al. (1992) [1386736].Nguyen T et al. (2001) [11179435].Ni NC et al. (2011) [21903747].Nickolls SA et al. (2003) [12604699].Nicole P et al. (2000) [10801840].Niedernberg A et al. (2003) [12618218].Nielsen MS et al. (1999) [10085125].Nieto‐Posadas A et al. (2012) [22101604].Nieuwenhuijs VB et al. (1999) [10092986].Nikaido Y et al. (2015) [25425658].Nilsson I et al. (2002) [11738246].Nilsson NE et al. (2003) [12684041].Ning Y et al. (2008) [18724386].Niswender CM et al. (2010) [20026717].Niswender CM et al. (2008) [18664603].No authors listed (1988) [3071214].No authors listed (2005) [16498716].Noble F et al. (1999) [10581329].Noda M et al. (2003) [12558985].Nonaka Y et al. (2005) [16185654].Nosjean O et al. (2000) [10913150].Nosjean O et al. (2001) [11331072].Nothacker H‐P et al. (1999) [10559967].Nothacker HP et al. (2000) [11093801].Nunn C et al. (2003) [12616335].Nygaard R et al. (2013) [23374348].Näsman J et al. (2000) [10799315].O'Brien JA et al. (2003) [12920211].O'Brien JA et al. (2004) [14747613].O'Flaherty JT et al. (1998) [9829988].O'Sullivan SE (2007) [17704824].Obiefuna PC et al. (2005) [16020631].Obika K et al. (1995) [8719417].Ochi T et al. (2005) [15686911].Ochiai S et al. (2013) [23831392].Oda T et al. (2000) [10973974].Oertel BG et al. (2009) [19116204].Offermanns S et al. (2011) [21454438].Ogita T et al. (1997) [9038918].Oh da Y et al. (2014) [24997608].Oh DY et al. (2010) [20813258].Ohashi T et al. (2015) [25959255].Ohki‐Hamazaki H et al. (1997) [9367152].Ohlmann P et al. (2013) [22892887].Ohsu T et al. (2010) [19892707].Ohta H et al. (2003) [14500756].Ohtaki T et al. (1999) [10601261].Ohtaki T et al. (2001) [11385580].Oka S et al. (2007) [17765871].Oka S et al. (2010) [20361937].Oka S et al. (2009) [18845565].Okamoto H et al. (1998) [9765227].Okamura N et al. (2007) [17669576].Okawa H et al. (1999) [10369464].Okinaga S et al. (2003) [12899627].Okuda‐Ashitaka E et al. (1996) [8940129].Okuno T et al. (2008) [18378794].Olender T et al. (2008) [19129093].Olianas MC et al. (1999) [9862767].Ongini E et al. (1999) [9933143].Oo ML et al. (2007) [17237497].Osada M et al. (2002) [12445827].Osborn O et al. (2012) [22653059].Ott TR et al. (2006) [16904643].Oury‐Donat F et al. (1995) [7616392].Overington JP et al. (2006) [17139284].Overton HA et al. (2006) [16517404].Padmanabhan S et al. (2009) [19059244].Palani A et al. (2012) [24900372].Palani A et al. (2001) [11585437].Pan S et al. (2013) [24900670].Pan S et al. (2006) [17114004].Pang L et al. (1998) [9832122].Pantel J et al. (2006) [16511605].Panula P et al. (2015) [26084539].Parent JL et al. (1996) [8798529].Park D et al. (2007) [17960134].Parker CA et al. (2012) [22223878].Parker EM et al. (1996) [8863519].Parody TR et al. (2004) [15207250].Paruchuri S et al. (2009) [19822647].Pasternak GW et al. (2013) [24076545].Patacchini R et al. (2003) [14645137].Patane MA et al. (1998) [9548811].Patel P et al. (2008) [18292294].Patel S et al. (1996) [8967990].Patel YC et al. (1994) [7988476].Patra MC et al. (2014) [24938207].Pauli A et al. (2014) [24407481].Pauwels PJ et al. (1988) [2462161].Pauwels PJ et al. (2003) [12649300].Payza K (2003) In The Delta Receptor Edited by Chang KJ: CRC Press: 261‐275 [ISBN: 0824740319].Pazos A et al. (1984) [6519175].Pearlstein R et al. (2003) [12747773].Peirce SM et al. (2001) [11406470].Pellegrini‐Giampietro DE et al. (1996) [8799579].Pellicciari R et al. (2009) [20014870].Pellicciari R et al. (1996) [8667369].Peltonen JM et al. (1998) [9760042].Pena A et al. (2007) [17300166].Pendergast W et al. (2001) [11206448].Peralta EG et al. (1987) [3443095].Perdonà E et al. (2011) [21034740].Pereira JP et al. (2009) [19597478].Perkins AV et al. (1995) [7595134].Perlman S et al. (1995) [7829475].Perretti M et al. (2002) [12368905].Perron A et al. (2005) [15637074].Pertwee RG (2012) [23108552].Pertwee RG (2000) [11060760].Pertwee RG et al. (2010) [21079038].Peter MG et al. (1996) [7881728].Petersen KF et al. (2001) [11719833].Petersen PS et al. (2011) [21784784].Petitet F et al. (1996) [8733746].Petrel C et al. (2003) [14506236].Petrie WK et al. (2013) [24379833].Phalipou S et al. (1997) [9334232].Phebus LA et al. (1997) [9395253].Pihlavisto M et al. (1998) [9824686].Pin J‐P et al. (1999) [10443583].Pin JP et al. (2002) [12769621].Pin JP et al. (2016) [27905440].Pin JP et al. (2009) [19723778].Pin JP et al. (2004) [15451400].Pin JP et al. (2007) [17329545].Pinard A et al. (2010) [20655485].Pisegna JR et al. (2000) [11193823].Pitkin SL et al. (2010) [20605969].Pittolo S et al. (2014) [25173999].Pizzonero M et al. (2014) [25380412].Planagumà A et al. (2013) [23607720].Plöckinger U et al. (2012) [22065857].Pohl SL et al. (1969) [4305077].Popova JS et al. (1995) [7798906].Popp BD et al. (2004) [14744619].Porcher C et al. (2005) [15726424].Porter RA et al. (2001) [11459658].Porter RH et al. (2005) [16040814].Portoghese PS et al. (1987) [2444704].Portoghese PS et al. (1988) [2832195].Poulain R et al. (2001) [11585443].Powell WS et al. (1999) [9920859].Powell WS et al. (1992) [1326548].Power CA et al. (1997) [9294137].Powers SP et al. (1988) [3410633].Poyner DR et al. (2002) [12037140].Prat M et al. (2009) [19653626].Price MJ (2017) [27886821].Price MR et al. (2005) [16113085].Primus RJ et al. (1997) [9262371].Procopiou PA et al. (2010) [20462258].Procopiou PA et al. (2011) [21381763].Prossnitz ER et al. (2015) [26023144].Pruneau D et al. (1999) [10596852].Prömel S et al. (2013) [23850273].Pugsley TA et al. (1995) [8531103].Putula J et al. (2014) [25132134].Putula J et al. (2011) [21362456].Pérez‐Garci E et al. (2006) [16701210].Qi T et al. (2013) [22946511].Quancard J et al. (2012) [22999882].Quinn SJ et al. (2004) [15201280].Quinn SJ et al. (1998) [9677383].Quinn SJ et al. (1997) [9357776].Quinton L et al. (2010) [20015090].Quock RM et al. (1997) [9178661].Raczka KA et al. (2010) [20628342].Rakowski E et al. (2005) [16171813].Rakugi H et al. (2014) [24742498].Ramachandran R et al. (2012) [22212680].Ramage AG et al. (2008) [19086344].Ramos‐Álvarez I et al. (2015) [25976083].Ramos‐Álvarez I et al. (2016) [26524625].Ramsay D et al. (2004) [15266013].Randeva HS et al. (2001) [11600545].Rashid M et al. (2003) [12738034].Rask‐Andersen M et al. (2014) [24016212].Rasmussen SG et al. (2011) [21228869].Rasmussen SG et al. (2011) [21772288].Ratnala VR et al. (2004) [15206929].Raufman JP et al. (1991) [1704369].Rawashdeh O et al. (2011) [21182402].Raychowdhury MK et al. (1994) [8034687].Raynor K et al. (1994) [8114680].Read C et al. (2016) [27475715].Reavill C et al. (1999) [10188965].Reavill C et al. (2000) [10945872].Regoli D et al. (1998) [9650825].Reid RC et al. (2014) [25259874].Reid RC et al. (2013) [24257095].Reinscheid RK et al. (2005) [16144971].Resnati M et al. (2002) [11818541].Revankar CM et al. (2005) [15705806].Revel FG et al. (2011) [21525407].Reynaud R et al. (2012) [22466334].Reynolds EE et al. (1995) [7733918].Reynolds GP et al. (1995) [7780656].Rezgaoui M et al. (2006) [16443751].Rhee MH et al. (1997) [9379442].Ricci A et al. (1994) [8051291].Ricci A et al. (1995) [7759603].Rice AS et al. (2014) [24507377].Richard F et al. (2001) [11723247].Richardson RM et al. (2003) [12626541].Riddy DM et al. (2017) [27864425].Rinaldi‐Carmona M et al. (1994) [8070571].Rinaldi‐Carmona M et al. (1998) [9454810].Rinaldi‐Carmona M et al. (1996) [8614277].Rivail L et al. (2004) [15351779].Rivier J et al. (1991) [1850267].Rivkees SA et al. (1999) [9920910].Rizzi A et al. (1997) [9095082].Robas N et al. (2003) [12915402].Roecker AJ et al. (2016) [26317591].Rohrer SP et al. (1998) [9784130].Romano M et al. (1996) [8757340].Roos RS et al. (1997) [9211859].Rosenbaum DM et al. (2011) [21228876].Rosengren AH et al. (2010) [19965390].Roseweir AK et al. (2009) [19321788].Rosier A et al. (1996) [9027929].Ross RA et al. (1999) [10188977].Roth BL et al. (2002) [12192085].Roth BL et al. (1994) [7908055].Rothman RB et al. (2000) [11104741].Roush ED et al. (1998) [9654151].Roussin A et al. (2005) [16129413].Rovati GE et al. (1992) [1329767].Rowley M et al. (1996) [8642551].Royer JF et al. (2007) [17714552].Ruffing N et al. (1998) [9790730].Ruffner H et al. (2012) [22815884].Ruiu S et al. (2003) [12663689].Ruiz‐Ferrer M et al. (2011) [21858136].Ruiz‐Medina J et al. (2011) [21352831].Russell FD et al. (1996) [8904635].Russell JL et al. (2012) [22462679].Ruzza C et al. (2015) [25692025].Ruzza C et al. (2010) [20172007].Ryan PJ et al. (2013) [24297931].Ryberg E et al. (2007) [17876302].Römpler H et al. (2005) [15987686].Rühmann A et al. (2002) [11835994].Saar I et al. (2013) [23600864].Sabbatini FM et al. (2010) [20593439].Sabroe I et al. (2000) [10854442].Sairam MR (1989) [2542111].Saito M et al. (1997) [9264324].Sakurai T et al. (1998) [9491897].Sallinen J et al. (2007) [17220913].Salmon M et al. (2013) [23435542].Salvatore CA et al. (2008) [18039958].Salvatore CA et al. (1993) [8234299].Sams AG et al. (2010) [20684563].Sanger GJ (2014) [24438586].Sanger GJ et al. (2011) [21531468].Sanger GJ et al. (2012) [23189978].Sanger GJ et al. (2009) [19374732].Sanna MG et al. (2004) [14732717].Sanna MG et al. (2006) [16829954].Sano H et al. (2004) [15203211].Sarau HM et al. (1999) [10462554].Sarau HM et al. (2001) [11226387].Sarau HM et al. (1997) [9190866].Sarau HM et al. (1997) [9336350].Sato H et al. (2007) [17825251].Sato M et al. (2007) [17717109].Sato M et al. (2008) [18684840].Sato Y et al. (1996) [8982677].Saussy DLJr et al. (1996) [8764344].Sautel F et al. (1995) [7756621].Sautel F et al. (1995) [8531087].Savall BM et al. (2014) [24495018].Scanlan TS et al. (2004) [15146179].Schachter JB et al. (1997) [9154346].Schaerlinger B et al. (2003) [12970106].Schaffhauser H et al. (2003) [14500736].Schally AV et al. (2004) [15350601].Schally AV et al. (1999) [10542394].Schechter LE et al. (2008) [17625499].Schiller PW et al. (1993) [8230106].Schioth HB et al. (1995) [7774675].Schiöth HB et al. (2005) [15862553].Schiöth HB et al. (1998) [9630346].Schlachter SK et al. (1997) [9098699].Schmid HA et al. (2004) [15477717].Schmidt J et al. (2011) [21220428].Schmitz B et al. (2015) [25666387].Schoepp DD et al. (2000) In IUPHAR Compendium of Receptor Characterization and Classification Edited by Watson SP, Girdlestone D: IUPHAR Press: 195‐208.Schoepp DD et al. (1997) [9144636].Schoepp DD et al. (1996) [9076745].Schotte A et al. (1996) [8935801].Schulte G (2010) [21079039].Schwartz JC, Carlsson A, Caron M, Scatton B, Civelli O, Kebabian JW, Langer SZ, Sedvall G, Seeman P, Spano PF, Sokoloff P, & Van Tol H (1998) In The IUPHAR Compendium of Receptor Characterization and Classification Edited by Girdlestone D: IUPHAR media: 141‐151.Schweitz H et al. (1999) [10567694].Schweitzer C et al. (2000) [10884552].Schwenk J et al. (2010) [20400944].Schwenk U et al. (1995) [7797484].Scola AM et al. (2009) [19100624].Scott DJ et al. (2005) [15956681].Scott DJ et al. (2005) [15956680].Scott DJ et al. (2006) [16963451].Scott FL et al. (2016) [26990079].Scott MK et al. (2000) [10896115].Sebhat IK et al. (2011) [24900253].Sebhat IK et al. (2002) [12361385].Seeman P (2001) Clinical Neuroscience Research 1: 53‐60.Seeman P et al. (1975) [1060115].Seeman P et al. (1997) [9015795].Seeman P et al. (1998) [9577836].Segala E et al. (2016) [27312113].Seifert R et al. (2003) [12626648].Seitzberg JG et al. (2008) [18720984].Selkirk JV et al. (1998) [9776361].Semple G et al. (2006) [16480258].Serradeil‐Le Gal C et al. (1996) [8981918].Serradeil‐Le Gal C et al. (2000) [11012895].Serradeil‐Le Gal C et al. (2004) [14722330].Serradeil‐Le Gal C et al. (2002) [11861823].Setoh M et al. (2014) [24884590].Seuwen K et al. (2006) [17118800].Sevigny LM et al. (2011) [21536878].Shabanpoor F et al. (2012) [22257012].Shabanpoor F et al. (2012) [22425984].Shabanpoor F et al. (2007) [17120268].Shabanpoor F et al. (2008) [18529069].Shabanpoor F et al. (2011) [20560146].Shahid M et al. (2009) [18308814].Sharif NA et al. (2002) [11999132].Sharif NA et al. (2006) [17076623].Sharif NA et al. (2001) [11572462].Sheffler DJ et al. (2009) [19407080].Shemesh R et al. (2008) [18854305].Shen HC et al. (2010) [20184326].Shibata K et al. (1995) [7651358].Shichijo M et al. (2003) [12975488].Shimizu N et al. (1999) [10233994].Shimomura Y et al. (2002) [12130646].Shimon I et al. (2004) [15636423].Shimpukade B et al. (2012) [22519963].Shinagawa Y et al. (2011) [24900301].Shinkre BA et al. (2010) [20801028].Shinohara T et al. (2004) [15037633].Shire D et al. (1996) [8679694].Shitara K et al. (2009) Patent number:US7504104.Shore DM et al. (2015) [25926795].Showalter VM et al. (1996) [8819477].Showell HJ et al. (1976) [1262785].Showell HJ et al. (1995) [7714764].Siegl AM et al. (1979) [372237].Siehler S et al. (1998) [9652348].Siehler S et al. (1999) [10598788].Siehler S et al. (1998) [9650799].Sikand P et al. (2011) [21593341].Sillard R et al. (1992) [1283627].0. Silver MR et al. (2005) [15878963].Sim LJ et al. (1996) [8987831].Simon MF et al. (2005) [15710620].Simonin F et al. (1995) [7624359].Simonin F et al. (2006) [16407169].Simonin F et al. (2001) [11239918].Singh G et al. (2004) [15261118].Singh L et al. (1995) [8605955].Sinha S et al. (2010) [20590605].Skerlj RT et al. (2010) [20297846].Skinner PJ et al. (2009) [19524438].Skofitsch G et al. (1986) [2436195].Skrzydelski D et al. (2003) [12869647].Slack JP et al. (2010) [20537538].Sleight AJ et al. (1998) [9647481].Sleight AJ et al. (1996) [8534270].Slipetz DM et al. (1995) [7651369].Sliwoski G et al. (2016) [27294784].Slusarski DC et al. (1997) [9389482].Small KM et al. (2006) [16605244].Smith CM et al. (2012) [21899720].Smith CM et al. (1997) [9029489].Smith JA et al. (2008) [18415081].Smith JP et al. (2002) [12429993].Smith KE et al. (1997) [9305929].Smith KE et al. (1998) [9722565].Smith MT et al. (2013) [23489258].Smith PW et al. (1995) [7562907].Smith RD et al. (1994) [7850406].Smits RA et al. (2006) [16854056].Sodin‐Semrl S et al. (2004) [15171815].Sofuoglu M et al. (1991) [1851833].Soga T et al. (2003) [12646212].Soga T et al. (2002) [12427552].Sokoloff P et al. (1992) [1354163].Sokoloff P et al. (1992) [1586393].Sokoloff P et al. (1990) [1975644].Solinski HJ et al. (2014) [24867890].Sollenberg UE et al. (2006) International Journal of Peptide Research and Therapeutics 12: 115‐119.Song H et al. (2008) [18955481].Song I et al. (1993) [8415658].Song J et al. (2008) [17898319].Song ZH et al. (1996) [8622639].Soriano‐Ursúa MA et al. (2009) [19168263].Southern C et al. (2013) [23396314].Spadoni G et al. (2015) [26334942].Spagnolo B et al. (2007) [17329552].Spalding TA et al. (2006) [16959945].Spalding TA et al. (2002) [12021390].Spengler D et al. (1993) [8396727].Speth RC et al. (1990) [2194459].Sprecher D et al. (2015) [25773497].Srivastava A et al. (2014) [25043059].Stalder H et al. (2011) [21237643].Stam NJ et al. (1997) [9303561].Stefano GB et al. (1992) [1329092].Steinfeld T et al. (2007) [17478612].Stenfeldt AL et al. (2007) [17687636].Stevens WC et al. (2000) [10893314].Stewart AJ et al. (2008) [17942747].Stewart M et al. (2004) [15194002].Stillman BA et al. (1999) [10462542].Stirrat A et al. (2001) [11158995].Stitham J et al. (2007) [17704830].Stocks MJ et al. (2010) [21036043].Stoddart LA et al. (2007) [17200419].Stoddart LA et al. (2008) [19047536].Storka A et al. (2008) [19021699].Straub RE et al. (1990) [2175902].Strizki JM et al. (2005) [16304152].Strosberg AD (1997) [9131260].Struthers RS et al. (2007) [17095587].Sturino CF et al. (2007) [17300164].Su SB et al. (1999) [9892621].Sudo H et al. (2008) [18164286].Sudo S et al. (2003) [12506116].Suen JY et al. (2012) [21806599].Sugahara K et al. (2017) [27714763].Sugden D et al. (1999) [10420436].Sugimoto H et al. (2005) [16256979].Sugo T et al. (2008) [17628210].Sugo T et al. (2006) [16460680].Sullivan GW et al. (2001) [11226132].Sumichika H et al. (2002) [12384495].Sun Q et al. (2010) [20685848].Sun R et al. (2004) [15210802].Sun Y et al. (2003) [12683933].Sunahara RK et al. (1991) [1826762].Sur C et al. (2003) [14595031].Suzawa T et al. (2000) [10746663].Suzuki G et al. (2007) [17609420].Suzuki M et al. (2013) [23449982].Suzuki T et al. (2008) [19007110].Suzuki T et al. (1993) [7902433].Svetlov S et al. (1993) [8380690].Swaney JS et al. (2011) [21159750].Swanson CJ et al. (2005) [16287967].Swayne GT et al. (1988) [2975605].Sykes D et al. (2014) Eur. Respir. J. 44: 4074.Sykes DA et al. (2016) [26916831].Säfholm A et al. (2008) [18927296].Tabata K et al. (2007) [17905198].Taggart AK et al. (2005) [15929991].Tahara A et al. (1998) [9884074].Tahara A et al. (1998) [9459574].Takabe K et al. (2008) [18552276].Takada Y et al. (2003) [12960358].Takahara M et al. (2014) [24739538].Takanashi H et al. (2007) [17183187].Takano T et al. (1997) [9151906].Takasaki J et al. (2000) [10913337].Takasaki J et al. (2001) [11502873].Takasu T et al. (2007) [17293563].Takayasu S et al. (2006) [16648250].Takechi H et al. (1996) [8621463].Takeda S et al. (2004) [15173198].Takekawa S et al. (2002) [11909603].Takinami Y et al. (1997) [9042983].Talmont F et al. (2009) [19682524].Tamamura H et al. (1998) [9918823].Tan CP et al. (2002) [12036292].Tan M et al. (2009) [19126537].Tanaka T et al. (2008) [18320172].Tang H et al. (2008) [18722346].Tang L et al. (1994) [8301592].Taniguchi H et al. (1996) [8813597].Taniguchi T et al. (1999) [10433504].Taniguchi Y et al. (2006) [16934253].Tatemoto K et al. (1998) [9792798].Teh MT et al. (1998) [9840420].Terakado M et al. (2016) [27774128].Terakita A (2005) [15774036].Testa R et al. (1997) [9190864].Thathiah A et al. (2009) [19213921].Theis JG et al. (1992) [1387312].Thibonnier M et al. (1994) [8106369].Thibonnier M et al. (1997) [9322919].Thielemans L et al. (2005) [15764739].Thomas BF et al. (1998) [9536023].Thomas DR et al. (2000) [10807680].Thomas DR et al. (1998) [9720804].Thomas JB et al. (2001) [11495579].Thomas NK et al. (2001) [11166323].Thomas P et al. (2005) [15539556].Thomsen AR et al. (2012) [22192592].Thomsen WJ et al. (2008) [18252809].Thoreson WB et al. (1997) [9144637].Thorsell A et al. (2013) [23761908].Thulesen J et al. (2002) [11738243].Thurmond RL et al. (2004) [14722321].Tian Y et al. (1996) [8702757].Tibaduiza EC et al. (2001) [11498540].Tiberi M et al. (1994) [7525564].Tice MA et al. (1994) [7862709].Tilakaratne N et al. (2000) [10871296].Timmermans PBMWM et al. (1993) [8372104].Ting KN et al. (1999) [10433507].Tobo A et al. (2015) [26070068].Toda N et al. (2013) [24900747].Todde S et al. (2000) [11087559].Tokita K et al. (2001) [11463790].Toledo MA et al. (2014) [24678969].Toll L et al. (1998) [9686407].Tomita K et al. (2008) [18302161].Torisu K et al. (2004) [15388164].Torrens Y et al. (1997) [9243521].Torres D et al. (2008) [18178816].Tosh DK et al. (2012) [22559880].Tough IR et al. (2006) [16807358].Tousignant C et al. (1990) [1705465].Townsend‐Nicholson A et al. (1994) [8300561].Tremblay MR et al. (2009) [19522463].Trivellin G et al. (2014) [25470569].Tränkle C et al. (2003) [12815174].Tsuchiya D et al. (2002) [11867751].Tsujihata Y et al. (2011) [21752941].Tsukada J et al. (2001) [11429400].Tuckmantel W et al. (1997) Bioorg Med Chem Lett. 7: 601‐606.Tudhope SR et al. (1994) [7698171].Tunaru S et al. (2003) [12563315].Turecek R et al. (2014) [24836506].Turner MR et al. (2005) [15689356].Tzschentke TM et al. (2007) [17656655].Uberti MA et al. (2005) [15615865].Uchida D et al. (1998) [9928019].Uehara H et al. (2011) [21729729].Uguccioni M et al. (1997) [9276730].Uhlenbrock K et al. (2002) [12220620].Uhlén S et al. (1994) [7996470].Ullmann H et al. (2005) [16250663].Ulman LG et al. (1993) [7693918].Ulrich 2nd CD et al. (1998) [9843782].Ulrich D et al. (2007) [17433877].Ulven T et al. (2005) [15715457].Unson C et al. (1987) [3035568].Unson CG et al. (1989) [2560175].Ursini A et al. (2000) [11020274].Uyama Y et al. (1997) [9106476].Vacher CM et al. (2006) [16606363].Valant C et al. (2012) [21989256].Valant C et al. (2008) [18723515].Valdes AM et al. (2010) [20090528].Van Brocklyn JR et al. (2000) [10753843].Van den Wyngaert et al. (1997) [9349523].vander Westhuizen et al. (2010) [20159943].Van Lith LH et al. (2009) [19641221].vanMuijlwijk‐Koezen JE et al. (2000) [10841801].Van Poppel H (2010) [21188095].Van Rampelbergh J et al. (1996) [8967982].Van Tol HHM et al. (1991) [1840645].vanWieringen JP et al. (2013) [24183974].Vanderheyden PML et al. (1999) [10193788].Vanover KE et al. (2004) [15102927].Vanti WB et al. (2003) [14559210].Varani K et al. (2005) [16219300].Varani K et al. (2000) [10779381].Varga JL et al. (1999) [9892695].Varga JL et al. (2004) [14755056].Varney MA et al. (1999) [10381773].Varnäs K et al. (2011) [20424633].Varty GB et al. (2008) [18492950].Vassileva G et al. (2006) [16724960].Vaudry H et al. (2015) [25535277].Vergura R et al. (2008) [18069089].Verheijen I et al. (2000) [11206708].Vigot R et al. (2006) [16701209].Vilardaga JP et al. (2008) [18193048].Villalón CM et al. (2007) [17703282].Virag T et al. (2003) [12695531].Vita N et al. (1998) [9851594].Vlachou S et al. (2011) [21181127].Volpe, DA, et al. (2011) [21215785].Volz A et al. (1995) [7589426].vonGeldern TW et al. (1999) [10479298].vonKügelgen I et al. (2011) [21586365].vonKügelgen I et al. (2016) [26519900].Vonvoigtlander PF et al. (1983) [6129321].Wacker D et al. (2013) [23519215].Wacker DA et al. (2002) [12067561].Waeber C et al. (1998) [9928243].Waelbroeck M et al. (1996) [8813552].Wainscott DB et al. (1993) [8450835].Wainscott DB et al. (2005) [15900510].Wainscott DB et al. (1998) [9459568].Waldo GL et al. (2002) [12391289].Walker AW et al. (2015) [25849482].Walker CS et al. (2010) [20633935].Walker CS et al. (2015) [26125036].Wallrabenstein I et al. (2013) [23393561].Walter S et al. (2013) [23674604].Walters MJ et al. (2010) [20660125].Walther A et al. (2000) [10882119].Wan W et al. (1990) [2213023].Wan Y et al. (2002) [12450563].Wang C et al. (2013) [23519210].Wang J et al. (2012) [23063522].Wang J et al. (2006) [16754668].Wang J et al. (2006) [16966319].Wang M et al. (2006) [16455645].Wang S et al. (1998) [9742938].Wang S et al. (1997) [9281594].Wang S et al. (1997) [9405385].Wang SZ et al. (1993) [7687290].Wank SA et al. (1992) [1313582].Ward SE et al. (2005) [15887956].Warne T et al. (2011) [21228877].Warne T et al. (2008) [18594507].Warner FJ et al. (1999) [10455255].Watakabe T et al. (1992) [1320877].Watanabe K et al. (1999) [10537280].Watanabe N et al. (2015) [26136644].Watanabe T et al. (1995) [7780649].Watanabe Y et al. (1999) [10349870].Watson M et al. (1984) [6546354].Watson SJ et al. (2012) [22282525].Watts AO et al. (2013) [23341447].Weber AE et al. (1998) [9873496].Webster EL et al. (1996) [8940412].Weinshank RL et al. (1991) [1834671].Weisman GA et al. (2012) [22963441].Wellendorph P et al. (2005) [15576628].Wen W et al. (2014) [25176330].Weng J et al. (2008) [18424556].Weng Y et al. (1998) [9660793].Wentland MP et al. (2009) [19282177].Wenzel‐Seifert K et al. (1993) [8387097].Wermuth CG et al. (1996) [8632404].Werner U et al. (2010) [20570597].Werry TD et al. (2008) [18554725].Wess J et al. (1991) [2043926].Westaway SM et al. (2009) [21544957].Wetzel JM et al. (1995) [7752182].Weyler S et al. (2006) [16902942].White JR et al. (1998) [9553055].White PJ et al. (2003) [12761346].Whitebread S et al. (1989) [2775266].Whitebread SE et al. (1991) [1764088].Whittle BJ et al. (2012) [22480736].Wichmann J et al. (2000) [11006485].Widler L et al. (2010) [20158186].Wieland HA et al. (1998) [9806339].Wieland HA et al. (1995) [7562543].Wieland K et al. (2001) [11714875].Wiener A et al. (2012) [21940398].Wiesenfeld‐Hallin Z et al. (1992) [1373497].Wiest SA et al. (1991) [1709220].Wilbanks A et al. (2001) [11290797].Williams BL et al. (2014) [25344287].Williams TJ et al. (1999) [10369480].Wilson RJ et al. (2006) [16604093].Wilson RJ et al. (2005) [15655509].Wilson S et al. (2005) [15946947].Wilson SM et al. (2011) [21173040].Windischhofer W et al. (1997) [9333122].Winrow CJ et al. (2012) [22019562].Wise A et al. (2003) [12522134].Witte ON et al. (2005) [15653487].Wittenberger T et al. (2001) [11273702].Wong AK et al. (1998) [9719594].Wood MD et al. (1999) [10323594].Wood MD et al. (2000) [11082110].Woodward DF et al. (2008) [18700152].Woodward DF et al. (2011) [21752876].Wright DH et al. (1998) [9579725].Wright DH et al. (1999) [10448933].Wu C et al. (1997) [9171878].Wu H et al. (2014) [24603153].Wu L et al. (1996) [8940121].Wu S et al. (1998) [9473604].Wulff BS et al. (2002) [12393057].Wurch T et al. (1998) [9855638].Wuyts A et al. (1998) [9692902].Wynick D et al. (1993) [7683428].Xi ZX et al. (2007) [17627675].Xia M et al. (1997) [9152366].Xiao C et al. (2016) [27055378].Xiao J et al. (2010) [23905199].Xiao J et al. (2010) [24260782].Xiao J et al. (2014) [24666157].Xiao J et al. (2013) [23764525].Xie Z et al. (1999) [10452531].Xie Z et al. (2009) [19482011].Xiong Y et al. (2004) [14722361].Xiong Y et al. (2013) [23403053].Xu F et al. (2011) [21393508].Xu L et al. (2006) [16757564].Xu Y et al. (2006) [16508674].Xu Y et al. (2000) [10806476].Xu YC et al. (1999) [9986723].Xu YL et al. (2004) [15312648].Yamamoto T (2000) [11107061].Yamamura MS et al. (1992) [1313133].Yamamura Y et al. (1998) [9864265].Yamamura Y et al. (1992) [1387020].Yamashita A et al. (2013) [23714700].Yan H et al. (1996) [8643460].Yan L et al. (2003) [14662005].Yan P et al. (2006) [17082621].Yanagisawa T et al. (2000) [11249148].Yang D et al. (1999) [10521347].Yang J et al. (2008) [18267071].Yang J et al. (2012) [22645144].Yang L et al. (1998) [9724791].Yang LV et al. (2007) [17145776].Yang P et al.ELABELA/Toddler, a critical regulator of cardiac development, is expressed in the human cardiovascular system and binds the apelin receptor. Accessed on 07/07/2015. http://circ.ahajournals.org/content/130/Suppl_2/A15352.Yao BB et al. (2006) [16894349].Yasuda H et al. (2007) [17214962].Yates L et al. (2006) [16553647].Yau MK et al. (2016) [26819675].Ye C et al. (2014) [24633425].Ye RD et al. (2009) [19498085].Yerxa BR et al. (2002) [12183642].Yin H et al. (2009) [19286662].Yin S et al. (2014) [24381270].Yokomizo T et al. (1997) [9177352].Yokomizo T et al. (2001) [11278893].Yokoyama K et al. (2009) [19081254].Yona S et al. (2008) [18789697].Yoshida R et al. (1997) [9153236].Yoshida R et al. (1998) [9507024].Yoshida S et al. (2010) [20804735].Yoshie O et al. (2000) [10714678].Yoshio R et al. (2001) [11459121].Yosten GL et al. (2013) [23759446].Young P et al. (1989) [2573535].Young RN et al. (2004) Heterocycles 64: 437‐446.Yu M et al. (2013) [24900757].Yung YC et al. (2011) [21900594].Zagon IS et al. (2002) [11890982].Zajdel P et al. (2013) [23279866].Zaratin PF et al. (2004) [14593080].Zaveri N (2003) [12801588].Zaveri NT et al. (2015) [25635572].Zech G et al. (2012) [22984835].Zhang C et al. (2015) [26057358].Zhang C et al. (2016) [27746744].Zhang D et al. (2015) [25822790].Zhang K et al. (2014) [24670650].Zhang L et al. (2013) [22911445].Zhang LL et al. (2011) [21924326].Zhang S et al. (2010) [20570702].Zhang SP et al. (1998) [9651119].Zhang SP et al. (2001) [11379050].Zhang WB et al. (2002) [11923301].Zhang Y et al. (2008) [18555684].Zhang Y et al. (2003) [12581520].Zhao DM et al. (2000) [10749750].Zhao P et al. (2015) [25878251].Zhao P et al. (2010) [20826425].Zhen J et al. (2010) [20122961].Zhou J et al. (2013) [23392769].Zhou QZ et al. (1990) [2168520].Zhu J et al. (1995) [7869844].Zhu J et al. (2008) [18582868].Zhu J et al. (1997) [9262330].Zhu K et al. (2001) [11535583].Zhu Y et al. (2001) [11179436].Zobel AW et al. (2000) [10867111].Zoffmann S et al. (2001) [11170631].Zygmunt PM et al. (1999) [10440374]. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Pharmacology Wiley

Loading next page...
 
/lp/wiley/the-concise-guide-to-pharmacology-2017-18-g-protein-coupled-receptors-ecRkz9H7X2

References (143)